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The NF-B family of transcription factors promotes the expression of survival, 
proliferation, inflammation, and differentiation programs in B-cells as well as in other 
cells of the immune system. Additionally, its aberrant constitutive activation is a 
hallmark of several B-cell neoplasms. Moreover, recurrent genetic lesions targeting the 
NF-B activation pathways have been identified in patient samples from different B-cell 
neoplasms. For instance, genetic abnormalities in A20, the negative regulator of the 
canonical NF-B pathway, and the alternative NF-B arm TRAF3/NIK have been 
reported in splenic marginal zone lymphoma (sMZL). In contrast, few genetic lesions 
affecting NF-B activation have been detected in chronic lymphocytic leukaemia (CLL), 
albeit the observed constitutive NF-B activation in CLL. It has been proposed that 
signals from the microenvironment might promote NF-B activation in CLL. Taken 
together, the recurrent observation of enhanced or constitutive NF-B activation and 
the broad spectrum of genetic lesions targeting NF-B in B-cell neoplasm, strongly 
suggest that NF-B activation could act as a general mechanism in B-cell transformation. 
To date, there is little evidence linking activation of the NF-B pathways directly to B-
cell transformation and there are few available in vivo models addressing the role of NF-
B activation in B-cell lymphomagenesis that bring a better understanding of the 
disease development, progression and therapeutic strategies. Therefore, the objective of 
this thesis was to investigate the role of aberrant NF-B activation in B-cell 
transformation and lymphomagenesis using available mouse models. First, the potential 
cooperation between canonical and alternative NF-B activation in predisposing mice to 
sMZL was investigated by making use of the published mouse strains mimicking the 
chromosomal gains in NIK and deletions in A20 observed in human sMZL patients. 
Second, the direct effect of constitutive canonical NF-B activation in B-cell 
transformation was investigated by conditionally expressing an IKK2 constitutive active 
mutant (IKK2ca) in B-cells, and in the E-TCL1tg mouse model for human CLL. 
 
As expected, the hemizygous ablation of A20 cooperated with NIK overexpression in 
expanding the marginal zone B-cell (MZB) pool in mice. However, homozygous ablation 
of A20 in combination with NIK overexpression resulted in an unexpected impaired 
mature B-cell homeostasis that was evident by a systemic depletion of mature B-cells in 
secondary lymphoid organs and recirculating B-cells in the bone marrow. Moreover, 
loss of A20 aggravated the previously reported block in adaptive immunity imposed by 
the overexpression of NIK in B-cells. Aberrant NF-B activation by ablation of A20 and 





NIK overexpression resulted in an abnormal pre-activated antigen presenting cell 
phenotype in B-cells that was accompanied by the altered expression of integrins, 
important for retaining cells in the MZ. Furthermore, the impairment in B-cell 
homeostasis was accompanied by the expansion of regulatory CD25+ CD4 T-cells in 
addition to effector-like CD4 and CD8 T-cells. This T-cell hyperplasia was maintained in 
aged mice that developed an expansion of myeloid cells with age. The concomitant 
effector T-cell hyperplasia and later expansion of myeloid cells, suggest a possible 
involvement of these cells in the observed reduced B-cell numbers. It seems that 
aberrant canonical and alternative NF-B activation in B-cells affect the terminal 
differentiation of mature B-cells forcing cells into a stage that fails to terminally 
differentiate into follicular B-cells and MZB-cells. Moreover, their aberrant phenotype 
possibly triggered a T-cell dependent immune response that may be involved in the 
elimination of these aberrant B-cells.  
 
On the other hand, constitutive canonical NF-B activation by expression of the IKK2ca 
mutant in B-cells resulted in the expansion of B1a-cells that with age developed into a 
disease reminiscent of human small lymphocytic lymphoma - a form of human CLL - 
where CD5+ B-cells infiltrated and accumulated in different lymphoid compartments. 
Moreover, constitutive NF-B activation in B-cells shortened mice life span in an IKK2ca 
dose dependent manner. Furthermore, expression of IKK2ca in B-cells cooperated with 
the TCL1tg oncogene in accelerating the disease progression in E-TCL1tg CLL mouse 
model also in a dose dependent manner. Strikingly, similar survival dynamics were 
observed when the conditional IKK2ca allele was activated during early B-cell 
development (CD19cre) or in a small percentage of mature B-cells (C1cre or AIDcre). 
Finally, adoptive transplant experiments demonstrated that constitutive NF-B 
activation failed to compensate for microenvironment dependent-signals required for 
the proper support of CLL-cells in vivo. 
 
In conclusion, aberrant NF-B activation in B-cells had different effects that were 
dependent on the mechanism of NF-B activation and transcriptional programs this 
regulated. While ablation of A20 in combination with NIK overexpression in B-cells 
impaired mature B-cell homeostasis; IKK2ca-dependent constitutive NF-B activation 
promoted the development of B-cell neoplasms in mice and collaborated with the TCL1 
oncogene accelerating CLL progression in mice. 
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In the recent decade, the advances made in DNA sequencing technologies have 
facilitated the analysis of diverse tumour samples generating an increasing amount of 
data regarding the mutations and genetic aberrations present in diverse lymphoid 
malignancies. However, further studies are needed to evaluate the biological 
significance of these genomic lesions and further validate them as potential drivers. One 
pathway particularly affected in B-cell lymphoid cancers activates the family of nuclear 
factor kappa-light-chain-enhancer of activated B-cells (NF-κB) transcription factors. 
Importantly, the NF-κB transcription factors are indispensable for the development of 
the immune system and regulate several steps during B-cell differentiation. This family 
of transcription factors regulates the expression of genes involved in proliferation, cell 
survival, adhesion, inflammation and other processes. There are two tightly regulated 
pathways that lead to the activation of NF-κB: the canonical and alternative pathway. 
Alterations in these pathways can lead to constitutive activation of NF-κB and as a result 
the aberrant expression of survival and proliferation genes. To date, several reports 
identified mutations in cancer affecting both canonical and alternative pathways. 
Particularly, enhanced or constitutive NF-κB activation is a hallmark of several 
lymphoid cancers [1-9], suggesting that these genetic aberrations might influence the 
regulation of NF-κB target genes. However, there is little evidence linking activation of 
the NF-κB pathways directly to B-cell transformation and there are few available in vivo 
models addressing the role of NF-κB activation in B-cell lymphomagenesis that bring a 
better understanding of the disease development, progression and therapeutic 
strategies. Therefore, taking advantage of available conditional mouse models I want to 
address the effect of deregulated NF-κB activation in B-cells lymphomagenesis in vivo as 
a first step towards understating the role of NF-κB activation in B-cell cancer.  
  





I.1 THE NF-B FAMILY OF TRANSCRIPTION FACTORS  
The nuclear factor-B (NF-B) proteins constitute a family of inducible transcription 
factors that bind the B sequences in the DNA. The NF-B family of transcription factors 
regulates different transcriptional programs involved in B-cell development, 
inflammation, cell adhesion, cell survival and proliferation. Deregulation in the tight 
control of these transcriptional programs can result in severe immune deficiencies 
leading to autoimmunity and inflammatory diseases.  
 
There are 5 different NF-B subunits, namely p105/p50 (NF-B1), p100/p52 (NF-B2), 
RelA (p65), RelB and c-Rel, all of which have a N-terminal Rel homology domain (RHD) 
required for dimerization and DNA binding [10-12]. The different NF-B subunits can 
act as homo- or heterodimers regulating the expression of different target genes. There 
are two pathways that promote their activation. Primarily, the classical pathway 
promotes the activation of p50, RelA and c-Rel (Figure 1A) while the alternative 
pathway activates p52 and RelB (Figure 1B) [11, 13].  
 
In their inactive states the RelA, RelB and c-Rel containing dimers are retained in the 
cytoplasm bound to inhibitory proteins belonging to the classic inhibitory of -B (I-B) 
family (Figure 1). The NF-b subunits p50 and p52 are a result of signal-induced 
processing of their inactive precursors proteins p105 and p100, respectively, containing 
an I-B homologous domain at their C-terminus. Additionally, both p50 and p52 lack the 
C-terminal transcription activation domain (TAD) and require binding to other subunits 
to promote gene expression [10, 13, 14]. While p105 undergoes mostly continued 
processing into p50, cell stimulation promotes phosphorylation of p100 targeting it for 
proteosomal processing to p52 (Figure 1B) [13]. The IB-like domain in p100 allows to 
function also as member of the I-B inhibitory proteins [13]. Cell stimulation induces 
phosphorylation of I-B proteins, which promotes their Lysine-48-linked (K48) 
polyubiquitination targeting them for proteosomal degradation. The release of the 
previously bound NF-B dimers unmasks the nuclear localization signal of the RelA, 
RelB and c-Rel subunits; thus allowing their translocation to the nucleus (Figure 1A) 
[10, 11, 15].  
 
Both NF-B activation pathways are tightly regulated and following particular stimuli 
promote NF-B nuclear translocation and activation of transcriptional programs. Key 
interactions are generated by post-translational modifications where Lysine-63-linked 





(K63) and linear (M1) polyubiquitin chains provide binding sites for interaction 
partners containing adequate ubiquitin binding domains. Following activation, proper 
signal termination is important particularly in immune cells where prolonged activation 
can result in inflammation, autoimmunity and even cancer. Therefore, there are several 
mechanisms for terminating canonical as well as the alternative NF-B activation.  
 
I.1.1 ACTIVATION OF THE CANONICAL NF-B PATHWAY 
The canonical NF-B activation is triggered by cytokines including Tumour necrosis 
factor- (TNF-) and Interleukin-1 (IL-1), by microbial products binding to Toll-like 
receptors (TLR) and antigen binding to the B-cell receptor (BCR) [10, 11]. Receptor 
triggering initiates signalling promoting the interaction of E2 and E3 ubiquitin ligases 
and scaffolding proteins involved in K63/M1 polyubiquitination of downstream 
signalling partners. These signalling pathways converge in the activation of the trimeric 
I-B kinase complex (IKK) by the transforming growth factor- (TGF- activated 
protein kinase 1 (TAK1) (Figure 1A) [10, 11]. The IKK complex is composed of a non-
catalytic regulatory subunit NF-B essential modulator (NEMO, also called IKK-) and 
two catalytic subunits IKK1 and IKK2 (also called IKK- - respectively). 
Activation of the IKK complex requires post-translations modification of NEMO 
consisting in linear polyubiquitination by the Linear Ubiquitin Chain Assembly Complex 
(LUBAC) [15, 16], and phosphorylation of IKK2 by TAK1 [11]. Although the main 
catalytic subunit in the canonical NF-B activation is IKK2, in the absence of IKK2, IKK1 
can also activate canonical NF-B. After IKK activation, IKK2 phosphorylates I-B 
inhibitors bound to NF-B dimers, marking them for K48 polyubiquitin-dependent 
proteosomal degradation. After degradation of the I-B inhibitor the NF-B dimers can 
translocate to the nucleus and promote gene transcription [10, 11].  
 
Distal signals activating canonical NF-B activation 
First, TNF- receptor 1 (TNFR1) binding promotes its oligomerization, followed by the 
recruitment of the TNFR1-associated DEATH domain protein (TRADD) and Receptor-
interacting protein 1 (RIP1) to its cytosolic tail. TRADD then recruits the TNFR 
associated factor (TRAF) 2 to form a complex with the E3 ubiquitin ligases Inhibitor of 
apoptosis proteins 1 (IAP1) and 2 (IAP2), where TRAF5 might also play a role. Although 
TRAF2 and TRAF5 are also E3 ubiquitin ligases, they mainly act as adaptors mediating 
the interaction between IAP1/2 and their substrate. The TRAF2/5-IAP1/2 complex adds 





K63-polyubiquitin chains to RIP1, which provides a binding site for the TAK1 complex 
and NEMO ubiquitin-binding domains (UBD). The TRAF2/5-RIP1-IAP1/2 complex 
interaction with the IKK complex is further stabilized by the linear ubiquitination of 
NEMO through LUBAC. TAK1 can then phosphorylate IKK1 and IKK2 in its activation 
loop activating the canonical NF-B pathway (Figure 1A) [10, 11, 16].  
 
Second, the canonical NF-B activation following IL-1 and LPS stimulation partakes in 
similar mechanisms. The IL-1 receptor 1 (IL-1R1) and TLR4 have a common 
intracellular homology domain Toll/IL-1R (TIR) that recruits the Myeloid differentiation 
factor 88 (MyD88) adaptor following activation (Figure 1A). MyD88 in turn recruits the 
IL-1 receptor-associated kinase 1 (IRAK1) and IRAK4 adaptor proteins. IRAK1 is 
phosphorylated by IRAK4 and can recruit TRAF6 to MyD88 promoting its 
oligomerization and activation (Figure 1A). Activated TRAF6 undergoes auto-K63-
polyubiquitination and ubiquitinates IRAK1 generating a K63-polyubiquitin chain 
scaffolding platform for the binding of the TAK1 complex and NEMO. TRAF6 then 
proceeds to activate TAK1, which can now phosphorylate the IKK complex and activate 
the canonical NF-B pathway [10, 11, 17, 18].  
 
Finally, canonical NF-B activation following B-cell receptor antigen recognition is more 
complex and requires more intermediate activation steps. Following antigen binding 
and oligomerization, the BCR complex composed of the membrane-bound IgM (mIgM) 
and its co-stimulatory molecules Ig and Ig will transduce the signal into the 
cytoplasm (Figure 1A). The molecules involved in proximal BCR signalling are the 
protein tyrosine kinases Spleen tyrosine kinase (Syk), Lyn and Burton’s tyrosine kinase 
(BTK) in addition to the protein adaptor (BLNK) [19-21]. These kinases will activate a 
signalling cascade that will trigger distal effector enzymes involved in the production of 
key second messengers in BCR signalling. The phosphorylated phosphoinositide-3-
kinase (PI3K) phosphorylates phosphatidyl-inositol-4,5-biphosphate (PIP2) into 
phosphatidyl-inositol-3,4,5-triphosphate (PIP3), which acts as a docking site for the 
phospholipase C2 (PLC2), among other enzymes. PLC2 in turn will convert PIP3 to the 
second messengers inositol-1,4,5-triphospate (IP3) and diacylglycerol (DAG) [19-21]. IP3 
is an important second messenger for the intracellular release of calcium following BCR 
activation [22]. The accumulation of intracellular calcium and the presence of DAG will 
activate the Protein kinase C- (PKC-) that links BCR signalling with canonical NF-B 
activation [19, 20, 23]. Active PKC proceeds to phosphorylate the scaffolding protein 





CARD11 (also know as CARMA1). This phosphorylation promotes the binding of BCL10 
and MALT1 to make the CARD11-BCL10-MATL1 (CBM) complex (Figure 1A). This 
complex can interact with TRAF2/6 and activate the canonical NF-B pathway via K63 
polyubiquitination of TAK1 and possibly NEMO [23, 24].  
 
I.1.2 ACTIVATION OF THE ALTERNATIVE NF-B PATHWAY  
The alternative NF-B pathway is activated following stimulation of TNFRs for the B-cell 
activation factor belonging to the TNF family (BAFF), CD40 ligand (CD40L), 
lymphotoxin- (LT), receptor activator of NF-B ligand (RANKL) and the TNF 
related weak inducer of apoptosis (TWEAK) [10]. The first step in the activation of the 
alternative pathway promotes the stabilization and accumulation of NF-B inducing 
kinase (NIK) levels. In un-stimulated cells NIK is constantly K48 polyubiquitinated and 
targeted for proteosomal degradation by an E3 ubiquitin-ligase complex composed of 
IAP1/2, and TRAF2/3 proteins (Figure 1B) [10, 13, 25]. When cells are stimulated 
TRAF2 binds the receptors cytosolic tail, where it recruits and K63-polyubiquitinates 
IAP1/IAP2. These modifications alter IAP1/2 specificity promoting K48-
polyubiquitination of TRAF3, targeting TRAF3 for proteosomal degradation. In the 
absence of TRAF3, stabilized levels of NIK in the cytosol can phosphorylate and activate 
IKK1 dimers [10, 13]. Active IKK1 dimers will in turn phosphorylate p100 in p100:RelB 
dimers promoting its partial ubiquitin-mediated proteolysis to active p52:RelB dimers, 
which can translocate to the nucleus (Figure 1B) [13].  
 
I.1.3 NEGATIVE REGULATION OF NF-B ACTIVATION 
The canonical NF-B activation results in a rapid but transient activation. Several 
negative regulatory loops are required to terminate the signal in a timely manner. First, 
the I-B inhibitors are canonical NF-B target genes. Therefore, in response to NF-B 
activation I-B inhibitors are de novo synthesized and bind to canonical NF-B dimers to 
extract them from the nucleus and sequester them in the cytosol, thereby terminating 
the response. Ablation of I-B, for instance, results in prolonged activation that can 
have deleterious effects [11, 26]. Therefore, a proper and timely regulation is required. 
 






Figure 1. Simplified illustration depicts NF-B activation pathways. 
(A) Canonical NF-B activation following TNF-, IL-1, LPS and antigen stimulation result in the 
activation of TAK1. Active TAK1 phosphorylates and activates the IKK complex that in turn marks the I-
B inhibitory protein for proteosomal degradation. Released NF-B dimers can translocate to the 
nucleus and drive gene expression. (B) Alternative NF-B in resting cells promotes NIK kinase 
proteosomal degradation by the TRAF2/3-IAP1/2 complex. Following stimulation, the TRAF2/3-IAP1/2 
complex is relocated to the receptor intracellular tail where TRAF3 is targeted for proteosomal 
degradation by TRAF2-IAP1/2 complex. NIK protein levels stabilize and the protein can phosphorylate 
and activate IKK1. Activated IKK1 will target p100-containing dimers for proteosomal processing to p52, 
which can now translocate to the nucleus and drive gene expression. BAFFR and CD40 signalling 
activate the canonical and alternative NF-B pathway. 
TNF- (tumour necrosis factor , IL-1interleukin-1), LPS (lipopolysaccharides), BAFFR (B-cell 
activation factor receptor)   





Second, the tumour necrosis factor-alpha-inducible gene (TNFAIP3) encodes A20, a 
negative regulator of the canonical NF-B activation [26]. Similar to the I-B inhibitors, 
A20 is also a canonical NF-B target and its expression is induced after TNF-, IL-1 
LPS and BCR stimulation [11, 26]. A20 is characterized by presenting an Ovarian 
Tumour domain (OTD) and 7 Zinc finger (ZnF) domains. A20 can have a dual ubiquitin 
editing enzyme activity in vitro, acting as a deubiquitinase (DUB) that removes K63-
polyubiquitin chains and as a E3 ubiquitin ligase coupling K48-polyubiquitin chains 
[27]. However, whether this dual activity is relevant in vivo remains unclear. A20 
removes K63-polyubiquitin chains from RIP1, RIP2, TRAF6 and MALT1 [28, 29]; and 
adding K48-polyubiquitin chains to RIP1 marking it for proteosomal degradation [11, 
27] Additionally, it has been reported that A20 inhibits IKK2 in a non-enzymatic way 
[30]. Therefore, A20 is involved in inhibiting distal signalling effects by destabilizing the 
interaction of complexes. 
 
A20 acts as part of the ‘A20 ubiquitin editing complex’ composed of TAXBP1 and the E3 
ligases Itch and RNF11, which are indispensable for A20 negative regulatory role in 
TNF-, IL-1 and LPS-induced NF-B activation [10, 11, 31]. Given that in vitro A20 
deubiquitinates K48-polyubiqutin chains [11] and that TAXBP1 interacts with TRAF6 
and other A20 substrates, it is most likely that TAXBP1 is involved in determining 
substrate specificity [11, 29, 32]. A20 also interacts with A20 binding inhibitor of NF-
B1 (ABIN), and it is likely that ABIN also serves as adaptor molecule to particular 
substrates such as NEMO [11]. Interestingly, A20 activity is positively regulated by 
phosphorylation through IKK2, while A20 itself is a proteolytic target of MALT1 [11]. 
Therefore, at least in the BCR signalling pathway MALT1 and A20 tightly regulate the 
threshold of canonical NF-B activation.  
 
Third, the tumour suppressor CYLD (cylindromatosis) is involved in terminating 
canonical NF-B activation by removing K63 polyubiquitin chains from NEMO, TRAF2, 
TRAF6, TAK1, BCL3 and RIP1 [10, 11, 33]. Similarly to A20, CYLD is phosphorylated by 
IKK2, however this phosphorylation inhibits CYLDs DUB activity [11]. Although A20 and 
CYLD have overlapping substrates, their functions are non redundant in B-cell activation 
[34]. It has been suggested that CYLD plays a role in regulating basal NF-B activation, 
while A20 acts in a negative regulatory loop that inactivates NF-B [11]. 
 





In contrast to the canonical NF-B pathway, the activation of the alternative NF-B 
pathway requires the translational accumulation of NIK, therefore requiring a longer 
activation period. In order to terminate the accumulation of NIK, the alternative NF-B 
has several negative regulatory loops that ensure a proper signal termination. First, the 
deubiquitinase Cezanne removes TRAF3 K48-polyubiquitin chains required for its 
proteosomal degradation following LT or CD40L signals [13]. Second, phosphorylation 
of NIK by IKK1 and other kinases results in NIK destabilization and alternative NF-B 
signal termination. Third, receptor trafficking and degradation also play a role in 
alternative NF-B signal termination [13].  
 
I.1.4 CROSS-TALK AND DUAL NF-B SIGNALLING 
The current understanding of how NF-B signals are activated and regulated by 
different stimuli is not completely understood. Most of the current knowledge comes 
from in vitro, in vivo and genetic studies from knockout and conditional knockout mice. 
In the recent decade, it has become evident that certain signals such as CD40 and BAFF 
have the ability to activate both the canonical and alternative NF-B pathways [35-37], 
pointing to a more complex system that requires further studies (Figure 1).  
 
Certain components of the individual activation pathways have been reported to 
modulate their partner NF-B pathway. First, weak antigen-independent BCR signalling 
regulates the expression of p100 and the BAFF receptor (BAFFR) by c-Rel, thereby 
modulating the alternative NF-B response to BAFF [38]. Second, although the main NF-
B subunits activated by the canonical pathway are p50, RelA and c-Rel, RelA can 
interact with p100 and therefore be regulated by the proteosomal processing of p100 
triggered by the alternative pathway [10, 39]. Similarly, RelB can bind to I-B and this 
portion of cellular RelB translocates to the nucleus only following canonical NF-B 
activation [13]. Second, following antigen stimulation, canonical NF-B activation will 
regulate the expression of p100 NF-B subunit, modulating the alternative NF-B 
response [38, 40]. Third, previous evidence suggest that both CD40 stimulation as well 
as BAFFR activation can also activate the canonical NF-B pathway [36, 41]. Finally, two 
reports have implicated TRAF3-NIK in activation of the canonical NF-B pathway [42, 
43]. Gray et al. (2014) identified constitutive accumulation of NIK accompanied by basal 
activation of the alternative NF-B pathway in NEMO-deficient peripheral blood 
lymphocytes from patients with NEMO immunodeficiency (NEMO-ID) [43]. The 





regulation of NIK was restored by expression of full-length NEMO [43]. In line with this 
finding, Zarnegar et al. (2008) provided evidence that TRAF3 also negatively regulates 
the canonical NF-B pathway. In the absence of TRAF3, the IKK complex was activated 
in a NIK dependent manner [42]. Particularly, in case of TNFR1 and LTR synergy, NIK 
could acts as an amplifier of the canonical NF-B pathway [42].  
 
Taken together, although the distinct pathways leading to the activation of NF-B 
respond to distinct stimuli, there is a potential for crosstalk between the canonical and 
alternative pathways.  
  





I.2 THE IMMUNE SYSTEM 
The immune system has evolved to protect complex organisms from foreign pathogens. 
In higher organisms, the immune system is comprised of two arms fighting against 
infections and foreign invaders: the innate and the adaptive immunity [44, 45]. The 
innate immunity is the first line of defence against foreign pathogens. It mounts an 
immediate response as soon as the infection or foreign pathogen has been detected. It is 
composed from a series of specialized cells - myeloid cells, natural killer cells, and 
marginal zone B-cells (MZB) and B1-cells - that will control de infection until the 
adaptive immunity has time to develop and clear the remaining pathogens. The adaptive 
immune response, as it name suggests, is a response that needs to adapt to the 
particular pathogen that has entered the organism. A complex series of events leads to 
pathogen recognition, the presentation of the antigens to cognate T- and B-cells with the 
final aim of producing high affinity antigen-specific antibodies that help clear the 
infection. NF-B activation plays an important role in T- and B-cell development and 
additionally is required to mount an appropriate immune response against pathogens.  
 
The process of generating antigen specific antibody producing cells is highly complex. It 
requires B-cells to undergo several rounds of proliferation and of genomic DNA editing 
where the cell is in a state of genomic instability [46]. It is during this process that many 
chromosomal translocations and genetic alterations take place that will later lead to the 
development of non-Hodgkin mature B-cell lymphomas and leukaemia [47]. 
  






B-cells are lymphocytes specialized in the production of antibodies. In addition to their 
humoral immune response, B-cells can also act as antigen presenting cells activating T-
cells and produce cytokines that can modulate immune responses [48]. There are two 
main subsets of mature naïve B-cells: B1-cells and B2-cells, which can be further 
subdivided into MZB- and follicular B-cells (FOB). B1- and MZB-cells are mainly involved 
in T-cell independent (TI) and innate-like immune responses, while FOB-cells are key 
players in T-cell dependent (TD) immune responses in adaptive immunity. 
 
I.3.1 EARLY B-CELL DEVELOPMENT  
B-cells develop from pluripotent hematopoietic stem cells (pHSC) in the foetal liver 
during embryonic development and in the bone marrow from the embryonic day E17.5 
onwards[49]. Following very tight specific cues, pHSC give rise to multipotent 
myeloid/lymphoid progenitors (MMP) that further differentiate into a common 
lymphoid progenitor (CLP), which give rise to the first B-cell committed stage: the pro-B 
cell stage (Figure 2A) [49-51].  
 
The early B-cell differentiation in the bone marrow consist on the progression from the 
pro-B cell stage to the large and later small pre-B cell, terminating in the immature B-
cell stage (Figure 2A). Pro-B cells are characterized by the expression of c-kit and IL-7 
receptor alpha (IL-7R) required for cell proliferation and survival [49-51]. When cells 
differentiate to pre-B cells, they down regulate the expression of c-kit and IL-7 receptor 
alpha (IL-7R) while they up regulate the expression of IL-2 receptor alpha (IL-2R or 
CD25) [49, 51]. The transition through these stages is tightly linked to survival signals 
produced by the efficient rearrangement of the immunoglobulin heavy-chain (IgH) and 
light-chain (IgL) loci to produce a functional non-self reactive BCR (Figure 2A) [49, 52]. 
Moreover, two major checkpoints involved in the development of central tolerance take 
place during early B-cell development. The first involves the recognition of self-antigens 
by the rearranged IgH within the pre B-cell receptor (pre-BCR). The second checkpoint 
involves the recognition of self-antigens by the fully formed BCR, after rearrangement of 
both IgH and IgL [53].  
 
The development of early B-cells is regulated by the expression of a network of 
transcription factors that proceed to commit the cell to the B-cell lineage, and the 
majority of published evidence suggests that NF-B does not play a role. Low levels of 





the transcription factor PU.1 at the MPP stage promote the transition to the CLP stage 
and they are associated with ensuing B-cell lineage commitment [50, 51]. A tight 
sequential expression of the transcription factors E2A, EBF and PAX5 among others 
drives the B-cell differentiation program. First, the transcription factor E2A is expressed 
at the pro-B cell stage and is involved in the expression of the recombination-activating-
genes (RAG) proteins [49, 54]. Second, the transcription factor EBF is expressed from 
the pro-B to the pre-B cell stage and in mature B-cells. Importantly, EBF regulates the 
expression of the Ig and Ig co-receptors required for the transduction of signals of the 
pre-BCR and the BCR, as well as the VpreB and 5 subunits of the surrogate light chain 
(SLC), and the transcription factor PAX5 [49, 51]. Finally, the transcription factor PAX5, 
expressed at the pre-B cell stage, commits the cell to the B-cell lineage and is required 
for the rearrangement of the IgH [49, 51].  
 
I.3.1.1 V(D)J recombination 
Part of the early B-cell development requires the expression of a functional BCR. The 
assembly of the IgH and IgL chains requires a series of site-specific somatic 
recombination events that will join the germline variability- (VH), diversity- (DH) and 
joining-gene segments (JH) or VL and JL gene segments, respectively. Upon successful 
completion, the process of V(D)J recombination of the immunoglobulin loci will 
generate a diverse BCR repertoire. 
 
In mice, the IgH is encoded on chromosome 12, while the IgL is encoded by two loci: 
immunoglobulin kappa (Ig) on chromosome 6 and immunoglobulin lambda (Ig) on 
chromosome 16 [52, 55]. Structurally, both IgH and IgL have N-terminal variable region 
specialized in antigen recognition, while only the IgH has a C-terminal constant region, 
which can be exchanged for other forms during class-switch recombination [52]. The 
IgH variable-region is formed by the rearranged VH-DH-JH while the IgL variable-region 
is formed by the VL-JL rearrangement [52]. The site-specific somatic recombination is 
directed by the endonucleases RAG1 and RAG2 [52, 56, 57]. In mice, the absence of one 
of these enzymes and other enzymes related to V(D)J recombination results in severe 
combined immune deficiency (SCID) due to an early block in B- and T-cell development 
[50, 57], indicating the importance of the BCR and TCR for the development of both cell 
types respectively.  
  






Figure 2. Simplified illustration depicts the different developmental stages in B-cell 
development. 
 (A) Early B-cell development in the bone marrow depends on the recombination of VH, DH, and JH 
gene segments to produce a functional pre-BCR and later VL and JL, for a functional BCR. (B) 
Immature B-cells can migrate to the spleen and differentiate to T2 cells by tonic BCR signals and 
survival signals provided by BAFF, or become anergic T3 cells by aberrant BCR activation signals. (C) 
Mature B-cell differentiation in the spleen depends on chronic BCR signals that promote the follicular B-
cell fate or the combination of BAFF and chronic BCR signals that promote the marginal zone B-cell 
fate.  
pHSC (pluripotent hematopoietic stem cell), MPP (myeloid/lymphoid multipotent precursor), CMP 
(common myeloid progenitor), CLP (common lymphoid progenitor), and T (transitional). 





The V(D)J recombination starts at the pro-B cell stage. First, during transition from CLP 
to pro-B cell, the RAG1 and RAG2 enzymes are expressed and both IgH alleles open to 
undergo the DH-to-JH recombination (Figure 2A) resulting in the rearrangement of both 
alleles [49, 52, 58, 59]. Second, during the differentiation to the large pre-B cell stage, 
the one DHJH rearrangement can recombine to the VH in the same allele (Figure 2A) 
[49, 51].  
 
If the VHDHJH rearrangement in the first allele is in frame and results in the productive 
expression of a functional IgH, downstream signals from the membrane-bound IgH on 
the surface promote the closing of the second IgH allele and down regulate expression of 
the RAG proteins, a process referred to as allelic exclusion [49, 52, 59] In this way, the 
cell avoid the recombination of the second allele and only expresses one IgH allele. 
Moreover, the functionality of the newly rearranged IgH is tested by pairing it to the SLC 
- formed by 5 and VpreB - to form the pre-BCR (Figure 2A) [49-51]. This is the initial 
checkpoint involved in B-cell tolerance [49, 51, 53]. First, signalling through the pre-BCR 
will activate canonical NF-B and the expression of pro-survival genes rescuing cells 
from apoptosis [49, 60, 61]. Second, pre-BCR signalling will down regulate the 
expression of the SLC thereby limiting the pre-BCR amount present at the surface, so 
that after a couple of cell divisions the amount of SLC becomes limiting and the cells 
becomes a resting small pre B-cell [49]. 
 
The last V(D)J recombination step takes place during the small pre-B cell stage (Figure 
2A) [49] where the RAG proteins are expressed and the IgL loci open up, both 
prerequisites for the JL-to-VL recombination [49]. The Ig locus is initially recombined. 
However, if the recombination is not productive, the cell can proceed to recombine the 
Ig locus [62]. The recombination into the Ig is dependent on NF-B signals [63].  
 
Rearranged IgH and IgL will combine to produce the BCR. The expression of a fully 
rearranged BCR on the cell surface is the second crucial checkpoint in B-cell 
development and central tolerance. Downstream signals from a functional not self-
reactive BCR will terminate the expression of the RAG proteins and close the IgL loci 
[49]. However, if the BCR is self-reactive, the expression of the RAG proteins is 
maintained and the IgL loci remain open to allow receptor editing by further 
recombination of the IgL loci to produce a non-self-reactive BCR [19, 49, 53, 57]. 
Alternatively, self-reactive B-cells are eliminated by apoptosis or are inactivated and 
become anergic [51].  





Finally, Pre-B cells differentiate into immature B-cells, which express the mIgM BCR that 
has undergone a negative selection process [19]. The immature B-cell can enter the 
circulation and migrate to the spleen where it will differentiate to naïve mature B-cells 
(Figure 2).  
 
V(D)J recombination gives rise to a diverse repertoire of variable-regions in the BCR. 
Additionally, the expression of the enzyme terminal deoxynucleotidyl transferase (TdT) 
adds random nucleotides in the sequence between the DH-to-JH and VH-to-DHJH 
junctions, called N-regions, adding another layer of diversity [49, 62]. Of importance, the 
major 5’ part of VH encodes the first and second constant determining regions (CDR1 
and CDR2) involved in antigen recognition of the IgH which confer germline diversity 
[62]. While the VHDHJH junction sequence encodes the third complementary-
determining region (CDR3) that confers somatic diversity to the IgH and plays a major 
role in antigen recognition and repertoire diversity [62]. In humans and mice, problems 
with V(D)J recombination can result in SCID and cancer [57, 64]. Humans with 
mutations in the V(D)J recombination enzymes develop T-cell and T-cell and B-cell 
related SCID [57, 64].  
 
I.3.2 TRANSITIONAL IMMATURE B-CELLS 
Immature B-cells in the bone marrow can enter the peripheral circulation and migrate 
to the spleen where they differentiate to transitional B-cells. The differentiation of 
immature to mature FO or MZ naïve B-cells is thought to follow linear developmental 
stages. A small proportion of immature B-cells remain in the bone marrow where they 
can differentiate into FOB-cells as well {Pillai:2009bs}. Transitional B-cells can be 
differentiated by their characteristic expression of different surface proteins (Figure 
2B), differential response to BCR signalling as well as to T-cell help and defined 
anatomical localization in the spleen [19, 65].  
 
Three developmental stages of transitional B-cells have been described (Figure 2B). 
Transitional 1 (T1) cells are the most immature cells and are characterized by 
expressing the AA4.1 surface marker as well the membrane bound IgM (Figure 2B: T1 
AA4.1+ CD21- CD23- IgMhigh IgD-) [48, 51, 65]. Transitional 2 (T2) cells are late immature 
cells characterized by the additional expression of membrane bound IgD and the surface 
markers CD21 and CD23 (Figure 2B: T2 AA4.1+ CD21+ CD23+ IgMhigh IgD+) [48, 51, 65]. 
This transitional B-cell subset will differentiate to the mature naive B-cells. There is an 





additional transitional 3 (T3) developmental stage, with lower IgM levels, otherwise 
similar to T2 [48, 51, 65]. It has been suggested that cells in the T3 subgroup correspond 
to self-reactive clones that have become anergic (Figure 2B) [48]. Transitional cells that 
mature in the spleen have a specific physical location. Early transitional cells locate to 
the outer periarteriolar lymphoid sheath (PALS), while later transitional cells migrate 
towards the B-cell follicle [65].  
 
Immature T1 B-cells are prone to apoptosis and require survival signals to rescue them 
from cell death and promote their differentiation [48]. Two main signals coordinate the 
expression of anti-apoptotic proteins and promote differentiation: (1) signals 
downstream of the BCR, and (2) signals from the pro-survival factor BAFF [19, 23, 53, 
66].  
 
Studies with genetically modified mice demonstrated the requirement of NF-B 
activation during the differentiation from T1 to T2 cells. Ablation of NEMO or both 
IKK1/2 in B-cells results in a developmental block at the T1 stage [63]. Similarly, 
ablation of c-Rel/RelA, NF-B1/NF-B2, c-Rel/RelB [36] or expression of the NF-B2 
dominant negative mutant (unable to be processed to p52) in B-cells also results in a T1 
developmental block (Reviewed in [67]). The fact that both canonical and alternative 
NF-B activation are indispensible for the transition of immature B-cells supports the 
requirement for both BCR and BAFF signals driving B-cell differentiation at this stage.  
 
I.3.2.1 BCR signalling and transitional B-cell differentiation 
Signals from the BCR are required for transition from T1 to T2 B-cells. The BCR 
signalosome is composed of a complex network of proximal and distal signalling 
molecules that culminates in the activation of the mitogen activated protein kinases 
(MAPK) in manner dependent on Ras, NF-B transcription factors (Figure 1A) and 
nuclear factor of activated T-cells (NFAT) that will coordinate the expression of genes 
required for proliferation and survival [19, 23].  
 
During the T1 developmental stage, weak tonic antigen-independent BCR signalling 
activates proximal PI3K and AKT that promote B-cell survival, rescuing cells from 
apoptosis [23, 53]. Progression to T2 developmental stage requires activation of distal 
BCR signalling resulting in canonical NF-B activation [67].  
 





It has been suggested that early transitional cells remain sensitive to negative selection 
and can undergo receptor editing or deletion depending on the BCR signal strength[65]. 
First, strong BCR signals can lead to re-expression of RAG enzymes [65] required for 
auto-reactive B-cells to continue the IgL editing process to recombine the Ig locus to 
produce a non-self reactive BCR [50, 53]. Weak tonic BCR signals down regulate the 
expression of the RAG proteins and other proteins involved in V(D)J recombination, thus 
terminating the BCR editing process [23, 53]. Second, T1 cells are sensitive to BCR-
mediated apoptosis via BIM [53, 65]. Recognition of a cognate-self antigen by auto-
reactive B-cells that results in strong BCR signalling leads to the expression of the pro-
apoptotic protein BIM [53], while tonic BCR signalling decreases BIM expression in an 
AKT-dependent manner promoting cell survival [53].  
 
Studies with genetically modified mice demonstrated the importance of BCR proximal 
signalling events in T1 development and distal ones in the T1-to-T2 transition [19, 65]. 
First, ablation of proximal BCR signalling molecules, such as the Syk kinase or the 
cytoplasmic tail of Ig, results in a developmental block at the T1 stage; while ablation 
of distal BCR signalling molecules results in a T2 developmental block (reviewed in [67], 
[65] and [19]). Therefore, T1 differentiation into T2 involves the development of a 
complete network of BCR signals [65]. Likewise, as they transition from T1 to T2 they 
become more responsive to T-cell-derived signals including IL-4 and CD40-ligand 
(CD40L) [19, 65].  
 
I.3.2.2 BAFF and transitional B-cell differentiation 
Transitional B-cell differentiation requires survival signals that rescue cells from 
apoptosis and promote differentiation. Additionally to weak tonic BCR signals, the 
differentiation of T2 cells requires the cytokine BAFF and signalling through its receptor 
[66]. BAFF is expressed as a membrane bound protein that is proteolytically cleaved and 
released to the circulation. There are three different receptors that can bind BAFF: the 
BAFF-receptor (BAFFR) [68], B-cell maturation antigen (BCMA) and the transmembrane 
activator and calcium modulator and cyclophilin ligand interactor (TACI) [66]. BAFFR 
expression increases as B-cells mature.  
 
Genetic studies in mice suggest that the major role of BAFF is to provide T1 cells with 
survival signals required for the differentiation into the T2 and later differentiation 
stages [19, 66, 69, 70]. Mice deficient in BAFF [69] or BAFFR [70] suffer from a B-cell 





developmental block at the T1 stage [66], which can be partially rescued by the enforced 
overexpression of the pro-survival protein BCL-XL at least in the absence of BAFFR [70]. 
In contrast, mice expressing a BAFF transgene develop a T2 cell hyperplasia, suggesting 
that excess of BAFF prolongs the survival of transitional cells [66]. BAFF promotes B-cell 
survival first by promoting the expression of the anti-apoptotic protein B-cell lymphoma 
2 (BCL2) and second by reducing the expression of pro-apoptotic proteins BIM and 
BCL2 modifying factor (Bmf) in an NF-B dependent manner (Figure 1B) [40, 71, 72]. 
BAFF-dependent NF-B activation is indispensable for the T1-to-T2 transition. Both 
canonical and alternative NF-B activation pathways seem to have a complementary 
role in controlling transcriptional programs required for this transition [36, 37, 61, 65]. 
Interestingly, enforced BCL2 expression does not compensate for the absence of NFB 
activation during B-cell maturation [40]. Additionally, it has been suggested that 
elevated BAFF levels, independently of T-cell help, can enhance the survival of low 
affinity auto-reactive B-cells in mice [53, 66, 73].  
 
Taken together, the transition from immature T1 to T2 cells requires survival signals 
provided by tonic BCR signalling and the BAFF cytokine. As cells mature towards the T2 
developmental stage, the BCR downstream signalling reaches a higher activation 
threshold, probably by a proper localization and organization of signalling complexes.  
 
I.3.3 MATURE NAÏVE B-CELLS 
Late transitional T2 cells can differentiate into FOB- or MZB-cells (Figure 2C). FOB-cells 
are characterized by expressing intermediate levels of CD21 and CD1d; high levels of 
CD23; and high membrane-bound IgD with reduced IgM expression. In contrast, MZB-
cells are characterized by expressing high levels of CD21 and CD1d; absence of CD23; 
and high membrane bound IgM with reduced IgD expression. The differentiation to 
MZB-cells includes an intermediate precursor stage: marginal zone precursor (MZP), 
during the differentiation from the MZP to MZB-cell the expression of CD23 is lost 
(Figure 2C).  
 
FOB-cells are involved in TD immune responses, as they can present antigens and 
participate in T-cell activation additionally to become activated, differentiate into 
germinal centre B-cells that will give rise to memory or antigen secreting plasma cells 
[47, 48]. Activated FOB-cells can become short-lived plasma cells in the spleen, but 
cannot migrate to different organs [46, 48]. Moreover, FOB-cells can circulate in the 





periphery into secondary lymphoid organs as well as recirculate to the spleen and bone 
marrow [48]. In the bone marrow, recirculating mature B-cells can also be involved in TI 
immune response to blood-borne pathogens [48, 74].  
 
MZB-cells on the other hand are mainly involved in TI immune responses to blood-
borne pathogens and mainly reside in the outer area of the B-cell follicle in the spleen 
[48]. MZB-cells are pre-activated B-cells, expressing high levels of the major 
histocompatibility complex class-II (MHC-II) and the co-stimulatory molecules CD80 
and CD86, and have the ability to self-renew [74]. Additionally, MZB-cells also express 
high levels of the integrin heterodimers alpha-L beta-2 leukocyte function-associated 
antigen 1 (LFA-1) and alpha-4 beta1 [75]. MZB-cells can become activated by antigens 
and differentiate into antibody producing plasma cells [48]. Moreover, they can act as 
antigen presenting cells (APC) as they (1) shuttle between the marginal zone and the 
follicle [76], (2) can carry antigens and immune complexes [77], and (3) express high 
levels of MHC-II, CD80 and CD86 required for the immunological synapse [48, 74]. It has 
been proposed that B-cell recognition of LPS or other bacterial products might decrease 
integrin activation rendering MZB-cells less static [48]. MZB-cells have also been 
implicated in TD immune responses to protein and lipid antigens [48].  
 
The development of FOB- and MZB-cells is regulated by NF-B signals, however it is 
even more critical for MZB-cell development. Ablation of NF-B1, NF-B1/c-Rel [78], 
NF-B2/BCL3, or NIK/BCL3 results in an impairment in FOB-cell development [67]; 
while ablation of the individual NF-B subunits NF-B1 or NF-B2 results in the absence 
of MZB-cells (Reviewed in [67]). Similarly, B-cells deficient in the components of the 
CBM complex, TRAF6, TAK1 or IKK2 fail to differentiate to MZB-cells [67]. Interestingly, 
the canonical NF-B negative regulator A20 is also required for normal differentiation of 
MZB-cells [79, 80]. Loss of A20 leads to the accumulation of MZP that cannot 
differentiate into functionally mature MZB-cells [79]. All the evidence suggests that 
there is stringent requirement for NF-B signals in the differentiation of FOB- and MZB-
cells.  
 
I.3.3.1 Follicular versus marginal zone B-cell fate decision 
Late immature B-cells need particular cues to differentiate into FOB- or MZB-cells. The 
current model for cell fate decision involves BCR chronic signalling, where signal 
strength and specificity will tip the balance towards either FOB- or MZB-cell 





differentiation [19, 48, 81]. In addition, BAFF as well as Notch2 and most likely integrin 
or cytokine dependent signals will influence MZB-cell fate decisions.  
 
First, evidence from mouse experiments supports the notion that intermediate strength 
BCR signalling will promote FOB-cell differentiation, while weak BCR signalling will 
favour the generation of MZB-cells [19, 74, 81]. Cariappa et al. (2001) have shown that 
relatively strong BCR signals induced by ablation of the transcription factor Aiolos in B-
cells results in FOB-cell expansion at the expense of MZB-cell development [82]. 
Similarly, absence of negative regulators of the BCR, SHP1 and PTEN, result in enhanced 
BCR signalling and defects in MZB-cell development [74]. In contrast, ablation of BTK, 
PLC2 or BCL10, which abrogate BCR downstream signalling (Figure 1A), or constitutive 
inhibition of canonical NF-B block FOB- and MZB-cell differentiation [60, 74, 83]. 
Recently, Shinohara et al. (2016) reported that the ablation of the kinase TAK1 (Figure 
1A) in B-cells results in aberrantly activated alternative NF-B and marginal zone B-cell 
expansion [84]. Taking into consideration that ablation of upstream BCR signals and 
downstream NEMO and IKK2 result reduced MZB-cells [40], TAK1 activation 
downstream BCR signalling could be involved in FOB- versus MZB-cell fate decisions.  
 
Second, experiments with genetically modified mouse strains expressing BCRs specific 
for self antigens (DNA) or microbial lipids (phosphoryl-choline) preferentially give rise 
to MZB-cells [48]. On the other hand, enforced expression of BCRs specific for the hen 
egg lysozyme (HEL) in the absence of selection results in FOB-cell differentiation [74]. 
Therefore, it is likely that self-reactive immature B-cells that have escaped negative 
selection can differentiate into the MZB-cell subset by BCR signalling.  
 
Third, the pro-survival factor BAFF plays a critical role in MZB-cells differentiation. 
While BAFF promotes the survival of both, FOB- and MZB-cells [85], distinct 
downstream NF-B transcriptional programs, independent of survival, are required for 
MZB-cell differentiation [40, 74]. The mechanism of BAFF-driven MZB-cell 
differentiation is not fully understood. However, activation of canonical and alternative 
NF-B pathways coordinates MZB-cell differentiation [36, 37, 40, 84, 86-89].  
 
Fourth, conditional mouse knockout experiments demonstrated the requirement for 
Notch2 signals for MZB-cell differentiation [48, 74]. Ablation of Notch2, its ligand Delta 
like canonical Notch ligand 1 (DLL1) or downstream effectors blocks MZB-cell 
development while Notch2 signalling overactivation results in strongly enhanced MZB-





cell formation [48, 74, 90]. Given the complex spleen architecture and that the 
expression of DLL1 takes place in the red pup venules and also in the follicle 
{Fasnacht:2014hm}, MZB-cell differentiation requires the recirculation of the cells in the 
spleen. The migration of future MZB-cells requires the reorganization of the actin 
cytoskeleton, which is associated to integrin activation. It is therefore likely that 
chemokine or BCR signals might influence MZB-cell homeostasis via integrin 
interactions [19, 20].  
 
Taken together, FOB-cell differentiation requires BCR signals of intermediate strength 
accompanied by BAFF-induced survival signals. MZB-cell differentiation is a more 
complex process where weak BCR signals synergize with Notch2- and BAFF-mediated 
signalling.  
 
I.3.4 B-CELLS IN ADAPTIVE IMMUNITY 
After naïve B2-cells encounter an antigen, they can experience three different fates. 
First, they can migrate to the outside of the follicle and mature into short-lived extra-
follicular plasmablasts that produce low-affinity antigen specific antibodies. Second, 
they can migrate to the border of the T-cell zone, and become memory B-cells [91, 92]. 
Third, they can migrate to the follicle where with the help of follicular helper T-cells 
(TFH) they develop into germinal centre (GC) B-cells and mature to long-term high-
affinity memory B-cells or antibody secreting plasma cells (PC) [46, 47, 92]. 
 
Upon activation by antigen, B-cells require a set of additional cues that promote their 
migration towards the T-cell zone interface in the secondary lymphoid organs where 
further direct interactions with cognate T-cells will result in additional activation [47, 
92]. Although it is still not satisfactorily clarified what determinates the extra-follicular 
versus the germinal centre cell-fate decision, it is likely influenced by positive antigen 
selection, as extra-follicular PC produce low affinity antibodies [46, 92]. Additionally, the 
responsiveness to the cytokine CXCL13 may play an important role, as GC B-cells are 
characterized by the expression of the CXCL13 receptor CXCR5, while extra-follicular B-
cell have lost its expression [46].  
 





I.3.4.1 Germinal centre reaction 
GC B-cells are defined by expressing high levels of the death receptor FAS (also know as 
CD95), and binding to peanut agglutinin (PNA) and the epitope bound by the GL7 
monoclonal antibody [46, 91]. Murine GC B-cells are additionally characterized by down 
regulating the expression of CD38 [91]. 
 
Cognate TFH provide co-stimulatory cell-to-cell signals and cytokines that will drive 
activated B-cells to form GC B-cells. TFH are characterized by the expression of CXCR5, 
Programmed cell death 1 (PD1), Inducible T-cell co-stimulator (ICOS) and CD40L, 
among others [46]. Several signals required for GC formation have already been 
identified: TCR binding to cognate peptide presented by the Major histocompatibility 
complex class II (MHC-II) in B-cells, CD40L binding to CD40 and CD28 binding to the co-
stimulatory molecules CD80 and CD86 on the B-cells [46]. Additionally TFH cells secrete 
IL-4 and IL-21 that are required for proper GC development [46, 92].  
 
At the beginning of the GC reaction, activated B-cells are highly proliferative. After 7 
days, the GC starts polarizing into distinct zones, termed dark zone (DZ) and light zone 
(LZ) for their appearance in histological sections {Zhang:2016ks}. The formation of the 
DZ and the LZ depend on the CXCL12 chemokine and its receptor CXCR4, while the 
proper DZ/LZ polarization depends on the chemokine CXCL13 and its receptor CXCR5 
{Allen:2004bi}. The current model for antibody affinity maturation involves the re-
cycling of GC B-cells through the DZ and LZ, which is influenced by the expression of 
CXCR4 in GC B-cells and the high CXCL12 gradient in the DZ, and a high CXCL13 gradient 
in the LZ [47, 92]. In the DZ highly proliferating B-cells, called centroblasts, reduce their 
BCR expression and undergo affinity maturation of their BCR via the process of somatic 
hyper-mutation (SHM) [46, 47, 92]. The cells stop proliferating, down regulate the 
expression of CXCR4 and migrate towards the high CXCL13 gradient in the LZ, facilitated 
by their expression of CXCR5 [47, 92]. In the LZ, GC B-cells up-regulate their BCR 
expression and compete for the interaction with cognate TFH and follicular dendritic 
cells. Through interactions with TFH and most likely follicular dendritic cells, GC B-cells 
carrying high affinity BCRs are recued from apoptosis to become centrocytes [46]. TFH 
cells may positively select GC B-cells that efficiently present the cognate antigen via 
MHC-II. It is likely that high affinity BCRs are more efficient at antigen capture and 
allowing centrocytes a higher antigen presentation through their MHC-II [46, 92]. In the 
LZ, the affinity of the BCR is tested and the cell can have one of three fates: (1) it can die 
in the absence of survival signals from the TFH, (2) the cell can recycle to the DZ to 





undergo another round of BCR affinity maturation, or (3) terminally differentiate into a 
memory B-cell or high affinity antibody secreting PC [46, 47]. Positively selected 
centrocytes in the LZ up-regulate the expression of CXCR4 and migrate to the DZ to 
further modify their BCR affinity [92].  
 
As mentioned before, SHM in the DZ is responsible for antibody affinity maturation. This 
process introduces single nucleotide exchanges into the immunoglobulin variable 
region. The process is initiated by the Activation-induced deaminase (AID) enzyme that 
deaminates cytidines converting C:G base pairs into U:G base pairs that need to be fixed 
by the cells DNA-repair machinery [47]. Therefore, GC experienced B-cells can be 
identified by mutations in their immunoglobulin variable region acquired during their 
transition through the GC.  
 
Once the B-cells have been positively selected for high affinity antibodies in the LZ, they 
undergo an additional process termed class switch recombination (CSR), where they 
change their immunoglobulin heavy chain mu (IgM) and delta (IgD) constant regions for 
a different class, in an AID-dependent mechanism. The different classes of heavy chains 
have different functions and different cytokines and co-stimulatory molecules 
determine to which class the recombination takes place. Known signals that coordinate 
the CSR process include CD40-CD40L, ICOS-ICOSL and stimulation of the TACI and 
BAFFR [47].  
 
The development and function of the GC reaction are regulated by the transcriptional 
repressor B-cell lymphoma 6 (BCL6) [93] and the transcription factor Interferon 
regulatory factor 4 (IRF4) [94-96]. In the DZ, BCL6 blocks transcriptional programs 
involved in cell cycle arrest and differentiation [97], thus generating a permissive 
environment for the genetic instability caused by high proliferation and DNA-damage 
associated with SHM [47]. Exit of the DZ and migration to the LZ requires the repression 
of BCL6. In the LZ, CD40 signalling rescues cells from apoptosis and promotes the NF-B 
dependent expression of the transcription factor IRF4. High IRF4 levels repress Bcl6, 
promote the expression of AID for CSR, and promote the expression of transcription 
factor B lymphocyte-induced maturation protein 1 (Blimp1) required for commitment 
to the PC state [46, 47, 98]. IL-4 is indispensible for DZ proliferation, SHM and 
production of memory B-cells. IL-21 is involved in early plasma cell formation and is 
required for the generation of antibody secreting PC [46, 99].  
 





Recent evidence demonstrates the requirement for a tight control of NF-B activation in 
GC maintenance and plasma cell differentiation [35, 100-103]. During positive selection, 
CD40 and BCR downstream signals in the LZ coordinate the activation of both canonical 
and alternative NF-B. Canonical NF-B activation via c-Rel and alternative NF-B 
activation of both RelB and p52 are both independently required for GC maintenance, 
regulating different transcriptional programs. The evidence suggests that while the 
canonical NF-B pathway regulates the metabolic requirements for centrocyte recycling 
from the LZ to the DZ [100], the alternative NF-B pathway regulates the expression of 
ICOSL required for TFH help in the LZ and for the re-entry of cells into the cell cycle 
required for further affinity maturation in the DZ [101]. Moreover, RelA-dependent 
canonical NF-B activation and alternative p52 activation are independently required 
for terminal differentiation into plasma cells [100, 101].  
 
The B-cells then egress the follicle and differentiate into long-lived plasma cell and 
memory B-cell. There is a tight transcriptional regulation at the germinal centre stage in 
B-cells during differentiation into plasma cells. Pax5, Bcl6 and Bach2 drive the B-cell 
transcriptional program, while Blimp1 and Xbp1 control plasma cell differentiation [98]. 
Long lived plasma cells can migrate to the bone marrow, where their survival is 
supported by BAFF- and APRIL-induced signals via BCMA [48].  
 
I.3.5 B1-CELL DEVELOPMENT 
In mice, B1-cells are a well-defined B-cell subset that is involved in innate-like and T-cell 
independent immunity [104]. B1-cells are mainly located in the pleural and peritoneal 
cavities, with a small population also present in the spleen and few cells observed in the 
peripheral blood, bone marrow and draining lymph nodes [104]. B1-cells are 
characterized by a surface phenotype of CD19hi B220lo IgM+ IgDvariable CD23- CD43+ [104, 
105] and can be subdivided into B1a- and B1b-cell subsets by the presence or absence of 
the inhibitory protein CD5, respectively. 
 
It has been suggested that splenic and peritoneal B1-cells are phenotypically and 
functionally different [106]. First, B1a-cells from the peritoneal cavity have 
constitutively active STAT3, while splenic B1a-cells do not [105]. Second, B1a-cells from 
the spleen are able to mobilize calcium after BCR crosslinking compared to B1a-cells 
from the peritoneal cavity [105]. Finally, B1a-cells in the spleen secrete the majority of 





natural antibodies, while the secretion of natural antibodies from B1a-cells in the 
peritoneum is negligible [107].  
 
In humans, the identification of a counterpart to murine B1a-cells has been challenging 
since human activated B-cells also express CD5 [108]. Several efforts of strictly sorted 
pure human B-cells have identified a human counterpart for B1-cells, with similar 
functions [109]. This finding underscores the relevance of studying B1-cell biology in 
suitable mouse models.  
 
To date, the best fitted model explaining B1-cell development in mice is the two-
pathway model [104]: During embryonic development in the mouse foetal pHSC give 
rise to self-renewable B1a- and B1b-cells with a restricted VH repertoire [49], while in 
the adult bone marrow early lymphoid progenitors (ELP) and to a lesser extent CLPs 
have the ability to differentiate into B1a- but mainly B1b-cells with a broader VH 
repertoire [110]. In the steady state the B1-cell pool in the adult mouse is maintained by 
the self-renewal capacity of foetal liver-derived B1a- and B1b-cells and the bone 
marrow-derived B1-cells have only a minor contribution [104]. It is in particular cases 
after B1-cell depletion that the bone marrow-derived B1-cells replenish the pool [104]. 
One report described the transformation of B2-cells into cells with a B1a phenotype by 
conditional expression of B1a-cell-derived anti-phosphatidyl-choline specific BCR [111]. 
This suggests the potential of B2-derived B1-cells, nonetheless it is unclear if these 
transformed B1a-cells behave physiologically as B1a-cells. Therefore, the mature B1 cell 
pool in the adult mouse consists mainly of self-renewable foetal liver-derived B1-cells 
with a small contribution of bone marrow-derived B1-cells.  
 
In mice, B1a-cells are the main source of natural antibodies [107, 108, 112]. These 
natural antibodies have low antigen-affinity, represent a skewed BCR repertoire, and 
are poly-reactive recognizing self-antigens, apoptotic cells and microbes [104, 105, 112]. 
The presence of stereotyped BCRs in B1-cells and evidence for a requirement of natural 
antigens engaging their cognate BCRs for B1-cell development support the model for 
positive antigen selection in B1-cell development [49, 104, 105, 112]. Genetic studies in 
mice demonstrated the requirement for the BCR signalling complex for the development 
and/or survival of B1-cells [105, 112-115]. Moreover, it appears that the strength of 
BCR signalling and not the affinity strength of the antibody to its cognate antigen plays a 
role in B1-cell development. Strong BCR signalling is required for B1-cell development 
while intermediate BCR signalling is associated with the development of FOB- and MZB-





cells [81]. Therefore, it is likely that both models are not mutually exclusive and play a 
role during the development of B1-cells.  
 
Additionally to producing natural antibodies, B1-cells can migrate into tissues and 
partially differentiate into antibody secreting cells: IgA-secreting cells in the gut-
associated lymphoid tissue (GALT), in particular lamina propia and mesenteric lymph 
nodes [116].  
 
The B1b-cell subset is somewhat less well studied. However, it is clear that B1b-cells are 
also involved in the production of natural antibodies [117]. Moreover, B1b-cells are 
responsible for producing an adaptive antibody response against pneumococcal 
polysaccharides [116].  
 
The BCR crosslinking in B1-cells seems to have a different effect compared to B2-cells 
[118]. After BCR crosslinking in vitro, calcium mobilization is minimal in B1-cells and 
they fail to proliferate [118]. Nonetheless, B1-cells are not anergic as AKT is activated in 
a phosphoinositide-3-kinase (PI3K)-dependent manner and MHC-II expression is up 
regulated after BCR crosslinking in B1-cells [104]. In contrast, other stimuli such as 
phorbol myristate acetate (PMA), CD40 and TLR ligands result in B1-cell proliferation in 
vitro [105, 112]. In response to TLR stimulation, B1-cells can produce IL-6 and IL-10 and 
thus modulate the immune response [119].  
 
Genetic experiments in mice demonstrated that NF-B activation plays an important 
role in B1-cell development and differentiation. Ablation of the NF-B subunits NF-B2, 
c-Rel/NF-B2 [78], NF-B1/NF-B2 as well as of NEMO or IKK2 [40] result in reduced 
numbers or a complete absence of B1-cells [67]. Additionally, LUBAC deficient B-cell 
cannot differentiate to B1-cells [35]. Moreover, ablation of components of the CBM 
complex in B-cells also results in impaired B1-cell development [67, 120]. Taken 
together, these studies demonstrate the requirement for canonical and alternative NF-
B signals in B1-cell development.  
 
Similarly, genetic experiment in mice demonstrated that B1-cell activation is tightly 
controlled by negative regulators of BCR signalling such as CD5 and the member of the 
CD22 family of sialic acid binding proteins Siglec-G. First, CD5 is a pan T-cell marker that 
is associated with decreased TCR sensitivity [105]. In B1a-cells, CD5 is associated with 
mIgM, therefore constantly modulating BCR activation. In CD5 knockout mice, B1-cells 





respond to BCR crosslinking by higher calcium mobilization, activation of NF-B and 
proliferation [105, 108]. It has been proposed that the CD5-SHP1 binding/association to 
mIgM lowers its sensitivity to antigen activation [105]. Second, ablation of Siglec-G in 
two different mouse models resulted in the abnormal expansion of B1a-cells associated 
with higher calcium mobilization post BCR-crosslinking [121] or NF-B activation [122] 
[123]. Therefore, these inhibitory signals may play a role at limiting B-cell self reactivity 
[108].  
 
B1-cells have also been implicated in autoimmune diseases by the fact that B1-cell 
numbers are expanded in Sjoegren’s syndrome, systemic lupus erythematosus, and 
rheumatoid arthritis in humans as well as in mouse models for systemic autoimmunity 
[105, 116]. There are several different mechanisms how B1-cells can modulate the 
immune response and trigger autoimmune diseases. First, the production of natural 
antibodies [107] can lead to the production of pathogenic antibodies that results in the 
deposit of immune-complexes that trigger autoimmune disease [105, 116]. Second, B1-
cells have the potential to act as antigen presenting cells to T-cells [119]. Therefore, if a 
self antigen is presented by a B1-cell it could trigger an immune response [105, 116]. 
Finally, the evidence suggests that activated B1-cells can produce and secrete cytokines 
such as IL-10 and affect surrounding cells [119]. Genetic experiments in mice have 
implicated B1a-cells in systemic autoimmune disease [114], collagen-induced arthritis 
model [124], haemolytic anaemia and lupus erythematosus [105, 116] amongst others. 
Therefore, a better understanding of B1-cell biology will help understanding the 
aetiology of and ultimately treating these autoimmune diseases.  
 
  





I.4 MALIGNANT TRANSFORMATION LEADING TO B-CELL NEOPLASMS  
During normal B-cell development, B-cells transition through several stages of genomic 
instability where single and double strand DNA breaks are tolerated for the generation 
of functional high-affinity BCRs: (1) V(D)J recombination during IgH and IgL assembly in 
early B-cell development, (2) SHM required for BCR affinity maturation, and (3) CSR for 
production of different classes of antibodies [47]. The nature of these processes 
predisposes B-cells for chromosomal translocations, amplifications and deletions, as 
well as somatic mutations that can activate oncogenes, generate fusion proteins, or 
inactivate tumour suppressor and thereby drive lymphomagenesis. 
 
Several chromosomal translocations implicating the immunoglobulin locus have been 
identified in many B-cell neoplasms: BCL2 translocations are common in follicular 
lymphoma (FL), translocation involving the oncogene Myc are common in Burkitt’s 
lymphoma (BL), translocations with the GC repressor BCL6 are common in diffuse-large 
B-cell lymphomas (DLBCL) [47], and translocations involving the MALT1 and BCL10 
proteins of the CBM complex downstream of BCR signalling are common in splenic 
marginal zone lymphoma (sMZL) [125]. Moreover, chromosomal translocations can also 
result in fusion proteins that drive lymphomagenesis. For instance, the chromosomal 
translocation t(11;18) produces IAP2-MALT1, a fusion protein implicated in sMZL. This 
fusion protein promotes the aberrant cleavage of RelB leading to its constitutive 
activation [125].  
 
The process of SHM also affects non-immunoglobulin genes. SHM hot spots have been 
identified for the GC repressor BCL6, where aberrant SHM introduces mutations in the 
5’ regulatory sequence of the gene affecting its expression [47]. Additionally, aberrant 
SHM can introduce mutations that affect the function or regulation proteins controlling 
cell survival and proliferation.  
 
I.4.1 CONSTITUTIVE ACTIVATION OF NF-B IN B-CELL MALIGNANCIES 
Several human B-cell neoplasms are characterized by the constitutive activation of NF-
B [1-9]. Aberrant NF-B activation can result in the enhanced expression of genes 
involved in (1) proliferation, including Cyclin D1, Cyclin D2, c-Myc and c-Myb; (2) 
survival, including BCL2 and BCL-XL; (3) cytokines, such as IL-2 and IL6; and (4) CD40L 
[10]. Moreover, a higher expression of these NF-B targets has been identified in 
different B-cell neoplasms, linked to nuclear NF-B [126-130], suggesting a role for NF-





B activation in B-cell transformation. Therefore, further studies are required to 
address its pathological role as a potential driver in B-cell transformation. 
 
In the past 15 years novel somatic mutations, chromosomal number alterations and 
translocations with the potential to deregulate NF-B activation have been identified in 
B-cell malignancies (summarized in Table 1), further supporting the involvement of NF-
B activation in lymphomagenesis. Novel mutations involved in innate immunity 
targeting TLR downstream proximal signalling partners MyD88 or TRAF6 (Table 1, 
Figure 1A) have been identified in chronic lymphocytic leukaemia (CLL) [131], FL [132], 
activated B-cell (ABC)-DLBCL [132-135] and sMZL (Table 3). Similarly, novel genomic 
alterations associated with antigen signalling targeting the BCR complex protein Ig or 
the downstream CBM complex (Table 1, Figure 1A) have been identified in mantel cell 
lymphoma (MCL) [136], FL [137], DLBCL [6, 134, 135, 138, 139], primary mediastinal B-
cell lymphoma (PMBL) [139], mucosa-associated lymphoid tissue (MALT) lymphoma 
[10] and sMZL (Table 3). The recurrent targets in diverse types of B-cell lymphomas 
(Table 1) suggest a potential role in NF-B activation as a common mechanism in B-cell 
neoplasm. 
 
Particular attention has been given in the past years to A20, a central negative regulator 
of canonical NF-B activation. The TNFAIP3/A20 locus maps to the recurrent 
chromosomal deletion 6q23.3-24 found in various types of B-cell neoplasms (Table 2). 
Additionally, several somatic mutations with a predicted loss-of-function phenotype 
have been reported for A20 (Table 2). Finally, the promoter of A20 is also recurrently 
silenced by methylation in lymphoma [140]. The combination of these genomic lesions 
results in A20 inactivation, where both alleles have been deleted or silenced [140]. This 
has prompted the idea of A20 acting as a classical two hit tumour suppressor in B-cell 
lymphomagenesis. However, genetic studies in mice found that ablation of A20 in B-cells 
results only in sporadic B-cell lymphomas in aged mice [79] Chu unpublished, 
suggesting that ablation of A20 alone is insufficient to efficiently transform B-cells, and 
additional genetic lesions are required.   





Table 1. Constitutive NF-B activation in B-cell neoplasms 





CLL Tumour microenvironment interactions RelA [141] 
 MyD88 somatic mutations Canonical [131] 
 Notch1 somatic mutations RelA [142] 
 I-B somatic mutations  RelA [143] 
MCL Tumour microenvironment interactions RelA [1] 
 
Chromosome 18q21 gains containing MALT1 
and BCL2 (12%, 4/33) 
 [136] 
 TRAF2 somatic mutations Canonical [144] 
FL 
Locus amplification c-Rel (28.8%, 5/52), 
TRAF6 (9.6%, 5/52) 
Canonical [132] 
and tFL 
Somatic mutations in A20, CARD11 and Ig; 
and chromosomal deletions in A20 
Canonical [137] 
DLBCL 
RelA deregulation  
(8.4% RelAhi, 50% RelA+) 
RelA [2] 
 
Somatic mutations in A20, CAR11 (11%), 
TRAF2 (3%), TRAF5 (5%), TAK1 (5%), RANK 
(8.1%) 




Locus amplification of c-Rel (29%,18/62), 
TRAF6 (11.3%, 7/62) 
Canonical [132] 





BCL3 expression (46.2%, 36/78) 
BCL3 gains (5.1%, 4/78) 
 [146] 
 
Somatic mutations affecting A20, Ig, MyD88, 
CARD11. 
Chromosomal gains in c-Rel or deletions in 





Somatic mutations in A20, CARD11, MyD88 
(ABC type) and Ig  
Canonical [133] 
 
Somatic mutations in MyD88 (24.3%, 43/177) 
and Ig  
Canonical [134] 
ABC-DLBCL 
Somatic mutations in IgBCL10, MyD88  
A20 somatic mutations and chromosomal 
deletions 
Canonical [135] 
CLL (Chronic lymphocytic leukaemia/lymphoma), MCL (Mantel cell lymphoma), FL (Follicular lymphoma), tFL 
(transformed follicular lymphoma), DCBCL (diffuse large B-cell lymphoma), ABC-DLBCL (Activated B-cell like 
DLBCL).  
  





Table 1 (continued). Constitutive NF-B activation in B-cell neoplasm 






Somatic mutations in CARD11, I-B and I-
B 
Canonical [135] 
 c-Rel locus amplification Canonical Reviewed in [10] 
 
3’ deletions in NF-B2  
(constitutive active p52) 
Alternative Reviewed in [10] 
PMBL 
A20 chromosomal deletions and Rel, BCL10 
and MALT1 chromosomal amplifications 
Canonical Reviewed in [139] 
 I-B somatic mutations  Canonical [147] 
MALT 
lymphoma 
BCR-CBM complex translocations (IAP-
MALT1 fusion protein, IgH-MALT1, IgH-
BCL10) 
Canonical Reviewed in [10] 
HL 
40-50% Rel locus amplification 
15-20% somatic inactivating mutations in I-B 
30-40% somatic inactivating mutations in A20 
Canonical Reviewed in [148] 
 RelB and NIK activation Alternative [149] 
Classical HL TRAF3 deletions and NIK amplifications Alternative [150] 
MM NF-B1, A20, CYLD, TACI mutations Canonical 
[151] 
[152] 
 NF-B2, NIK, TRAF2/3, IAP1/2 mutants Alternative 
[151] 
Reviewed in [7] 
EBV 
LMP1 c-Rel dependent activation 
LMP1 NIK p52 activation 
Canonical 
Alternative 






vFLIP activation of IKK2 Canonical Reviewed in [10] 
HCV induced 
BCL (DLBCL) 





GCB-DLBCL (Germinal centre B-cell like DLBCL), PMBL (primary mediastinal B-cell lymphoma), MALT (mucosa-
associated lymphoid tissue), HL (Hodgkin’s lymphoma), MM (multiple myeloma), EBV (Epstein-Barr virus), HCV 









Table 2. Inactivation of A20 as a current event in B-cell neoplasms 
Tumour entity A20 inactivation mechanism Incidence Citation 
MZL1 Somatic mutations 19% [154] 
 6q23.3-24 chromosomal deletions 37.5% [155, 156] 
MALT 
lymphoma2,3,4 
Somatic mutations 28.6% [157] 
 6q23.3-24 chromosomal deletion 7-17.2% [157-159] 
 
Biallelic inactivation by 6q23.3-24 
chromosomal deletions and somatic 
mutations 
21.8% [132] 
Classical HL5 Somatic mutations 33.3-44% [132, 160] 
 





MCL 6q23.3-24 chromosomal deletion 31%  [158] 
DLBCL 





ABC-type Somatic mutations 24.3% [6] 
 6q23.3-24 chromosomal deletion 48-50% [6, 158] 
GCB-type Somatic mutations 2.3% [6] 
 6q23.3-24 chromosomal deletion 22% [158] 
PMBL-type Somatic mutations 36%  [160] 
FL 6q23.3-24 chromosomal deletion 26%  [158] 
MM 6q23.3-24 chromosomal deletion 17.7%  [152] 
CLL 
6q23.3-24 chromosomal hemizygous 
deletion 
25%  [163] 
1 Cohort in Novak et al. (2009) includes splenic (1/8), nodal (3/9) and extranodal (2/11) MZL. 2Chromosomal 
deletions in cohort in Chanudet et al. (2009) were only identified in ocular adnexa (8/42), salivary glands (2/28), 
thyroid (1/11) and liver (1/2) MZL. 3,5Cohorts in Kato et al. (2009) includes stomach (3/23), ocular (13/43) and lung 
(2/12) extranodal MZL and HL of the nodular sclerosis type. 4 Cohort in Bi et al. (2012) analysed ocular adnexal 
extranodal MZL.  
MZL (Marginal zone lymphoma), MALT (mucosa-associated lymphoid tissue), HL (Hodgkin’s lymphoma), MCL 
(Mantel cell lymphoma), DCBCL (diffuse large B-cell lymphoma), ABC- (Activated B-cell like DLBCL), GCB (Germinal 
centre B-cell like DLBCL), PMBL (primary mediastinal B-cell lymphoma), FL (Follicular lymphoma), MM (multiple 
myeloma), and CLL (Chronic lymphocytic leukaemia/lymphoma) 
  





To date, the role of the mutations associated with NF-B activation are still incompletely 
understood. Two independent studies demonstrated the cooperation of NF-B 
activation with other oncogenic events in the development of DLBCL in mice. First, 
Calado et al. (2010) showed that constitutive canonical NF-B activation collaborates 
with Blimp1 deletions in B-cells in the development of ABC-DLBCL in mice [164]. 
Second, Zhang et al. (2015) found that alternative NF-B activation cooperates with 
overexpression of BCL6 in B-cells in the development of GC-DLBCL in mice [165]. 
Moreover, Calado et al. (2010) also found that constitutive canonical NF-B expression 
in GC B-cells resulted in plasma cell hyperplasia [164]. Thus, the evidence supports the 
involvement of NF-B activation in cooperation with oncogenic events in B-cell 
transformation.  
 
Moreover, it has been proposed that signals from the microenvironment might play a 
role in NF-B activation in cases were no evident genetic lesions affecting NF-B 
activation have been detected. Evidence for this hypothesis has been put forward in CLL 
[141, 166, 167] and in MCL[1]. Additionally, a subset of DLBCL is characterized by high 
expression of RelA accompanied by nuclear translocation of RelA, in the absence of any 
known genomic aberration that could promote RelA activation [2], which may also 
imply a role of the microenvironment in NF-B activation. 
 
Taken together, the recurrent observation of enhanced or constitutive NF-B activation 
and the broad spectrum of genetic lesions targeting NF-B in B-cell neoplasm, suggest 
that NF-B activation could act as a general mechanism in B-cell transformation. 
Therefore, further studies are required to investigate the roles of canonical and 
alternative NF-B activation in different B-cell malignancies.  
 
I.4.2 SPLENIC MARGINAL ZONE LYMPHOMA AND NF-B ACTIVATION 
MZLs are an indolent type of lymphoma that can be subdivided into three different 
subtypes: sMZL, nodal marginal zone lymphoma (nMZL) and extra-nodal marginal zone 
lymphoma of the MALT type (also known as MALT lymphoma) [125]. sMZL accounts for 
2-5% of lymphoid neoplasms [168]. The disease is characterized by splenomegaly 
accompanied by bone marrow, peripheral blood and in some cases liver infiltration 
[169]. It is likely that the cell of origin is a pre- or post-GC B-cell [168]. Although the 
disease patho-mechanism are unknown, the biased IGHV gene usage [170, 171], high 





incidence of hepatitis C virus infections among patients [171, 172] and association with 
chronic inflammation or autoimmune diseases suggest that antigen stimulation plays a 
role [125, 168, 169]. Moreover, 30% of the sMZL cases are of the aggressive form with 
worst prognosis and out of those, 5-10% can transform into diffuse large B-cell 
lymphoma (DLBCL) [20, 173]. Therefore, a better understanding of the disease 
pathogenesis could lead to improved treatment options, for example through preventing 
transformation into a more aggressive form.  
 
The most common genetic abnormalities found in sMZL are deletions of 7q21-32 
present in about 30% of the patients [171, 173] and chromosomal translocations 
involving the immunoglobulin heavy and light chain loci such as t(11;18), t(1;14) and 
t(14;18) [125, 154]. 
 
Advances in whole genome sequencing (WGS) and whole exome sequencing (WES) in 
the past decade have identified a variety of novel mutations related to sMZL (Table 3). 
The most commonly affected pathways include the NF-B [154, 171, 174-177] and the 
Notch2 [178-181] pathways, required for normal MZB-cell differentiation [90, 182].  
 
Analysis of sMZL patient biopsies demonstrated the constitutive activation of NF-B in 
50% of the samples analysed [176, 183]. In addition, several genomic alterations 
resulting in potential NF-B activation have been reported in sMZL patient samples 
(summarised in Table 3). First, the NF-B genomic alteration in sMZL affect both the 
canonical NF-B arm (IKK2/A20, Table 3) and alternative NF-B arm 
(TRAF3/IAP1/NIK, Table 3) and have the potential to promote stronger or constitutive 
NF-B activation [154, 179, 183]{Kai:2014iw}. Genetic lesions affecting canonical NF-B 
signalling have been identified in IKK2 and A20 (Table 3). The positions of the somatic 
mutations in IKK2 suggest that they are gain-of-function mutations. While somatic 
mutations in A20 most likely result in loss-of-function. Therefore, they would both 
result in enhanced and/or prolonged activation of NF-B. The alternative NF-B 
pathway has been affected by somatic mutations resulting in loss-of-function or 
chromosomal deletions affecting TRAF3 and IAP proteins, as well as chromosomal gains 
affecting the NIK locus (Table 3). TRAF3 mutations putatively affect NIK binding and 
recruitment for ubiquitination, while IAP1 mutations affect ubiquitination of NIK 
required for its proteosomal degradation [125, 179, 183].  
 
 













NF-B pathway 34-36%  [174, 183] 
Canonical arm    
TNFAIP3/A20 6-21% 7-9% [154, 171, 174, 177, 183] 
IKBKB/IKK2 1-7%  [174, 177, 183] 
Alternative arm    
BIRC3/IAP1 4-6% 5-6% [174, 177, 183] 
TRAF3 3-15% 5-7% [174, 177, 183] 
MAPK14/NIK 1% 6-7% b [174, 183] 
TLR and BCR    
MyD88 5-15%  [171, 174, 177, 180] 
CARD11 6-10%  [171, 174, 177] 
BCL10 3%  [177] 
KLF2 17-40%  [177, 181] 
Notch Pathway 32%  [174] 
Notch2 10-25%  [174, 177, 178, 180, 181] 
a Chromosomal deletions and gains 
b Chromosomal gains 
 
  





Second, the most prevalent genetic alternation observed in sMZL patients was the loss-
of-function of the transcription factor Kruppel-like factor 2 (KLF2, Table 3) activated 
downstream BCR and Toll-like receptor (TLR) stimulation and associated with NF-B 
repression that resulted in NF-B hyper-activation [125, 177, 180, 181].  
 
Third, additional genetic alterations potentially resulting in constitutive NF-B 
activation were reported for the B-cell receptor downstream activators CARD11 [171, 
174, 177] and BCL10 [177], and the TLR associated protein MyD88 mutation L256P 
[171, 174, 177, 180]. While mutations in CARD11 and BCL10 would promote the 
spontaneous formation of the BCM complex, the L256P MyD88 mutation affects its 
interaction with IRAK1 and IRAK4 promoting a spontaneous complex formation [125].  
 
Finally, methylation changes have also been implicated with silencing and 
overexpression of genes involved in NF-B activation [125]. Therefore, all the evidence 
suggests that constitutive canonical and alternative NF-B activation could play a 
prominent role in sMZL development and pathogenesis.  
 
Importantly, the studies of Rossi et al (2011) and Rossi et al (2012) claimed that the 
genetic lesions affecting NF-B activation seem to be mutually exclusive where 11-15% 
of the samples analysed had lesions affecting the canonical NF-B arm, while 21% of the 
samples presented lesions in the alternative NF-B arm (Figure 3). However a further 
analysis of their results revealed that 4-7% of the patients presented with lesions 
involving both A20 and the alternative NF-B arm [179, 183].  
 
Genetically modified mice provided evidence for the role of alternative NF-B 
TRAF3/IAP1/NIK arm in MZB-cell development and lymphomagenesis. Activation of the 
alternative NF-B transcription factor pathway in B-cells by the conditional 
overexpression of NIK leads to the expansion of MZB-cells in mice [89]. Ablation of the 
adaptor TRAF3 in B-cells leads to development of clonal sMZL and B1a lymphomas in 18 
months old mice [184].  
 
 






Figure 3. Genomic alterations affecting the canonical and alternative NF-B activation 
arms in splenic marginal zone lymphoma patients. (Data analysed from [179, 183]) 
 
Similarly, genetic mouse models provided direct and indirect evidence for the role of 
canonical NF-B activation in MZB-cell development and lymphomagenesis. The 
conditional expression of the constitutive active mutant IKK2 in B-cells results in 
enlarged pool of MZB-cells [37]. Transgenic mice overexpressing the BCL10 protein in 
B-cells have increased MZB-cell numbers and can develop features of human MZL [185]. 
Moreover, BCL10 overexpression is accompanied by canonical and alternative NF-B 
activation [185]. Ablation of BCL10 in mice affects the development of mature B-cells, 
resulting in reduced MZB-cell numbers with reduced functionality [83]. Supporting the 
role of KLF2 mutations in sMZL, ablation of KLF2 transcription factor in mice results in 
increased MZB-cell numbers and splenic marginal zone hyperplasia [186, 187]. 
However, ablation of the NF-B negative regulator A20 in B-cells results in the 
accumulation of MZP with impaired migration to the MZ and terminal differentiation 
into MZB-cell [79, 80].  
 
In summary, sMZL is a very heterogeneous disease and the pathological mechanisms 
resulting in sMZL are poorly understood. The identification of genetic alterations in 
sMZL activating NF-B, in addition to the fact that NF-B signals are indispensible in 
MZB-cell development, suggest that constitutive activation of the canonical and 
alternative pathway are involved in sMZL transformation. Therefore, the potential 
involvement of canonical and alternative NF-B activation as pathogenic mechanism in 
sMZL needs to be investigated.  





I.4.3 CHRONIC LYMPHOCYTIC LEUKAEMIA 
Chronic lymphocytic leukaemia (CLL) is an indolent type B-cell neoplasm, characterized 
by the slow accumulation of small CD5+ IgM+ B-cells. CLL is the most common Western 
World B-cell neoplasm and to date there is no cure. Treatment often results in relapse 
due to the selection of resistant clones [188, 189]. Moreover, about 10% of CLL patients 
develop Richter syndrome (RS), a transformation to a more aggressive disease, usually 
DLBCL [190, 191]. CLL can be divided by the presence or absence of somatic mutations 
in the immunoglobulin gene in a more indolent mutated-CLL type or an aggressive 
unmutated-CLL type, respectively. It has been speculated that the cell of origin for the 
mutated-CLL is a germinal centre experienced cell, while the origin of the unmutated-
CLL is pre-GC B-cell [192].  
 
CLL is a very genetically heterogeneous disease [193] with several genetic aberrations 
targeting different pathways (Table 4), suggesting that different pathogenic insults can 
converge in the development of CLL. To date, the most recurrently mutated genes in CLL 
identified by WGS and WES are Notch1, SF3B1, I-B, IAP1 (BIRC3) and MyD88 [147, 
191, 194] (summarized in Table 4). Their involvement in CLL development and 
pathogenesis is partially understood. First, Notch1 deletions in CLL target the C-
terminal PEST domain. The predicted effect of these mutations result in impaired 
degradation and accumulation of the active Notch1. Notch1 activates different 
transcriptional programs, and a potential effect of Notch1 mutations is the expression of 
NF-B molecules [191]. Second, the SF3B1 protein is involved in splicing and mRNA 
metabolism, however the predicted role of these mutations and its involvement in CLL is 
unknown. Third, I-B mutations result in decreased NF-B inhibition, increased p65 
phosphorylation and nuclear translocation [143]. Fourth, the mutations and 
chromosomal deletions affecting IAP seem to constitutively activate the alternative NF-
B pathway [191]. Moreover, the IAP locus maps to the commonly deleted region 
11q22-q23, previously associated with ATM deletion in CLL. Finally, the MyD88 protein 
activates TLR downstream signals leading to canonical NF-B activation (Figure 1A). 
The most prevalent MyD88 mutation L256P, found in 3% of CLL patients and present in 
other types of B-cell neoplasms, results in the constitutive activation of canonical NF-B 
downstream of the TLR [191].  
 
CLL is characterized by canonical NF-B activation, with patients samples exhibiting 
different levels of activation [166, 195, 196], that is required for the survival of CLL-cells 





[197] [198]. Moreover, canonical NF-B activation, particularly RelA, have been 
suggested as a prognostic marker and potential therapeutic target [199, 200].  
 
The mechanism by which canonical NF-B is activated in CLL is poorly understood. 
First, it has been suggested that signals from the microenvironment activate canonical 
NF-B [141] and regulate the expression of anti-apoptotic proteins such as BCL-xL [201-
203]. It has been reported that the cytokines BAFF and APRIL induce canonical NF-B 
activation in cultured CLL-cells [203]. Similarly, cell-to-cell contact possibly via CD40 or 
other interactions results in NF-B activation [167, 201, 202]. Additionally, Lutzny et al. 
(2013) found that CLL-cells remodel their microenvironment, in a cell-to-cell contact-
dependent fashion. This microenvironment remodelling, that induces the expression of 
the PKC-II splice-variant in stromal cells of the microenvironments, is indispensable 
for CLL survival [167].  
 
Second, it has been suggested that BCR signals activate NF-B in CLL-cells and promote 
their survival [204]. There is strong evidence supporting the role of BCR activation in 
CLL pathogenesis. Several inhibitors targeting the downstream BCR kinase BTK inhibit 
BCR signals, reduce NF-B activation and reduce proliferation of CLL-cells [205-207]. 
Interestingly, 30% of all CLL patients express stereotyped BCRs, suggesting a positive 
antigen selection process during lymphomagenesis [208]. 
 
Finally, somatic mutations or chromosomal deletions targeting NF-B related genes 
have been identified in CLL in a small percentage of patients (Tables 1 and 4).  
 
Various mouse models have been made to investigate the role of recurrent genetic 
lesions or oncogenes in the development of CLL [228]. The overexpression of the human 
oncogene TCL1 in B-cells results in the development of a CLL-like disease in mice [229]. 
Several mechanisms have been associated with TCL1 overexpression and CLL 
development, one being activation of canonical NF-B, but further studies are required 
to validate their pathogenic role in CLL [230-233].  
 
  





Table 4. Most common genetic abnormalities identified in CLL 
Targeted pathway or 
gene 
Mechanism Incidence Citation 
Cell cycle, survival 
(BCL2 regulation) 
13q14 deletion: lncRNAs 
(Dleu1 and Dleu2) and 
miRNAs (miR15-16) 
60-70% [209-212] 
ATM, IAP 11q22.3 deletion 27% [211, 213] 
Cell cycle? Trisomy 12 29% [214] 




7-37% [215, 216] 
IRF4 6p25.3 deletion 7% [211, 217] 
MYC 8q24.21 gains 5% [211] 
Pre-mRNA processing 
Somatic mutations in the 
splicing factor SF3B1 
10-26% [194, 212, 213, 216, 218-220] 
Notch, 
canonical NF-B 
Somatic mutations in Notch1 6-15% [131, 194, 212, 213, 216, 219-223] 
TLR, 
canonical NF-B 
Somatic mutations in MyD88 1-3% [131, 194, 212, 213] 
mRNA export Somatic mutations in XPO1 2-8% [131, 194] 
BCR signalling Somatic mutations in EGR2 8% [194] 
Canonical NF-B I-B mutations 7-11% [147, 194] 
Alternative NF-B IAP mutations 6.5% [219] 
Cell cycle and 
proliferation 
Mutations in TP53 6-30% [194, 212, 213, 220, 221, 223] 
Genomic abnormalities 
Somatic mutations in POT1 
(Protection of telomeres 1) 
3.5% [224] 
GC B-cell related Somatic mutations in KLHL6 1.8% [131] 
IRF4 Somatic mutations 1.5% [225] 
NF-B activation? CYLD downregulation  [226] 
Canonical NF-B 
(IKK2) 
miR708 promoter and 
enhancer methylation 
 [227] 
lncRNA (long non-coding RNA).   





Two individual studies have modelled the role of the recurrent 13q14 chromosomal 
deletion in CLL in mice [234, 235]. Klein et al. (2010) targeted the two loci mapped to 
the minimal deleted region (MDR) 13q14: miR25/16 and Dleu2. They found that 
ablation of mRI15/16 in B-cells resulted in the development of human CLL-like disease 
in 21% of the animals, while ablation of the MDR resulted in a similar disease in 27% of 
the animals [234]. Lia et al. (2012) targeted the common deleted region 13q4 that 
included the Dleu1 locus. They observed a similar incidence of 24-25% of the animals 
developing human CLL-like disease between the heterozygous deletion of the MDR and 
the common deleted region [235]. 
 
The role APRIL produced by the microenvironment and BCR signals in the development 
of CLL have also been investigated using mouse models. First, the transgenic expression 
of APRIL promotes B1-cell neoplasms in mice [236]. Moreover, the transgenic 
expression of APRIL accelerated the disease progression in APRIL-tg TCL1-tg compound 
mice [237]. Second, overexpression of human BTK in the murine mouse model for CLL 
IgH.ETmu accelerated the disease progression [238]. Thus, supporting the role of both 
cytokines present in the microenvironment and BCR signals in CLL development.  
 
In summary, diverse pathogenic mechanisms converge in the development of a disease 
similar to human CLL in mice. However, the role of canonical NF-B activation by the 
microenvironment in CLL pathogenesis remains to be elucidated. 
 
 





II AIM OF THE THESIS 
 
Constitutive NF-B activation is a hallmark of several B-cell neoplasms [1-9], however to 
date there is no direct evidence linking NF-B activation to B-cell transformation. Taken 
into consideration the stringent requirement for NF-B regulated transcriptional 
programs in B-cell development and activation, and the presence of diverse recurrent 
genetic lesions targeting both canonical and alternative NF-B pathways in different B-
cell neoplasms; it is of outmost importance to investigate participation of NF-B 
activation in the development of B-cell neoplasms. Thus, the aim of this thesis was to 
investigate the direct role of NF-B activation in B-cell transformation and 
lymphomagenesis using genetic mouse models.  
 
First, I wanted to investigate the potential cooperation of canonical and alternative NF-
B activation in predisposing mice to splenic marginal zone lymphoma (sMZL) using 
already available mouse strains mimicking the chromosomal gains in NIK [89] and 
deletions in A20 [239] observed in human sMZL patients (Table 3). 
 
Second, I wanted to investigate if constitutive canonical NF-B activation in B-cells could 
promote B-cell neoplasms in mice using the already available mouse strain that allows 
conditional expression of a constitutive active IKK2 mutant (IKK2ca)[37]. In addition, I 
wanted to investigate the effect of the observed constitutive canonical NF-B activation 
in human chronic lymphocytic leukaemia (CLL) in the disease development and 
progression by constitutively activating canonical NF-B in the E-hTCL1 mouse model 
for human CLL [229].  





III MATERIALS AND METHODS 
 
GENETICALLY MODIFIED MOUSE STRAINS 
All mouse lines used in this study have been previously published. All mice used for this 
study were backcrossed to or generated in the C57BL/6 background. All mice were bred 
and kept in specific pathogen-free (SPF) conditions following the guidelines of the 
Region of Upper Bavaria (Regierun von Oberbayern) and the European Union.  
 
Mice were housed at the mouse facilities of the Max-Planck Institute of Biochemistry in 
Munich, the Centre for Preclinical Research of the MRI (Zentrum für Präklinisches 
Forschung, ZPF) in Munich, Harlan in Milan and Charles River in Calco, Italy. 
 
To model potential splenic marginal zone lymphoma (sMZL) I bred the A20FL mouse 
strain[240] to the R26-StopFLNik (NIK-tg) mouse strain [89] in combination with the 
CD19cre mouse strain[113, 241]. 
 
To model aspects of chronic lymphocytic leukaemia I bred the E-hTCL1tg (TCL1tg) 
mouse strain[229] to the R26-StopFLikk2ca (R26-IKK2ca) mouse strain[37] in 
combination with the CD19cre strain [113, 241]. Additionally, I bred the E-hTCL1tg 
mouse strain to the R26-StopFLikk2ca or to the R26/CAG-CAR1StopF[242] (R26-CAR) in 
combination with the C1cre[243] strain or the AIDcre strain[244]. Moreover, the PKC- 
knockout mouse strain Prkcbtm1Tara [245] was back crossed to the C57BL/6 genetic 
background and breed heterozygous or homozygous as recipients for transplantation 
experiments.  
  
Mouse lines were genotyped for the different mutations combinations by polymerase 
chain reaction (PCR). Genomic DNA was extracted from tail or ear biopsy by Proteinase 
K treatment, followed by isopropanol precipitation. The PCR protocols are included in 
the supplementary material. Primers were produced by Metabion International AG 
(Munich, Germany) or Eurofins Genomics (Munich, Germany) and sequences are shown 
in Table 5. 
 
 





Table 5. PCR primers used for genotyping mouse strains 
Targeted 
allele 
Primer name Sequence (5´-3’ orientation) Amplicon size 
CD19cre 
Cre8 CCCAGAAATGCCAGATTA Wild type allele: 452bp 
CD19c AACCAGTCAACACCCTTCC Knock-in allele: 500bp 
CD19d CCAGACTAGATACAGACCAG  
C1cre 
Cg1Cre A TGTTGGGACAAACGAGCAATC Wild type allele: 250bp 
Cg1Cre B GGTGGCTGGACCAATGTAAATA Knock-in allele: 470bp 
Cg1Cre C GTCATGGCAATGCCAAGGTCGCTAG  
Rosa26-
Knock-in* 
790 rosa fw  AAAGTCGCTCTGAGTTGTTATC Wild type allele: 570bp 
791 rosa rev  GATATGAAGTACTGGGCTCTT Knock-in allele: 450bp 
792 Neo rev  GCATCGCCTTCTATCGCCT  
Rosa26-
CAR 
CARIIonly fw CCTGCTGTGCTTCGTGCTCC Wild type allele: N.P. 
CARIIonly RV CGTAACATCTCGCACCTGAAGGC Knock-in allele: 435bp 
E-TCL1tg 
Tcl1 fw AGTGGTAAATATAGGGTTGTCTACACG Wild type allele: N.P. 
Tcl1 rv CCCGTAACTGTAACCTATCCTTTA Transgene allele: 250bp 
A20 
A20_28 Fw  CACAGAGCCTCAGTATCATGT Wild type allele: 150bp 
A20_31Rv  CCTGTCAACATCTCAGAAGG Floxed allele: 230bp 
A20_30Fw  GCAGCTGGAATCTCTGAAATC Deleted allele: 370bp 
PKC- KO 
PKCbeta-fw CAGGGTCGAATTGCCATCCTCCA Wild type allele: 391bp 
PKC-MO13-fw CTTGGGTGGAGAGGCTATTC Knock out allele: 800bp 
PKCbeta_rv new AGCCACTCTCGGTGCTGTG  
* Used to genotype both R26-IKK2ca or R26-CAR 
N.P. not possible 
 
MOUSE EXPERIMENTS 
Animals were analysed at 2-3 months of age to assess effects of combining different 
genomic alteration in the immune development. Furthermore, mice were aged to 
monitor for disease development and progression. Animals were closely monitored for 
signs of cancer development: splenomegaly, hepatomegaly, enlarged lymph nodes or 
anaemia. When modelling for chronic lymphocytic leukaemia (CLL) in mice, blood 
samples were taken monthly to monitor for the development of malignant cells in 
peripheral blood. Animals were considered to be sick when the CLL-like cell burden in 
peripheral blood reach over 50% of total living cells, or there was visible lymphoid 
organ enlargement. In the absence of disease mice were analysed at 12-18 months of 
age. All animal experiments were approved by the Regierun of Oberbayern. 
 
PERIPHERAL BLOOD BLEEDING 
Blood samples were collected by pouch bleeding into 1.5mL tubes with 50ul of heparin 
(20U/ml, Sigma-Aldrich). For serum collection, heparin treated Microvette® (Cat. No. 





16.443, Sarstedt) or clotting activator treated Microvette® (Cat. No. 20.1343, Sarstedt) 
were used. If peripheral blood sample was to be furthered processed, red blood cell lysis 
of erythrocytes was done using ACK lysis buffer. Cells were later washed with cell buffer 
solution containing 2% foetal bovine serum (FBS), penicillin/streptomycin in phosphate 
buffered saline (PBS) (all Gibco). Cells were further processed for FACS staining.  
 
ADOPTIVE TRANSPLANT INTO PKC- KNOCK-OUT MICE 
Splenic CLL-like cells from either (1) TCL1tg CD19cre or (2) TCL1 R26-IKK2ca CD19cre 
donor mice were enriched by depleting for lineage positive cells and intra-peritoneally 
injected into non-irradiated PKC-beta KO heterozygous and homozygous recipients.  
 
Magnetic assorted cell sorting (MACS): Single cell suspension of splenic CLL-like cells 
were labelled with biotinylated antibodies against CD3e, F4/80, CD11c, Ter119, IL7R, 
Gr1 and IgD to deplete for T-cells, myeloid cells and IgD+ B-cells (Table 2). Labelled cells 
were later incubated with anti-biotin magnetic beads (130-090-485, Miltenyi Biotec) 
and manually separated through a magnetic LS column (130-042-401, Miltenyi Biotec). 
Cell enrichment purity was assessed by Flow Cytometry, with a minimal threshold of 
95%. 
 
Table 6. Biotinylated antibodies used for MACS negative selection 
Antigen Clone Vendor Catalogue Nr. 
CD3e eBio500A2 eBioscience 13-0033-81 
F4/80 CI:A3-1 AbD serotec MCA497B 
CD11c N418 eBioscience 13-0114-81 
Ter119 Ter119 eBioscience 13-5921-81 
IL7R  A7R34 eBioscience 13-1271-82 
Gr1 (Ly-6G) RB6-8C5 eBioscience 13-5931-81 
IgD 11-26 eBioscience 13-5993-81 
 
Enriched CD5+ B1a-like cells were washed and resuspended to a density of 20 million 
cells in 200ul in PBS (Gibco). Each paired aged matched recipient, PKC- heterozygous 
and homozygous, was injected intra-peritoneally with 20 million donor cells. Recipient 
mice weight was monitored after transplant, and peripheral blood was collected weekly 
to monitor for disease development and progression.  
 
Mice were followed up for a period of 6 months after transplant. If after the 6 months no 
CLL-like symptoms had been observed, animals were analysed.  






Cells from the peritoneal cavity were extracted by lavage with 5ml cell buffer solution. 
Liver and spleen masses were weight before processing. Total mesenteric lymph nodes 
were harvested, as well as all visible Payer’s Patches structures. Draining lymph nodes 
(inguinal, axillary brachial and superficial cervical) were collected and pooled as 
indicated. A single cell suspension was obtained from spleen, lymph nodes and payer’s 
patches by crushing organs with glass slides and resuspending cells in cell buffer. Bone 
marrow was collected from one tibia and femur. Cells were obtained by crushing bones 
in a mortar.  
 
Erythrocytes were removed from spleen and bone marrow samples using the Gey’s 
solution for red blood cell lysis. Single cell suspensions were filtered and viable total cell 
numbers were calculated using a Neubauer counting chamber with Trypan Blue (Gibco) 
exclusion dye.  
 
FLOW CYTOMETRY 
Two to 3 million cells were stained for flow cytometry. Cells were pre-stained with the 
anti-mouse CD16/CD32 (clone 93, eBioscience, 14-0161-81), to block Fc receptor 
binding and prevent any unspecific binding. Cells were then stained with different 
fluorescently labelled antibodies to identify defined immune populations. Surface 
extracellular labelling was done using FACS buffer (0.5% Azide, 2M EDTA, 2% FBS in 
PBS). Cell viability was assessed using the non-fixable dye eBioscienceTM 7-AAD Viability 
Staining Solution (Thermo Fisher Scientific, 00-5523-00) or the LIVE/DEADTM Fixable 
Near-IR Dead Cell Staining Kit (Thermo Fisher Scientific, L10119) for 633/635nm 
excitation. For intracellular labelling with antibodies, cells were previously fixated in 2% 
paraformaldehyde (PFA) solution followed by a methanol permeabilization, or 
alternatively using the eBioscienceTM Foxp3/Transcription Factor Staining Buffer Set 
(eBioscience, 00-5523-00). Tables 3 and 4 shows a list of all fluorescently couples 
antibodies used.  
 
Single staining for compensation were done using splenocytes, eGFP expressing 
splenocytes or with UltraComp eBeadsTM Compensation Beads (Thermo Fisher 
Scientific, 01-2222-42). 
 





Flow cytometry measurements were done in a BD FACS CantoTM II System (BD 
Bioscience, Cat. No. 338962) or BD FACS CantoTM (BD Bioscience, Cat. No. 657338). Flow 
cytometry sorting was performed in a BD FACS AriaTM II Flow Cytometer and BD FACS 
AriaTM III Flow Cytometer (BD Bioscience, 643180). Flow cell analysis was done using 
the software FlowJo version 9 and FlowJo version X (Tree Star Inc.).  
 
APOPTOSIS ASSAY – CASPASE 3 ACTIVATION 
Cell death by apoptosis was assessed via flow cytometry by staining for pan-Caspases. 
Cells were stained using the CaspGLOWTM Red Active Caspase Staining Kit (BioVision, 
K190-25) following the manufacturers instructions. Briefly, cells were incubated with 
the pan-Caspase inhibitor Red-DEDV-FMK that binds irreversibly to active Caspases. 
 
PRIMARY MOUSE CELL CULTURE  
Sorted or MACS purified B-cells were cultured in RPMI 1640 medium supplemented 
with 10% heat inactivated FBS, non-essential amino acids, HEPES, sodium-pyruvate, -
mercaptoethanol, penicillin/streptomycin and L-glutamine (all Gibco). 
 
In vitro proliferation assay 
Sorted B1a-like cells (CD19+ B220lo CD5+ and eGFP+ for the samples expressing the 
IKK2ca knock-in) or B2-like cells (CD19+ B220hi and eGFP+ for the samples expressing 
the IKK2ca knock-in) were pre-labelled with the eBioscienceTM Cell Proliferation Dye 
eFluorTM 450 (Thermo Fisher Scientific, Cat. No. 65-0842-85) following manufacturers 
instructions. Ex vivo cell proliferation was evaluated under resting conditions or in the 
presence of different concentrations of anti-IgM (Jackson ImmunoRe- search 
Laboratories) or the soluble B-cell activating factor (BAFF).  
 
Cell viability was assed by flow cytometry using Annexin-V (BD Bioscience) and 7AAD to 
identify viable (Annexin-V- 7AAD-), apoptotic (early apoptotic Annexin-V+ 7AAD- and 
late apoptotic Annexin-V+ 7AAD+) and dead cells (Annexin-V- 7AAD+). Additionally, 
123count eBeads counting beads (Thermo Fisher Scientific, Cat. No. 01-1234-42) were 
used calculate the total cell numbers using flow cytometry, following the manufacturer 
instructions. Cell proliferation was assessed using the FlowJo Proliferation analysis 
Package (Tree Star Inc.).  
  





Table 7. Fluorescently coupled antibodies used for flow cytometry 
Antigen Clone Manufacturer 
AA4.1 AA4.1 eBioscienceTM 
B220 RA3-6B2 BioLegends 
CD138 281-2 BD Bioscience 
CD19 MB19-1 eBioscienceTM 
CD1d 1B1 eBioscienceTM 
CD21/CD35 eBio8D9 eBioscienceTM 
CD23 B3B4 eBioscienceTM 
CD25 PC61.5 eBioscienceTM 
CD38 90 BioLegend 
CD4 RM4-5 BioLegend 
CD44 IM7 eBioscienceTM 
CD5 53-7.3 eBioscienceTM 
CD62L MEL-14 eBioscienceTM 
CD62L MEL-14 BioLegend 
CD69 H1-2F3 eBioscienceTM 
CD8-alpha 53-6.7 eBioscienceTM 
CD80 16-10A1 eBioscienceTM 
CD86 GL1 eBioscienceTM 
CD95 Jo2 BD Bioscience 
cKIT 2B8 eBioscienceTM 
CXCR5 2G8 BD Bioscience 
CXCR5 2B11/CXCR4 BD Bioscience 
F4/80 CI:A3-1 AbD serotec 
GL7 GL7 eBioscienceTM 
Gr-1 RB6-8C5 eBioscienceTM 
Icos 7E.17G9 eBioscienceTM 
Ig-kappa 187.1 BD Bioscience 
Ig-lambda R26-46 BD Bioscience 
Ig-lambda5 LM34 BD Bioscience 
IgA 11-44-2 eBioscienceTM 
IgD 11-26c/11-26 eBioscienceTM 
IgG1 X56 eBioscienceTM 
IgG1 10.9 BD Bioscience 
IgG2a m2a-15F8 eBioscienceTM 
IgM II/41 eBioscienceTM 
Integrin alpha-4 (CD49d) 9C10 BD Bioscience 
Integrin alpha-5 (CD49e) 5H10-27 PharMingen 
Integrin alpha-L (CD11a) M17/4 eBioscience 
Integrin alpha-M (CD11b) M1/70 eBioscienceTM 
Integrin alpha-X (CD11c) N418 eBioscienceTM 
Integrin beta-1 (CD29) HMbeta1-1 BioLegend 
Integrin beta-2 (CD18) C71/16 BD Bioscience 
Integrin beta-3 (CD61) 2C9.G3 eBioscience 
Integrin beta-7 FIB504 eBioscienceTM 
 





Table 7 (continued). Fluorescently coupled antibodies used for flow cytometry 
Antigen Clone Vendor 
MHC-II M5/114.15.2 eBioscienceTM 
PD-1 J43 eBioscienceTM 
Siglec-F E50-2440 BD Bioscience 
TCR-beta H57-597 eBioscienceTM 
 
Table 8. Fluorescently couples antibodies used for intracellular flow cytometry 
Antigen Clone Vendor 
BCL6 K112-91 BD Bioscience 
Blimp1 5E7 BD Bioscience 
IRF4 3E4 eBioscienceTM 
human TCL1 eBio1-21 eBioscienceTM 
human TCL1 27D6/20 MBL 
Zap70 1E7.2 eBioscienceTM 
 
IMMUNOGLOBULIN HEAVY-CHAIN JOINING-GENE SEGMENT USAGE 
As an initial step to determine the clonality of the CD5+ B1a-like cells, the usage of the 
BCR JH-gene segment was assessed. A PCR was designed to amplify the recombined 
variable (VH)-, diversity (DH)- and JH-gene segments (VDJ) of the IgH.  
 
A degenerate forward primer binds up-stream of the VH-gene segments and reverse 
primer binds at the 3´ end of the JH4-gene segment (See Table 5 for BCR amplification 
primer sequences). The different amplified PCR VDJ IgH rearrangements can be 
visualized by separating them by size by agarose electrophoresis: rearrangements into 
JH1 will produce amplicon of 1.6 Kb size, while rearrangements into JH2, JH3 and JH4 
will have a size of 1.3 Kb, 1 Kb and 500 bp, respectively (Figure S 31, lane 5).  
 
The PCR reaction was done using Phusion Taq (2U/L, Thermo Scientific F-530S, 
Germany), the 5X Phusion GC Buffer, 3% DMSO, 0.2mM dNTPs (Takara, US), 1.5mM 
MgCl2, 0.16M of each primer, Ampuwa water and 150ng of genomic DNA. Thermal 
cycling conditions were: 
Initial denaturation 98° C x 10 min  
Denaturation  98° C x 10 s 
X 35 cycles Annealing 69° C x 20 s 
Extension 72° C x 60 s 
Final extension 72° C x 10min  





All PCRs were performed in a thermal cycler Biometra TProfessional Trio (Analytik Jena, 
Germany). 
 
IMMUNOGLOBULIN HEAVY-CHAIN VDJ CLONING  
To further assess CD5+ B1a-like tumours clonality, the IgH VDJ rearrangements were 
amplified, subsequently cloned into destination vectors, and finally sequenced using 
Sanger sequencing.  
 
The IgH VDJ rearrangement was amplified using a forward primer that binds up-stream 
the most commonly used VH-gene segments. Rearrangements into JH1 and JH4-gene 
segments were amplified using a the reverse primer JH1/4 Arnaout, while 
rearrangements into JH2 and JH3-gene segments were amplified using primers JH2/3 
Arnaout and JH2 Arnaout (modified from [246]) (Figure S 32A) [247].  
 
Table 9. Primers used for amplifying the B-cell receptor 
Primer name Sequence (5´-3’ orientation) Amplicon size 
MsVhE AH TCGAGTTTTTCAGCAAGATGAGGTGCAGCTGCAGGAGTCTGG  
JH1/4 Arnaout CTTACCTGAGGAGACGGTGAC 350bp 
JH2/3 Arnaout AGGACTCACCTGAGGAGAC 350bp 
JH2 Arnaout AGGACTCACCTGCAGAGAC 350bp 
JH4rev CTGAGGAGACGGTGACTGAGG 
JH1   1.6kb 
JH2   1.3kb 
JH3   1.0kb 
JH4   0.5kb 
 
For each PCR reaction, 100ng of genomic DNA were amplified using 1 U of Phusion® 
High-Fidelity DNA Polymerase (2U/L, Thermo Scientific F-530S) with the 5X Phusion 
HF Buffer (Thermo Scientific), 1.5mM MgCl2, 0.2mM dNTPs (Takara), 0.16M of each 
primer in PCR-grade water (Ampuwa). Thermal cycling conditions were as follows: 
Initial denaturation 98° C x 10 min  
Denaturation  98° C x 10 s 
X 35 cycles Annealing 69° C x 20 s 
Extension 72° C x 60 s 
Final extension 72° C x 10min  
 
A small sample of the PCR product was run in an agarose gel to qualitatively determine 
the success of the reaction. The rest of the sample was column purified using the 





QIAquick PCR purification kit (Qiagen, 28106) to remove for any primer dimers or 
excess dNTPs following manufacturers instructions. Samples were eluted in Qiagen 
elution buffer. Purified PCR samples were later quantified using the Quibit dsDNA High 
Sensibility (HS) kit (Thermo Fisher Scientific). 
 
QUICK AND CLEAN CLONING (QC CLONING) OF THE B-CELL RECEPTOR 
Quick and clean cloning (QC cloning) was used to clone the amplified VDJ 
rearrangements into JH1, JH2, JH3 or JH4 catch sequence (CS) specific destination 
vectors [248].  
 
All vectors had similar structure: A CS for the specific JH-gene segments. The lacZ- gene 
flanked by binding sites for the type-II restriction enzyme BsmBI, used for blue/white 
screening. The cDNA of the eco47IR enzyme divided in two parts: the 5`sequence (part 
1) and the 3`sequence (part 2) divided by the insert targeting site and Lac-Z screening 
marker. In the absence of this insert, the cDNA of the enzyme would be reconstituted 
and function as a suicide gene. The ampicillin resistance gene that allows for positive 
selection of transfected bacteria (Vector maps and sequences can be found in the 
Supplementary material).  
 
Destination vectors (see Supplemental methods) were digested with the type-II 
restriction enzyme BsmBI (New England BioLabs Inc., R0580S) to remove the lacZ- 
sequence. Fragments were separated by agarose electrophoresis. The linearized 
backbone was purified using the QIAquick Gel Extraction Kit (Qiagen, 28706), and later 
quantified using the Quibit dsDNA High Sensibility (HS) kit (Thermo Fisher Scientific). 
 
For the QC cloning, 15ng of the linearized backbone and 25ng of the corresponding 
purified amplicon were mixed in a 0.2mL PCR tube in a final volume of 20L. The DNA 
Polymerase I Large (Klenow) Fragment (New England BioLabs Inc., M0210S) was used 
as the 3’ to 5’ exonuclease in combination with the NEB2 buffer. The mix was incubated 
2 hours at 37° C in a Biometra Tprofessional Trio (Analytik Jena, Germany) thermal 
cycler.  
 
Five l of the reaction were transformed into 100l of commercial chemically 
competent NEB® 10-beta Competent E. coli (High Efficiency), DH10 (New England 
BioLabs Inc., C3019I). Either 10% and 90% or 100% of the transformation was plated 





on LB agar plates with ampicillin and X-gal (all Sigma-Aldrich) agar plates and incubated 
over night at 37° C and blue/white colonies were counted. An average of 10 colonies per 
JH-gene segment were picked, grown overnight in 2ml 96-well plate with LB media with 
ampicillin and sent for processing and Sanger sequencing (BigDye 3.1 chemistry, 
Applied Biosystems) to Eurofins MWG Operon in Martinsried, Munich.  
 
Sequencing results were analysed with SeqMan Pro (DNASTAR V15.0). Backbone 
sequences were trimmed, sequences were aligned using the Pro Assembler (Match size 
250bp, minimum match percentage 99) and contigs with identical sequences were 
annotated. The VDJ insert sequence was later analysed with IMGT/HighV-QUEST 
(Immuno Genetics) [249]. CDR3 sequences of productive rearrangements were 
compared between the different clones from the same sample. VH-gene segments were 
also compared to germ-line. If the sequence differed > 5% from the germ-line, the 
samples were considered to have undergone somatic hypermutation.  
 
III.1 STATISTICAL ANALYSIS 
Total cell numbers and other calculations were performed using Excel (Microsoft Office 
2011). Flow cytometry contour plots were generated using FlowJo version 9 or version 
10 (Tree Start Inc.). Bar charts and heatmaps were generated with GraphPad Prism 
version 7 (GraphPad Software). Statistical analysis was calculated using GraphPad 
Prism. Normal distribution of the samples was assessed using the D’Angostino and 
Pearson normality test. Statistical analysis for normally distributed populations was 
calculated using T-test or One-way ANOVA (Holm-Sidak’s multiple comparisons test), 
while the Kurskal-Wallis non-parametric test (Dunn’s multiple comparison test) was 
calculated for samples without a normal distribution. Significance lower than p<0.05 
was is indicated in figures and legends. 
 
Illustrations and figures where prepared using Adobe Illustrator (Adobe Systems). 
 
 







IV.1 LOSS OF A20 IN COMBINATION WITH ENHANCED EXPRESSION OF THE 
ALTERNATIVE NF-B REGULATOR NIK IN B-CELL BIOLOGY 
 
Initially, I wanted to combine two different genetic alterations, loss of A20/Tnfaip3 and 
activation of alternative NF-B pathway, to model aspects of splenic marginal zone 
(sMZL) lymphoma in mice. Genetic abnormalities in both NF-B related pathways have 
been observed in sMZL patient samples [183]. Moreover, loss of A20 and deregulation of 
the alternative NF-B pathway have been proposed as candidates in sMZL. By 
combining them in an in vivo model, I wanted to address the question of whether 
mutations in A20 and the TRAF3/NIK arm can cooperate in sMZL development.  
 
I made use of the available conditional mouse strain lines A20FL, R26-StopFLNik and 
CD19cre to generate mice with B-cells that mimic the genetic alterations that have been 
identified in sMZL patients. Using the A20FL mouse line I could inactivate one (A20F/wt) 
or both alleles of A20 (A20F/F) in B-cells in vivo [240]. Activation of the alternative NF-B 
pathway, by loss of BIRC3 and TRAF3 or gain of MAP3K14, could be mimicked with the 
gain of one allele of a conditional NIK transgene (NIK-tg) knocked into the ROSA26 locus 
[89]. For that purpose, I used the R26-StopFLNik mouse strain that expresses NIK after 
Cre-mediated excision of a loxP-flanked STOP cassette, always heterozygously (NIK-tg: 
R26-StopFLNikI/wt). B-cells that express the NIK-tg after Cre-mediated recombination 
also express the enhanced green fluorescent protein (eGFP) as a reporter, located after 
an internal ribosomal entry site (IRES) sequence 3’ from the NIK cDNA, thus allowing 
the tracking of the recombined cells. To conditionally inactivate or activate my genes of 
interest, I used the CD19cre mouse strain [241]. The Cre recombinase is expressed as 
knock-in under control of the endogenous CD19 promoter instead of endogenous CD19, 
thus CD19creI/wt mice are heterozygous for CD19cre. In the CD19cre mice, the Cre 
recombinase expression starts as early as the pro-B cell stage and recombination can be 
observed from the pre-B cell stage onwards. 
 





IV.1.1 HOMOZYGOUS LOSS OF A20 IN COMBINATION WITH ALTERNATIVE NF-B 
ACTIVATION LEADS TO MASSIVE REDUCTION OF B-CELLS IN SPLEENS OF YOUNG 
MICE 
The constitutive expression in B-cells of an additional allele of NIK (NIK-tgI/wt 
CD19creI/wt, from now on referred to as NIK-tg CD19cre) leads to slightly bigger spleens 
and a tendency for increased B-cell numbers (Figure 4A and B) [89]. The additional loss 
of one allele of A20 (A20F/wt NIK-tgI/wt CD19creI/wt, from now on referred to as A20F/wt 
NIK-tg CD19cre) leads to a higher splenic cellularity, accompanied by a 10% increase in 
B-cell percentage and increase in total cell numbers (Figure 4A and B). However, loss of 
the second allele of A20 (A20F/F NIK-tgI/wt CD19creI/wt, from now on referred to as 
A20F/F NIK-tg CD19cre) surprisingly results in a significant reduction of B-cell 
percentage and B-cell numbers (Figure 4B), although spleen mass and cellularity are 
increased compared to wild type and NIK-tg CD19cre controls (Figure 4A).  
 
Interestingly, the percentage and cell numbers of ex vivo isolated B-cells expressing the 
eGFP transgene reporter are also significantly reduced in the A20-/-;NIK+ B-cells 
compared to the NIK+ alone or A20+/-;NIK+ ex vivo B-cells (Figure 4C). Moreover, the 
number of ex vivo eGFP negative B-cells in the A20F/F NIK-tg CD19cre mice is higher 
than that observed in the NIK-tg CD19cre or A20F/wt NIK-tg CD19cre age matched 
controls (Figure 4C) suggesting a negative selection of the eGFP+;A20-/-;NIK+ cells.  
 
Given the strong ex vivo phenotype observed on B-cells when the absence of A20 is 
combined with activation of the alternative NF-B pathway, I decided to focus my 
attention on the diminished ex vivo B-cell numbers observed.  
 






Figure 4. Reduced A20-/-;NIK+ B-cell numbers in spleen of young mice 
Ex vivo analysis of B-cells from spleens of young mice using flow cytometry. (A) Spleen mass in 
milligrams and splenocytes cell numbers. Contour plots depict percentages and bar charts indicate cell 
numbers for (B) B-cells and (C) eGFP reporter expressing B-cells. All flow cytometry plots are 
representative of at least 2 experiments. Bar charts depict medians and the values are indicated below 
each histogram. Statistical analysis was done using One-way ANOVA (*** p<0.001, **** p<0.0001) or 
Kruskal-Wallis (¥ p<0.05).  
eGFP (enhanced green fluorescent protein), pos. (positive), neg. (negative), B-cells (B220+), eGFP pos. 
(B220+ eGFP+), eGFP neg. (B220+ eGFP-). 
 
  





IV.1.2 HOMOZYGOUS LOSS OF A20 IN COMBINATION WITH ALTERNATIVE NF-B 
ACTIVATION LEADS TO SYSTEMIC DEPLETION OF B-CELLS IN SECONDARY 
LYMPHOID ORGANS OF YOUNG MICE 
Since the spleens of young A20F/F NIK-tg CD19cre mice present a significant loss of B-
cells, I proceeded to analyse other secondary lymphoid organs to determine whether the 
observed loss of B-cells was a general phenomenon in these mice.  
 
The lymph nodes (LN) cellularity, normalized to 1 LN, presented a tendency for higher 
numbers in the A20F/F NIK-tg CD19cre animals, compared to the other genotypes 
analysed (Figure 5A). The loss of one allele of A20 in a NIK-tg CD19cre background led 
to an increase in B-cell percentages, but the cell numbers remained constant. However, 
the percentages and total cell number of B-cells when the second allele of A20 was lost 
were significantly reduced (Figure 5B). The percentage and number of ex vivo eGFP 
expressing B-cells were also significantly reduced in the A20F/F NIK-tg CD19cre mice.  
 
Similarly, the ex vivo analysis of the mesenteric lymph nodes (mLN) revealed a massive 
reduction in B-cell percentages and numbers in A20F/F NIK-tg CD19cre mice (Figure S 
1B). The loss of the second allele of A20 lead to almost absent B-cells in the mLN, 
decreasing from 12.3 million A20+/-;NIK+ B-cells to less than 1 million B-cells in the 
A20F/F NIK-tg CD19cre mice (Figure S 1B). The eGFP expressing cells were almost 
completely absent in the A20F/F NIK-tg CD19cre mice (Figure S 1C). 
 
Likewise, the ex vivo analysis of B-cells in the Peyer’s patches (PP) also revealed a 
drastic reduction in B-cell percentages and cell numbers in the A20F/F NIK-tg CD19cre 
compared to the other mice analysed (Figure S 2B). Of the few B-cells observed in these 
mice, only 20-30% expressed the eGFP reporter (Figure S 2C). Moreover, the total 
number of cells in the PP of the A20F/F NIK-tg CD19cre mice was significantly lower 
than the observed for A20F/wt NIK-tg CD19cre mice (Figure S 2A). 
 
Finally, the ex vivo analysis after the lavage of the peritoneal cavity of the A20F/F NIK-tg 
CD19cre mice also revealed a significant reduction in B-cell percentages and total cell 
numbers compared to A20F/wt NIK-tg CD19cre and the wild type controls (Figure 6B). 
It is remarkable that the increase in B-cell numbers, and cellularity of the lavage, 
observed from the NIK-tg CD19cre to the A20F/wt NIK-tg CD19cre is lost when the 
second allele of A20 is ablated (Figure 6A and B). Moreover, the percentage and thereof 





number of ex vivo B-cells expressing the eGFP reporter in the peritoneal cavity of the 
A20F/F NIK-tg CD19cre mice is extremely low, 10%, compared to other organs (Figure 
6C). 
 
Interestingly, the negative effect observed in ex vivo A20-/-;NIK+ B-cells in the 
peritoneal cavity affects all different B-cell subsets but to different extents. The ex vivo 
analysis of the NIK-tg CD19cre mice showed that 50% of the B-cells belong to the B2 
subset, and the other 50% to the B1 subset, but it only reflects in a one-fold increase in 
cell numbers compared to wild type control ( Figure 7A). The additional loss of one 
allele of A20, favoured the B1 subset and in particular the B1b subset ( Figure 7A and B). 
 
 
Figure 5. Reduced A20-/-;NIK+ B-cell numbers in lymph nodes of young mice  
Ex vivo analysis of B-cells from lymph nodes of young mice using flow cytometry, normalized to one 
lymph node. (A) Cell numbers for one lymph node. Contour plots depict percentages and bar charts 
indicate cell numbers for (B) B-cell and (C) eGFP positive B-cell. All flow cytometry plots are 
representative of at least 2 experiments. The NIK-tg CD19cre contour plots do not belong to the same 
experiment as A20-deficient NIK-tg CD19cre plots. Bar charts depict medians and the values are 
indicated below each histogram. Statistical analysis was done using One-way ANOVA (** p<0.01, **** 
p<0.0001). 
LN (lymph node), eGFP (enhanced green fluorescent protein), pos (positive), B-cells (B220+) and eGFP 

















































































































































































The loss of the second allele of A20 in B-cells in the peritoneal cavity affects drastically 
the B1 subset, and specially the B1b subset ( Figure 7B). Although the B2 subset is also 
massively reduced in A20F/F NIK-tg CD19cre mice, it corresponds to the majority of B-
cells found in this compartment. However, the near absence of B1-cells in the A20F/F 
NIK-tg CD19cre mice is interesting, since they are self-replenishing population and have 
a different developmental origin than the B2-cells [250]. This phenomenon could point 
to a negative cooperation between A20 and activation of NIK in alternative NF-B 




Figure 6. Reduced A20-/-;NIK+ B-cell numbers in peritoneal cavity of young mice 
Ex vivo analysis of B-cells in peritoneal cavity of young mice using flow cytometry, after lavage. (A) 
Peritoneal cavity cell numbers. Contour plots depict percentages and bar charts indicate total cell 
numbers for (B) B-cells and (C) eGFP positive B-cells. The NIK-tg CD19cre contour plots do not belong 
to the same experiment as A20-deficient NIK-tg CD19cre plots. Bar charts depict medians and the 
values are indicated below each histogram. Statistical analysis was done using One-way ANOVA (*** 
p<0.001, **** p<0.0001) and statistical significance when P<0.5 is indicated. 









































































































































































 Figure 7. Reduced A20-/-;NIK+ B1 population in peritoneal cavity of young mice 
Ex vivo analysis of B-cells subsets in peritoneal cavity of young mice using flow cytometry. Contour 
plots depict the percentages and bar charts indicate total cell numbers for (A) B2 and B1 B-cell subsets, 
and (B) B1a and B1b B1 subsets. All flow cytometry contour plots are representative of at least 2 
experiments. The NIK-tg CD19cre contour plots do not belong to the same experiment as A20-deficient 
NIK-tg CD19cre plots. Bar charts depict medians and the values are indicated below each histogram. 
Statistical analysis was done using One-way ANOVA (* p<0.05, ** p<0.01, **** p<0.0001). 
PC (peritoneal cavity), B-cells (CD19+), B2 (CD19+ B220hi), B1 (CD19+ B220lo), B1a (CD19+ 
B220lo CD5+) and B1b (CD19+ B220lo CD5-),. 
The percentage of ex vivo B-cells observed in lymph nodes (Figure 5), mesenteric lymph 
nodes (Figure S 1), Peyer’s patches (Figure S 2) and peritoneal cavity (Figure 6 and  
Figure 7) for the A20F/F NIK-tg CD19cre mice was significantly lower compared that of 
A20F/wt NIK-tg and NIK-tg alone. Furthermore, the low percentages of ex vivo 
eGFP+;A20-/-;NIK+ B-cells observed suggests a systemic negative effect of combining 
loss of A20 with gain of NIK in B-cells.  






To determine whether the detrimental effect of strong NF-B activation by the loss of 
the second allele of A20 in cooperation with an extra copy of NIK-tg in B-cells was due to 
a developmental block in B-cell development, as it appears to be for the B1-subset, I first 
proceeded to characterize the different stages of B-cell development. 
 
IV.1.3 ROLE OF LOSS OF A20 IN COMBINATION WITH ACTIVATION OF THE 
ALTERNATIVE NF-B PATHWAY IN B-CELL DEVELOPMENT 
IV.1.3.1 Homozygous loss of A20 in combination with alternative NF-B activation 
leads to a loss of mature B-cells in spleen of young mice  
In spleens of young mice, there is an increase in the percentage and numbers of ex vivo 
A20+/-;NIK+ mature B-cells compared to NIK+ only mature B-cells (Figure 8A and B). 
This B-cell expansion in the A20F/wt NIK-tg CD19cre mice is more pronounced in the 
MZB population (two-fold increase in MZB-cell numbers compared to the NIK-tg 
CD19cre mice, Figure 8C and E). Nonetheless, there is also a clear follicular B-cell (FOB) 
expansion (Figure 8D). The combination of both heterozygous loss of A20 in 
combination with the activation of the alternative NF-B pathway by overexpression of 
NIK-tg cooperate in expanding the MZB pool up to 10 million cells (three-fold compared 
to wild type), as originally hypothesized (Figure 8C and E).  
 
Loss of the second A20 allele in NIK+ B-cells leads to lower ex vivo mature B-cell 
percentages and a significant reduction in ex vivo cell numbers (Figure 8A and B) 
compared to the A20+/-;NIK+ mature B-cells. Both FOB and MZB populations are 
strongly affected. Interestingly, almost all A20-/-;NIK+ MZB-cells (CD21hi CD1dhi) 
express the eGFP reporter, were as only 8 out of the 11 million of FOB-cells express the 
eGFP reporter (Figure 8D and E).  
 






Figure 8. Reduced mature B-cells in spleens from A20F/F NIK-tg CD19cre mice 
Ex vivo analysis of B-cells from spleens of young mice using flow cytometry. Contour plots depict 
percentages and bar chart indicate total cell numbers for (A, B) immature and mature B-cell, and (C, D, 
E) follicular B-cells, marginal zone B-cells and eGFP positive cells. All flow cytometry plots are 
representative of at least 2 experiments. Bar charts depict medians and the values are indicated below 
each histogram. Statistical analysis was done using One-way ANOVA (** p<0.01, **** p<0.0001) or 
Two-tailed paired T-test (¥¥¥ p<0.001). 
eGFP (enhanced green fluorescent protein), B-cells (B220+), Mature (B220+ AA4.1-), FOB (Follicular B-
cell, B220+ AA4.1- CD21int CD1dint), and MZB (Marginal Zone B-cell, B220+ AA4.1- CD21hi CD1dhi). 
 
 
It is important to keep in mind that the ex vivo expression of the markers used to define 
the mature B-cell population (ie. CD21, CD1d and CD23), especially in A20-/-;NIK+ B-
cells, is directly or indirectly modified by NF-B activation (Figure 8C and Figure S 3A). 





Ex vivo eGFP+;A20-/-;NIK+ mature B-cells have intermediate expression levels of CD21 
accompanied with higher levels of CD1d compared to eGFP+;NIK+ or eGFP+;A20+/-
;NIK+ mature B-cells (Figure S 3A). On the other hand, the expression of the surface 
marker CD23, a known NF-B target gene, is lower in ex vivo eGFP+;A20-deficient;NIK+ 
mature B-cells than in eGFP+;NIK+ or eGFP+;A20+/-;NIK+ mature B-cells (Figure S 3A).  
 
MZB-cells are characterized for having a higher expression of CD1d and CD21, and 
lacking the expression of CD23 [251]. The altered expression patter of CD23 and CD1d 
in ex vivo A20-deficient NIK-expressing mature B-cells could be therefore representative 
of MZ-like phenotype (Figure S 3A). However, using alternative MZB-cell gating 
strategies the MZB population seems to be absent in A20-deficient NIK-expressing 
mature B-cells (Figure S 3B), making it difficult to properly define this population. 
 
The loss of the second allele of A20 in combination with the expression of an extra copy 
of NIK leads to a clear failure to produce or maintain mature B-cells in A20F/F NIK-tg 
CD19cre mice and it affects both the FOB and the MZB compartment. To further 
understand if the reduced ex vivo B-cell numbers are result of a developmental block I 
analysed the immature B-cell compartment in the spleen of young mice.  
 
IV.1.3.2 Homozygous loss of A20 in combination with alternative NF-B activation 
drives a faster transition through the immature B-cell stages in the spleen 
of young mice  
The expression of a NIK transgene specifically in B-cells leads to an increase of mature 
B-cell numbers that is further enlarged by the additional loss of one allele of A20. 
However, the further loss of the second allele of A20 leads to a completely different 
scenario, where B-cells are negatively affected. To identify whether this negative effect 
is due to a developmental block in B-cells, I further characterized the immature B-cell 
subsets in the spleen of young mice. 
 
The number of ex vivo immature B-cells and eGFP expressing immature B-cells in the 
different NIK-tg and A20 compound mice are all similar (Figure 9B). However, the loss 
of A20 affects the transitional 1 (T1) B-cells subset by lowering the percentage and total 
cell numbers in an A20 dose dependent manner (Figure 9C and D) in a NIK-tg 
background.  
 





In particularly, there is a significant reduction of the T1 subset of ex vivo A20-/-;NIK+ 
immature B-cells compared to wild type controls, accompanied by a slight increase in 
the transitional 2 (T2) subset cell numbers (Figure 9D). Moreover, this is accompanied 
by a significant reduction in eGFP positive T1 B-cells compared to A20F/wt NIK-tg 
CD19cre mice (Figure 9E). Only 20% of A20-/-;NIK+ T1 B-cells (0.2 million / 1 million 
cells) actually expresses eGFP where as about 66% of the T2 B-cells (1.8 million / 2.9 
million cells) expresses the eGFP reporter (Figure 9E).  
 
Although the expression of surface protein CD23 is also used for defining the different 
transitional stages of immature B-cells, the ex vivo expression levels of CD23 are 
relatively similar between NIK+ alone, A20+/-;NIK+ or A20-/-;NIK+;eGFP+ immature B-
cells (Figure S 4A). Interestingly, when defining immature B-cells by CD23 expression 
alone, CD23 low transitional 1 (T1CD23) and CD23 high transitional 2 (T2CD23) [252], 
there is a increase in the percentage of T2CD23 B-cells in an A20-loss dependent manner 
(Figure S 4B). This translates into significantly lower T1CD23 B-cell numbers in the 
A20F/F NIK-tg CD19cre mice compared to wild type controls, accompanied by 
significantly lower eGFP positive T1CD23 B-cells compared to NIK-tg CD19cre mice 
(Figure S 4E).  
 
Alternatively, immature B-cells could be defined by the expression of the CD21 protein 
alone into CD21 low transitional 1 (T1CD21) and CD21 high transitional 2 (T2CD21) B-cells 
[252]. Although it has been reported that CD21 is also an NF-B target gene, the ex vivo 
expression levels of CD21 are also relatively similar between NIK+ alone, A20+/-;NIK+ 
or A20-/-;NIK+;eGFP+ immature B-cells (Figure S 4A). In this case there is also an 
increase in the percentage of T2CD21 B-cells in an A20-loss dependent manner (Figure S 
4C). Moreover, this is accompanied by significantly lower fraction of eGFP positive cells 
for the A20-/-;NIK+ T2CD21 B-cells (Figure S 4C). However, the observed T1CD21 and 
T2CD21 B-cell numbers are similar for all the genotypes analysed.  
 
Finally, the combination of both CD21 and CD23 expression to define the transitional 
immature B-cells leads to similar increased transitional 2 (T2) percentages in an A20-
loss dependent manner (Figure S 4D). Although this translates into similar T1 and T2 B-
cell numbers for all the genotypes analysed, there is a significant decrease in eGFP 
positive cell percentages and cell numbers in the T1 population for the A20F/F NIK-tg 
CD19cre mice compared to the A20F/wt NIK-tg CD19cre mice (Figure S 4D and G).  
 






Figure 9. Reduced Transitional 1 immature B-cells in A20F/F NIK-tg CD19cre mice 
during B-cell development in the spleen 
Ex vivo analysis of immature B-cells from spleen of young mice using flow cytometry. Contour plots 
depict percentages and bar charts indicate total cell numbers for (A) immature and eGFP positive 
immature B-cells, (B, C) transitional B-cells and (D) eGFP positive transitional B-cells. All flow cytometry 
plots are representative of at least 2 experiments. Bar charts depict medians and the values are 
indicated below each histogram. Statistical analysis was done using One-way ANOVA (p< 0.05, ** 
p<0.01). 





Figure 9 (continued) Immature (B220+ AA4.1+), eGFP (enhanced green fluorescent protein), T1 
(Transitional 1, B220+ AA4.1+ IgM+ CD23-), T2 (Transitional 2, B220+ AA4.1+ IgM+ CD23+), T3 
(Transitional 3, B220+ AA4.1+ IgMint CD23+) and eGFP pos (eGFP+). 
 
 
Although the total immature B-cells numbers seem not affected by the combination of 
NIK overexpression and loss of A20, when A20 is homozygously inactivated the 
transition from T1 to T2 immature B-cells balance shifts towards the T2 subset. Taking 
together the classical and all the alternative transitional immature B-cell definitions it is 
clear that homozygous loss of A20 in combination with overexpression of NIK leads to a 
significant reduction of eGFP expressing T1 B-cells (Figure 9and Figure S 4). 
 
IV.1.3.3 Homozygous loss of A20 in combination with alternative NF-B activation 
reduces the recirculating/mature B-cell pool in the bone marrow of young 
mice  
To further address if the negative effect of A20 ablation in combination with gain of NIK 
transcends to the early B-cell development in the bone marrow, I proceeded to analyse 
the different early B-cell stages in the bone marrow of young animals. Following to the 
Hardy classification, B-cells development in the bone marrow starts from a CLP that 
after receiving the proper stimuli and activating the right transcription program 
commits to the B-cell lineage [50]. B-cell development starts with the pro-B cell, where 
it undergoes the immunoglobulin heavy locus rearrangement, followed by pre-BCR 
expression during the pre-B cell stages. The final stage in the bone marrow terminates 
with the immature B-cell where the BCR is tested for autoreactivity. Some immature B-
cell can mature in the bone marrow, but most migrate to peripheral secondary lymphoid 
organs, such as the spleen, where they mature to MZB- and FOB-cells. B-cells enter the 
circulation, scan the entire organism for foreign antigens and can migrate back to the 
bone marrow as mature/recirculating B-cells [51]. 
 
The ex vivo bone marrow cell numbers for the different genotypes analysed are all 
similar (Figure 10A). There is a trend for slightly lower percentages and cell numbers of 
B-cells in the bone marrow from A20F/wt NIK-tg CD19cre to A20F/F NIK-tg CD19cre 
mice, although not statistically significant (Figure 10B and C). The proportion of ex vivo 
eGFP expressing B-cells in the bone marrow was reduced from 45% in the A20F/wt 
NIK-tg CD19cre mice to 18% in the A20F/F NIK-tg CD19cre mice (Figure 10D). 
Accordingly, there was a significant reduction in ex vivo eGFP expressing B-cell numbers 





although the number of ex vivo eGFP negative B-cells remained constant among the NIK-




Figure 10. Reduced eGFP+;A20-/-;NIK+ B-cells in bone marrow from young mice 
Ex vivo analysis of B-cells from bone marrow of young animals using flow cytometry. (A) Bone marrow 
cell numbers for one leg after red blood cell lysis. Flow cytometry contour plots depict percentages and 
bar charts indicate total cell numbers for (B, C) B-cells and (D, E) eGFP expressing B-cells (B220+ 
eGFP+). Flow cytometry plots are representative of at least 2 experiments, except for NIK-tg CD19cre 
mice. The NIK-tg CD19cre contour plots do not belong to the same experiment as A20-deficient NIK-tg 
CD19cre plots. Bar charts depict medians and the values are indicated below each histogram. Statistical 
analysis was done using One-way ANOVA (**** p<0.0001). 
BM (bone marrow), eGFP (green fluorescent protein), B-cells (B220+), eGFP pos. (eGFP positive B-






























































































































































































Figure 11. Reduced mature/recirculating A20-/-;NIK+ B-cells in bone marrow 
Ex vivo analysis of B-cells from bone marrow of young animals using flow cytometry. Flow cytometry 
contour plots depict percentages and bar chart indicate percentages of eGFP positive cells for (A) 
mature/recirculating B-cells, (B) immature B-cells and (C) pro-B cells and pre-B cell. (D) Bar charts 
indicate cell numbers for pro-B, pre-B, immature and mature/recirculating B-cells. The median 
percentage values of immature, pre-B and pro-B are indicated on top of each contour plot. Flow 
cytometry plots are representative of at least 2 experiments, except for NIK-tg CD19cre mice. The NIK-
tg CD19cre contour plots do not belong to the same experiment as A20-deficient NIK-tg CD19cre plots. 
Bar charts depict medians and the values are indicated below each histogram. Statistical analysis was 
done using One-way ANOVA (* p<0.05, *** p<0.001, **** p<0.0001). 
BM (bone marrow), eGFP (enhanced green fluorescent protein), mature/recirculating (B220+ IgD+), 
eGFP pos (eGFP+), immature (B220+ IgM+ IgD-), pro-B (B220+ IgD/IgM- CD25+ cKIt-) and pre-B (B220+ 
IgD/IgM- CD25- cKit+). 
 
  





The ex vivo bone marrow analysis revealed that the ex vivo mature/recirculating B-cells 
are the main population affected by the loss of A20 in combination with the 
overexpression of NIK.  
 
First, there is a significant reduction in the percentage of mature/recirculating B-cells 
from 40% in the NIK-tg CD19cre alone or A20F/wt NIK-tg CD19cre to 9% in the A20F/F 
NIK-tg CD19cre mice (Figure 11A). Moreover, the percentage of ex vivo eGFP-expressing 
mature/recirculating cells in the A20F/F NIK-tg CD19cre mice is reduced to 62%. The 
total number of A20-/-;NIK+ mature/recirculating B-cells is also significantly reduced 
compared to the wild type control, and the A20F/wt NIK-tg CD19cre aged matched mice 
(Figure 11D). As observed before (Chu et al., Blood Supplement), the number of 
recirculating/mature B-cells in the A20F/F CD19cre mice are also reduced compared to 
control (Figure 11D).  
 
Second, the ex vivo immature B-cell numbers in the bone marrow are not affected by the 
combination of loss of A20 and gain of the NIK-tg (Figure 11B). There is a slight increase 
in the percentage of the A20-/-;NIK+ immature B-cells, but that is due to the low 
percentage of mature/recirculating B-cells. Moreover, the percentage of immature cell 
expressing the eGFP reporter is similar among all NIK-tg compound mice (Figure 11B). 
 
Third, in the earlier stages of B-cell development there is a small trend for higher pro-B 
cell and lower pre-B cell numbers in an A20-loss dependent manner in NIK-tg 
compound mice (Figure 11D). Moreover, there is a small increase in the percentage of 
pre-B and pro-B cells as more alleles of A20 are inactivated, but again it accounts to 
missing mature/recirculating B-cells in the bone marrow (Figure 11A and C).  
 
Taking into account the similar cell numbers of pro-B, pre-B and immature B-cells in the 
bone marrow of young mice, the loss of A20 in combination with the gain of one copy of 
NIK does not significantly affect early B-cell development in the bone marrow.  
 
IV.1.3.4 Immunoglobulin light chain ratios vary from immature to mature B-cells in 
A20-/-;NIK+ B-cells 
Given that the negative effect of combining loss of A20 with overexpression of NIK 
becomes evident after the immature B-cell stage, I decided to look for an additional 
control point in normal B-cell development: the proportions of kappa and lambda 





immunoglobulin light chain expressing B-cells. During B-cell development, there is a 
tight control for the rearrangement and expression of a functional BCR. After the heavy 
chain locus has been rearranged and the pre-BCR has been expressed, the cell proceeds 
to rearrange the immunoglobulin light chain locus to produce a functional BCR. If 
rearrangements in the kappa locus lead to the inactivation of the locus, the cell will 
subsequently rearrange the lambda locus. It has been proposed that although the 
generation of kappa-chain positive cells is independent of NF-B activation, the 
generation of lambda-chain positive cells depends on NF-B signals [63]. Therefore, 
strong activation of NF-B by overexpression of NIK in combination with loss of A20, 
could lead to the selection of lambda-chain positive cells.  
 
In the bone marrow of young mice, although there is tendency for higher lambda light 
chain positive immature B-cells in the A20F/wt NIK-tg CD19cre mice compared to wild 
type mice (Figure 12A and C), the overall levels of kappa light chain positive cells are 
similar for all NIK-tg compound mice. Interestingly, in the lambda light chain positive 
immature B-cells, there is a higher percentage of eGFP positive cells as each allele of A20 
is deleted in the NIK-tg CD19cre compound mice, although not statistically significant 
(Figure 12A). On the other hand, the percentage of eGFP positive B-cells in the kappa 
light chain positive cells are all similar.  
 
At the mature/recirculating B-cell stage in the bone marrow, there is a significant 
increase in the percentage of lambda light chain positive A20-/-;NIK+ cells compared to 
the wild type controls (Figure 12B). This is accompanied by a significant decrease in the 
percentage of kappa light chain positive cells compared to wild type and A20-/- 
controls. Moreover, the percentage of kappa light chain positive cells expressing eGFP is 
significantly reduced in A20F/F NIK-tg CD19cre mice compared to the A20F/wt NIK-tg 
CD19cre mice. However, this is not the case for the lambda light chain positive cells, 
were all NIK-tg CD19cre background mice have similar percentages of eGFP expressing 
cells (Figure 12B). 
 
At the immature B-cell stage in the bone marrow the percentage and cell numbers of 
kappa and lambda light chain are similar between the A20F/wt NIK-tg CD19cre and the 
A20F/F NIK-tg CD19cre mice (Figure 12A, C and D). However, at the 
mature/recirculating B-cell stage, the loss of the second allele of A20 in combination of 
NIK overexpression drastically reduces the cell numbers of both kappa and lambda light 
chain expressing cells (Figure 12C). Interestingly, although there are similar 





percentages of kappa and lambda light chain cells, the fractions that actually express 
eGFP within each group is lower in the A20F/F NIK-tg CD19cre mice compared to the 
A20F/wt NIK-tg CD19cre mice (Figure 12C).   
 
 
Figure 12. B-cell receptor light chain isotype in the bone marrow. 
Ex vivo analysis of the immunoglobulin light-chain in B-cells from bone marrow of young animals. Bar 
charts indicate the percentage of (A) immature and (B) mature B-cells expressing the immunoglobulin 
light chain isotype Ig-kappa or Ig-lambda, and the percentage of eGFP expressing cells for each 
isotype. (C) Pie charts depict the mean percentage of Ig-kappa and lambda cells expressing or not 
eGFP for the A20-/-;NIK+ and A20+/-;NIK+ immature and mature/recirculating B-cells. (D) Bar charts 
depict the mean number and standard error of the mean of kappa light chain and lambda light chain 
expressing immature and recirculating B-cells. Data is representative of at least 2 experiments, except 
for NIK-tg CD19cre mice. Bar charts depict medians and the values are indicated below each histogram. 









































































































































































































































Figure 12 (continued). Ig-kappa (immunoglobulin kappa light chain), Ig-lambda (immunoglobulin 
lambda light chain), immature B-cells (B220+ IgM+ IgD-) and mature/recirculating (B220+ IgD+).  
 
 
The normal ratios of kappa and lambda light chain immature A20-/-;NIK+ B-cells 
indicate that the loss of A20 in combination with the overexpression of NIK does not 
affect the early B-cell development in the bone marrow into the immature B-cell stage. 
Second, the lambda light chain positive pool is not favoured by the combination of these 
mutations. It is in the secondary lymphoid organs, starting in the spleen that impairment 
in homeostasis can be observed. It is interesting that the mature recirculating pool in the 
bone marrow of the A20F/F NIK-tg CD19cre mice is reduced to 50% of that observed for 
the A20F/wt NIK-tg CD19cre mice, unlike the increase observed in the spleen. 
 
IV.1.4 REDUCED POOL OF MATURE B-CELLS IN A20F/F NIK-TG CD19CRE MICE IS 
NOT DUE TO INCREASED APOPTOSIS 
Mice with homozygous loss of A20 in combination with a transgenic copy of NIK in B-
cells have a clear reduction in mature B-cell numbers, specifically affecting the eGFP 
positive population. In order to determine if apoptosis had a role in the B-cell reduction 
observed, I assessed pan-Caspase ex vivo activation, by incubating cells with the 
irreversible pan-Caspase inhibitor Red-VAD-FMK for 1 hour followed by flow cytometry 
analysis. 
 
In the bone marrow as well as in the spleen, the percentages of ex vivo activated pan-
Caspases in either eGFP positive A20+/-;NIK+ or A20-/-;NIK+ total B-cells is similar to 
or lower compared to wild type controls (Figure 13A and B). Interestingly, 
eGFP+;A20+/-;NIK+ B-cells have a lower percentage of ex vivo pan-Caspase activation 
compared to their eGFP+;A20-/-;NIK+ counterparts (Figure 13A). Furthermore, while 
eGFP positive A20+/-;NIK+ B-cells in the spleen display a reduction in ex vivo pan-
Caspase activation compared to wild type control (8.8% to 2.3%), loss of the second 
allele of A20 leads to reduced Caspase activation compared to wild type (8.8% to 3.7%) 
and increased Caspase activation compared to A20+/-;NIK+ counterparts (Figure 13B). 
Additionally, both ex vivo eGFP negative A20+/-;NIK+ and A20-/-;NIK+ B-cells from the 
spleen show a four- and two-fold increase in the ex vivo pan-Caspases activation 
compared to wild type, respectively (Figure 13B) likely due to the absence of one allele 
of the CD19 signal transduction molecule involved in B-cell survival{Otero:2003wk} or 
the Cre-recombinase dependent toxicity {Sharma:2001ch}. Alternatively, the higher 





percentage of eGFP negative apoptotic B-cells in the A20F/wt NIK-tg CD19cre and the 
A20F/F NIK-tg CD19cre mice could indicate a pro-apoptotic effect triggered by the eGFP 
positive B-cells in these mice. Throughout the B-cell development, eGFP+;A20+/-;NIK+ 
immature B-cells in the bone marrow and spleen have relative higher ex vivo pan-
Caspase activation compared to wild type control (Figure 13C). The loss of the second 
allele of A20 further increases the ex vivo pan-Caspases activation in immature B-cells 
from the bone marrow, however it leads to reduced ex vivo pan-Caspase activation in the 
spleen compared to the A20F/wt NIK-tg CD19cre mice (Figure 13C).  
 
The drop in B-cell numbers in A20F/F NIK-tgCD19cre mice is observed at the mature B-
cell stage. The percentage of ex vivo activated pan-Caspases in eGFP positive A20-/-
;NIK+ B-cells in spleen is lower to that observed for the wild type control (Figure 13C). 
Interestingly, although the eGFP negative mature B-cells have a similar percentage of 
early apoptotic cells, a much higher percentage are at the late apoptotic stage. This same 
phenotype is observed for the mature A20+/-;NIK+ B-cells, where the eGFP positive 
cells have an even lower percentage of activated pan-Caspase, and the eGFP negative 
cells have a higher percentage of early and late apoptotic cells, compared to wild type 
control (Figure 13C).  
 
In the mature/recirculating B-cell stage, both the eGFP positive A20+/-;NIK+ and A20-/-
;NIK+ B-cells showed similar ex vivo Caspase activation levels compared to the wild type 
controls (Figure 13C). Surprisingly, the eGFP negative A20+/-;NIK+ B-cells showed an 
elevated percentage of late apoptotic cells, compared to the other genotypes analysed.  
 
The reduced eGFP positive B-cell numbers observed in A20F/F NIK-tg CD19cre mice are 
not a result of enhanced programmed cell death due to increased Caspase activation. 
Furthermore, in the presence of the NIK-tg, which is co-expressed with eGFP from the 
same mRNA, there is lower activation of pan-Caspases observed. Thus, the presence of 
the NIK-tg provides an anti-apoptotic advantage, as observed for both the A20+/-;NIK+ 
and the A20-/-;NIK+ mature B-cells.  






Figure 13. Reduced A20-/-;NIK+ B-cell numbers are not related to increased apoptosis 
Ex vivo programmed cell death analysis. Apoptotic cells were incubated with the irreversible pan-
Caspases inhibitor Red-VAD-FMK for one hour, and followed by flow cytometry analysis. Percentage of 
ex vivo activated pan-Caspases in B-cells from (A) bone marrow and (B) spleen. (C) Percentage of ex 
vivo activated pan-Caspases through B-cell development: immature B-cells in the bone marrow and 
spleen, mature B-cells in the spleen and mature/recirculating B-cells in bone marrow. Bar charts depict 
medians and the values are indicated below each histogram. 
BM (bone marrow), SPL (spleen), early apoptotic (Red-VAD-FMK+ 7AAD-), late apoptotic (Red-VAD-
FMK+ 7AAD+), B-cells (B220+), immature B-cells (BM: B220+ IgM+ IgD- or SPL: B220+ AA4.1+), mature 
B-cells (BM: B220+ IgD+ or SPL: B220+ AA4.1-). 
 
 
IV.1.5 LOSS OF A20 ACCENTUATES THE REDUCED GERMINAL CENTRE B-CELLS AND 
PLASMA CELLS OBSERVED IN THE PRESENCE OF ENHANCED ALTERNATIVE NF-B 
ACTIVATION  
Germinal centres (GC) are physiological structures in secondary lymphoid organs where 
antigen-activated B-cells mature to plasma cells or memory B-cell to produce high 
affinity antigen specific antibodies [47, 92]. In gut associated lymphoid tissues (GALT), 
including mLN and PP, constant antigen presentation derived from the gut microflora 
drives GC B-cells to produce an adaptive immune response to the microorganisms found 
in the gut. It has been reported that the loss of A20 in B-cells affects germinal centre B-
cells and results in autoimmunity {Chu:2011dz}, the GC reaction in unimmunized mice 
was characterised to assess the role of the combination of A20 with enhanced 
expression of NIK.  





 In unimmunized mice, spleens and LNs from NIK-tg compound mice show a reduction 
in the percentage of spontaneous ex vivo GC B-cells in comparison with wild type and 
A20-deficient compound mice (Figure 14A and C, respectively). Spleens of NIK-tg 
CD19cre mice have similar numbers of ex vivo GC B-cells as wild type controls (Figure 
14B). However, the additional loss of one allele of A20, instead of increasing the number 
of GC B-cells as observed in the A20F/wt CD19cre mice [79], leads to lower ex vivo GC B-
cell numbers compared to the NIK-tg CD19cre mice (Figure 14D). Moreover, the loss of 
the second allele of A20 in combination with overexpression of NIK leads to almost 
complete absence of ex vivo GC B-cells (Figure 14A and B). Interestingly, almost no eGFP 
positive ex vivo A20-/-;NIK+ GC B-cells are observed (Figure 14B).  
 
Similarly, the number of ex vivo GC B-cells in LNs from the NIK-tg compound mice are 
reduced compared to their NIK-tg negative counterparts (i.e. A20F/wt NIK-tg CD19cre 
vs. A20F/wt CD19cre) (Figure 14C and D). There is a trend for higher number of ex vivo 
GC B-cells as each allele of A20 is lost in the NIK-tg CD19cre background (Figure 14D), 
but only a small fraction of the GC B-cells express eGFP, which reports for NIK 
expression (Figure 14D).  
 
In the GALT, a similar phenotype can be observed in both the mLN and the PP. The few 
ex vivo GC B-cells observed in the NIK-tg CD19cre mice are reduced as A20 is ablated 
(Figure 14E-H). There is a significant reduction in the number of ex vivo GC B-cells in the 
A20F/F NIK-tg CD19cre mice compared to the wild type control especially in the PP 
(Figure 14H). Interestingly, although the number of GC B-cells for the A20F/wt NIK-tg 
CD19cre mice is similar to the one for the A20F/F NIK-tg CD19cre mice, there is a 
significant reduction of eGFP ( NIK) expressing cells when the second allele of A20 is 
lost (Figure 14H).  
 
Additionally, the overexpression of NIK in B-cells leads to cells with higher expression of 
the death receptor protein CD95 (FAS) (Figure 16A, Figure S 5A and Figure S 6A). 
Surprisingly, the higher expression of CD95 does not lead to a higher percentage of 
apoptosis. In fact, the eGFP positive A20+/-;NIK+ and eGFP positive and negative A20-/-
;NIK+ GC B-cells have lower ex vivo activation of pan-Caspases compared to wild type 
controls (Figure S 5B). 
 






Figure 14. Diminished germinal centre B-cells in unimmunized NIK-tg compound mice 
Ex vivo analysis of germinal centre B-cells in secondary lymphoid organs from unimmunized young 
mice using flow cytometry. Contour plots depict percentages of germinal centre B-cells from (A) spleens 
and (C) draining lymph nodes,. Bar charts show germinal centre B-cells and eGFP positive cells 
numbers for (B) spleens, (D) lymph nodes Draining inguinal, axillary and superficial cervical lymph 
nodes were pooled and data was normalized to one lymph node. All flow cytometry plots are 
representative of at least 2 experiments. Bar charts depict medians and values are indicated below each 
histogram. Statistical analysis was done using Kruskal-Wallis (* p<0.05, ** p<0.01, *** p<0.001) or Two-
tailed paired T-test (¥ p<0.05, ¥¥ p<0.01). 






Figure 14 (continued). Diminished germinal centre B-cells in unimmunized NIK-tg compound 
mice 
Ex vivo analysis of germinal centre B-cells in secondary lymphoid organs from unimmunized young 
mice using flow cytometry. Contour plots depict percentages of germinal centre B-cells from (E) 
mesenteric lymph nodes, and (G) Peyer’s patches. Bar charts show germinal centre B-cells and eGFP 
positive cells numbers for (F) mesenteric lymph nodes, and (H) Peyer’s patches. All flow cytometry plots 
are representative of at least 2 experiments. Bar charts depict medians and values are indicated below 
each histogram. Statistical analysis was done using Kruskal-Wallis (* p<0.05, ** p<0.01, *** p<0.001) or 
Two-tailed paired T-test (¥ p<0.05, ¥¥ p<0.01). 
SPL (spleen), LN (lymph node), mLN (mesenteric lymph nodes), PP (Peyer’s patches), GCB (germinal 
centre B-cells, B220+ CD38- CD95+), eGFP (enhanced green fluorescent protein) and eGFP pos 
(eGFP+). 
 






Figure 15. Decreased plasma cell numbers in unimmunized A20F/F NIK-tg CD19cre 
mice 
Ex vivo analysis of plasma cells from bone marrow, spleen and mesenteric lymph nodes of 
unimmunized young mice, by flow cytometry. (A) Flow cytometry contour plots depict the percentage of 
plasma cells and B-cells in spleen. Bar chart indicates the percentage of eGFP positive NIK expressing 
plasma cells in the NIK-tg CD19cre compound mice. Bar charts indicate numbers for plasma cells in (B) 
bone marrow, (C) spleen and (D) mesenteric lymph nodes. (E) Bar charts indicate the number of eGFP 
positive NIK expressing plasma cells and eGFP negative plasma cells in spleen. Data is representative 
of at least 2 experiments, except for NIK-tg CD19cre mice. Bar charts depict medians and the values 
are indicated below each histogram. Statistical analysis was done using One-way ANOVA (* p<0.05, *** 
p<0.001, **** p<0.0001). 
BM (bone marrow), Spl (spleen), mLN (mesenteric lymph nodes), eGFP (enhanced green fluorescent 
protein), Plasma Cells (B220- CD138+), eGFP pos (eGFP+) and eGFP neg (eGFP-). 
 
 
The end product of the germinal centre reaction is the generation of high affinity specific 
plasma cells. The loss of one allele of A20 results in the increase in percentage and cell 
numbers of total ex vivo plasma cells in A20F/wt NIK-tg CD19cre mice compared to 
NIK-tg CD19cre mice (Figure 15). Interestingly, the number of ex vivo plasma cells 
observed in the spleen of the A20F/F NIK-tg CD19cre mice is similar to the wild type 
controls, but significantly reduced compared to the A20F/wt NIK-tg CD19cre mice 





(Figure 15C). Moreover, only 20% of the plasma cells in the A20F/F NIK-tg CD19cre 
mice express the eGFP NIK-reporter (Figure 15A and E). Similarly, the loss of the second 
allele of A20 in the NIK-tg CD19cre background results in reduced plasma cells numbers 
in the BM and more drastically in the mLN compared to the A20F/wt NIK-tg CD19cre 
mice (Figure 15A and C). 
 
Taking into account the low GC B-cell numbers and few plasma cells observed in the 
unimmunized A20F/F NIK-tg CD19cre mice, and the fact that most of these cells are 
actually eGFP negative, my data point towards the idea that alternative NF-B signalling 
is sufficient to hinder the GC reaction. The additional homozygous loss of A20, a negative 
regulator of the canonical NF-B signalling, blocks further the GC fate of these cells and 
additionally prevents general plasma cell differentiation.  
 
IV.1.6 LOSS OF A20 IN COMBINATION WITH ALTERNATIVE NF-B ACTIVATION 
DRIVES ABERRANT EXPRESSION OF CO-RECEPTOR MOLECULES THAT LEADS TO A 
PRE-ACTIVATED ANTIGEN PRESENTING CELL PHENOTYPE  
The overexpression of NIK in combination with the loss of one allele of A20 (A20+/-
;NIK+) leads to an expansion of B-cells that have a MZ-like phenotype. Furthermore, 
A20F/wt NIK-tg CD19cre mice (Figure 15) have reduced GC B-cells (Figure 14), but 
slightly increased plasma cell numbers compared to wild type mice. However, the loss of 
the second allele of A20 (A20-/-;NIK+) leads to massive reduction of mature B-cells as 
well as inefficient GC B-cell and plasma cell formation. Given the already observed 
altered expression of different surface proteins such as CD23 and CD95, I decided to 
take a closer look at the combined effect of loss of A20 and overexpression of NIK in the 
expression of B-cell activation markers, B to T-cell collaboration proteins, and 
transcription factors that are essential for B-cell fate and function. 
 
B-cells interact with T-cell through several surface proteins and are modulated by the 
production of several cytokines produced by T-cells. First, B-cells express ICOS-L that 
binds the ICOS protein in the T-cell. Second, B-cells also express the activations markers 
CD80 and CD86 that are required to bind CD28 on T-cells during the presentation of 
antigens. Third, the MHC-II in B-cells binds the TCR to present antigens. Fourth, the 
cytokines IL-25 and interferon- (IFN-) are important signals for B-cell activation and 
survival. Moreover, the surface protein CD44 functions as a marker of cell activation in 
T-cell lymphocytes.  






Figure 16. Aberrant expression of activation makers, receptors and transcription 
factors in A20-/-;NIK+ B-cells from spleens of young mice.  
Ex vivo analysis of B-cells from spleen of young mice using flow cytometry. (A) Heat maps depict the 
geometric mean of the MFI in B-cells relative to the wild type control. (B) Scatter plots show the absolute 
MFIs of receptors and ligands (ICOS-L, CD119, CD25, CD44 and FAS/CD95), activation markers 
(CD69, CD80, CD86 and MHC-II) and transcription factors (BCL6 and IRF4). 
N.A. (not available), eGFP (enhanced green fluorescent protein), MFI (Median Fluorescent Intensity) 
 
 
A20 deficiency in B-cells (A20+/- and A20-/-) leads to lower ex vivo expression levels of 
both ICOS-L and CD119 (IFN- receptor) compared to wild type controls (Figure 16 and 
Figure S 6A). The additional gain of one allele of the NIK-tg does not rescue the 
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expression of ICOS-L and CD119 is also reduced in eGFP negative B-cells, to levels 
observed in the A20-/- B-cells (Figure 16A and Figure S 6A). On the other hand, the ex 
vivo expression of the surface marker proteins CD25 and CD44 is mildly increased by 
the loss of A20, and the further gain of an extra copy of NIK does not alter their 
expression (Figure 16 and Figure S 6A). 
 
The relative ex vivo expression of the activation makers CD69, CD80 and CD86 is 
increased in A20-/- B-cells [79]. This is further reinforced by the expression of the NIK-
tg as seen in the eGFP+;A20+/-;NIK+ B-cells (Figure 16 and Figure S 6B). The same 
cannot be said for the A20+/- B-cells, where the gain of NIK transgene does not have the 
same effect. Interestingly, only the combination of loss of both alleles of A20 with gain of 
the NIK transgene, leads to an up regulation of the MHC-II molecule (Figure 16 and 
Figure S 6B). Again, the eGFP-;A20-/-;NIK- B-cells have a similar expression to the A20-
/- B-cells.  
 
As mentioned in the previous section, the expression of the NIK transgene drives higher 
expression of the FAS/CD95 death receptor in B-cells (Figure S 5A). The heterozygous 
loss of A20 already leads to a higher number of GC B-cells, partly explaining the relative 
higher expression observed for the A20+/- B-cells. The further activation of the 
alternative NF-B pathway by expressing the NIK transgene further increases CD95 
expression, reaching a maximum level when the second allele of A20 is inactivated in B-
cells. Interestingly, the eGFP-;A20-/-;NIK+ B-cells have an increase of two-fold, 
compared to the A20-/- B-cells, which could be indicative of a B-cell extrinsic phenotype 
(Figure 16 and Figure S 6A).  
 
Finally, the BCL6 and IRF4 are major players deciding B-cell differentiation. Loss of A20 
in B-cells leads to a relative small decrease in ex vivo BCL6 expression. The presence of 
the NIK transgene in B-cells also decreases the relative expression of BCL6 (Figure 16B 
and Figure S 6C). However, A20-/-;NIK+ B-cells have a two-fold increase of BCL6 
compared to wild type control. On the other hand, loss of A20 in B-cells leads to an 
increase in the relative ex vivo expression of IRF4. The additional gain of NIK further 
potentiates that expression.  
 
Taken all together, eGFP+;A20-/-;NIK+ B-cells have a surface protein signature 
reminiscent of an antigen presenting cells, have an aberrant expression T-cell co-





stimulatory proteins required for the GC reaction and elevated BCL6 and IRF4 
expression levels.  
 
IV.1.7 ALTERNATIVE NF-B ACTIVATION COMBINED WITH LOSS OF A20 LEADS TO 
ALTERED INTEGRIN EXPRESSION PATTERNS IN B-CELLS 
The loss of A20 in combination with overexpression of NIK in B-cells leads to an antigen 
presenting cell-like phenotype in eGFP (NIK) positive B-cells. Therefore, I decided to 
analyse the expression of particular integrins that are important for the immune system. 
During B-cell development and inflammation, B-cells need to migrate through 
circulation to secondary lymphoid organs where they populate particular niches. The 
expression of integrins and their activation at particular time points is essential for 
normal B-cell physiology. Therefore, inappropriate or altered expression of integrins 
could partly explain the reduced B-cell numbers in the secondary lymphoid organs.  
 
The ex vivo expression of alpha-4, alpha-5, alpha-V, alpha-L, alpha-M and alpha-X 
integrins in B-cells was analysed using flow cytometry. Similarly, the ex vivo expression 
of beta-1, beta-2, beta-3 and beta-7 integrins was analysed in B-cells. Overall, three 
different ex vivo expression patterns were observed in B-cells when A20 was ablated 
alone or in combination with the expression of the NIK transgene.  
 
The ex vivo expression of alpha-4, alpha-L, alpha-5 and alpha-V integrins is affected by 
both loss of A20 and overexpression of NIK. First, the relative expression of alpha-4 and 
alpha-L integrins is already reduced in A20 deficient B-cells compared to wild type 
controls. Interestingly, the ex vivo alpha-4 expression returns to normal levels in 
eGFP+;A20-/-;NIK+ B-cells (Fehler! Verweisquelle konnte nicht gefunden werden. 
and Figure S 5A), while the expression of alpha-L increases two-fold. Second, the relative 
expression of alpha-5 integrin is reduced in A20+/- B-cells, but normal in A20-/- B-cells. 
Third, the relative expression of alpha-V integrin is increased when A20 is inactivated, 
independently of NIK expression.  
 
The relative ex vivo expressions of alpha-M is increased in A20+/- B-cells. Additional 
expression of NIK leads to a slight increase. However, the relative expression in A20-/- 
B-cells, independent of the expression of NIK, is similar to that of wild type (Fehler! 
Verweisquelle konnte nicht gefunden werden.A and Figure S 7A). 
 






Figure 17. A20-/-;NIK+ B-cells have altered integrin expression  
Ex vivo analysis of B-cells from spleen of young mice using flow cytometry. (A) Heat maps depicting the 
geometric mean of the MFI for alpha- and beta-integrins in B-cells relative to wild type. (B) Scatter plot 
show the absolute MFIs of alpha- and beta-integrins in B-cells. 
N.A. (not available), eGFP (enhanced green fluorescent protein), MFI (Median Fluorescent Intensity) 
 
 
The relative ex vivo expression of beta-2 integrins in A20-/- B-cells is significantly 
reduced to 50%. However, the overexpression of NIK leads to a significant increase that 
not only rescues but also overcomes the effect of A20 loss. 
 
The relative ex vivo expression of beta-1 integrins was reduced in A20+/- B-cells, and 
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expression for A20-/- B-cells was not done, the relative expression in A20-/-;NIK+ B-
cells was similar to wild type control.  
 
Interestingly, alpha-L and beta-2 integrins, the only two integrins with significantly 
changed expression levels in eGFP+;A20-/-;NIK+ B-cells, had similar expression 
patterns. They bind ICAM-I and are important for marginal zone B-cells. 
 
IV.1.8 ROLE OF B-CELL EXTRINSIC FACTORS IN THE NEGATIVE EFFECT OF LOSS OF A20 
IN COMBINATION WITH OVEREXPRESSION OF NIK IN B-CELLS 
The loss of A20 in combination with the overexpression of NIK leads to significantly 
lower mature B-cell numbers in secondary lymphoid organs. The B-cell intrinsic factors 
analysed, such as a block in development, an increase in apoptosis, enhanced antigen 
presenting cell-like phenotype, or altered integrin expression profile alone do not 
necessarily explain the observed phenotype in A20F/F NIK-tg CD19cre mice. I therefore, 
proceeded to analyse the T-cell and myeloid compartments in these animals. 
IV.1.8.1 Expansion of CD25+ CD4 regulatory, effector-like CD4 and effector-like CD8 
T-cells in spleens of A20F/F NIK-tg CD19cre mice 
The loss of A20 in combination with the overexpression of NIK leads to significant lower 
B-cell numbers in secondary lymphoid organs, affecting particularly the eGFP+;A20-/-
;NIK+ B-cell population. Since T-cells are the central players in adaptive immune 
response and can modulate B-cells in different ways, I decided to analyse the T-cell 
compartment using flow cytometry.  
 
In spleens of young A20F/F NIK-tg CD19cre mice, there is an evident increment in ex 
vivo T-cell percentages compared to A20F/wt NIK-tg CD19cre and NIK-tg CD19cre mice 
(Figure 18A). This increment translates to a significant increase in T-cell numbers 
compared to the wild type controls (Figure 18C). Interestingly, the A20F/wt NIK-tg 
CD19cre mice already display a trend for increased T-cell numbers compared to wild 
type mice (Figure 18C). 
 
The increase in ex vivo T-cell numbers in A20F/F NIK-tg CD19cre mice affects all T-cells 
subsets. First, there is an increase in ex vivo CD8 T-cell numbers in A20F/F NIK-tg 
CD19cre mice (Figure 18D), although the percentage of CD8 T-cells in spleen of young 
mice is similar among the NIK-tg compound mice (Figure 18B). The ex vivo CD8 T-cells 





numbers in the other compound mice analysed are constant (Figure 18D). Second, there 
is a significant increase in ex vivo conventional CD4 (cCD4) T-cell numbers in A20F/F 
NIK-tg CD19cre mice compared to WT controls (Figure 18D), even though the cCD4 T-
cell subset percentages are also similar among NIK-tg compound mice (Figure 18B). 
Finally, the percentage of CD25+ CD4 T-cells increases in an A20-loss dependent manner 
in NIK-tg compound mice (Figure 18B). This translates to significantly higher ex vivo 
number of CD25+ CD4 T-cells in A20F/F NIK-tg CD19cre mice compared to A20F/wt 
NIK-tg CD19cre and wild type controls (Figure 18D). These CD25+ CD4 T-cells express 
higher levels of the FoxP3 transcription factor compared to their cCD4 counterparts 
(Figure S 8), indicating a regulatory effector function in these cells. Interestingly, there is 
also an expansion of CD25+ CD4 regulatory T-cells in the A20F/F CD19cre mice 
comparable to the A20F/wt NIK-tg CD19cre mice (Figure 18D).  
 
Ex vivo flow cytometry analysis of cCD4 T-cells in the spleens of young mice showed 
reduced percentages of memory-like T-cells accompanied by increased percentages of 
effector-like T-cells in mice that were either A20F/F NIK-tg CD19cre or A20F/wt NIK-tg 
CD19cre compared to NIK-tg CD19cre controls (Figure 19A). Mice with A20+/-;NIK+ B-
cells had 45% of effector-like cCD4 T-cells, where as A20-/-;NIK+ B-cells resulted in 
31,2% of effector like cCD4 T-cells, compared to 19% in NIK-tg CD19cre controls (Figure 
19A). The increase observed in effector-like cells percentage translates into significant 
higher cell numbers in A20F/F NIK-tg CD19cre mice compared to WT control (p<0.05), 
and similar numbers compared to the A20F/wt NIK-tg CD19cre mice (Figure 19B). The 
A20F/F NIK-tg CD19cre mice have a trend for higher naïve-like and lower memory-like 
CD4 T-cell percentage and numbers (Figure 19B).  
 
Ex vivo characterization of CD8 T-cell activation in spleens of young mice revealed 
significant lower percentage of naïve-like T-cells accompanied by a significant increase 
in effector-like T-cells (Figure 19C). This naïve- to effector-like activation is A20-loss 
dependent, being stronger in the A20F/F NIK-tg CD19cre mice. The elevated effector-
like cell percentage observed translates into a significant five-fold increase in effector-
like CD8 T-cell numbers in A20F/F NIK-tg CD19cre mice compared to the A20F/wt NIK-
tg CD19cre (Figure 19D).  
 






Figure 18. A20F/F NIK-tg CD19cre mice develop T-cell hyperplasia 
Ex vivo analysis of T-cell populations in spleen of young mice using flow cytometry. Contour plots depict 
percentages and bar charts indicate cell numbers for (A, C) T-cells, and (B, D) conventional CD4, CD8, 
and CD25+ CD4 T-cells. All flow cytometry plots are representative of at least 2 experiments, except for 
NIK-tg CD19cre mice. The NIK-tg CD19cre contour plots do not belong to the same experiment as A20-
deficient NIK-tg CD19cre plots. Bar charts depict medians and the values are indicated below each 
histogram. Statistical analysis was done using One-way ANOVA (* p<0.05, *** p<0.001) or Kruskal-
Wallis (¥ p<0.05), and statistical significance when P<0.5 is indicated. 
T-cells (TCR+), CD8 (TCR+ CD4- CD8+), CD4 (TCR+ CD4+ CD8-), cCD4 (conventional CD4, TCR+ 
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Figure 19. A20F/F NIK-tg CD19cre mice have an effector-like T-cell phenotype 
Ex vivo analysis of T-cell activation in spleen of young mice using flow cytometry. Contour plots depict 
percentages and bar charts indicate total cell numbers for naïve-like, effector-like and memory-like 
activation status in (A) conventional CD4 and (B) CD8 T-cells. All flow cytometry plots are 
representative of at least 2 experiments, except for the NIK-tg CD19cre mice. The NIK-tg CD19cre 
contour plots do not belong to the same experiment as A20-deficient NIK-tg CD19cre plots. Bar charts 
depict medians and the values are indicated below each histogram. Statistical analysis was done using 
One-way ANOVA (* p<0.05, ** p<0.01). 
+ CD4+ CD25- + CD8+), naïve (CD62L+ CD44-), effector 
(CD62L- CD44+) and memory (CD62L+ CD44+). 
 
 
There is another CD4 T-cell subset that is required for the GC reaction. Follicular helper 
T-cells (TFH), defined by a high expression of CXCR5, PD1 and BCL6, as their name 
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percentage of PD1high CXCR5high CD4 T-cells, reminiscent of TFH cells, increases in an A20 
loss dependent manner in NIK-tg compound mice (Figure 20A), in spite of the few GC B-
cells present in these mice (Figure 11A and C). Moreover, the total number of PD1high 
CXCR5high CD4 T-cells in spleen of A20F/F NIK-tg CD19cre mice is significantly higher 
than in wild type (p<0.01) and A20F/wt NIK-tg CD19cre mice (Figure 20B). Preliminary 
results show that these PD1high CXCR5high CD4 T-cells present a higher expression of the 
transcription factor BCL6 (Figure S 9) suggesting that they are actually TFH and not 
simply T-cells that have up-regulated PD1 expression. However, further experiments 
need to be performed to confirm their TFH phenotype.  
 
Taken all together, loss of A20 and overexpression of NIK in B-cells leads to an activated 
T-cell phenotype in cCD4 and particularly in CD8 T-cells. Moreover, there is an 
expansion of CD25+ CD4 regulatory T-cells and potentially TFH in these mice. Given the 
strong antigen presenting cell-like phenotype observed in eGFP+;A20-/-;NIK+ B-cells 
(Figure 16), the observed reduced B-cell numbers could be a result of T-cell dependent 




Figure 20. PD1hi CXCR5hi CD4 T cells reminiscent of TFH cells are expanded in A20F/F 
NIK-tg CD19cre mice 
Ex vivo analysis of follicular helper T-cells in spleens of young mice using flow cytometry. (A) Flow 
cytometry contour plots depict the percentage and (B) bar chart show the number of PD1hi CXCR5hi 
CD4 T-cells. All flow cytometry plots are representative of at least 2 experiments, except for the NIK-tg 
CD19cre mice. Bar charts depict medians and the values are indicated below each histogram. Statistical 
analysis was done using Kruskal-Wallis (¥¥ p<0.01). 
TFH (follicular helper T-cells, TCRb+ CD4+ PD1hi CXCR5hi). 





IV.1.8.2 PD1 positive exhausted-like phenotype in CD8 T-cells in spleens of A20F/F 
NIK-tg CD19cre mice 
To further characterize the activation of cCD4 and CD8 T-cells in spleens of A20F/F NIK-
tg CD19cre animals, I decided to analyse the expression of the proteins ICOS and PD1, 
both markers for T-cell activation and exhaustion. In spleens of young mice the 
additional expression of the NIK-tg in A20+/- B-cells leads to a subpopulation of CD4 T-
cells with a higher ICOS and PD1 surface expression levels (Figure 21A, upper panels). 
On the other hand, the additional expression of NIK-tg in A20-/- B-cells results in CD4 T-
cells with similar ICOS expression while a higher PD1 expression (Figure 21A, lower 
panels). However, the higher percentage of PD1 positive CD4 T-cells in A20F/F NIK-tg 
CD19cre mice partially corresponds to the higher TFH numbers observed in these 
animals (Figure 20). 
 
The ex vivo flow cytometry analysis of CD8 T-cells in spleens from young mice showed 
an increase in PD1 expression in response to biallelic loss of A20 in B-cells, which is 
intensified in the presence of NIK expression (Figure 21B, lower panel) but absent in the 
A20F/wt compound mice. The percentage of PD1 high CD8 T-cells is significantly higher 
for A20F/F NIK-tg CD19cre mice compared to the A20F/wt and A20F/F CD19cre 
controls. This translates into a significant 19-fold increase in PD1 positive CD8 T-cell 
numbers in A20F/F NIK-tg CD19cre mice compared to wild type and A20F/wt NIK-tg 
CD19cre mice (Figure 21B). Moreover, there is a small increase in the expression of ICOS 
in CD8 T-cells in response to A20-/- or A20-/-;NIK+ B-cells, absent in A20F/wt 
compound mice.  
 
Mice with A20-deficient;NIK+ B-cells have a higher activation in T-cells. In A20F/F NIK-
tg CD19cre mice, both CD4 and CD8 T-cells show higher PD1 ex vivo expression levels 
compared to the other compound mice analysed. The expression of PD1 in CD8 T-cells 
has been reported as a marker for T-cell exhaustion[253], pointing to a possible 
exhausted phenotype in the effector-like CD8 T-cells expansion observed in the A20F/F 
NIK-tg CD19cre mice. 
 
 






Figure 21. CD8 T-cells in A20F/F NIK-tg CD19cre mice have an exhausted phenotype 
Flow cytometry analysis of ICOS and PD1 ex vivo expression in T-cells from spleen of young mice. 
Histograms depict the expression of ICOS and PD1 and bar charts indicate the percentage or cell 
numbers of positive cells in (A) CD4 and (B) CD8 T-cells. Flow cytometry histograms are representative 
of at least 2 experiments. Bar charts depict medians and the values are indicated below each histogram. 
Statistical analysis was done using One-way ANOVA (* p<0.05, ** p<0.01, **** p<0.0001). 
CD4 T (TCRb+ CD4+ CD8-) and CD8 T (TCRb+ CD4- CD8+). 
 
 
IV.1.8.3 The expansion of CD25+ CD4, effector-like CD4 and effector-like CD8 T-cells 
is systemic in A20F/F NIK-tg CD19cre mice 
After identifying the expansion of several T-cell populations in A20F/F NIK-tg CD19cre 
mice, I proceeded to investigate the different T-cell populations in the bone marrow and 
the LN, to determine if this T-cell phenotype was systemic or localized to the spleen. 
 
In the bone marrow of young mice, there is a significant two-fold increase in ex vivo T-











































































































































































































CD19cre mice and wild type aged matched controls (Figure S 10A). Additionally, the 
total number of ex vivo cCD4 T-cells as well as CD8 and CD25+ CD4 T-cells are increased 
in the A20F/F NIK-tg CD19cre mice compared to controls (Figure S 10B). First, there is a 
two-fold increase in the number of cCD4 T-cells in A20F/F NIK-tg CD19cre mice 
compared to wild type control and A20F/wt NIK-tg CD19cre mice. Second, there is a 
small increase in the number of CD8 T-cells, although not statistically significant (Figure 
S 10B). Finally, there is a significant three-fold increase in CD25+ CD4 T-cells as 
consequence of the loss of the second allele of A20 in NIK-tg B-cells (Figure S 10B). 
 
Ex vivo flow cytometry analysis of cCD4 T-cells in the bone marrow, revealed that the 
number of effector-like CD4 T-cell numbers in A20F/F NIK-tg CD19cre mice is 
significantly higher compared to controls (Figure S 10C). However, the number of naïve- 
and memory-like cCD4 T-cells is similar to that of A20F/wt NIK-tg CD19cre animals, and 
lower than that observed for the wild type controls (Figure S 10C).  
 
Similarly, the number of effector-like CD8 T-cells in A20F/F NIK-tg CD19cre mice is 
significantly increased compared to controls (Figure S 10D). Moreover, the numbers of 
naïve- and memory-like CD8 T-cells are also similar to that of A20F/wt NIK-tg CD19cre 
mice and lower that wild type controls (Figure S 10D).  
 
In the LN of young mice, there is also a significant two-fold increase in total ex vivo T-cell 
numbers in A20F/F NIK-tg CD19cre mice compared to wild type controls (Figure S 
11A). This increase is accompanied by a significant increase in CD4 T-cells and to a 
lesser extent in CD8 T-cells (Figure S 11B). Additionally, the ex vivo flow cytometry 
analysis of CD4 T-cells in the lymph nodes revealed a significant increase in CD25+ T-
cells in the A20F/F NIK-tg CD19cre mice compared to the A20F/wt NIK-tg CD19cre mice 
(Figure S 12A). Moreover, although the majority of cCD4 and CD8 T-cells were in a 
naïve-like state, there was a significant increase in the number of effector-like cCD4 and 
CD8 T-cells in the A20F/F NIK-tg CD19cre mice (Figure S 12B and C).  
 
Therefore, compared to NIK-tg and A20wt/- NIK-tg B-cells, the loss of two alleles of A20 
in NIK-tg expressing B-cells leads to an expansion of CD25+ CD4 T-cells and effector-like 
cCD4 and CD8 T-cells in the bone marrow, accompanied by a similar phenotype in the 
LN.  
 





IV.1.8.4 The myeloid compartment is not affected by the combination of loss of 
A20 and overexpression of NIK-tg in B-cells 
Given the expanded T-cells populations observed in the different lymphoid organs, I 
proceeded to analyse the myeloid populations in these mice. Myeloid cells are antigen 
presenting cells and produce cytokines that can modulate B- and T-cells responses. It is 
already known ablation of A20 in B-cells leads to an expansion of myeloid cells [79].  
 
The ex vivo analysis of myeloid cells in the spleens of young mice revealed a significant 
increase in the percentage of monocytes in spleens of A20F/F NIK-tg CD19cre mice 
compared to the A20F/wt NIK-tg CD19cre mice (Figure S 13A). Furthermore, there was 
a small increase in the percentage of neutrophils and dendritic cells in A20F/F NIK-tg 
CD19cre mice compared to wild type control (Figure S 13A). While the percentage of 
eosinophils was similar for all mice analysed.  
 
The slightly increased percentage of myeloid cells in spleens of A20F/F NIK-tg CD19cre 
mice, however, was not reflected by the number of myeloid cells. In the A20F/F NIK-tg 
CD19cre mice there was a tendency for slightly higher numbers of dendritic cells, 
monocytes and neutrophils compared to controls (Figure S 13B), but this increase did 
not reach statistical significance. Moreover, the loss of A20 alone in B-cells is sufficient 
to elicit a similar phenotype ([79] and Figure S 13B). Thus in the bone marrow of young 
mice the total numbers of the different myeloid cells are constant for all the different 
genotypes analysed (Figure S 13C). 
 
In young mice, the reduced B-cell numbers and exhausted T-cell phenotype observed 
A20F/F NIK-tg CD19cre mice seems to be independent of the myeloid compartment. 
The small increase observed in neutrophils and monocytes in these mice phenocopies 
the increase in neutrophils and monocytes observed in A20F/F CD19cre mice, therefore 
most likely is A20 dependent. 
 
IV.1.9 EFFECT OF LOSS OF A20 IN COMBINATION WITH ALTERNATIVE NF-B 
ACTIVATION IN B-CELLS IN AGED MICE 
Initially the basis of this project was to combine loss of A20 and activation of the 
alternative NF-B pathway, by overexpressing NIK, in B-cells, to evaluate whether this 
predisposes them to splenic marginal zone lymphoma in mice. For that purpose, a 





cohort of mice was aged over 400 days and monitored for any signs or symptoms of 
disease. After the animals reached 400 days they were analysed by flow cytometry.  
 
IV.1.9.1 Reduced A20-/-;NIK+ B-cell pool is maintained in aged animals 
In young mice, the combination of homozygous loss of A20 with activation of the 
alternative NF-B pathway, by over expression of NIK, in B-cells leads to reduced B-cell 
numbers in spleen and other secondary lymphoid organs.  
 
In aged mice, the homozygous loss of A20 in B-cells leads to larger spleens compared to 
CD19cre controls (Figure 19A). On the other hand, the over expression of NIK in B-cells 
leads to spleens similar in size as controls. Combining loss of A20 and overexpression of 
NIK in B-cells leads to an A20-loss dose dependent increase in both spleen mass and 
cellularity (Figure 22A).  
 
The ex vivo analysis of spleens of aged mice revealed that the observed reduced B-cell 
numbers in young A20F/F NIK-tg CD19cre mice are maintained in old age (Figure 22B). 
Both the over expression of NIK in B-cells, as well as the loss of A20 in B-cells, leads to a 
two-fold increase in B-cell numbers in spleens of aged mice compared to CD19cre 
controls (Figure 22C). Combining the heterozygous loss of A20 with overexpression of 
NIK in B-cells leads to a two-fold increase in B-cell numbers compared to the NIK-tg 
CD19cre mice (over three-fold increase from CD19cre controls) (Figure 22C). However, 
the additional inactivation of the second allele of A20 leads to reduced B-cell 
percentages (Figure 22B) and numbers similar to the CD19cre control mice (Figure 
22C).  
 
The expression of the NIK-tg can be followed through expression of the eGFP reporter. 
The ex vivo flow cytometry analysis splenic B-cells shows that 90 to 95% of NIK+ and 
A20+/-;NIK+ B-cells express eGFP, compared to only 60% of the GFP positive A20-/-
;NIK+ B-cells (Figure 22D). In spleens of aged mice, there is a two-fold increase in 
eGFP+;A20+/-;NIK+ B-cell numbers compared to eGFP+;NIK+ B-cells. While the loss of 
the second allele of A20 leads to significant 75% reduction in eGFP positive B-cell 
numbers compared to the eGFP+;A20+/-;NIK+ B-cells (Figure 22E). At the same time, 
the number of eGFP-;A20-/-;NIK+ B-cells is significantly increased in spleens of A20F/F 
NIK-tg CD19cre aged mice compared to other NIK compound mice (Figure 22E). 
 






Figure 22. Reduced B-cell numbers are maintained in A20F/F NIK-tg CD19cre mice  
Ex vivo analysis of B-cells in spleens from aged mice using flow cytometry. (A) Spleen mass and 
splenocytes numbers. Flow cytometry contour plots depict the percentages and bar charts indicate the 
numbers for (B, C) B-cells and (D, E) eGFP reporter expression in B-cells. All flow cytometry plots are 
representative of at least 2 experiments, except for the A20F/F NIK-tg/tg CD19cre mice. Bar charts 
depict medians and the values are indicated below each histogram. Statistical analysis was done using 
Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
eGFP (enhanced green fluorescent protein), pos. (positive), neg. (negative), B-cells (B220+), eGFP pos 
(B220+ eGFP+), eGFP neg (B220+ eGFP-) 
 
 
Loss of A20 combined with activation of the alternative NF-B signalling leads to a more 
aggressive B-cell phenotype. Although I only aged and analysed one A20F/F NIK-tgI/I 
CD19creI/wt (from now on referred to as A20F/F NIK-tg/tg CD19cre) mouse, the B-cell 
phenotype observed is magnified. This one animal had a larger spleen than the median 
spleen mass for the A20F/F NIK-tg CD19cre mice and presented high cellularity (Figure 
22A). Moreover, this mouse presented reduced B-cell numbers comparable to that of the 
A20F/F NIK-tg CD19cre mice (Figure 22C). Finally, the total number of eGFP positive B-
cells was 50% lower than the median value observed in eGFP+;A20-/-;NIK+ B-cells, and 





the total number of eGFP negative B-cells was similar to that of eGFP-;A20-/-;NIK+ B-
cells (Figure 22E).  
 
In summary, strong activation of the alternative NF-B pathway in B-cells leads to B-cell 
hyperplasia in young and old age. Similarly, activation of the canonical NF-B pathway 
in B-cells by inactivation of A20, a negative regulator, also leads to B-cell hyperplasia in 
aged mice. Moreover, the combination of heterozygous loss of A20 with over expression 
of NIK, leads to exacerbated B-cell hyperplasia in young and old mice. However, the 
additional inactivation of the second allele of A20 leads to reduced B-cell numbers in 
young and aged animals.  
 
IV.1.9.2 The T-cell activated phenotype is maintained in aged A20F/F NIK-tg 
CD19cre mice 
In young mice, the loss of A20 combined with the overexpression of NIK in B-cells leads 
to a T-cell hyperplasia that affects mainly CD25+ CD4 regulatory T-cells, as well as 
effector-like CD4 and CD8 T-cells. 
 
In spleen of aged mice, there is a clear increase in the percentages of ex vivo T-cells in 
A20F/F NIK-tg CD19cre mice compared to other NIK compound mice (Figure 23A). 
Moreover, this translates in significant higher T-cell numbers in the spleen compared to 
NIK-tg CD19cre control mice (Figure 23C).  
 
The analysis of the different T-cells subpopulations in the spleen of aged mice was 
consistent with the phenotype observed in young mice. The CD25+ CD4 regulatory T-
cells in A20F/F NIK-tg CD19cre mice are present in higher percentages and higher cell 
numbers than in A20F/wt NIK-tg CD19cre or NIK-tg CD19cre mice (Figure 23B and D). 
The increase in CD25+ CD4 regulatory T-cells is accompanied by a reduction in cCD4 T-
cell percentages (Figure 23B), however this is not reflected in the cCD4 T-cell numbers. 
Although the differences are not statistically significant, the A20F/F NIK-tg CD19cre 
mice have higher cCD4 T-cell numbers compared to the NIK-tg CD19cre mice, while the 
A20 F/wt NIK-tg CD19cre have intermediate numbers (Figure 23D).  






Figure 23. T-cell hyperplasia is maintained in aged A20F/F NIK-tg CD19cre mice 
Ex vivo analysis of T-cells from spleens of aged mice using flow cytometry. Contour plots depict 
percentages and bar charts indicate cell numbers for (A, C) T-cells and (B, D) CD8 T, cCD4 T and 
CD25+ CD4 T-cell subsets. All flow cytometry plots are representative of at least 2 experiments, except 
for the A20F/F NIK-tg/tg CD19cre mice. Bar charts depict medians and the values are indicated below 










































































































































































































































Figure 23 (continued). T-cells (TCR+), CD8 T (TCR+ CD8+), CD4 T (TCR+ CD4+), cCD4 T 




Figure 24. Effector-like T-cells are expanded in aged A20F/F NIK-tg CD19cre mice 
Ex vivo analysis of T-cell activation in spleens from aged mice using flow cytometry. Contour plots 
depict the percentage of naïve-like, effector-like and memory-like cells and bar charts indicate cell 
numbers for (A) cCD4 and (B) CD8 T-cells. All flow cytometry plots are representative of at least 2 
experiments, except for the A20F/F NIK-tg/tg CD19cre mice. Bar charts depict medians and the values 
are indicated below each histogram. Statistical analysis was done using One-way ANOVA (** p<0.01) or 
Kruskal-Wallis (¥ p<0.05). 
cCD4 (conventional CD4, TCR+ CD4+ CD25-), CD8 (TCR+ CD8+), Naïve (CD62L+ CD44-), Effector 
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In spleens of aged mice the percentages of CD8 T-cells increased slightly as A20 is lost in 
NIK-tg CD19cre compound mice (Figure 23B). However this translates into a clear 
expansion of CD8 T-cells in the A20F/F NIK-tg CD19cre mice (Figure 23D), while the 
NIK-tg CD19cre have similar CD8 T-cell numbers as the CD19cre controls. Interestingly, 
the additional loss of one allele of A20 leads to an intermediate phenotype in CD8 T-cell 
numbers (Figure 23D). 
 
Ex vivo flow cytometry analysis of cCD4 T-cells in the spleen of aged mice revealed a 
similar increase in effector-like CD4 T-cells in A20F/F NIK-tg CD19cre and A20F/wt 
NIK-tg CD19cre mice compared to controls (Figure 24A and B). Even though not 
significant, these mice also presented with higher numbers of memory-like CD4 T-cells 
than the NIK-tg CD19cre controls (Figure 24B). 
 
Likewise, the number of ex vivo effector-like CD8 T-cells in A20F/F NIK-tg CD19cre aged 
mice is significantly increased compared to NIK-tg CD19cre controls (Figure 24D). 
Again, in mice with A20+/-;NIK+ B-cells, the numbers of CD8 effector-like T-cells are 
intermediate between the A20F/F NIK-tg CD19cre and the NIK-tg CD19cre mice. Finally, 
there is an increase in naïve- and memory-like CD8 T-cells numbers in A20F/F NIK-tg 
CD19cre mice compared to controls (Figure 24D).  
 
Additionally, the one A20F/F NIK-tg/tg CD19cre mouse analysed presented with a 
similar T-cell phenotype to the A20F/F NIK-tg CD19cre mice. This mouse presented 
increased T-cell numbers and increased CD25+ CD4 regulatory T-cell numbers 
comparable to the A20F/F NIK-tg CD19cre mice (Figure 23C and D). Furthermore, most 
of the cCD4 and CD8 T-cells had an effector-like phenotype (Figure 24B and E). 
 
Therefore, in aged mice the presence of A20-deficient;NIK+ B-cells is accompanied by T-
cell hyperplasia that affects all T-cell subsets, similarly to young mice. The elevated ex 
vivo effector-like cCD4 and CD8 T-cell numbers present in these mice suggest a 
sustained activation of these T-cells during the mouse life.  
  
  





IV.1.9.3 Myeloid expansion in aged A20F/F NIK-tg CD19cre mice 
In young mice the loss of A20 in combination with the overexpression of NIK has no 
evident effect on the myeloid populations. Nonetheless, it is in aged the A20F/F CD19cre 
mice that the myeloid expansion is stronger.[79, 254] Therefore, I decided to 
characterise myeloid cells in the spleen of aged mice.  
 
The ex vivo flow cytometry analysis of spleens from aged mice revealed an expansion of 
myeloid cells in A20F/F NIK-tg CD19cre mice. There is a tendency for higher myeloid 
percentages and cell numbers correlating with increasing loss of A20 alleles. The main 
myeloid population that is affected are the neutrophils. There is a significant four-fold 
expansion of neutrophil percentages in the A20F/F NIK-tg CD19cre mice compared to 
both the A20F/wt NIK-tg CD19cre and NIK-tg CD19cre mice (Figure 25B). This 
expansion translates into a significant five-fold increase of neutrophil cell numbers 
compared to A20F/wt NIK-tg CD19cre mice (Figure 25A). Second, there is a significant 
two to three-fold increase in monocyte percentages and a three to four-fold increase in 
cell numbers in the A20F/F NIK-tg CD19cre mice compared to other NIK-tg mice (Figure 
25A and B). Third, there is an increase in eosinophil percentages that translates into a 
significant two-fold expansion of eosinophils in A20F/F NIK-tg CD19cre mice compared 
to compound NIK-tg mice. Fourth, there is also a significant increase in the percentage of 
dendritic cells that translates into a four-fold expansion in cell numbers in the A20F/F 
NIK-tg CD19cre mice compared to NIK-tg CD19cre aged mice. Moreover, the A20F/wt 
NIK-tg CD19cre mice already had a significant increase in dendritic cell numbers 
compared to NIK-tg CD19cre controls (Figure 25A). 
 
Interestingly, the only A20F/F NIK-tg/tg CD19cre mouse analysed has higher dendritic 
and eosinophil cell numbers compared to the A20F/F NIK-tg CD19cre aged mice. 
Therefore, this late onset of myeloid expansion could be a long term phenotype arising 
from B-cell signals with strong aberrant NF-B activation.  
 






Figure 25. Myeloid cell expansion in aged A20F/F NIK-tg CD19cre mice 
Ex vivo analysis of myeloid cells in spleens from aged mice using flow cytometry. Bar charts show (A) 
cell numbers and (B) percentages of the different myeloid cells. Bar charts depict medians and the 
values are indicated below each histogram. Statistical analysis was done using One-way ANOVA (* 
p<0.05, ** p<0.01) or Kruskal-Wallis (¥ p<0.05, ¥¥¥ p<0.001). 
DC (dendritic cells, CD11c+), EOs (eosinophils, CD11c+ CD11b+ SiglecFhi F4/80hi); Mono (monocytes, 











































































































































































IV.1.9.4 NK and NKT cells in aged mice 
The presence of B-cells that have activated both the canonical and the alternative NF-B 
pathways in aged mice leads to the development of T-cell hyperplasia that is 
accompanied by a myeloid expansion. In some instances, the aged A20F/F NIK-tg 
CD19cre mice develop gut inflammation that results in bleeding. To exclude the 
possibility of an autoimmune phenotype, I analysed a small cohort of aged mice for the 
presence of natural killer cells (NK) and natural killer T-cells (NKT). 
 
In spleen of aged mice, the percentage of ex vivo NK cells in A20F/F NIK-tg CD19cre mice 
did not differ from that of control mice (Figure S 14A-C). The total number of NK cells 
observed is similar for all mice except the A20F/F CD19cre animals (Figure S 14D). 
Additionally, the percentage of ex vivo NKT cells observed in A20F/F NIK-tg CD19cre 
mice is higher than that of the A20F/wt NIK-tg CD19cre mice, but not significantly 
different from the controls (Figure S 14C). Moreover, the number of NKT cells in the 
A20F/F NIK-tg CD19cre animals was two-fold higher than that of the A20F/wt NIK-tg 
CD19cre mice, but similar to the controls. The A20F/F CD19cre mouse also had lower 
numbers of NKT cells. 
 
Therefore, the reduced B-cell numbers observed in young and aged A20F/F NIK-
tg CD19cre mice are not a consequence of an innate immune response associated 
with NK or NKT cells.  





IV.2 ROLE OF CANONICAL NF-B IN B-CELL TRANSFORMATION 
 
Canonical NF-B target genes are involved in proliferation and cell survival, however to 
date there is no clear evidence that canonical NF-B activation alone results in B-cell 
lymphomagenesis [37]. Therefore, I wanted to address the role of canonical NF-B 
signalling in driving B-cell lymphomagenesis.  
 
In order to constitutively activate the canonical NF-B pathway specifically in B-cells I 
made use of the available conditional mouse strain R26LSL-Ikk2ca and the CD19cre 
mouse strain. The constitutive activation of the canonical NF-B pathway can be 
induced by the gain of one or two alleles of a conditional constitutive active mutant of 
the IKK2/IKK- subunit (IKK2ca) knocked into ROSA26 locus [37]. For that purpose I 
used the R26LSL-Ikk2ca mouse strain that expresses IKK2ca after Cre-mediated excision 
of the loxP-flanked STOP cassette either heterozygously (R26LSL-Ikk2caI/wt) or 
homozygously (R26LSL-Ikk2caI/I). B-cells that express the IKK2ca knock-in after Cre-
mediated recombination will also express the eGFP reporter, located after an IRES 
sequence 3’ of the IKK2ca cDNA, thus allowing the identification of recombined cells by 
flow cytometry. To conditionally activate my gene of interest specifically in B-cells, I 
used the CD19cre mouse strain heterozygously (CD19creI/wt) [241]. As mentioned 
before, this mouse strain expresses the Cre recombinase as a knock-in under the control 
of the CD19 promoter instead of the endogenous CD19; the resulting CD19creI/wt mice 
are heterozygous knockout for CD19 and express the Cre recombinase.  
 
IV.2.1 CANONICAL NF-B PROMOTES B1A CELL DEVELOPMENT 
It has already been described in young mice that constitutive canonical NF-B activation 
in B-cells by the conditional expression of one copy (R26LSL-Ikk2caI/wt CD19creI/wt, from 
now on referred to as R26-IKK2ca CD19cre) or two copies of the knock-in IKK2ca 
(R26LSL-Ikk2caI/I CD19creI/wt from now on referred to as R26-IKK2ca/ca CD19cre) 
present enlarged spleens and B-cell hyperplasia [37] in a dose dependent manner 
(Figure S 16). Additionally, constitutive canonical NF-B activation promotes expansion 
of the B1 lineage in these mice, affecting mainly the B1a subset but B1b subset in same 
cases (Figure S 17). This B1a expansion is not limited to the peritoneum, but can also be 
observed in the spleen of young mice, where the R26-IKK2ca/ca CD19cre mice present a 
significant 15-fold increase in B1a cell numbers compared to CD19cre controls and R26-





IKK2ca CD19cre mice (Figure S 18). Therefore, constitutive canonical NF-B activation 
leads to B-cell hyperplasia and to the expansion of B1a-cells.  
 
IV.2.2 CONSTITUTIVE CANONICAL NF-B ACTIVATION IN B-CELLS DRIVES B-CELL 
EXPANSION RESEMBLING SMALL LYMPHOCYTIC LYMPHOMA IN AGED MICE 
In young mice, constitutive canonical NF-B activation leads to the expansion of the B1a 
subset. In order to study the role of constitutive NF-B activation in B-cell 
lymphomagenesis, mice were aged and monitored for the development of B-cell 
malignancies. With age, constitutive canonical NF-B activation leads to the progressive 
accumulation of B1a cells in the lymphoid organs in mice reminiscent of chronic 
lymphocytic leukaemia in mice. To further characterize this B1a expansion, aged mice 
conditionally expressing the IKK2ca knock in in B-cells were compared to the already 
established model for murine CLL, E-TCL1tg {Bichi:2002fc}. In this part of the results I 
will first describe the role of constitutive canonical activation in B-cell 
lymphomagenesis. Second, I will compare the results from the aged IKK2ca cohort with 
the TCL1tg mice.  
 
IV.2.2.1 Constitutive canonical NF-B activation in B-cells drives a CD5+ B-cell 
expansion in aged mice 
In order to address the role of constitutive NF-B activation in B-cell lymphomagenesis 
a cohort of mice was aged in order to monitor development of disease. Interestingly, 
expression of IKK2ca in B-cells led to a dose-dependent reduction in life-span in mice: 
R26-IKK2ca CD19cre mice presented a median survival of 476 days, compared to 351 
days for the R26-IKK2ca/ca CD19cre mice (Figure 26A). Therefore, the constitutive 
activation of NF-B in B-cells leads to a reduced median survival in aged mice compared 
to CD19cre control mice (Figure 26A), linking the activation of NF-B in B-cells with a 
shorter life-span.  
 
The analysis of nine-months or older R26-IKK2ca compound mice revealed slightly 
enlarged livers that were infiltrated with lymphocytes (Figure 26B and data not shown). 
Similarly, spleens were significantly enlarged in an IKK2ca dose dependent manner with 
a two-fold and four-fold mass increase in the R26-IKK2ca CD19cre and R26-IKK2ca/ca 
CD19cre mice, respectively (Figure 26B).  
 





Ex vivo flow cytometry analysis of spleens from aged mice showed that the B-cell 
hyperplasia observed at young age is maintained throughout the life of the animal 
(Figure 26C). Interestingly, a substantial percentage of B-cells in the spleens of R26-
IKK2ca/ca CD19cre mice is phenotypically similar to the B1a subset (Figure 26D and 
Figure S 19). While R26-IKK2ca CD19cre spleens showed a two-fold increase in B1a-like 
cells compared to CD19cre controls, R26-IKK2ca/ca CD19cre spleens had a significant 
19-fold and 59-fold increase in B1a-like cell numbers compared to R26-IKK2ca CD19cre 
and CD19cre control mice respectively (Figure 26C, D and Figure S 19). On the other 
hand, there was a significant two-fold increase in B2-cells in both R26-IKK2ca/ca 
CD19cre and R26-IKK2ca CD19cre mice compared to CD19cre controls in spleen (Figure 
S 19). 
 
Similarly, the long term effect of constitutive canonical NF-B activation in B-cells 
resulted in a significant dose dependent increase in cellularity in the peritoneal cavity in 
aged mice compared to CD19cre controls (Figure 27A). Moreover, a small number of 
cases additionally presented with fluid in the peritoneal cavity (4 out of 14). Finally, the 
expression of the IKK2ca knock-in in B-cells resulted in a significant dose dependent 
increase of total B-cell and B1a cell numbers in the peritoneum of aged mice (Figure 27).  
 
Moreover, in 10-12 months aged R26-IKK2ca/ca CD19cre mice B1a-like cells can be 
detected in the draining inguinal, axillary, and superficial cervical lymph nodes (Figure 
28 and Figure S 20) and to a lesser extent in the mesenteric lymph nodes (Figure S 21). 
The expression of the IKK2ca knock-in specifically in B-cells leads to aged mice with 
enlarged lymph nodes accompanied by a significant increase in cellularity and B-cell 
numbers in a dose dependent manner compared to CD19cre control mice (Figure 28A). 
There is a significant four-fold and 13-fold increase in B-cell numbers in the lymph 
nodes of the R26-IKK2ca CD19cre and R26-IKK2ca/ca CD19cre mice (Figure 28B and C). 
Moreover, constitutive canonical NF-B in B-cells leads to a dose dependent increase in 
B2-cell numbers. Additionally, there is an infiltration of B1a-like cells and to a lesser 
extent B1b-cells in the draining lymph nodes (Figure 28D, E and Figure S 20).  
 
Likewise, constitutive canonical NF-B activation in B-cells leads to significantly 
enlarged mLN with higher number of B-cells, particularly in the R26-IKK2ca/ca CD19cre 
mice (Figure S 21A and B). Moreover, although a few R26-IKK2ca CD19cre mice present 
an infiltration of B1a-like cells in the mLN, in the R26-IKK2ca/ca CD19cre aged mice this 
infiltration is more prominent (Figure S 21D and E).  







Figure 26. Canonical NF-B activation causes splenic B1a cell expansion in aged mice 
Ex vivo analysis of B-cells in spleens of aged mice (> 9 months) using flow cytometry. (A) Kaplan-Meier 
survival curve analysis for R26-IKK2ca CD19cre compound mice and TCL1tg CD19cre mice, number of 
deceased and censored animals is indicated, as well as the median survival age in days. (B) Bar charts 
show the liver and spleen mass. (C) Bar charts show the number of splenocytes, B-cells and B1a-cells 
in spleen. (D) Flow cytometry contour plots depict the percentage of B1a-like cells. All flow cytometry 
contour plots are representative of at least 2 experiments. Histograms depict medians, and values are 
indicated below each histogram. Statistical analysis was done using One-way ANOVA (* p<0.05, *** 
p<0.001) or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
Spl (spleen), Lymph. (lymphocytes), B-cells (CD19+), and B1a (CD19+ B220lo CD5+ or CD19+ CD5+). 






Figure 27. Canonical NF-B activation causes B1a cell expansion in the peritoneal 
cavity of aged mice 







Figure 28. Canonical NF-B activation causes B1a cell expansion in the lymph nodes 
of aged mice 
 





Figure 27 (continued). Canonical NF-B activation causes B1a cell expansion in the peritoneal 
cavity of aged mice 
Ex vivo analysis of B-cells in peritoneal cavity of aged mice using flow cytometry. (A) Peritoneal cavity 
cell numbers after lavage. (B) Bar charts show total cell numbers and (C) flow cytometry contour plots 
depict percentages for B-cells and eGFP positive B-cells. (D) Bar charts show B-cell subset B2, B1a 
and B1b numbers after lavage. (E) Flow cytometry contour plots depict percentages of B2, B1, B1a and 
B1b-cells. All flow cytometry contour plots are representative of at least 2 experiments. Histograms 
depict medians, and values are indicated below each histogram. Statistical analysis was done using 
Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
PC (peritoneal cavity), Lymph. (lymphocytes), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), B2 (CD19+ 
B220hi), B1 (CD19+ B220lo), B1a (CD19+ B220lo CD5hi) and B1b (CD19+ B220lo CD5-). 
 
 
Figure 28 (continued). Canonical NF-B activation causes B1a cell expansion in the lymph nodes 
of aged mice 
Ex vivo analysis of B-cell in lymph nodes of aged mice using flow cytometry. Draining inguinal, axillary, 
and superficial cervical lymph nodes were pooled and analysed together. (A) Bar charts show cell 
numbers for pooled lymph nodes. (B) Bar charts show cell numbers and (C) flow cytometry contour 
plots depict percentages for B-cell and eGFP positive B-cells. (D) Bar charts show the number of B2, 
B1a and B1b subsets in lymph nodes of aged mice. (E) Flow cytometry contour plots depict percentage 
of B1a-like cells in lymph nodes. All flow cytometry contour plots are representative of at least 2 
experiments. Histograms depict medians, and values are indicated below each histogram. Statistical 
analysis was done using Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
LN (lymph nodes), Lymph. (lymphocytes), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), B2 (CD19+ 
B220hi), B1a (CD19+ CD5hi or CD19+ B220lo CD5hi) and B1b (CD19+ B220lo CD5-). 
 
 
Finally, the ex vivo analysis of the bone marrow in aged mice shows slightly reduced 
median B-cell numbers in the R26-IKK2ca CD19cre compound mice compared to the 
CD19cre control (Figure S 22B). Reduced B2-like median cell numbers caused this 
reduction in an R26-IKK2ca knock-in dose dependent manner. Additionally, the R26-
IKK2ca/ca CD19cre mice presented with a small B1a-like population (Figure S 22C). 
 
Together, I show here that the constitutive activation of NF-B in B-cells leads to a 
significant accumulation of B1a-like cells with age that can migrate to different 
lymphoid compartments, such as draining lymph nodes (Figure 28). Of the CD5+ B-cell 
lymphoproliferative disorders described in humans, the novel phenotype described for 
aged R26-IKK2ca/ca CD19cre mice is reminiscent of a variant of human chronic 
lymphocytic leukaemia (CLL): human small lymphocytic leukaemia (SLL). Human 
SLL/CLL is characterized by the expansion of small CD5+ IgM+ B-cells that accumulate 
with age. The main difference between SLL and CLL is that in the former the spleen and 
lymph nodes are compromised, while in the latter the CD5+ cells are also detected in the 
circulation.  
 





IV.2.2.2 Comparison of the CD5+ B-cell expansion in R26-IKK2ca/ca CD19cre mice 
with TCL1tg-driven CLL-like murine disease 
Given the reduced survival and CD5+ B220lo B-cell expansion observed in aged R26-
IKK2ca/ca CD19cre mice, it is likely that constitutive canonical NF-B activation leads to 
a disease similar to SLL/CLL in mice. There are several mouse strain lines available that 
model different aspects of CLL in mice with different penetrance levels [228]. One of the 
most used and best validated lines is the E-TCL1 transgenic (E-TCL1tg) line that 
expresses the human TCL1 oncogene under control of the E enhancer element in B-
cells [229]. Mice carrying E-TCL1tg develop a disease similar to human CLL, where 
there is a gradual accumulation of CD5+ CLL-like cells in the mice that infiltrate 
lymphoid niches and cause a reduced median survival of 12-14 months [229].  
 
Given the SLL-like phenotype observed in aged R26-IKK2ca/ca CD19cre mice, I aged a 
cohort of E-TCL1tgpos CD19creI/+ (from now on referred to as TCL1tg CD19cre) mice to 
compare this murine CLL model to the R26-IKK2ca/ca CD19cre diseased mice. The 
CD19cre knock-in transgene was added to TCL1 to control for the effects of Cre 
expression and heterozygous knockout of CD19. Aged TCL1tg CD19cre mice have a 
media survival of 308 days, that although significantly shorter than the R26-IKK2ca/ca 
(351 days) shows relative similar dynamics (Figure 26A).  
 
The ex vivo analysis of terminally sick mice revealed that both the R26-IKK2ca/ca 
CD19cre and TCL1tg CD19cre aged mice had significant B1a-like population present in 
the spleen and other lymphoid organs (see below). The two main differences between 
the TCL1tg CD19cre mice and the R26-IKK2ca/ca CD19cre mice were: first, the TCL1tg 
CD19cre driven CLL-like disease in mice has a stronger B1a-like cell burden than the 
R26-IKK2ca/ca CD19cre SLL-like disease described here; second, while there was a 
clear B1a-like cell expansion in both compound mice, there was a severe reduction of 
B2-like cells in the TCL1tg CD19cre mice while the B2- and B1b-cells subsets were 
expanded in the aged R26-IKK2ca/ca CD19cre mice. 
 
The ex vivo analysis of aged TCL1tg CD19cre mice revealed, similarly to the R26-
IKK2ca/ca CD19cre mice, the presence of enlarged livers and spleens compared to the 
CD19cre aged matched controls ([229] and Figure 26B). Moreover, the median number 
of CD5+ CLL-like cells in the spleens of burdened TCL1tg CD19cre mice was only two-
fold bigger than in the R26-IKK2ca/ca CD19cre mice (Figure 26C and D). Interestingly, 





the constitutive canonical NF-B activation in B-cells allowed for the persistence of B2-
cells in R26-IKK2ca/ca CD19cre mice, whereas in the TCL1tg CD19cre mice was reduced 
to 17% of the CD19cre control (median value of 5 million cells compared to 29 million 
cells) ([229], Figure 26D and Figure S 19).  
 
Furthermore, in the ex vivo analysis of the peritoneal cavity of burdened TCL1tg 
CD19cre mice showed a significant increase in total, B-cell and B1a-cell numbers 
compared to the CD19cre control mice, however not as drastic as observed in the R26-
IKK2ca or R26-IKK2ca/ca CD19cre compound mice (Figure 27A, B and D). Additionally, 
the B-cell compartment in the peritoneum was mainly consistent of B1a-like cells in the 
TCL1tg CD19cre mice, while there were also B2- and B1b-cells in the R26-IKK2ca/ca 
CD19cre mice (Figure 27D and E).  
 
Similarly to the R26-IKK2ca/ca CD19cre mice, the TCL1tg CD19cre mice also presented 
with CD5+ CLL-like cells in lymph nodes and in some instances in the mesenteric lymph 
nodes (Figure 28 and Figure S 21). In the lymph nodes particularly, there were two-folds 
higher B1a-like cells in the aged R26-IKK2ca/ca CD19cre aged mice compared to the 
burdened TCL1tg CD19cre mice (Figure 28D). Moreover, in the R26-IKK2ca/ca CD19cre 
the CD5+ B-cells corresponds only to 6% of all B-cells, whilst it represents 34% in the 
TCl1tg CD19cre mice (Figure S 20B). Additionally, the TCL1tg CD19cre mice had 
significantly lower B-cell numbers compared to the R26-IKK2ca CD19cre compound 
mice (Figure 28B), which corresponded mainly to the reduced B2- cell numbers in the 
lymph nodes (Figure 28D). 
 
Finally, the burdened TCL1tg CD19cre mice had an infiltration of 0.2 million CD5+ CLL-
like cells in the bone marrow, which was two-fold higher than that observed in the aged 
R26-IKK2ca/ca CD19cre mice. The TCL1tg CD19cre mice had significantly lower 
cellularity, a tendency for less B-cells and significantly lower B2-cells in the bone 
marrow compared to aged R26-IKK2ca/ca CD19cre mice (Figure S 22).  
 
The similar phenotypes observed in R26-IKK2ca/ca CD19cre and TCL1tg CD19cre mice 
suggest a role in constitutive canonical NF-B signalling in the development of an 
SLL/CLL-like disease in mice. The slight differences observed in the latency periods are 
mirrored by the lower burden and infiltration of CD5+ B1a-like cells in the R26-
IKK2ca/ca CD19cre compared to the TCL1tg CD19cre mice.  
 





IV.2.3 EFFECT OF CONSTITUTIVE CANONICAL NF-B ACTIVATION IN THE TCL1 
CHRONIC LYMPHOCYTIC LEUKAEMIA MOUSE MODEL 
Strong canonical NF-B activation in B-cells leads with age to the development of a 
SLL/CLL-like disease in mice, where there is a steady accumulation of CD5+ B1a-like 
cells in different lymphoid organs. To further understand the involvement of canonical 
NF-B activity in SLL/CLL development I generated compound mice that expressed both 
the IKK2ca knock-in allele and the E-TCL1tg in B-cells using the CD19cre mouse strain. 
Mice were aged and monitored for the development of disease. 
 
Blood monitoring allowed to determinate the time point when the animal had reached a 
burdened phenotype. The humane end point was set to the presence of over 50% of 
CD5+ B-cells of all living nucleated peripheral blood cells or the development of 
splenomegaly, hepatomegaly and/or anaemia. The control for disease development was 
the TCL1tg CD19cre mouse model. As already mentioned above, the median survival for 
the TCL1tg CD19cre mice was 308 days (Figure 26A and Figure 29A). In the TCL1tg 
CD19cre compound mice the CD5+ CLL-like B-cells can be detected in the peripheral 
blood from two months of age onwards (geometric mean 1.5% of living cells). There is a 
slow progressive accumulation of these cells with time reaching 5% at 5 months and 
29% of living cells within 9 months of age (Figure 29B and Figure S 23A).  
 
IV.2.3.1 Constitutive NF-B activation in B-cell cooperates with the TCL1 oncogene 
by accelerating the disease progression  
The survival analysis and blood monitoring shows that constitutive NF-B activation in 
B-cells cooperates with the TCL1 oncogene in promoting a CLL-like disease in mice in a 
shorter time frame in an IKK2ca dose dependent manner (Figure 29). The E-TCL1tgpos 
R26LSL-Ikk2caI/I CD19creI/+ compound mice (from now on referred to as TCL1tg R26-
IKK2ca/ca CD19cre) show the strongest phenotype. These mice have the shortest 
median survival, 121 days (Figure 29A), and show the most aggressive accumulation of 
CD5+ B-cells in peripheral blood in the fastest time frame (Figure 29B and Figure S 23C). 
At 2 months of age 9% of all living cells in the peripheral blood are CD5+ B1a-like cells, 
rising to 37% at 3 months of age and reaching 72% within 4 months of age (Figure 29B 
and Figure S 23C).  
 





In contrast, the E-TCL1tgpos R26 LSL-Ikk2caI/+ CD19creI/+ mice (from now on referred to 
as TCL1tg R26-IKK2ca CD19cre) showed an intermediate phenotype. The TCL1tg R26-
IKK2ca CD19cre mice had a median survival of 186 days, 65 days significantly longer 
than the TCL1tg R26-IKK2ca/ca CD19cre and 122 days significantly shorter than the 
TCL1tg CD19cre mice (Figure 29A). There was an intermediate progression in the 
accumulation of CD5+ B1a-like cells in the peripheral blood, reaching 32% of all living 
nucleated cells in the peripheral blood at 6 months of age (Figure 29B and Figure S 23B).  
 
Ex vivo analysis of the spleen of burdened TCL1tg compound mice further supports the 
cooperation of constitutive canonical NF-B activation with the TCL1tg oncogene in 
promoting the CLL-like disease in mice. Expression of the IKK2ca knock-in in B-cells in 
combination with the TCL1tg oncogene resulted in enlarged spleens with higher B-cell 
and CD5+ B1a-cell numbers in a shorter time frame in an IKK2ca dose dependent 




Figure 29. Co-operation between IKK2ca and TCL1 in CLL-like disease 
Monitoring of TCL1tg CLL-dependent development in the presence of canonical NF-B activation. (A) 
Kaplan-Meier survival curve analysis for TCL1tg and R26-IKK2ca compound mice. Number of deceased 
and censored animals is indicated, as well as the median survival age in days. (B) Scatter plot shows 
the percentage of B1a-like cells present in peripheral blood after red blood cell lysis, over a period of 13 
months. The connecting line represents the mean for each time point. 





First, both 3-months-old TCL1tg R26-IKK2ca/ca CD19cre and 5-months-old TCL1tg 
R26-IKK2ca CD19cre mice had a two-fold increase in spleen size compared to 9-month-
old TCL1tg CD19cre mice (Figure 30A). Second, the constitutive canonical NF-B 
activation resulted in a small increase in B-cell percentages in the spleen (Figure S 24A). 
Moreover, there was a significant increase in B-cell numbers caused by the combination 
of IKK2ca and TCL1 compared to the individual transgene. While the addition of one 
copy of the IKK2ca knock-in to the TCL1tg resulted in a significant five-fold increase in 
B-cells numbers at 5 months of age, two copies led to a significant eight-fold increase at 
3 months of age compared to 9-month-old TCL1tg CD19cre controls (Figure 30B). The 
B-cell expansion observed is associated to IKK2ca-mediated canonical NF-B activation 
since more than 92% of the B-cells expressed the eGFP reporter (Figure S 24B).  
 
Finally, the ex vivo analysis of the spleens revealed that 80-90% of all B-cells present 
were CD5+ B1a-like cells (Figure 30C, D, E and Figure S 24). There was a significant 
increase in CD5+ B1a-like cell numbers in the R26-IKK2ca TCL1tg compound mice 
compared to the aged R26-IKK2ca compound mice. Moreover, the canonical NF-B 
activation in B-cells when combined with the TCL1tg oncogene resulted in a 190-fold or 
18-fold increase of CD5+ B1a-like cell numbers in the presence of one or two IKK2ca 
alleles respectively (Figure 30E).  
 
Interestingly, the additional constitutive NF-B activation in B-cells rescued the 
diminished B2 population observed in the TCL1tg CD19cre mice, were most of the B2-
cells where drastically reduced in burdened mice (Figure 30D and E). The increase in 
B2-cell numbers in the TCL1tg CD19cre compound mice happens in an IKK2ca dose 
dependent manner. Nonetheless, the TCL1tg R26-IKK2ca CD19cre mice had significantly 
lower B2-cell numbers compared to the R26-IKK2ca CD19cre mice.  
 
The CD5+ B1a-like expansion in burdened mice is also observed in the peritoneum 
(Figure 31 and Figure S 27), the draining inguinal, axillary, and superficial cervical 
(Figure 32 and Figure S 28) and to a lesser extent the mesenteric lymph nodes (Figure S 
29) and in the bone marrow (Figure S 30). There was a significant increase in cell 
infiltration in the TCL1tg R26-IKK2ca/ca CD19cre mice in all organs analysed compared 
to the TCL1tg CD19cre control.  
 






Figure 30. Co-operation between IKK2ca and TCL1 in splenic B-cells 
Ex vivo analysis of spleen from burdened TCL1 compound mice using flow cytometry. Bar charts show 
(A) spleen mass and (B) B-cell numbers. Flow cytometry contour plots depict the percentage of CD5+ 
B1a-like cells from (C) lymphocytes and (D) B-cells in spleens from sick mice. (E) Bar charts show B2- 
and CD5+ B1a-like cell numbers in spleen from burdened mice. As indicated, burdened TCL1tg R26-
IKK2ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre cohorts were analysed between 3-4 months and 
5-6 months of age, respectively. TCL1tg CD19cre mice and aged matched controls were analysed 
between 9-12 months of age. All flow cytometry contour plots are representative of at least 2 
experiments. Histograms depict medians, and values are indicated below each histogram. Statistical 
analysis was done using Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
mo./m (months of aged), Spl. (spleen), Lymph. (lymphocytes), B-cells (CD19+), B1a (CD19+ CD5hi or 
CD19+ B220lo CD5hi), B2-like (CD19+ B220hi CD5-). 
 






Figure 31. Co-operation between IKK2ca and TCL1 in peritoneal B-cells 
Ex vivo analysis of B-cells in the peritoneal cavity of burdened mice using flow cytometry. Bar chart 
shows (A) total and (B) B-cell cell numbers after lavage. Flow cytometry contour plots depict the 
percentage of CD5+ B1a-like cells from (C) lymphocytes and (D) B-cells in the peritoneum of burdened 
mice. (E) Bar charts show B2- and CD5+ B1a-like cell numbers in PC from burdened mice. As indicated, 
TCL1tg R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre mice cohorts were analysed 
between 3-4 months and 5-6 months of age, respectively. TCL1tg CD19cre mice and aged matched 
controls were analysed between 9-12 months of age. All flow cytometry contour plots are representative 
of at least 2 experiments. Histograms depict medians, and values are indicated below each histogram. 
Statistical analysis was done using Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
mo./m (months of aged), PC (peritoneal cavity), Lymph. (lymphocytes), B-cells (CD19+), B1a-like 
(CD19+ CD5hi or CD19+ B220lo CD5hi), B2-like (CD19+ B220hi CD5-), B1b-like (CD19+ B220lo CD5-). 
 
 






Figure 32. Co-operation between IKK2ca and TCL1 in lymph node B-cells 
Ex vivo analysis of draining lymph nodes of burden mice using flow cytometry. Draining inguinal, 
axillary, and superficial cervical lymph nodes were pooled and analysed together. Bar chart shows (A) 
cell numbers, (B) B-cell and eGFP positive B-cell numbers for pooled draining lymph nodes. (C) Flow 
cytometry contour plots depict the percentage of B1a-like cells from lymphocytes in lymph nodes of sick 
mice. (D) Bar charts show B2-, B1a- and B1b-like cell numbers in lymph nodes of sick mice. As 
indicated, sick TCL1tg R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre mice cohorts were 
analysed between 3-4 months and 5-6 months of age, respectively. TCL1tg CD19cre mice and aged 
matched controls were analysed between 9-12 months of age. All flow cytometry contour plots are 
representative of at least 2 experiments. Histograms depict medians, and values are indicated below 





Figure 32 (continued) each histogram. Statistical analysis was done using Kruskal-Wallis (¥p<0.05, ¥¥ 
p<0.01, ¥¥¥¥ p<0.0001). 
mo./m (months of aged), LN (lymph nodes), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), Lymph. 
(lymphocytes), B1a-like (CD19+ CD5hi or CD19+ B220lo CD5hi), B2-like (CD19+ B220hi CD5-), B1b-like 
(CD19+ B220lo CD5-). 
 
 
Notably, 3-4 months old TCL1tg CD19cre mice present with a small CD5+ B1a-like 
population (median 2.9 million) in the spleen, which is two-fold bigger in the TCL1tg 
R26-IKK2ca CD19cre aged matched mice (Figure S 25E). While one additional copy of 
the IKK2ca knock-in transgene drastically tips the balance towards a CLL-like 
phenotype. Two months later, in 5-6 months old TCL1tg CD19cre mice, this CD5+ B1a-
like population has almost doubled in size (median 5.2 million), while it has massively 
expanded to 421 million in TCL1tg R26-IKK2ca CD19cre mice (Figure S 26E). The 
kinetics of CD5+ B1a-like cell accumulation further points towards a strong cooperation 
between TCL1 and canonical NF-B in the disease progression.  
 
Therefore, the combination of constitutive canonical NF-B activation and the 
expression of the TCL1tg oncogene strongly cooperate in the development of CLL-like 
disease in mice. There are several possible mechanisms of how canonical NF-B could 
accelerate disease progression. It could be possible that a certain NF-B activation 
threshold needs to be reached for the disease to take its course. Alternatively, strong 
canonical NF-B activation could accelerate the proliferation of CLL-like cells, thus 
shortening the expected survival of the mice. Another hypothesis could be that the B1-
cell hyperplasia generated by strong canonical NF-B could increase the number of 
possible CLL precursor cells, thus shortening the survival of the mice.  
 
IV.2.3.2 Characterization of constitutive canonical NF-B activation in the TCL1tg 
murine CLL model 
The constitutive canonical NF-B activation caused by two knock-in transgenes of 
IKK2ca in B-cells leads in age to the accumulation of CD5+ B1a-like cells in lymphoid 
organs and to a median survival of 351 days. When constitutive canonical NF-B 
activation is combined with the TCL1tg, both events cooperate in dramatically 
accelerating disease progression. The CLL-like disease developed in the TCL1tg mouse is 
characterized by a mono to oligoclonal expansion [229]. I therefore, wanted to assess 
whether constitutive activation of the canonical NF-B pathway affects the clonality of 





the disease. If by constitutive activation of the canonical NF-B pathway increases the 
number of potential murine CLL precursors, there might be a higher chance that 
multiple independent events within the same animal would give rise to a clonal 
expansion, translating into a polyclonal disease.  
 
IV.2.3.2.1 Constitutive canonical NF-B activation leads to an oligoclonal 
CLL-like disease in the TCL1tg mouse model 
In order to determine whether constitutive canonical NF-B activation in B-cells has an 
effect on the clonality of the CD5+ B1a-like expansion observed in the TCL1tg mice, I 
decided to take advantage of the BCR diversity analysing the VDJ recombination of the 
immunoglobulin heavy-(IgH) chain. In the C57BL/6 mouse line, a total of 152 VH-gene 
segments, 17-20 DH-gene segments and four JH-gene segments have been described 
(Figure 33A). Taking into account the random process of VDJ recombination and the 
amount of VH, DH and JH gene segments combinations possible, the probability that two 
B-cells share the same VDJ rearrangement is extremely small. Additionally, in the 
process of J and D joining, and DJ to V joining additional variation is added by the 
deletion and insertion of bases, giving rise to unique VDJ rearrangement. The particular 
region of the BCR where the V, D and J gene segments join forms coding determination 
region 3 (CDR3), which recognizes the antigen in the antibody and is the most variable 
part of the antibody.  
 
IV.2.3.2.1.1 JH-gene segment usage analysis 
As an initial step, a PCR was set up that would amplify the IgH VDJ rearrangements. One 
primer binds at the 3’ end of the JH4-gene segment, thus amplifying rearrangements 
into all four JH-gene segments independent of which JH-gene segment was used. The 
other primer binds to the 5’ end of the most commonly used V-gene segments in the 
murine genome. Therefore, amplicons of four different molecular sizes would be visible 
accounting for the rearrangements into the JH1 (1.6Kb), JH2 (1.3Kb), JH3 (1Kb) and JH4 
(500bp) gene segments (Figure S 31A, lane 5).  
 
Genomic DNA was extracted from splenocytes of wild type controls and burdened 
TCL1tg CD19cre, TCL1tg R26-IKK2ca CD19cre or TCL1tg R26-IKK2ca/ca CD19cre mice 
to amplify the IgH VDJ sequence. If after the PCR only one amplicon is detected, or one 
particular amplicon has a stronger intensity, a higher percentage of B-cells rearranged 





into that specific JH-gene segment, one indication for clonal B-cell expansion. To 
illustrate this point, the PCR amplicons for one TCL1tg CD19cre, three TCL1tg R26-
IKK2ca CD19cre and one CD19cre control sample where separated on an agarose gel 
(Figure S 31B). In lane 1 and 4, a band of 1.5Kp is visible in addition to bands of lower 
molecular weight and intensity; therefore the majority of B-cells in both of these 
samples will have a BCR that has rearranged into the JH2-gene segment. Similarly, in 
lane 2 and 3, a band of 500bp is visible in addition to bands of higher molecular weight. 
This means that both samples have a significant percentage of B-cells with BCRs that 
have rearranged into the JH4-gene segment.  
 
IgH VDJ cloning and sequencing of control samples 
In order to assess VDJ rearrangements in more detail, I devised a cloning strategy 
(Figure 33C) described in detail in the Materials and methods section. Briefly, the VDJ 
rearrangements were amplified by PCR and homology cloned into vectors specific for 
each JH-gene segment. An adaptor sequence homologous to the cloning vector was 
introduced upstream of the VH-gene sequence, while a specific sequence homologous to 
a unique sequence within each JH-gene segments termed the catch sequence (CS), was 
cloned into the different JH cloning vectors. Therefore, only amplicons carrying the right 
CS would be cloned into the specific JH destination vectors [248]. 
 
The VDJ rearrangement of the immunoglobulin heavy-chain was cloned from B-cells 
from wild type controls (n=4) or terminally sick TCL1tg CD19cre (n=2), TCL1tg R26-
IKK2ca CD19cre (n=6) or TCL1tg R26-IKK2ca/ca CD19cre (n=3) mice. Two PCR 
multiplex amplifications were designed for rearrangements into JH1 and JH4, as well as 
JH2 and JH3 (Figure S 32). Interestingly, rearrangement into JH2 and JH3 could also be 
detected with the JH1/JH4 PCR reaction (Figure S 32B). Similarly, the rearrangement 
into JH1 could also be amplified with the JH2/JH3 PCR reaction (Figure S 32C). 
 






Figure 33. Strategy for cloning the VDJ rearrangements of the immunoglobulin heavy-
chain.  
(A) Germ line locus for the immunoglobulin heavy-chain (IgH) in the mouse C57BL/6 background. (B) 
The four possible VDJ rearrangements into the different joining-gene segments. (C) First, the genomic 
DNA is extracted from splenocytes containing B-cells. Second, the VDJ rearrangements of the IgH of 
the BCR repertoire are amplified by PCR. Third, the individual amplicons are cloned into JH specific 
plasmids using quick and clean cloning. Forth, blue and white screening is used to identify and quantify 
the number of JH specific colonies. Finally, colonies are picked and the cloned IgH VDJ sequenced. (D) 
Representation of cloned IgH VDJ repertoire in control wild type samples. Total number of white 
colonies obtained for each JH CS plasmid is indicated inside a circle. Blue arrow indicates major clones 
identified for each plasmid, clone type, number of clones with identical sequences and number of 
colonies sequenced (see Tables S1 and S6-S8). Three type of rearrangements were identified: 
sequence type A were unique, sequence type B were identified by different JH CS plasmids, and 
sequence type C were identified more than once within the same JH CS plasmid. 
Figure 33 (continued). VH (variable, yellow), DH (diversity, green), JH (joining, pink), CH (constant, 
blue), Kb (kilo bases), bp (base pairs), PCR (polymerase chain reaction) 
 





The analysis of VDJ rearrangements cloned from wild type B-cells showed that 
additionally to productive rearrangements, unproductive rearrangements could be 
detected (Table S 2, Table S 3, Table S 4 and Table S 5). These unproductive 
rearrangements represent the second heavy-chain allele of a B-cell with a productive 
rearrangement. In the four wild type samples used as controls, these unproductive 
rearrangements represented 27 (20/73 sequences in wild type sample 4) to 44% 
(21/44 sequences in wild type sample 2) of the clones identified. Moreover, rearranged 
sequences with different JH-gene segments located 5’ from the plasmid specific JH catch 
sequences (CS) used could be additionally detected (see Materials and methods). 
 
Interestingly, only in one of the four wild type samples analysed all the sequenced 
colonies had unique VDJ sequences (Table S 2). In the other three wild type samples 
several VDJ sequences found were not unique. In wild type control 3, nine VDJ 
sequences were identified at least twice in the analysis (n=9/80, Table S 4). Similarly, in 
wild type control 4, 13 VDJ sequences were identified at least a second time (n=15/73, 
Table S 6). Moreover, in wild type control 2 (Clone_01, n=4/12; Table S 3), wild type 
control 3 (Clone_058, n=3/24; Table S 4) and wild type control 4 (Clone_08, n=4/22; 
Clone_29 n=3/24; Table S 5) the VDJ rearrangement was identified more than twice in 
the picked colonies. Additionally, in wild type control 4, Clone_15 was identified with 
both with the J2 and the J3 CS plasmids, but belonged to the J1 rearranged samples 
(Table S 5). All other instances, the sequences identified a second time were cloned with 
the same JH CS plasmid. Interestingly, in wild type control 4 two different VDJ 
rearrangements produced the same CDR3 amino acid sequence (Clone_60 and Clone_61; 
Table S 5). 
 
Finally, the IgH VDJ cloning provided information associated with the mutational status 
of each VDJ rearrangement. A 95% of sequence identity with the germ line sequence 
was set as the cut-off value. Any IgH VDJ sequence with an identity above 95% was 
defined as unmuted. However, if the IgH VDJ sequence had less than 95% identity with 
the germ line sequences, then that particular BCR was mutated. That mutational status 
could be used as an indicator of somatic hypermutation and transition through the 
germinal centre. Interestingly, for the majority of the rearrangements cloned the 
sequences had more than 95% identity with the germ line (Table S 2, Table S 3, Table S 
4 and Table S 5). However, in every sample at least one mutated IgH VDJ sequence could 
be identified (Clones 05, 10 and 26 in wild type control 1, Table S 2; Clone_09 in wild 
type control 2, Table S 3; Clones 20, 28, 42 and 62 in wild type control 3, Table S 4; and 





Clones 9 and 14 in wild type control 4, Table S 5). The low number of mutated IgH VDJ 
sequences identified is most likely due to the fact for the wild type controls the bulk of 
B-cells were used, therefore there is a reduced number of germinal centre experienced 
B-cells. 
 
Given that in nature, the possibility for two independent B-cells to generate the same 
VDJ sequence is minimal, the fact that in the current VDJ rearrangement several 
rearrangements have been identified more than once is contradictory. It is likely that 
using genomic DNA as template for the amplifying and cloning the VDJ rearrangements 
in B-cells the same strand of DNA is amplified more and thus there is a higher 
probability for it to be cloned into the JH CS specific destination plasmids. Moreover, the 
identification of both IgH VJD productive and unproductive rearrangements points to 
the possibility of cloning both IgH alleles from the same B-cell with the methodology 
employed here.  
 
IgH VDJ cloning and sequencing of tumour samples 
Given the IgH VDJ rearrangement diversity observed in the wild type control samples in 
the previous part, I decided that the further sequencing of at least eight colonies from 
each JH CS plasmid should be sufficient to determine the clonality of the TCL1tg derived 
lymphomas. Clonal VDJ rearrangements were identified by their higher frequency in the 
pool of sequenced colonies within each JH CS specific plasmid.  
 
The analysis of the cloned VDJ rearrangements from burdened TCL1tg CD19cre mice 
revealed that the CD5+ B1a-like tumours were oligoclonal (Figure 34A and Table 10). In 
the TCL1tg CD19cre sample CLL_00425 two productive and one unproductive clonal 
VDJ rearrangements were identified. As CLL-cells depend on a functional BCR for their 
survival, the identification of an unproductive VDJ clonal rearrangement represents the 
second IgH allele of a productive rearrangement, which is either detect at a similar 
frequency in the analysis or cannot be detected. Interestingly, the CLL_00425 Clone_01, 
containing a rearrangement involving the JH1-gene segment, was detected with both the 
JH2 and JH3 CS specific plasmids. In the case of the TCL1tg CD19cre sample CLL_32284 
four clonal VDJ rearrangements were identified, three of them productive and one 
unproductive. It is likely that the unproductive VDJ rearrangement, Clone_04, 
corresponds to the second IgH allele of one of the other three clones with productive 
rearrangements. Therefore, in reality three main clones would be present in the TCL1tg 





CD19cre sample CLL_32284. These results constitute further evidence of a reduced BCR 
repertoire in these samples. 
 
Further enhanced constitutive activation of canonical NF-B through expression of two 
copies of the IKK2ca transgene does not affect the oligoclonal nature of the CD5+ B1a-
like tumours, as oligoclonal tumours were found in both TCL1tg R26-IKK2ca CD19cre 
(Table 11) and TCL1tg R26-IKK2ca/ca CD19cre burdened mice (Table 12). From the six 
TCL1tg R26-IKK2ca CD19cre samples analysed up to 5 clones were identified per 
sample, not taking into account the functionality of their heavy chain rearrangements 
(Table 11). Importantly, although no functional clonal VDJ rearrangement was identified 
for sample CLL_01140, two clonal unproductive rearrangements were detected. The fact 
that 100% of the sequenced colonies for the JH4 CS plasmid were identical (30/30 
colonies, Figure 34B and Table 11) strongly supports the idea of an oligoclonal 
lymphoma where one clone is dominant.  
 
Table 10. Analysis of IgH VDJ rearrangements cloned from splenocytes of burdened 
TCL1tg CD19cre mice 
Mouse ID Major clones identified 
CLL_32284 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_03 Productive V14-4 D1-1 JH1 99.31 15 CTTSYTTVVADWYFDVW 2/8 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V5-2 D1-1 JH1 99.31 16 CARPHYYGSSRNWYFDVW 2/8 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_02 Productive V1-80 D2-3 JH3 98.96 8 CATNDGFAYW 3/8 
Clone_04 Unproductive V1-67 D1-2 JH3 98.96 X CARTL##WFAYW 2/8 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
All 7 sequences were unique. 
CLL_00425 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-39 D6-3 JH1 99.0 13 CARTRPLWNWYFDVW 16/30 
Clone_03 Unproductive V1-67 P D2-1 JH2 99.3 X CARSTMV#YFDYW 11/30 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-39 D6-3 JH1 99.0 13 CARTRPLWNWYFDVW 3/30 
Clone_02 Productive V1-4 D1-1 JH3 99.0 12 CARYYGSSYWFAYW 24/30 
Clone_03 Unproductive V1-67 P D2-1 JH2 99.3 X CARSTMV#YFDYW 3/30 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
§ Number of colonies with identical sequence and total number of colonies sequenced, * Stop codon in CDR3 region, out-of-frame CDR3, # restored 
frameshift for out-of-frame junctions  





Table 11. Analysis of IgH VDJ rearrangements cloned from splenocytes of burdened 
TCL1tg R26-IK2ca CD19cre mice 
Mouse ID Major clones identified 
CLL0_1140 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Unproductive V1-67 P D2-4 JH4 99.0 16 CARWLL*LRRRHYAMDYW 1/6 





JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Unproductive V1-67 P D2-4 JH4 99.3 16 CARWLL*LRRRHYAMDYW  30/30 
CLL_32351 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V12-3 D2-3 JH1 98.61 12 CAGDSDGYWYFDVW 3/8 
Clone_02 Productive V1-39 D1-1 JH4 98.96 12 CAIDTTVVKAMDYW 2/8 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
CLL_31937 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Unproductive V5-2 D2-5 JH2 99.3 X CARL*##FDYW 8/8 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Not done. 
§ Number of colonies with identical sequence and total number of colonies sequenced, * Stop codon in CDR3 region, out-of-frame CDR3, # restored 
frameshift for out-of-frame junctions 
 
  





Table 11 (continued): Analysis of IgH VDJ rearrangements cloned from splenocytes of 
burdened TCL1tg R26-IK2ca CD19cre mice 
Mouse ID Major clones identified 
 
CLL_32100 
JH1 CS plasmid 




D1-1 JH2 99.3 13 CARHYYGSSYYFDYW 1/10 
Clone_02 Productive V11-2 D2-1 JH1 98.6 11 CMRYGNYWYFDVW 5/10 
Clone_03 Unknown V1-18  JH1 99.0 X 
Rearranged sequence but  
no junction found 
4/10 
JH2 CS plasmid 




D1-1 JH2 99.3 13 CARHYYGSSYYFDYW 5/8 
Clone_02 Productive V11-2 D2-1 JH1 98.6 11 CMRYGNYWYFDVW 1/8 
JH3 CS plasmid 




D1-1 JH2 99.3 13 CARHYYGSSYYFDYW 2/10 
Clone_05 Unproductive V5-2 D2-4 JH3 99.3 X CARHYYDYDGA#WFAYW 2/10 
Clone_04 Unproductive V1-31 D4-1 JH3 99.3 X CARYWD#FAYW 3/10 
JH4 CS plasmid 




D1-1 JH2 99.3 13 CARHYYGSSYYFDYW 10/10 
CLL_32371 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-81 D1-1 JH1 98.96 14 CAERFTTVVARYFDVW 1/7 
Clone_03.0 Productive V11-2 D2-5 JH1 98.61 11 CMRYSNYWYFDVW 6/7 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-81 D1-1 JH1 98.96 14 CAERFTTVVARYFDVW 1/8 
Clone_03.1 Productive V11-2 D2-5 JH1 98.61 11 CMKYSNYWYFDVW 1/8 
Clone_03.0 Productive V11-2 D2-5 JH1 98.61 11 CMRYSNYWYFDVW 3/8 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_03.0 Productive V11-2 D2-5 JH1 98.61 11 CMRYSNYWYFDVW 5/8 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_02 Productive V1-82 D1-1 JH2 98.96 13 CARSGYYGSSPLDYW 2/8 
CLL_31938 
JH1 CS plasmid 




D2-3 JH1 98.96 17 CARHEEEGYYGLGGYFDVW 2/7 
Clone_05 Unproductive V1-70 P D1-1 JH4 98.96 X CARTGGLLR**V#YYAMDYW 2/7 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_02 Productive V1-39 D2-3 JH1 98.96 12 CARYDGNYGVFDVW 2/7 
Clone_03 Productive V1-67 D2-3 JH2 98.96 10 CARDYDGYFDYW 2/7 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_04 Unproductive V1-82 D4-1 JH3 98.96 X CARSNW#AWFAYW 3/6 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_05 Unproductive V1-70 P D1-1 JH4 98.96 X CARTGGLLR**V#YYAMDYW 7/8 
§ Number of colonies with identical sequence and total number of colonies sequenced, * Stop codon in CDR3 region, out-of-frame CDR3, # restored 











Table 12. Analysis of IgH VDJ rearrangements cloned from splenocytes of burdened 
TCL1tg R26-IK2ca/ca CD19cre mice 
Mouse ID Major clones identified 
 CLL_32299 
 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_02 Unproductive V1-67 D2-3 JH1 99.3 X CASMMVTTT#YFDVW 2/10 
Clone_03 Unproductive V1-21-1 P  JH1 99.0 X SARLR**LLVLRCL 3/10 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-9  JH2 99.3 6 CARWFDYW 8/10 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
All 10 sequences were unique, 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-9  JH2 99.3 6 CARWFDYW 2/10 
CLL_32274 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_04 Productive V1-47 D4-1 JH1 98.96 10 CAVANWDYFDVW 1/12 
Clone_05 Productive V14-2 D2-13 JH1 99.31 10 CAWGSFWYFDVW 3/12 
Clone_06 Productive V1-81 D2-2 JH1 98.96 11 CAYGYGYWYFDVW 3/12 
Clone_08 Unproductive V5-17 D1-1 JH1 99.31 X CAITTVVA##YWYFDVW 5/12 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_04 Productive V1-47 D4-1 JH1 98.96 10 CAVANWDYFDVW 3/10 
Clone_09 Unproductive V14-4 D2-4 JH2 99.31 X CTKGMITTGA#YYFDYW 2/10 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V1-19 D3-1 JH3 96.18 10 CAREGGATLAYW 2/10 
Clone_03 Productive 
V5-6 
 (or V5-6-1) 
D4-1 JH3 99.31 7 CARLTGAYW 3/10 
Clone_07 Productive V14-4 D1-1 JH3 99.31 12 CTLFITTVVDLAYW 3/10 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 




D4-1 JH3 99.31 7 CARLTGAYW 4/ 
CLL_32987 
JH1 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_01 Productive V12-3 D2-3 JH1 98.61 12 CAGDYDGYWYFDVW 2/11 
Clone_02 Productive V1-75 D2-12 JH1 98.61 14 CARGYYGYDVWYFDVW 3/11 
JH2 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_03 Unproductive V5-2 D2-3 JH2 99.31 X CARLM#YFDYW 10/12 
JH3 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_03 Unproductive V5-2 D2-3 JH2 99.31 X CARLM#YFDYW 4/12 
JH4 CS plasmid 
Clone Functionality VH-gene DH-gene JH-gene Identity (%) CDR3 length CDR3 amino acid sequence Colonies§ 
Clone_03 Unproductive V5-2 D2-3 JH2 99.31 X CARLM#YFDYW 7/11 
§ Number of colonies with identical sequence and total number of colonies sequenced, * Stop codon in CDR3 region, out-of-frame CDR3, # restored 










Figure 34. Cloned IgH VDJ rearrangements point to oligoclonal lymphomas 
Clonality analysis of the BCR repertoire from splenocytes of burdened mice of the following genotypes: 
(A) TCL1tg CD19cre, (B) TCL1tg R26-IKK2ca CD19cre and (C) TCL1tg R26-IKK2ca/ca CD19cre 
burden mice. Total number of white colonies obtained for each JH CS plasmid is indicated inside a 
circle. Blue arrow indicates major clones identified for each sample, rearrangement productivity, JH-
gene segment, number of clones with identical sequences and number of total colonies sequenced (see 
Tables S6-8).  
 





Interestingly, for sample TCL1tg R26-IKK2ca CD19cre CLL_31937 only JH2-gene 
segment containing VDJ rearrangements were detected by PCR (Figure S 32B and C). 
Therefore, only the VDJ rearrangements into JH2-gene segment were cloned using the 
JH2 CS specific plasmid. Under these conditions, only one unproductive VDJ 
rearrangement was identified for this sample (Frequency 0.1, Table 11). Similarly, for 
sample CLL_32351 solely JH1-gene segments specific rearrangements were detected by 
PCR. Thus, JH1-gene segments were cloned using the JH1 CS specific plasmid. Two 
productive clonal VDJ rearrangements were detected, suggesting the presence of an 
oligoclonal CLL expansion in this sample. 
 
In the remaining three TCL1tg R26-IKK2ca samples (CLL_32100, CLL_32371 and 
CLL_31938) two to three productive clonal VDJ rearrangements were identified in 
addition to up to two unproductive rearrangements (Table 11, Figure 34B). For 
instance, for the TCL1tg R26-IKK2ca CD19cre sample CLL_32371, out of the three clones 
identified, Clone_03 was the mostly prominent clone: being identified in 85% (6/7), 
50% (4/8) and 62% (5/8) of the JH1 CS, JH2 CS and JH3 CS sequenced colonies, 
respectively (Table 11 and Figure 34B). On the other hand, Clone_01 was detected in 
14% (1/7) and 12% (1/8) of the sequenced colonies for the JH1 and JH2 CS plasmids, 
respectively; while Clone_02 was detected in 25% (2/8 colonies) of sequenced colonies 
for the JH4 CS plasmid. 
 
Finally, from the three TCL1tg R26-IKK2ca/ca CD19cre samples analysed up to nine 
major clones were identified per sample, independently of their functionality (Table 12). 
Sample CLL_32274 had the highest number of clonal VDJ rearrangements, out of which 
7 were productive and 2 were unproductive. While in the remaining two samples, three 
clonal VDJ rearrangements were identified (Figure 34C). In sample CLL_3229 only one 
major clonal rearrangement was identified (Clone_01), in addition to two clonal 
unproductive rearrangements. In comparison, in sample CLL_32987 the major clonal 
rearrangement identified was unproductive (Clone_03), while the other two clonal 
productive rearrangements identified were present at a lower frequency.  
 
In addition to the identification of clonal IgH VDJ rearrangements present in the 
lymphoma samples analysed, their sequencing also provided the mutational status of 
the VH-gene segments. In human CLL the CD5+ B1a-like cells can be classified 
accordingly to their BCR mutational status: unmutated-CLL have a poor prognosis, while 
mutated-CLL is more indolent [215, 255]. In the TCL1tg-driven murine CLL the disease 





has an unmutated-like status [256]. I could confirm that in the two TCL1tg CD19cre 
lymphoma samples analysed here, the clones identified had over 98% identity with the 
germ line VH-gene segment (Table 10). Further enhanced NF-B activation did not 
affect the mutational status of the CLL-cells. Both TCL1tg R26-IKK2ca CD19cre (Table 
11) and TCL1tg R26-IKK2ca/ca CD19cre clonal lymphomas (Table 12) had over 95% 
identity with the germ line VH-gene segments. Therefore, the mutational status of the 
disease is not altered by the combination of constitutive canonical NF-B activation with 
TCL1.  
 
The analysis of the IgH VDJ recombination in B-cells of control and burdened mice 
shows that the CD5+ B1a-like cells in the TCL1tg compound mice have an unmutated IgH 
VDJ status and are at least oligoclonal, compared to the wild type controls where a much 
higher diversity of VDJ recombination was observed. Moreover, the analysis of a higher 
number of colonies renders a more accurate picture of the clonal dynamics and clone 
size for each lymphoma sample.  
 
IV.2.3.2.2 Ex vivo immunophenotyping of burdened CLL/SLL mice 
In human CLL, it is now accepted that the tissue microenvironment has a pathogenic or 
modulatory role on the disease. Herishanu et al. (2011) have proposed the lymph node 
as a particular pathogenic niche in CLL, where a transcriptional analysis points to 
activation of BCR- and canonical NF-B of CLL-cells [141]. Therefore, constitutive 
activation of canonical NF-B could mimic aspects of niche interactions. Thus, to gain a 
better understanding in the role of constitutive canonical NF-B activation and the TCL1 
oncogene in the development of CLL-like disease in mice, the ex vivo expression of 
several immunoreceptors, the CD69 cell surface receptor, chemokine associated 
receptors, regulators of apoptosis, the IRF4 transcription factor and CLL associated 
proteins were assessed by flow cytometry in the bone marrow, spleen, peritoneal cavity 
and draining lymph nodes from burdened and aged control mice. For the comparison, 
the ex vivo expression of each marker was assessed using flow cytometry and the MFI of 
each marker was normalized to the B2 CD19cre control subpopulation. Although in the 
mouse B1a-cells are a normal subset found mainly in the peritoneum and to a lesser 
extent in the spleen, for this particular comparison B1a-like populations in the bone 
marrow and lymph nodes were also included in the analysis of control mice.  
 





Ex vivo comparison of B1a-like cells in burdened mice 
The comparison of B1a-like cells in burdened mice resulted in a significantly differential 
expression of the immunoreceptor MHC-II and the chemokine receptor CXCR4. 
Additionally, differential expression trends were also observed for the 
immunoreceptors CD25, CD40 and CD86; the cell surface receptor CD69; the anti-
apoptotic protein BCL2; and the CLL-associated proteins Zap70 and PD1.  
 
First, two different relative expression trends were observed for MHC-II. In the bone 
marrow, the relative expression of MHC-II increased in an IKK2ca dose dependent 
manner (Figure 35 and Figure S 33F). Additionally, there was a significant increase in 
the expression of MHC-II on B1a-like cells from burdened TCL1tg R26-IKK2ca CD19cre 
mice compared to R26-IKK2ca CD19cre mice, pointing to the potential role of TCL1 and 
canonical NF-B cooperation in MHC-II expression in the bone marrow niche (Figure S 
33F). Interestingly, the situation in the peritoneum was inverted; there was trend for 
lower relative MHC-II levels in an IKK2ca dose dependent manner (Figure 35 and Figure 
S 35F). Moreover, there was a significant decrease in MHC-II expression in the TCL1tg 
R26-IKK2ca CD19cre B1a-like cells compared to the CD19cre control mice. The trend of 
reduced MHC-II expression levels associated with NF-B constitutive activation was also 
observed in B1a-like cells from the lymph nodes (Figure 38 and Figure S 36F) and was 
less evident in the spleen (Figure 36 and Figure S 34F) of burdened mice. 
 
Furthermore, the comparison of burdened TCL1tg R26-IKK2ca CD19cre with aged 
matched controls (Figure S 37F) also showed increased expression levels MHC-II in the 
bone marrow in both B2- and B1a-like cells compared to CD19cre controls. On the other 
hand, an inverse trend was observed in B2-cells present in spleen, peritoneal cavity and 
lymph nodes, where the expression of IKK2ca and IKK2ca in combination with TCL1tg 
lowered the surface expression of MHC-II. This trend was also observed for and B1a-like 
cells in the peritoneal cavity and lymph nodes. Similar results were observed in the 
comparison of burdened TCL1tg R26-IKK2ca/ca CD19cre mice with aged matched 
controls (Figure S 38G). 
 
Given the different relative expression trends observed between B-cells from the bone 
marrow and the other organs analysed (spleen, peritoneum and lymph nodes), it is 
possible that the niche has an additional influence in the collaboration between strong 
canonical NF-B activation and the TCL1tg oncogene in modulating the MHC-II surface 
expression. Furthermore, the low MHC-II expression levels observed could indicate a 





reduced ability of the CLL-like cell to elicit an immune response in these particular 
niches. The higher MHC-II expression observed in the bone marrow is puzzling. It could 
be possible that in the bone marrow niche the CLL-like cell might be generating an 
inflammatory phenotype. Alternatively, canonical NF-B activation alone could affect 
the ubiquitination or the internalization and further degradation of MHC-II [257, 258], 
also the intracellular MHC-II expression remains to be investigated.  
 
Second, the expression of the chemokine receptor CXCR4 showed a trend for reduced 
levels in B1a-like cells of burdened mice in an IKK2ca dose depended manner in the 
spleen (Figure 36 and Figure S 34I), peritoneum (Figure 37 and Figure S 35I) and the 
lymph nodes (Figure 38 and Figure S 36I), and to lesser extent in the bone marrow 
(Figure 35 and Figure S 33I). Furthermore, in the peritoneum there was a significant 
decrease in CXCR4 expression in R26-IKK2ca CD19cre B1a-like cells compared to 
CD19cre controls (Figure S 35I). Moreover, the analysis of burdened TCL1tg R26-IKK2ca 
CD19cre and aged matched control mice showed a significant reduction in CXCR4 
relative levels in R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca CD19cre compared to 
CD19cre B1a-like cells (Figure S 37H) in the peritoneum. A similar effect was observed 
for the other organs analysed and for the analysis of TCL1tg R26-IKK2ca/ca CD19cre 
burden mice and aged matched controls (Figure S 38I). Therefore, it is likely that the 
main negative regulator of CXCR4 expression is constitutive canonical NF-B activation 
and that TCL1tg has negligible effects on its expression. This reduced CXCR4 expression 
could point to a higher mobility of IKK2ca+; TCL1+ CLL-like cells into the periphery 
compared to normal B1a-like cells or TCL1+ B1a-like cells. Additionally, the lower 
CXCR4 surface expression observed could make them more independent of the SDF1 
producing stroma cells in the niche. Interestingly, Chen et al. have reported that BTK 
inhibition by ibrutinib directly reduced CXCR4 levels in CLL-like cells promoting their 
migration [259]. These results are contradictory to the observation of reduced CXCR4 
expression in the B1a-like cells present in TCL1tg R26-IKK2ca compound mice that 
show an accelerated disease progression compared to the CD19cre TCL1tg mice.. 
Further analyses are necessary to address the role of reduced CXCR4 surface expression 
in TCL1tg R26-IKK2ca and its potential association to a more aggressive type of CLL.  
 
Third, there was a trend for lower CD25 expression levels in B1a-like cells in the bone 
marrow of burdened mice when the TCL1tg was present (Figure S 33A). However, in the 
spleen and lymph nodes the reduced CD25 expression occurred in an IKK2ca dose 
dependent manner (Figure S 34A and Figure S 36A).   






Figure 35. Bone marrow B2- vs. B1a-like cells immunophenotyping 
Ex vivo immunophenotyping of B-cell subsets B2- and B1a-like in bone marrow from burden and control 
mice by flow cytometry. Heatmaps depicts geometric mean for the MFI each marker relative to B2 
CD19cre controls. At least 2 (2-10) mice were analysed per genotype.  
B2-like (CD19+ B220hi), B1a-like (CD19+ B220lo), N.D. (not done). 
 
 






Figure 36. Splenic B2- vs. B1a-like cells immunophenotyping 
Ex vivo immunophenotyping of B-cell subsets B2- and B1a-like in spleen from burden and control mice 
by flow cytometry. Heatmaps depicts geometric mean for the MFI each marker relative to B2 CD19cre 
controls. At least 2 (2-10) mice were analysed per genotype.  
B2-like (CD19+ B220hi), B1a-like (CD19+ B220lo), N.D. (not done). 
 






Figure 37. Peritoneal cavity B2- vs. B1a- cells immunophenotyping 
Ex vivo immunophenotyping of B-cell subsets B2- and B1a-like in peritoneal cavity from burden and 
control mice by flow cytometry. Heatmaps depicts geometric mean for the MFI each marker relative to 
B2 CD19cre controls. At least 2 (2-10) mice were analysed per genotype.  
B2-like (CD19+ B220hi), B1a-like (CD19+ B220lo), N.D. (not done). 
 






Figure 38. Lymph node B2- vs. B1a-like cells immunophenotyping 
Ex vivo immunophenotyping of B-cell subsets B2- and B1a-like in draining lymph nodes from burden 
and control mice by flow cytometry. Heatmaps depicts geometric mean for the MFI each marker relative 
to B2 CD19cre controls. At least 2 (2-10) mice were analysed per genotype.  
B2-like (CD19+ B220hi), B1a-like (CD19+ B220lo), N.D. (not done). 
 
  





In comparison, CD40 presented a trend for higher expression levels in B1a-like cells 
from burden mice in an IKK2ca dose dependent manner (Figure S 33B, Figure S 34B, 
Figure S 35B and Figure S 36B). Moreover, the analysis of burdened TCL1tg R26-IKK2ca 
CD19cre and aged matched controls showed that TCL1tg R26-IKK2ca CD19cre B1a-like 
cells have a significantly higher expression than the CD19cre controls, while the R26-
IKK2ca CD19cre B1a-like cells have an intermediate CD40 expression (Figure S 37B). A 
similar trend was observed in the TCL1tg R26-IKK2ca/ca CD19cre burden mice (Figure 
S 38C). Thus, it is likely that both canonical NF-B and TCL1tg contribute to increase 
CD40 expression.  
 
Similarly, CD86 presented a trend for higher expression in B1a-like cells in spleen 
(Figure S 34E), peritoneum (Figure S 35E) and lymph nodes (Figure S 36E) from 
burdened mice in an IKK2ca dose dependent manner and as well as the presence of 
TCL1tg. Moreover, in the lymph nodes the expression level in B1a-like cells of R26-
IKK2ca/ca CD19cre and TCL1tg CD19cre cells is relatively similar, but the combination 
of both leads to a stronger relative CD86 expression. Furthermore, the comparison of 
burdened TCL1tg R26-IKK2ca CD19cre and their aged matched controls showed that, at 
least in young age (5-6 months of age), the significant increase in CD86 relative MFI 
levels is a result of TCL1tg expression (Figure S 37E).  
 
Fourth, the expression levels of the cell surface receptor CD69 were affected by the 
presence of IKK2ca. There is a trend for higher relative CD69 MFI when the second allele 
of IKK2ca is present in B1a-like cells in bone marrow (Figure S 33G), spleen (Figure S 
34G) and peritoneal cavity (Figure S 35G). While in the TCL1tg compound mice, the 
trend for higher CD69 expression occurs in an IKK2ca dose dependent manner in B1a-
like cells from bone marrow and spleen. However, in the peritoneum the effect is the 
opposite resulting in a trend for reduced CD69 expression in both B2- and B1a-like cells. 
Surprisingly, there is a significant increase in the relative expression of CD69 in B1a-like 
cells from the peritoneum of TCL1tg R26-IKK2ca CD19cre burdened mice compared to 
B1a-cells in aged matched controls (Figure S 37G). 
 
Fifth, the anti-apoptotic protein BCL2 has a very particular expression pattern. There is 
a trend for higher BCL2 expression in the R26-IKK2ca heterozygous B1a-like cells 
compared to the homozygous or wild type cells (Figure S 33J, Figure S 34J, Figure S 35J 
and Figure S 36J). Interestingly, the R26-IKK2ca/ca CD19cre and TCL1tg CD19cre B1a-
like cells have similar BCL2 expression levels. The comparison of TCL1tg R26-IKK2ca 





CD19cre burdened mice with aged matched controls, also points to a positive effect of 
hemizygous IKK2ca and additional effects of TCL1 in the expression of BCL2 in B1a-like 
cells (Figure S 37I).  
 
Sixth, there is a trend for lower Zap70 expression in an IKK2ca dose dependent manner 
in the B1a-like cells in the absence of TCL1tg (Figure S 33N, Figure S 34N, Figure S 35N 
and Figure S 36N). This is also true for B1a-cells positive for TCL1tg in bone marrow and 
spleen. However, in the peritoneum and to a lesser extent in the lymph nodes, the 
combination of the TCL1tg with one allele of IKK2ca results in relative higher Zap70 
levels. Notably, in 5-6 months old mice, at least in the peritoneum and the lymph nodes, 
the TCL1tg B1a-like cells have a relative lower expression of Zap70 compared to TCL1tg 
R26-IKK2ca CD19cre or R26-IKK2ca CD19cre mice (Figure S 37N).  
 
Finally, the relative MFIs for PD1 appear to go down in an IKK2ca dose dependent 
manner in B1a-like cells from burdened mice (Figure S 33O, Figure S 34O, Figure S 35O 
and Figure S 36O). The highest level of expression is observed in the TCL1tg CD19cre 
B1a-like cells.  
 
Therefore, constitutive canonical NF-B activation as well as the TCL1tg alone or in 
combination with a particular microenvironment can modulate the expression of 
activation markers and other proteins.  
 
Ex vivo comparison of B2-cell subset in burdened mice 
The B2 subset comparison from burdened mice shows a significantly differential 
expression of CD40, CD86, MHC-II and CXCR4. First, there is a significant increase in the 
relative expression of CD40 in B2-cells in an IKK2ca dose dependent manner in spleen 
(Figure S 34B), peritoneal cavity (Figure S 35B) and lymph nodes (Figure S 36B) that 
also affected TCL1tg positive B2-cells similarly. This trend for higher CD40 expression 
was also observed in bone marrow B2-like cells (Figure S 33B). The comparison of 
burdened TCL1tg R26-IKK2ca CD19cre mice had similar results (Figure S 37). There 
was a significantly higher expression of CD40 in B2-cells from R26-IKK2ca CD19cre 
controls and TCL1tg R26-IKK2ca CD19cre burdened mice compared to CD19cre aged 
matched controls. 
 





Second, there is a trend for higher levels of the activation marker CD86 in an IKK2ca 
dose dependent manner in B2-cells from burdened mice (Figure S 33E, Figure S 34E, 
Figure S 35D and Figure S 36E). Moreover, the expression of CD86 was significantly 
increased in R26-IKK2ca/ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre B2-cells 
compared to CD19cre controls in the peritoneum (Figure S 35E).  
 
Third, the relative expression of the immunoreceptor MHC-II was significantly reduced 
in TCL1tg CD19cre and TCL1tg R26-IKK2ca CD19cre B2-cells from burdened mice 
compared to the CD19cre controls in spleen (Figure S 34F) and lymph nodes (Figure S 
36F). Similarly, the comparison of aged matched 3-4 (Figure S 38G) and 5-6 old (Figure 
S 37F) mice revealed a significant negative effect on the expression of MHC-II in 
eGFP+;IKK2ca+;TCL1+ B2-cells compared to CD19cre aged matched controls in the 
spleen and lymph nodes. It appears that the presence of TCL1tg negatively affects the 
expression of MHC-II in B-cells.  
 
Finally, there was a significant lower expression of CXCR4 in R26-IKK2ca/ca CD19cre 
B2-cells compared to TCL1tg CD19cre B2-cells in the spleen of burden mice (Figure S 
34I).  
 
Ex vivo comparison between B2- and B1a-like cells in burdened mice 
The comparison of the B2- and B1a-cells subsets in spleen and peritoneal cavity from 
CD19cre controls showed that the relative expression of CD25 (Figure S 35A and Figure 
S 37A) and Zap70 (Figure S 35N, Figure S 34N and Figure S 37N) were significantly 
increased in the latter compared to the former. Therefore the differential expression of 
CD25 and Zap70 is likely to be B-cell type specific. 
 
Additionally, in the analysis of 5-6 months old mice, the surface receptor CD69 was 
significantly higher in the B1a compared to B2-cells in the spleen; while the opposite 
was true for the peritoneum where the B1a-cells had a significantly lower CD69 
expression than B2-cells (Figure S 37G). Moreover, the expression of CXCR4 was 
significantly higher in B1a-cells compared to their B2 counterpart in spleens of CD19cre 
and R26-IKK2ca CD19cre mice (Figure S 37H).  
 
Meanwhile, the comparison between B1a-like and their B2 counterpart in burdened 
mice revealed a significant increase in the relative expression levels of activation 





markers CD83 (Figure S 34D, Figure S 35D, Figure S 36D and Figure S 37D) and CD86 
(Figure S 33E, Figure S 34E, Figure S 35E, Figure S 36E and Figure S 37E); the anti-
apoptotic protein BCL2 (Figure S 33J, Figure S 34J, Figure S 35J and Figure S 36J), the 
transcription factor IRF4 (Figure S 33M, Figure S 34M, Figure S 35M and Figure S 36M) 
and the CLL-related signalling molecule Zap70 (Figure S 33N, Figure S 34N, Figure S 35N 
and Figure S 36N) in the TCL1tg R26-IKK2ca CD19cre mice. Additionally, there was a 
significant decrease in the relative MFI for the chemokine receptor CXCR4 (Figure S 
35I). 
 
Similarly, in burdened TCL1tg CD19cre mice, the B1a-like cells had a significantly higher 
expression of BCL2 in the spleen (Figure S 34J) and Zap70 in the draining lymph nodes 
(Figure S 36N) compared to their B2 counterparts.  
 
It is likely that the higher Zap70 expression observed in both TCL1tg CD19cre mice as in 
the TCL1tg R26-IKK2ca CD19cre mice is cell-type related rather than TCL1tg or IKK2ca 
dependent. The relative expression of Zap70 in B1a-like cells in spleens of TCL1tg R26-
IKK2ca CD19cre mice (geo. mean 2.6) is similar to that of CD19cre controls (geo. mean 
2.6, Figure S 34N). Moreover, in both cases there is a 1.5-fold increase in the relative 
expression. 
 
Furthermore, in 5-6 months old mice B1a-cells presents with higher IRF4 expression in 
B1a compared to B2-cells in spleen and peritoneum (Figure S 37L). Therefore, it is 
possible that the higher IRF4 relative MFI in B1a-like cells in the burdened TCL1tg R26-
IKK2ca CD19cre mice might be rather a cell-type specific pattern, than the actual role of 
constitutive canonical NF-B or TCL1tg expression. 
 
IV.2.3.2.3 In vitro characterization  
Constitutive canonical NF-B activation in B-cells prolongs their survival in vitro and in 
vivo by replacing the requirement for BAFF [37]. Given that the TCL1tg CLL mouse 
model is accelerated in an IKK2ca dose dependent manner, I wanted to see if this 
accelerated disease progression was a result of either prolonged B-cell survival, a higher 
proliferation rate driven by canonical NF-B or a cooperative effect between 
constitutive canonical NF-B activation and TCL1tg. 
 





In vitro survival and proliferation 
In order to determine whether the combination of the TCL1tg oncogene and the IKK2ca 
knock-in had an effect in B-cell survival, a pilot experiment was performed where either 
sorted B2- or CD5+ B1a-like cells stained with cell trace were cultured in vitro for a 
period of nine days in the absence of any stimuli.  
 
As it is to be expected, resting sorted B2-cells numbers were drastically reduced after 24 
hours in culture (Figure S 39C). Interestingly, although both the CD19cre control and 
TCL1tg CD19cre B2-cells essentially all died by day two, there was a small population of 
B2-cells in the R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca CD19cre cultures that 
survived until day nine in the absence of proliferation (Figure S 39). Therefore, at least 
in vitro, these results are in agreement with published results [37]. In this instance it 
was not possible to address the in vitro survival for R26-IKK2ca/ca CD19cre and R26-
IKK2ca/ca TCL1tg CD19cre B2-cells. There were insufficient cell numbers obtained after 
the sort and cell trace staining. 
 
Comparably to cultured B2-cells, the numbers of B1a-like cells were drastically reduced 
after 24 hours of culture (Figure 39C). The canonical NF-B constitutive activation 
resulted in a reduced percentage of apoptotic cells at days two and three compared to 
culture TCL1tg CD19cre B1a-like cells. Moreover, combination of the IKK2ca knock-in 
allele reduced the percentage of apoptotic cells in both TCL1tg R26-IKK2ca CD19cre and 
TCL1tg R26-IKK2ca/ca CD19cre B1a-like cells in vitro comparable to their TCL1- 
controls (Figure 39A). 
 
Surprisingly, at day three some of the cultured TCL1tg R26-IKK2ca CD19cre B1a-like 
cells were proliferating (Figure 39B). The observed proliferation phenotype was 
maintained at days six and nine. The proliferation index for the TCL1tg R26-IKK2ca 
CD19cre B1a-like cells increased from 1.18 in day three, to 1.97 in day six reaching a 
maximum of 2.21 at day nine (Table 13). Moreover, the percentage of apoptotic cells in 
the TCL1tg R26-IKK2ca CD19cre B1a-like cells remained constant, 20%, during the first 
three days of culture but increased at day six and nine (Figure 39A). Interestingly, 
balance between in vitro proliferation and apoptosis resulted in a constant absolute 
number of cells at day three, six and nine (Figure 39C). In other words, the rate at which 
cells were replicating was sufficient to compensate for the rate at which cells were dying 
in vitro.  
 






Figure 39. Effect of IKK2ca and TCL1tg in B1a-like cells in vitro proliferation 
Sorted B1a-like cells were cultured in B-cell media in resting conditions for 9 days and in vitro cell 
proliferation and cell survival was assessed by flow cytometry. (A) Bar charts show the percentage of 
apoptotic cells present in the culture as mean and SEM. (B) Histograms depict the in vitro proliferation 
of B1a-like cells. (C) Scatter plot and table show the absolute number of living B1a-cells in culture.  
B1a (CD19+ B220- CD5+), Apoptotic cells (Annexin-V+ 7AAD-/Annexin-V+ 7AAD+) and Living cells 
(Annexin-V- 7AAD-). 
 





Table 13. B1a in vitro proliferation analysis 
Days in 
culture 





TCL1tg R26-IKK2ca CD19cre 




















TCL1tg R26-IKK2ca CD19cre 
TCL1tg R26-IKK2ca CD19cre, Conc.⌘ 























TCL1tg R26-IKK2ca CD19cre 
TCL1tg R26-IKK2ca CD19cre, Conc.⌘ 



















* Division index, average number of divisions for all cells in the culture. 
¥ Proliferation index, average number of divisions responding cells have undergone 
± Percentage divided, percentage of cells that have undergone at least one round of cell division 
⌘ 0.6 million cells were used for culture at day 0  
 
 
An additional culture condition was used for the TCL1tg R26-IKK2ca CD19cre B1a-like 
cells where 10 times more cells, 0.6 million cells, were seeded at day zero. Although 
proliferation was not assessed at day three, it was evident at day six and nine (Figure 
39B). Although both culture conditions displayed similar the proliferation Index values 
(1.97 vs. 1.77, Table 13) at day six, at day nine the concentrated culture had a 
proliferation index of 2.76 compared to 2.21 for the standard culture. Moreover, the 
stronger proliferation in combination with cell death resulted in an accumulation of 
absolute B1a-like cell numbers from day six to day nine (data not shown). This 
difference in proliferation indexes and proliferation behaviours could point to a density 
threshold that would push the proliferation forward. Although there is no evidence to 
suggest so, it is tempting to speculate that cell-to-cell contacts or paracrine signals 
potentiate the proliferative capacity of these cells in vitro.  
 
 Similarly, cultured TCL1tg R26-IKK2ca/ca CD19cre B1a-like cells also started 
proliferating at day three (Figure 39B). Thereafter, the resting TCL1tg R26-IKK2ca/ca 
CD19cre B1a-like cells displayed a more proliferative phenotype, reaching a maximum 
proliferation index of 2.5 at day six (Table 13). As a consequence, the absolute cell 
numbers increased exponentially with time (Figure 39C). Additionally, a fraction of the 
resting B1a-like R26-IKK2ca/ca CD19cre cells but not R26-IKK2ca CD19cre cells were 





proliferating in vitro at day six (Figure 39B and Table 13). This proliferative phenotype 
was observed also at day nine, however the absolute number of cells was lower.  
 
Even though no proliferation was observed in the sorted TCL1tg CD19cre and the R26-
IKK2ca CD19cre B1a-like cells, the combination of the TCL1tg with one allele of IKK2ca 
resulted in proliferation at day three. Moreover, the combination of the TCL1 transgene 
with constitutive NF-B activation resulted higher division index and proliferation index 
in vitro compared to the R26-IKK2ca/ca CD19cre B1a-like cells (Figure 39C). 
Interesting, the B1a-like TCL1tg R26-IKK2ca/ca CD19cre cells had a higher division and 
proliferation index than the TCL1tg R26-IKK2ca CD19cre cells. Although these results 
are preliminary, they point to a potential collaboration between constitutive canonical 
NF-B activation and the TCL1tg oncogene in in vitro proliferation in B1a-like but not 
B2-cells. This in vitro proliferation could be translated in vivo to a proliferation 
advantage of IKK2ca+;TCL1+ B-cells thus explaining the accelerated disease onset 
observed in TCL1tg R26-IKK2ca compound mice.  
 
BCR stimulation 
Given the potential role of BCR signals in driving NF-B activation and promoting 
survival in CLL patients cell, an additional pilot experiment was set up to assess the role 
of BCR stimulation in proliferation of CD5+ B1a-like cells.  
 
As a reference control, B2-cells were stimulated in vitro with 15ug/ml of anti-IgM and 
cultured for three days. Already at 12 hours all samples showed a higher expression of 
the activation markers CD86 and MHC-II (Figure S 40A) indicating cross-linking of the 
BCR and activation of downstream signals. After three days of stimulation, B2-cells from 
all the genotypes analysed were proliferating (Figure S 40B). Interestingly, there was an 
increase in the proliferation index of TCL1tg CD19cre B2-cells in an IKK2ca dose 
dependent manner. Additionally, although the TCL1tg R26-IKK2ca/ca CD19cre B2-cells 
had the lowest division index and percentage of divided cells values, they also had the 
highest proliferation index value (Figure S 40C).  
 
B1a-like cells were sorted from TCL1tg R26-IKK2ca/ca CD19cre or R26-IKK2ca/ca 
CD19cre mice, followed by cell trace staining. Finally, cells were stimulated with 
2.5ug/ml or 5ug/ml dose of anti-IgM and cultured up to nine days. Although no 
proliferation was observed after 24 hours (Figure S 41A, Day 1), the B1a-like cells were 





in an activated state (Figure S 41B). Both doses of anti-IgM stimuli resulted in increased 
MHC-II expression in R26-IKK2ca/ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre B1a-
like cultured cells. Paradoxically, there was a population of cells that had reduced 
expression of the activation marker CD86.  
 
In vitro proliferation after anti-IgM stimulation was assessed on days three and nine of 
culture. As mentioned previously, at day three the resting TCL1tg R26-IKK2ca/ca 
CD19cre B1a-like cells had started proliferating (Figure 39B). Interestingly, although at 
day three the resting TCL1tg R26-IKK2ca/ca CD19cre B1a-like cells had a higher 
division index compared to the cells stimulated with 5ug/mL of anti-IgM, they had a 
lower proliferation index (Figure S 41C). Indicating that compared to the resting TCL1tg 
R26-IKK2ca/ca CD19cre only a small fraction of stimulated cells was responsive (Figure 
S 41A). Moreover, at day nine the TCL1tg R26-IKK2ca/ca CD19cre B1a-like cells 
stimulated with a dose of 5ug/ml anti-IgM had both a higher division and proliferation 
index compared to the resting cells (Figure S 41C). Additionally, there was an increase in 
TCL1tg R26-IKK2ca/ca CD19cre B1a-like absolute cell numbers from day three to day 
nine, where a higher dose of stimuli led to a sharper increase (Figure S 41D).  
 
Interestingly, although the control TCL1tg R26-IKK2ca/ca CD19cre resting B1a-like cells 
were proliferating at days three and nine, the absolute numbers decreased in that time 
frame (Figure S 41D). This could be explained to the increased apoptosis observed at 
day nine (data not shown).  
 
In spite of the fact that these results are preliminary, it appears that BCR stimulation of 
either R26-IKK2ca/ca CD19cre or TCL1tg R26-IKK2ca/ca CD19cre CD5+ B1a-like cells 
retards proliferation.  
 
IV.2.3.2.4 Constitutive canonical NF-B activation is insufficient to 
overcome the niche dependence of murine TCL1tg driven CLL  
In human CLL, the NF-B activation observed in patient biopsy samples is to a large 
extent a consequence of interactions of the CLL-cells with its surrounding environment. 
The contact of TCL1tg CLL-like cells with the niche microenvironment will drive a bi-
directional remodelling to allow the TCL1tg CLL-cells to survive, proliferate, evade the 
immune system and potentially become resistant to chemotherapy. For instance, when 
the TCL1tg CLL-cells are in contact with the bone marrow-derived stromal cell 





(BMDSC), the interaction induces the expression of the PCK-II isotype in the BMDSC. In 
the absence of stromal PCK-, the CLL-like cells are unable to remodel the niche and 
cannot survive [167]. Therefore, this bi-directional remodelling is fundamental for the 
development of CLL. 
 
I wanted to address whether constitutive canonical NF-B activation could overcome 
the dependence of external signals from the microenvironment for the survival of 
TCL1tg CLL-cells in mice. In order to do so, I set up transplant experiments where 
malignant cells were harvested from spleens of burdened TCL1tg CD19cre or TCL1tg 
R26-IKK2ca CD19cre mice (Figure 40A). Donor cells were enriched for TCL1tg CLL-like 
cells and transplanted into PKC- knockout heterozygous (from now on referred to as 
PKC-+/-) and homozygous (from now on referred to as PKC-
[167, 245]. The transplanted mice were bled once a week and monitored for up to 6 
months for the development of any symptoms.  
 
The peripheral blood monitoring of the transplanted recipients revealed that only PKC-
+/- mice, but not homozygous knockout mice, developed a progressive accumulation of 
CD5+ B1a-like cells in the blood independently of the genotype of the transplanted CLL-
like cells (Figure 40C).  
 
The median survival for both TCL1tg CD19cre and TCL1tg R26-IKK2ca CD19cre 
transplanted PKC-+/- recipients was 8 weeks after the start of the transplant, and no 
cases showed development of CLL-like symptoms after 12 weeks from the start of the 
transplant (Figure 40B). Interestingly, not all of the recipient mice developed the CLL-
like disease. Only four out of seven TCL1tg CD19cre CLL-like cell and 10 out of 15 TCL1g 
R26-IKK2ca CD19cre CLL-like cell transplanted mice developed CLL-like disease (Figure 
40B). Moreover, only two out of three TCL1tg CD19Cre donors used were 
transplantable, while all three TCL1tg R26-IKK2ca CD19cre donors were transplantable 
(Figure 40C).  
 
The ex vivo analysis of the burdened PKC-+/- recipients revealed enlarged spleens with 
high cellularity and increased B-cell and B1a-like cell numbers (Figure 41A and B). The 
B1a-like cells comprised over 80% of B-cells present in the organ for both transplanted 
genotypes (Figure 41C). Ex vivo intracellular flow cytometry analysis of the B1a-like 
cells revealed that they were positive for the human TCL1 protein (data not shown). 
Moreover, the CLL-burdened mice transplanted with the TCL1tg R26-IKK2ca CD19cre 





CLL-cells presented with eGFP positive B1a-like cells when analysed (data not shown). 
Therefore, the B1a-like cells expanded in the PKC-+/- recipient mice had arisen from 





Figure 40. IKK2ca expression does not compensate for niche survival signals  
Transplant of TCL1tg murine CLL-like cells into PKC- KO recipients. (A) Scheme represents the 
experiment design. Briefly, splenocytes were harvested from sick mice; CLL-like cells were ex vivo 
enriched by MACS depletion of non B-cells; enriched CLL-like cells were intra-peritoneally injected into 
PKC- or KO recipients and followed up for 6 months for the development of CLL-like disease 
symptoms. (B) Kaplan-Meier survival curve analysis for PKC- KO recipients transplanted with either 
TCL1tg R26-IKK2ca CD19cre or TCL1tg CD19cre control CLL-like cells. Number of recipients that 
developed CLL vs. total number of recipients transplanted is indicated. (C) Scatter plot shows the 
percentage of B1a-like cells present in peripheral blood after red blood cell lysis, over a period of 6 
months after the transplant for PKC- and KO recipients of individual CLL-like lymphomas.  
CLL (Chronic lymphocytic leukaemia), I.P. (intra peritoneal), Tx (transplant), Het (Heterozygous), Ho 
(Homozygous), PB (peripheral blood), B1a-like (CD19+ B220- CD5+) 






Figure 41. B1a-like cells spleen infiltration in PKC-+/- recipients  
Ex vivo analysis of spleens from CLL-burdened PKC-+/- recipient mice using flow cytometry. Bar 
charts show (A) spleen mass, (B) splenocytes and B1a-like cell numbers, and (C) percentage of B1a-
like cells from B-cells in PKC-+/- recipients. Each bar represents a CLL-like lymphoma of the indicated 
genotype transplanted into multiple recipients. 
B1a-like (CD19+ B220lo CD5+) and B-cells (CD19+) 
 
 
Additionally, the B1a-like cells were expanded in the peritoneum (Figure S 43A), and 
detected in the draining lymph nodes (Figure S 43B) and bone marrow (Figure S 43C) in 
the PKC-+/- recipient mice. There was an increase from 20% B1a-cells in un-
transplanted control PKC-+/- mice to 80% B1a-like cells in the peritoneum of 
transplanted mice with either genotype of donor cells. There was a variable range 
infiltration of donor-derived B1a-like cells to the lymph nodes and bone marrow. There 
was a clear donor dependent variation, with some donors showing a more aggressive 
behaviour translating to an earlier disease onset and higher burden in lymph nodes and 
bone marrow.  
 
In striking contrast, the PKC- KO recipients were followed up to 6 months after the 
transplant without any signs of CLL-like symptoms. After the 6 months follow up period 
ended, the mice were analysed by flow cytometry. No B1a-like cells were detected in the 
spleens or other secondary lymphoid organs. Moreover, few B1a-like cells were present 
in the peritoneum of these animals. Finally, the B-cells of these animals were negative 
for the human TCL1 protein and also did not express the eGFP reporter gene of the R26-





IKK2ca allele. Therefore, the PKC- KO homozygous mice were resistant to TCL1tg R26-
IKK2ca CD19cre transplantation.  
 
Together these results show that the cell intrinsic constitutive canonical NF-B 
activation in the murine TCL1tg mouse model is not sufficient to overcome the PKC--
dependent niche interaction required for long-term permanence and survival in vivo.  
 
IV.2.4 TOWARDS IDENTIFYING THE TCL1 PRECURSOR CELL IN MURINE CLL 
In human CLL, to date there is no clear cell of origin for the disease. The current 
understanding is that different insults in either GC experienced B-cells or naïve B-cells 
lead to a disease with similar characteristics [192]. The TCL1 murine CLL model 
develops a disease with unmutated BCRs, reminiscent of a naïve non-GC B-cell 
precursor [256]. Similarly, the TCL1tg R26-IKK2ca compound mice also develop a 
disease with unmutated BCRs (Tables 6-9). By taking advantage of the accelerated 
disease progression in the TCL1tg R26-IKK2ca CD19cre mice, I wanted to investigate the 
precursor cell in the TCL1tg mouse model for CLL. For that purpose I used two different 
Cre mouse strains that express the Cre recombinase mainly in B-cells at the germinal 
centre stage: C1cre [260] and AIDcre [244]. Given the unmutated BCR status of the 
TCL1tg R26-IKK2ca derived CLL-like cells, it was unlikely that the precursor cell was a 
post-GC B-cell in these mice. IKK2ca-expression reduces GCs in mice [164] but 
collaborates with TCL1 to dramatically expand the B1a-like cell pool. Therefore, it was 
of great interest to examine the consequences of TCL1 and IKK2ca co-expression mostly 
in GC B-cells in both the C1cre and AIDcre mouse models.  
 
IV.2.4.1 C1cre-driven IKK2ca expression dramatically collaborates with TCL in 
murine CLL development 
A small cohort of TCL1tg R26-IKK2ca C1cre compound mice and controls were aged 
and monitored for the development of disease as in the CD19cre compound mice 
analysis (see above).  
 
Surprisingly, TCL1tg R26-IKK2ca C1cre mice have a median survival of 205 days 
(Figure 42A), only 19 days longer than the TCL1tg R26-IKK2ca CD19cre mice (Figure 
29A). Additionally, the analysis of the peripheral blood showed the presence of CD5+ 
B1a-like cells from 2-3 months of age onwards (Figure 42B). Interestingly, at 3 months 





of age the majority of B1a-like cells in the peripheral blood are eGFP-negative;TCL1+ 
cells. While from 4 months onwards a small fraction of eGFP-negative cells remains, the 
progressively larger fraction is composed of eGFP+;IKK2ca+;TCL1+ cells. In 2 cases out 
of 3, eGFP+;IKK2ca+;TCL1+ B1a-like cells have expanded dramatically in absence of 
further eGFP-negative;TCL1+ cell expansion (Figure 42C). At this stage, it is not clear 
whether eGFP+;IKK2ca+;TCL1+ B1a-like cells have a competitive advantage over the 
eGFP-negative cells, or if the eGFP-negative cells over time recombine the STOP cassette 
and therefore start to express eGFP and IKK2ca. However, in the TCL1tg R26-CAR 
C1cre control mice, although B1a-like cells can be also detected in the blood at 2-3 
months of age, the expression of the CAR reporter gene, also knocked into the rosa26 
locus [242], can only be observed in maximally 3% of living cells at 5 months of age in 2 
out of 5 cases (Figure 42D). The absence of a progressive increase of CAR-expressing 
B1a-like cells in TCL1tg R26-CAR C1cre mice strongly argues for a competitive 
advantage of eGFP+;IKK2ca+;TCL1+ B1a-like cells over eGFP-negative;TCL1+ B1a-like 
cells in the TCL1tg R26-IKK2ca C1cre mice.  
 
The ex vivo analysis of burdened TCL1tg R26-IKK2ca C1cre mice shows enlarged 
spleens accompanied by a drastic increase in B-cell numbers compared to their aged 
matched controls (Figure S 44A and B); with the main B-cell population being B1a-like 
cells (Figure 42E). The conditional activation of the IKK2ca knock-in allele results in a 
38-fold increase in B1a-like cell numbers compared to the TCL1tg C1cre and TCL1tg 
R26-CAR C1cre aged matched controls. Moreover, the expression of the reporter genes 
CAR or eGFP in these mice shows that 98% of the B1a-like cells in the spleen from 
TCL1tg R26-IKK2ca C1cre are eGFP+, while there are less than 0.1% of CAR+ B1a-like 
cells in the TCL1tg R26-CAR C1cre mice (Figure 42F). On the other hand, 33% of the 
B1a-like cells in the R26-IKK2ca C1cre mice were eGFP+ (0.2 million 
eGFP+;IKK2ca+/0.6 million B1a-like cells, Figure 42E and F), while 10% were CAR+ in 
the R26-CAR C1cre controls (0.1million CAR+/1 million B1a-like cells, Figure 42E and 
F). This differential expression of the CAR and eGFP reporter genes again points towards 
a competitive advantage of eGFP+;IKK2ca+;TCL1+ B1a-like cells over eGFP-
negative;TCL1tg+ B1a-like cells. 
 
The similar CLL-disease dynamics in the TCL1tg R26-IKK2ca C1cre (Figure 42) and 
TCL1tg R26-IKK2ca CD19cre (Figure 29) is unexpected. As mentioned above, in the 
C1cre strain the Cre recombinase is mainly expressed at the GC stage. However, there is 





a 1% of B1-cells in the peritoneum of R26-YFP C1cre that show Cre dependent 
recombination and expression of the enhanced yellow fluorescent protein (eYFP) 
reporter [243]. Given the role of constitutive canonical NF-B activation in B1 cell 
development (Figure 27) and the fact that constitutive canonical NF-B activation 
prevents GC formation (Figure S 48 and Figure S 49), the most reasonable explanation is 
that the population of 1% of C1cre-dependent recombination in B1-cells is giving rise 
to the eGFP+;IKK2ca+;TCL1+ B1a-like cells and not their transition through the GC.  
 
Indeed, six out of ten 1-year-old R26-IKK2ca C1cre mice develop B1-cell hyperplasia in 
the peritoneum (Figure S 45B and Figure S 46C) compared to 1 out of 16 aged matched 
C1cre controls (Figure S 46B). The B1-cell expansion observed in the 1-year-old R26-
IKK2ca C1cre mice affects either or both B1a and B1b subsets (Figure S 45 and Figure S 
46). Moreover, Cre-mediated recombination in R26-CAR C1cre 1-year-old mice results 
in 1.4% CAR+ B1a-cells and 6.6% CAR+ B1b-cells in the peritoneum (Figure S 46D, first 
column and Figure S 46A) compared to 60% eGFP+;IKK2ca+ B1a-cells and 39% of 
eGFP+;IKK2ca+ B1b-cells in R26-IKK2ca C1cre 1-year-old mice (Figure S 45D, second 
column and Figure S 46A). In the cases with B1-cell hyperplasia, over 95% of the B1b- or 
B1a-cells are eGFP+ (Figure S 45D, third and fourth column correspondingly). Although 
these eGFP+;IKK2ca B1-cells only express IgM (Figure S 45C), I cannot exclude that they 
transitioned through the GC at some point. Interestingly, in 2-months-old R26-IKK2ca 
C1cre mice only 5% of B1a- and B1b-cells in the peritoneum express eGFP (Figure S 
47). Given that B1-cells possess self-replenishing capacities, the B1-cell expansion 
observed with age might not reflect the number of cells that have undergone Cre 
dependent recombination but might reflect the positive effect of constitutive canonical 
NF-B activation on self-renewal/cellular expansion or a cumulative effect of 
recombination of eGFP-negative B1-cells in time.  
 






Figure 42. C1cre driven IKK2ca expression cooperates with TCL1 in murine CLL  
 





Figure 42 (continued). C1cre driven IKK2ca expression cooperates with TCL1 in murine CLL  
Monitoring of TCL1tg murine CLL development in the presence C1cre-dependent canonical NF-B 
activation. (A) Kaplan-Meier survival curve analysis for TCL1tg and R26-IKK2ca compound mice. 
Number of deceased and censored animals is indicated, as well as their median survival age in days. 
(B) Scatter plot shows the percentage of B1a-like cells present in peripheral blood after red blood cell 
lysis for each individual mouse, over a period of 10 months. (C) Scatter plot shows the percentage of 
eGFP- and eGFP+ B1a-like cells present in peripheral blood of the TCL1tg R26-IKK2ca C1cre. (D) 
Scatter plot shows the percentage of CAR- and CAR+ B1a-like cells present in peripheral blood of the 
TCL1tg R26-CAR C1cre. Bar charts show (E) total B2- and B1a-like cell numbers, and (F) number of 
CAR+ or eGFP+ expressing B2- and B1a-like cells in spleens of aged TCL1tg R26-IKK2ca C1cre 
burdened mice and aged matched controls. The connecting lines in C and D represent means for each 
time point. Histograms in E and F depict medians, and values are indicated below each histogram.  
PB (peripheral blood), SPL (spleen), B1a-like (B1a, CD19+ B220- CD5+) and B2 (CD19+ B220+). 
 
 
Additionally, the analysis of the germinal centre reaction in 1-year-old R26-IKK2ca 
CD19cre (Figure S 48) and R26-IKK2ca C1cre (Figure S 49) compound mice confirms 
the negative role of constitutive canonical NF-B activation in the GC reaction. Briefly, 
the presence of the IKK2ca knock-in reduces the percentage of GC B-cells in the spleen 
of aged mice in both CD19cre (Figure S 48A) and C1cre (Figure S 49A) compound mice. 
Moreover, in the CD19cre compound mice the percentage of eGFP+;IKK2ca+ GC B-cells 
in the spleen is extremely low (Figure S 48A and B). Similarly, in R26-IKK2ca C1cre 
mice the percentage of eGFP+;IKK2ca+ GC B-cells is lower (10%) compared to the 
percentage of CAR+ GC B-cells in the aged matched R26-CAR C1cre controls, were 
about 50% of all the GC B-cells express CAR (Figure S 49B and C).  
 
Together, the eGFP+;IKK2ca+ B1-cell expansion and reduced eGFP+;IKK2ca+ GC B-cells 
in 1-year-old R26-IKK2ca C1cre mice further support the role of constitutive canonical 
NF-B activation in B1-cell expansion. It still remains unresolved whether the precursor 
cell in TCL1-derived CLL-like disease in mice has transiently entered the germinal 
centre reaction or not. In any case, it is remarkable that expression of IKK2ca in 1% of 
B1-cells in TCL1tg R26-IKKca C1cre mice [243] leads to essentially the same dramatic 
acceleration in CLL progression compared to IKK2ca expression in over 90% of all B-
cells in TCL1tg R26-IKKca CD19cre mice. This finding strongly argues to a cell-intrinsic 
co-operation between the TCL1 and IKK2ca oncogenes in CLL development. 
 





IV.2.4.2 AIDcre-driven IKK2ca expression dramatically collaborates with TCL1 in 
murine CLL development 
To gain further understanding of the potential transition through the germinal centre of 
the CLL-precursor cell in the TCL1tg mouse model I used the AIDcre mouse strain[244]. 
This strain expresses the Cre recombinase under the promoter of the Aicda gene and the 
1% of B1-cells recombined observed in the C1cre[243] should not be present. 
 
Unexpectedly, the median survival of the TCL1tg R26-IKK2ca AIDcre mice was 202 days 
(Figure 43A), similar to the TCL1tg R26-IKK2ca C1cre (Figure 42A) and only 16 days 
longer than for TCL1tg R26-IKK2ca CD19cre mice (Figure 29A). Similarly as in the 
TCL1tg R26-IKK2ca C1cre mice, at 3 months of age eGFP-negative;TCL1+ B1a-like cells 
can be detected in the peripheral blood of these mice, while two months later 
eGFP+;IKK2ca+;TCL1+ B1a-like cells have outcompeted them (Figure 43B and C). 
Moreover, there was a significant expansion of CD5+ B1a-like cells in the spleens of 
TCL1tg R26-IKK2ca AIDcre mice compared to aged matched controls (Figure S 50A).  
 
Interestingly, 90% of the B1a-like cells in the spleen express the eGFP reporter in the 
TCL1tg R26-IKK2ca AIDcre mice compared to 13% of B1a-cells in the R26-IKK2ca 
AIDcre aged matched control (Figure S 50B). Furthermore, the eGFP+;IKK2ca;TCL1+ 
B1a-like cells in the spleen of the TCL1tg R26-IKK2ca AIDcre mice are IgM+ IgD- 
pointing towards a non-GC origin. 
 
Given the presence of eGFP+;IKK2ca+;TCL1+ B1a-like cells in the TCL1tg R26-IKK2ca 
AIDcre mice it remains unclear whether AID is or was expressed in these cells. 
Therefore, at this point I cannot conclude whether or not the CLL-precursor is actually a 
germinal centre experienced cell or whether CLL-like cells transition through the 
germinal centre or a GC-like state and whether this exposure is sufficient to drive AIDcre 
dependent recombination. Kaku et al. have reported expression of AID in CD25+ B1a-
like cells [261]. Indeed, in AIDcre mice Cre-mediated recombination leads to conditional 
expression of genes not only in the germinal centre, but also in B1a and B1b subsets in 
the spleen and peritoneum ([262] and Figure S 51). Furthermore, in 7-months-old R26-
IKK2ca AIDcre mice both B1a and B1b-cells in the peritoneum express eGFP (Figure S 
52), supporting the idea of AID expression in the B1 subset. 
 







Figure 43. AIDcre driven IKK2ca expression strongly cooperates with TCL1tg in murine 
CLL development.  
Monitoring TCL1tg murine CLL development in the presence AIDcre-dependent canonical NF-B 
activation. (A) Kaplan-Meier survival curve analysis for TCL1tg and R26-IKK2ca compound mice. 
Number of deceased and censored animals is indicated, as well as the median survival age in days. (B) 
Scatter plot shows the percentage of B1a-like cells present in peripheral blood after red blood cell lysis 
for each individual mouse, over a period of 8 months. (C) Scatter plot shows the percentage of eGFP- 
and eGFP+ B1a-like cells present in peripheral blood of the TCL1tg R26-IKK2ca AIDcre. The 
connecting line represents the mean for each time point. 
PB (peripheral blood), B1a-like (CD19+ B220- CD5+) 
 
 
Taking these data into consideration, it is not surprising that the TCL1tg R26-IKK2ca 
AIDcre mice are burdened with eGFP+;IKK2ca;TCL1+ B1a-like CLL-cells and have a 
similar median survival as observed for the C1cre compound mice. Nonetheless, the 
observed 7% recombination B1a-like cells in the spleen and 4% in the peritoneum of 
TCL1tg R26-IKK2ca AIDcre mice results in an ultimately lethal expansion of CLL-like 
cells with a strikingly similar kinetic as in the TCL1tg R26-IKK2ca CD19cre mice were 
recombination takes place in 95% of all B-cells. This constitutes compelling evidence for 
a strong cooperation of TCL1tg and constitutive canonical NF-B activation at the single 
cell level in CLL-like development in mice.  
 





Although the C1cre and AIDcre conditional expression could not shed light into the 
precursor cell for TCL1tg-dependent CLL in mice, it further supports the strong co-
operation of canonical NF-B activation in CLL.  
 







V.1 LOSS OF A20 IN COMBINATION WITH ENHANCED EXPRESSION OF THE 
ALTERNATIVE NF-B REGULATOR NIK IN B-CELL PHYSIOLOGY 
 
The NF-B family of transcription factors drive the expression of survival, proliferation, 
inflammation and differentiation in B-cells as well as in other cells of the immune 
system. The protein A20 acts as a negative regulator of the canonical NF-B pathway, 
and in the absence of A20 canonical NF-B signalling cannot be timely terminated [263, 
264]. A major player in the activation of the alternative NF-B pathway is the NF-B 
inducing kinase NIK. Under steady state conditions the pathway is inactivated by the 
constant ubiquitination and consequent proteosomal degradation by TRAF2/3 and 
cIAP1/2 complex [265]. When the pathway is activated by external stimuli, NIK protein 
levels are stabilized by recruitment of the TRAF2/3 complex away from NIK, and NIK 
can activate the IKK1 kinase, and together they activate alternative NF-B transcription 
factors [265].  
 
Given the high prevalence of genetic lesions associated with A20, a negative regulator of 
the canonical NF-B pathway as well as the alternative NF-B pathway in B-cells in 
autoimmune disease and cancer, it is of high importance to gain further understanding 
of their role in disease development and progression. Genetic abnormalities in A20 and 
the alternative NF-B arm TRAF3/NIK have been reported in patients with splenic 
marginal zone lymphoma (sMZL) [154, 179, 183]. Therefore, I wanted to address the 
question whether mutations in A20 and the cIAP2/3-TRAF2/3-NIK arm cooperate in 
sMZL development. My data provide evidence that hyper-activation of the alternative 
NF-B pathway by expression of an additional allele of NIK in combination with 
inactivation of A20 do not cooperate in sMZL development in mice. Instead, homozygous 
loss of A20 combined with overexpression of NIK in B-cells resulted in an unexpected 
reduced mature B-cell pool. This impairment in mature B-cells homeostasis challenges 
the current understanding of NF-B activation in B-cell development and homeostasis. 
Moreover, I also show that aberrant NF-B activation resulted in an activated antigen 
presenting-like phenotype in mature B-cells that was accompanied by T-cell activation.  
 





Convincing evidence documents the requirement of both canonical [37, 40, 61, 79, 266] 
and alternative [36, 89, 100, 103, 267-269] NF-B activation in B-cell development and 
fitness. This is in line with my own observations where enhanced canonical NF-B 
activation due to heterozygous loss of A20 combined with NIK overexpression driving 
alternative NF-B activation cooperates in mature B-cell development. In striking 
contrast, I observe that bi-allelic loss of A20, instead of promoting marginal zone B-cell 
expansion, results in reduced mature B-cell numbers. Given the nature of NF-B target 
genes, proliferation and survival, it is completely unexpected that NF-B activation by 
integration of the canonical and alternative pathways leads to reduced mature B-cell 
numbers. There are several possible reasons that can cooperate in the development of 
the observed impaired B-cell homeostasis. 
 
ABERRANT NF-B ACTIVATION MAY ALTER THE T1 TO T2 B-CELL STAGE TRANSITION 
My data shows that activation of canonical NF-B by loss of A20 in combination with 
activation of alternative NF-B by expression of one additional allele of NIK in B-cells, 
which should provide a pro-survival and proliferation advantage, paradoxically results 
in reduced mature B-cell numbers in mice. Given the reduced mature B-cell numbers 
observed in A20F/F NIK-tg CD19cre mice, it is possible that aberrant activation of both 
canonical and alternative NF-B pathway may alter normal B-cell development resulting 
in reduced mature B-cell numbers. My data shows that early B-cell development was 
largely unaffected by hyper-activation of either or both canonical and alternative NF-B 
pathway in B-cells, however there was a small trend towards reduced immature T1 and 
increased T2 B-cell numbers (Figure 9 and Figure S 4) associated with the dual 
activation of the canonical and alternative NF-B pathway by loss of A20 and gain of NIK 
expression, respectively. During normal B-cell development BAFF is a key player in the 
transition of T1 to T2 B-cells as well as in the generation and survival of mature B-cells 
[69, 270]. Binding of BAFF to its cognate receptor drives the induction of pro-survival 
genes and reduction of pro-apoptotic proteins via NF-B in a NIK-dependent fashion 
[89, 271, 272]. Moreover, genetic studies in mice where transcription factors of the 
canonical and alternative NF-B pathway were ablated in B-cells support the idea that 
pro-survival and proliferation signals downstream of both canonical and alternative NF-
B would are indispensable for the transition of T1 to T2 [36, 61, 268]. These studies 
showed that B-cells deficient of p50/p52 [61], RelB/c-Rel [36] and p52/RelB [268] 
suffer a developmental block a the T1 B-cell stage. Moreover, at least in p50/p52 mutant 





mice c-Rel dependent expression of Bcl-xl and Cyclin-E are able to rescue the T1 
developmental block [61]. On the other hand, overexpression of BAFF rescues self-
reactive T2 cells from peripheral deletion [73]. Additionally, combined loss of IB, 
IB, c-Rel and TNF, which leads to B-cells with hyper-activated NF-B, results in 
reduced T1 cell numbers as well as MZB-cell expansion [36]. On the other hand, loss of 
A20 in B-cells results in increased T2 cell numbers [79]. Taken together, all the previous 
evidence points to a requirement for both the canonical and alternative NF-B pathways 
in the transition from T1 to T2 B-cells. This might explain why aberrant activation of 
both pathways results in a faster transition into the T2 developmental stage as shown 
here. Moreover, an accelerated B-cell development by a faster transition into the T2 B-
cell developmental stage or a higher sensitivity to BAFF could affect the negative B-cell 
selection process and allow for the survival and further differentiation of auto-reactive 
B-cells. 
 
Interestingly, my data also shows that the strong activation of the canonical and 
alternative NF-B pathways in B-cells increased the expression CD21 and CD23 in A20-
deficient NIK-tg B-cells (Figure S 3A and Figure S 4A). Both surface proteins are NF-B 
target genes [252] and are used to phenotypically define the transitional B-cell stages 
according to their differential expression, in addition to surface IgM and surface IgD. 
Given that CD21 and CD23 had higher expression in the A20F/F NIK-tg CD19cre mice it 
would be important to confirm the proper identification of the T1 and T2 stages to have 
a better understanding on the role of dual activation of the canonical and alternative NF-
B pathways on the transition to the T2 stage. Histology sections depicting the spleen 
architecture could clarify if the T2 cells are at their proper location, or if the higher 
number of T2 cells actually corresponds to T1 cells with aberrant expression of CD21 
and CD23. Moreover, transcriptional profiles of sorted T1 and T2 cells could provide 
further information to their actual biological state.  
 
ABERRANT NF-B ACTIVATION IMPAIRS MATURE B-CELL HOMEOSTASIS 
My data shows that homozygous loss of A20 in combination with expression of a knock-
in NIK transgene in B-cells results in reduced B-cell numbers in mice affecting both 
follicular B-cells (FOB) and marginal zone B-cells (MZB). The aberrant NF-B activation 
resulting from combining loss of A20 and overexpression of the NIK transgene could 
affect (1) the differentiation of B-cells into MZB-cells and (2) FOB-cells, (3) the 





expression of integrins required for cell migration and proper localization, and (4) the 
cell survival and its sensitivity to cell death signals.  
 
First, the finding that combination of heterozygous loss of A20 with overexpression of 
NIK leads to an expansion of mature B-cells affecting both FOB- and MZB-cells is in 
accordance with previous reports on the role the canonical as well as the alternative NF-
B pathway play in MZB- and FOB-cell development [36, 37, 73, 89, 184, 268]. In fact, 
genetic studies in mice provide evidence supporting the requirement of both the 
canonical and alternative NF-B pathways in MZB development [36, 86, 268]. Although 
ablation of RelB or c-Rel is dispensable for B-cell development, the combined deletion of 
both NF-B members drastically reduces the number of MZB-cells in young mice [36]. 
Moreover, the ablation of p52 and RelB further intensifies this phenotype [268]. In the 
case of A20, the evidence points to its requirement for proper MZB differentiation [79, 
80]. A20F/F CD19cre mice have an accumulation of MZP and an improper localization of 
MZB-cell within the spleens [79]. In contrast, combined loss of IB, IB, c-Rel and 
TNF, which leads to B-cells with hyper-activated NF-B, results in expansion of MZB-
cells [36]. Similarly, constitutive activation of the canonical NF-B pathway through 
expression of a constitutively active IKK2 in B-cells leads to increased MZB-cell numbers 
[37]. Moreover, ablation of the TRAF3 protein adaptor, a negative regulator of the 
alternative NF-B pathway upstream of NIK, in B-cells leads to development of clonal 
sMZL or B1a-cell lymphomas in 18-months-old mice [184]. Paradoxically, my data 
shows that while heterozygous loss of A20 in combination with expression of the NIK 
transgene resulted in an expansion of MZB-cells, homozygous deletion of A20 in 
combination with the expression of the NIK transgene results in dramatically reduced 
MZB-cells numbers. Therefore, it seems plausible that a tight control of NF-B activation 
is indispensable for proper MZB-cell development.  
 
Second, reduced mature B-cell numbers in A20F/F NIK-tg CD19cre mice could be 
explained by altered B-cell differentiation to the FOB stage. Although loss of A20 has no 
apparent effect on FOB-cell development [79], constitutive canonical NF-B signalling 
results in FOB-cell expansion in mice [37]. Likewise, NIK-tg overexpression in B-cells 
results in FOB-cell expansion [89]. Moreover, while RelB-/- and c-Rel-/- mice have normal 
FOB-cell numbers RelB-/- c-Rel-/- double knockout mice have reduced FOB-cell numbers 
[36]. Therefore, all the evidence points to the requirement of signals that activate both 
canonical and alternative NF-B pathways for FOB-cell development and homeostasis. 





Paradoxically, my data shows that the combination of loss of A20 and NIK-tg 
overexpression resulted in reduced FOB-cell numbers (Figure 8). This finding is 
contradictory with the requirement of both NF-B activation pathways in FOB-cell 
differentiation. Therefore, it seems plausible that a tight control of NF-B activation is 
indispensable for proper mature B-cell development in general. 
 
Interestingly, the aberrant activation of NF-B by loss of A20 and overexpression of NIK 
elevated the expression of CD1d, CD21 and reduced expression of CD23 in mature B-
cells (Figure S 3A). However, there was an absence of CD23low CD21high CD1d high B-cells 
(Figure S 3). The absence of CD23low CD21 high CD1d high B-cells points to the possibility 
that all MZB-cells identified in A20F/F NIK-tg CD19cre mice might actually be MZB-cell 
precursors or that FOB-cells might actually be closer to MZB-cell precursors than FOB-
cells. The effects of strong NF-B activation on the expression of these surface markers 
complicate the proper identification of MZB-cells and their precursors. The true identity 
of these cells remains to be resolved and further experiments are required to properly 
characterize the biological nature of these B-cells. Analysing the expression profile of 
FACS-purified eGFP positive CD1d high CD21 high potential MZB-cells will bring light into 
their biological characteristics. Furthermore, ex vivo differentiation into plasma cells 
after a T-cell-independent stimulus such as LPS would further confirm their biological 
function. Taken together, my data suggests that activation of the NF-B pathway over a 
particular threshold could lead to differentiation signals that drive cells into the MZB 
linage or alternatively to hyper-sensitive state that leads to a negative fitness of these 
cells.  
 
Third, the reduced mature B-cell numbers in A20F/F NIK-tg CD19cre mice could be 
explained by the altered integrin expression affecting the migration and homing of 
mature B-cells. A20-deficient B-cells with overexpression of the NIK transgene have 
higher alpha-L/beta-2 integrin expression accompanied by a slightly increased beta-1 
integrin expression (Fehler! Verweisquelle konnte nicht gefunden werden. and 
Figure S 7). These findings further support the role of alternative NF-B signalling in 
integrin expression [182, 268]. For instance, DeSilva et al. (2016) have associated beta-2 
integrin expression with alternative NF-B activation. B-cells deficient for relb/nfkb2 
have a strong reduction in the expression of beta-2 integrin compared to controls [268]. 
Overexpression of BAFF promotes a higher expression of alpha-L, beta-2 and to a lesser 
extent beta-1 integrins mainly in MZB-cells, but also FOB-cells, in an p52-dependent 
fashion [182]. The LFA-1 complex, formed by alpha-L and beta-2 integrins, is important 





for keeping B-cells in the marginal zone [75]. At the same time, it has been reported that 
alpha-4/beta-1 integrin dimers are also expressed in MZB-cells and play a role in their 
localization [75]. The current understanding of MZB-cell biology suggests that they are 
highly motile cells within the spleen, recirculating between the MZ and the follicle. FOB-
cells can also migrate from the follicle to the MZ in the spleen, and their lower integrin 
expression in part prevents their retention and permits their passive flow into the red 
pulp [76]. It has been proposed that the reduced numbers of mature MZB-cells in the 
A20F/F CD19cre mice is due to aberrant migration. In fact, in these mice, the splenic 
marginal zone is nearly devoid of B-cells [79]. Interestingly, my data shows that A20F/F 
CD19cre B-cells had significantly lower surface expression of beta-2 integrins (Fehler! 
Verweisquelle konnte nicht gefunden werden. and Figure S 7B), which could explain 
their failure to localize to or be retained in the splenic marginal zone. Therefore, 
aberrant overexpression of LFA-1 and beta-1 integrins in FOB-cells could promote their 
retention to the marginal zone and alter the normal B-cell homeostasis. Additional 
histological studies providing evidence of the localization of the FOB- and MZB-cells 
within the splenic architecture will confirm if the aberrant integrin expression is 
associated with a migration and homing defect.  
 
Furthermore, aberrant integrin expression caused by strong activation of NF-B in B-
cells could further enhance the retention of B-cells in the spleen niche [182] and affect 
the egress, migration or homing of B-cells to secondary lymphoid organs in the 
periphery. This could account for the reduced B-cell numbers observed in the non-
splenic secondary lymphoid organs (Figure 5, Figure 6 and S1-2) and the reduced 
recirculating B-cells in the bone marrow (Figure 11 and Figure 12) of A20F/F NIK-tg 
CD19cre mice. Additional analysis of integrin expression in B-cells in the periphery and 
in B-cells that recirculate to the bone marrow could shed light into their association 
with the reduced B-cell numbers observed in the secondary lymphoid organs. Moreover, 
proper migration and homing of transplanted eGFP+;A20-/-;NIK+ B-cells could shed 
light into the role of integrins in the observed reduced B-cell numbers in secondary 
lymphoid organs. In addition, using integrin-neutralizing antibodies could assess the 
role of integrins in the retention of B-cells in the spleen and their reduced numbers in 
the secondary lymphoid organs. 
 
Fourth, the unexpected reduced mature B-cell numbers in A20F/F NIK-tg CD19cre mice 
could be a result of higher cell death of mature B-cells. Although there is no evidence 
that hyper-activation of NF-B leads to higher apoptosis in the A20F/F NIK-tg CD19cre 





mice (Figure 13), it is known that A20 protects cells against cell death in various cell 
types in an NF-B independent fashion [79, 254, 273, 274]. It is possible that external 
signals such as TNF-[273], IFN- [275] and CD95L[276] are required to induce cell 
death in B-cells. Supporting this role of A20, Onizawa et al. (2015) reported that loss of 
A20 in CD4 T-cell results in Caspase-independent nectroptosis [274]. Paradoxically, 
Tavares et al. (2010) have shown that loss of A20 in B-cells results in reduced FASL-
depended cell death [254]. Therefore, it is possible that in the current context of 
aberrant B-cell activation, A20 might also protect B-cells from a Caspase-independent 
cell death program. Interestingly, Boutaffala et al. (2015) reported a novel pro-apoptotic 
role for NIK that is independent of alternative NF-B activation in response to TNF 
[277]. In their paper, they show that in hepatocytes loss of cIAP1 and cIAP2 increases 
NIK protein levels that will in turn drive Caspase-8 activation in a RIP1-dependent 
manner. However, very high protein levels of NIK lacking a TRAF3 binding domain 
(NIKT3) in B-cells do not result in reduced but highly expanded B-cell numbers [89]. 
Therefore, high expression of NIK alone is insufficient to induce B-cell death. It is worth 
mentioning that these mice have high levels of TRAF2 and TRAF3 and thus may have 
increased levels of cIAP1 and cIAP2. The role of the absence of these proteins in the NIK-
dependent cell death model is unclear. Thus, if the loss of A20 had a similar effect as loss 
of cIAP1 and cIAP2 in NIK+ B-cells, then external signals could trigger a NIK-dependent 
cell death program. It is therefore necessary to further investigate the role of NIK in cell 
death in the absence of A20.  
 
Interestingly, my data also shows that B1-cells had a similar fate to mature B-cells in 
A20F/F NIK-tg CD19cre mice (Figure 7). Although B1-cells can also be produced from 
bone marrow HSCs, they are thought to mainly develop from foetal liver HSCs during 
embryonic development and are maintained in the adult due to their self-renewing 
ability [110, 278-280]. Loss of A20 on its own already has a negative effect on B1-cell 
numbers [79]. Additionally, the absence of NEMO or IKK2 results in reduced MZB- and 
B1-cells pools [40]. Taking into account overexpressing BCL2 in these scenarios is 
unable to rescue both B-cell subsets suggests that additional canonical NF-B target 
genes are required for the long-term persistence of B1-cells [40]. The fact that aberrant 
activation of NF-B by loss of A20 and overexpression of NIK dramatically reduces B1-
cell numbers brings another level of complexity to the role of NF-B in mature B-cell 
homeostasis. If the reduced cell numbers were a result of increased cell death, then 
these results would support the role of A20 in protecting B1-cells against cell death. 
Alternatively, the reduced B1-cell numbers could indicate differentiation into short-





lived plasmablast or plasma cells [281, 282]. Further experiments are required to 
determine how aberrant NF-B activation affects B1-cell development. Competitive 
foetal liver derived chimeras as well as bone marrow derived chimeras could provide an 
insight into the potential role of NF-B in B1-cell development. Identification of natural 
IgM and IgG3 antibodies in serum or deposits in organs could indicate an increased 
differentiation of B1-derived plasma cells and explain the reduced B1-cell numbers  
 
My data shows that loss of A20 in combination with over expression of the NIK 
transgene resulted in reduced mature B-cell numbers. Four non-mutually exclusive cell 
intrinsic mechanisms could explain the reduced B-cell numbers observed here. First, 
defects in the development into mature MZB-cells, and second, FOB-cells stages could 
explain the reduced mature B-cell numbers. Although signals activating both canonical 
and NF-B pathways are required for proper FOB- and MZB-cell development, the my 
data suggest that a specific activation threshold might be required for development and 
aberrant NF-B activation may force B-cells into an abnormal MZB-like precursor 
phenotype that fails to terminally differentiate. Third, the higher expression of the LFA-
1 complex and additional integrins may affect migration and homing of mature B-cells 
into their functional niches. Finally, loss of A20 in combination with over expression 
with NIK might result in a higher sensitivity to cell death that is NF-B independent, 
thus making B-cells hyper-sensitive to death stimuli and reducing the mature B-cell 
pool.  
 
ABERRANT NF-B ACTIVATION IN B-CELLS PROMOTES AN EXTRINSIC INFLAMMATORY 
PHENOTYPE 
My data shows that aberrant activation of NF-B by loss of A20 and overexpression of 
NIK results in T-cell hyperplasia in young and aged mice (Figure 18 and Figure 23, 
respectively). Given (1) the pre-activated antigen presenting-like phenotype in A20-
deficient NIK+ B-cells, (2) the accumulation of effector-like CD4 and CD8 T-cells, (3) the 
higher proportion of ICOS and PD1 high T-cells, (4) the accumulation of regulatory T-
cells, and (5) a myeloid expansion in old age; I suspect that the T-cell hyperplasia 
observed is a response to aberrantly pre-activated A20-deficient NIK+ B-cells with the 
potential to drive a chronic inflammation in these mice.  
 





First, my data show that A20-deficient NIK+ B-cells have a pre-activated antigen 
presenting cell-like phenotype characterized by a higher expression of CD69, CD86, 
MHC-II and to a lesser extent CD80. This expression profile is characteristic of MZB-cells 
[251]. As such these B-cells have the potential to present antigens to T-cells and start an 
immune response. Moreover, evidence points to the role B-cells as APC in vitro and in 
vivo [283-286] further supporting this hypothesis. Second, my data shows that a 
considerable proportion of CD4 and CD8 T-cells have an activated effector-like 
phenotype, pointing to an on-going immune reaction in these mice. Interestingly, Chu et 
al. (2011) reported that loss of A20 in B-cells is sufficient to drive an expansion of 
effector-like T-cells [79]. Moreover, Afshar-Sterle et al. (2014) reported the role of CD8 
T-cells in mediating immune surveillance against the spontaneous development of B-cell 
lymphoma [276]. They showed that in the absence of T-cells, abnormal cancerous B-
cells could survive and develop into tumours. Consequently, if signals from pre-
activated B-cells or the B-cells themselves are driving a T-cell expansion, then T-cells 
may also be involved in in clearing the pre-activated B-cells in these mice. Therefore, it 
is likely that A20-deficient NIK+ B-cells present antigens to T-cells in A20F/F NIK-tg 
CD19cre mice, and that as a result of that interaction T-cells become activated.  
 
Third, my data show that a significant percentage of CD4 and CD8 T-cells express higher 
levels of ICOS and PD1, indicative of T-cell activation [287] and exhaustion [288-290]. 
Moreover, the increased numbers of PD1high CD8 T-cells positively correlate with the 
reduced B-cell numbers observed in the A20F/F NIK-tg CD19cre mice (Figure S 15). 
Given the increased numbers of effector-like T-cells and the expression of PD1, I 
speculate that a percentage of those T-cells are anergic or exhausted as a result of 
constant activation by pre-activated B-cells. Analysis of the expression of additional T-
cell exhaustion markers such as Tim-3 is required to confirm this hypothesis. 
 
Fourth, I show here that in A20F/F NIK-tg CD19cre mice have increased numbers of 
CD25+ regulatory CD4 T-cells and follicular helper T-cells. The cell numbers of CD25+ 
CD4 T-cells are indicators of the regulatory burden on the immune system [291]. The 
higher number of CD25+ CD4 T-cells could be represent a regulatory response to the 
immune activation present in A20F/F NIK-tg CD19cre mice. Moreover, a direct 
interaction between pre-activated B-cells and CD25+ CD4 regulatory T-cells could 
promote an expansion of the latter. Supporting this hypothesis, one report showed B-
cell-dependent regulatory T-cell activation in retroviral infections via the 
glucocorticoid-induced receptor superfamily member 18 (GITR) ligand in mice [292]. If 





the combination of A20 inactivation with overexpression of NIK resulted in higher GITR 
ligand levels, then direct contact between CD25+ CD4 regulatory T-cells may expand 
them. Another outcome from direct interaction between CD25+ CD4 regulatory T-cells 
and pre-activated B-cells could be a regulatory T-cell-dependent clearance of the B-cells. 
Supporting this hypothesis, Zhao et al (2006) show that regulatory T-cells kill antigen 
presenting B-cells preferentially in vitro [293]. Therefore, It is likely that CD25+ 
regulatory CD4 T-cells expansion is caused by the pre-activated B-cell phenotype in the 
A20F/F NIK-tg CD19cre mice, and the CD25+ CD4 T-cells may be involved in clearing 
mature B-cells in these mice.  
 
Another interesting aspect of my data is the increased number of follicular helper T-cells 
(TFH) in the absence of GCs (discussed below) in A20F/F NIK-tg CD19cre mice. 
Phenotypically, TFH are characterized by a higher expression of the surface makers PD1 
and CXCR5, and elevated levels of the transcription factor BCL6. Although my 
preliminary data suggest that PD1high CXCR5high CD4 T-cells have higher BCL6 expression 
levels compared to their PD1low CXCR5low CD4 T-cells counterparts (Figure S 9), it is 
evident that they have clearly upregulated PD1 to a higher extent than CXCR5 (Figure 
20) and could therefore be activated, exhausted CD4 T-cells (Figure 21). Further 
analysis of their BCL6 expression should resolve their identification  
 
Nonetheless, one possible explanation for the TFH expansion is the higher expression of 
activation markers such as CD80 and CD86 in the eGFP+;A20-/-;NIK+ B-cells. B-cells 
with a higher expression of CD80 and CD86 could positively modulate the activation and 
expansion of TFH. Genetic studies in mice showed the importance of B-cell CD80 
expression on the development of TFH [294]. Moreover, it has been proposed that 
memory B-cells with high expression of CD80 can interact with TFH generating a positive 
feedback loop of CD28/CD80 that drives T-cell expansion [295, 296]. Therefore, higher 
expression of CD80 and CD86 in the pre-activated antigen presenting-like A20-deficient 
NIK+ B-cells, in addition to driving conventional T-cell activation, could promote TFH 
differentiation explaining the high TFHs numbers observed in the absence of GCs in 
A20F/F NIK-tg CD19cre mice.  
 
Another possible explanation for the TFH expansion observed in A20F/F NIK-tg CD19cre 
mice may be an inappropriate immunological synapse between the B-cell and its 
cognate TFH-cell. Several reports point to the importance of ICOS-L expression in B-cells 
and MZB-cells, specifically, for the proper development of TFH [297, 298]. The observed 





low ICOS-L protein levels in B-cells accompanied by increased number of TFHs are 
therefore puzzling. Hu et al. (2011) showed that NIK is required in for the expression of 
ICOS-L in B-cells and this ICOS-L expression supports the development of TFH [299]. 
Paradoxically, RelB-/- NF-B2-/- double knockout GC B-cells have a slight reduction, 
although not significant, of ICOS-L expression [101]. One explanation for the lower ICOS-
L surface levels in B-cells would be a higher shedding of ICOS-L by ADAM10 [297]. I 
therefore speculate that if NIK+ A20-deficient B-cells were to have a higher expression 
or a higher activation level of ADAM10, the higher levels of ADAM10 activity would 
result in stronger ICOS-L shedding reducing its detection. This to be tested hypothesis 
would fit with the higher number of TFH observed.  
 
Finally, my data show that with age A20F/F NIK-tg CD19cre mice develop an expansion 
of myeloid cells (Figure 25), in addition to the T-cell hyperplasia that is maintained in 
old age. It has been proposed that chronic inflammation by the release of cytokines such 
as IL6 can lead to the expansion of myeloid cells in aged animals [79, 254]. Therefore it 
is likely that similar mechanisms take place in the A20F/F NIK-tg CD19cre mice, where 
aberrant activation of the NF-B pathways in B-cells results in a B-cell extrinsic 
inflammatory phenotype. A better understanding of the cytokine milieu present in these 
animals might enlighten the current understanding. ELISAs or flow cytometry analysis 
of IFN, TNF, IL10 and IL6 cytokines would add to our understanding of the 
inflammatory scenario present in these mice.  
 
In summary, the antigen presenting-like phenotype in A20-deficient NIK+ B-cells and 
the finding that both CD4 and CD8 T-cells have an effector-like phenotype suggest that 
the B-cells can present antigens to their cognate T-cells, thus activating them and 
starting an immune reaction. Moreover, the presence of ICOS and PD1 high expressing 
CD4 and CD8 T-cells points to a scenario with repetitive activation of T-cells resulting in 
anergy, supporting the notion of B-cell-driven inflammation. Furthermore, the increased 
number of regulatory T-cells suggests a need for regulating an inflammatory response 
under conditions where B-cells fail to become GC B-cells and only T-cells are activated. 
All of the above suggest that pre-activated B-cells have a role in the T-cell hyperplasia 
observed in the A20F/F NIK-tg CD19cre mice. Given the activation T-cell status that may 
even result in anergy in response to B-cell hyper-activation, it is likely that the T-cells 
are responsible for clearing hyper-activated B-cells and thus reduce mature B-cell 
numbers.  
 





Further experiments are required to evaluate the actual role of T-cells in the 
homeostasis of aberrantly activated B-cells. To address the role of T-cells in the 
impairment of B-cell homeostasis observed here transplant experiments into T-cell 
deficient mice versus wild type or RAG KO mice could shed light into the specific 
involvement of T-cells in clearing B-cells. Furthermore, crosses to CD3-/- mice, which 
are devoid of T-cells, would be an ideal system to test the effect of T-cells in the 
observed phenotype. If the A20-/-;NIK+ B-cells cannot replenish the B-cell compartment 
then the aberrant NF-B activation most likely plays a role in B-cell survival or 
proliferation. That would imply that the phenotype observed is cell intrinsic, and T-cell 
independent. However, if in this scenario the B-cell compartment is replenished by the 
transplant, most likely the effector T-cells would have a role in B-cell clearance. These 
experiments would add to my finding that T-cells are activated in A20F/F NIK-tg 
CD19cre mice and to the potential role of pre-activated B-cells in initiating an 
inflammatory response. 
 
ABERRANT NF-B ACTIVATION NEGATIVELY AFFECTS THE GC REACTION AND THE 
DEVELOPMENT OF ADAPTIVE IMMUNITY 
My data provides additional evidence on the previous hypothesis on the negative role of 
NIK in germinal centre B-cells. Here, I show that the majority of the GC B-cells in the 
NIK-tg compound mice are eGFP negative and therefore do not express NIK (Figure 14). 
Moreover, there are very few eGFP positive plasma cells (Figure 15). Therefore, my data 
supports the notion that strong alternative NF-B signalling negatively affects the 
germinal centre reaction. Similarly to the results presented here, Zhang et al. (2015) 
found that constitutive activation of the alternative NF-B pathway by overexpression of 
NIK-tg at the GC B-cell stage has a negative effect in the GC reaction [165].  
 
One interesting finding in this study was that the combination of loss of A20 and NIK 
overexpression resulted in higher levels of IRF4 and BCL6 in mature B-cells compared 
to controls (Figure 16 and Figure S 6). It is possible that elevated levels of both 
transcription factors inhibit the progression of B-cells into GC reaction. Supporting this 
hypothesis, Zhang et al. (2015) associated NIK overexpression in GC B-cells with 
significantly higher IRF4 expression [165]. In the same publication, they showed that 
C1cre IBCL6 NIK-tg mice had lower percentage of GC B-cells compared to BCL6, NIK-
tg or YFP-tg reporter controls. Moreover, reduced percentages of GC B-cells expressed 





the eGFP reporter for the NIK-tg compound mice 21 days post immunization [165]. 
These observations further support the hypothesis that at least higher expression of 
BCL6 in combination with over expression of NIK negatively selects GC B-cells.  
 
Moreover, in mature B-cells BCL6 mRNA is readily available, and once the cell enters the 
GC reaction its translation is initiated. However, the regulatory mechanism for the 
translation and expression of BCL6 in GC B-cells is not understood [300]. I speculate 
that if there is a higher BCL6 protein content in mature B-cells here, A20 and NIK could 
play a role influencing this unknown regulatory mechanism.  
 
The role of alternative NF-B activation in the GC reaction is complex. On the one hand, 
Zhang et al. (2015) have shown that NIK impairs the GC reaction [165]. On the other 
hand, De Silva et al. (2016) provide evidence for the requirement of both RelB and p52, 
members of alternative NF-B family of transcription factors, for B-cells to progress to 
GC reaction [268]. They propose that loss of the alternative NF-B pathway leads to 
reduced ability to enter the cell cycle, since ex vivo stimulated double knockout RelB-/- 
p52-/- B-cells show a proliferation defect [101]. Interestingly, Zhang et al. (2015) 
speculated that additional canonical NF-B activating mutation may confer a survival 
advantage to NIK+ B-cells [165]. However my data shows that canonical NF-B 
activation by heterozygous or homozygous loss of A20 in NIK+ B-cells did not rescue the 
GC B-cell phenotype. It is possible that a different mechanism for canonical NF-B 
activation might result in a different outcome. Tavares et al. (2010) and Chu et al. [79] 
found that loss of A20 in B-cells resulted in increased GC B-cell numbers in vivo, which 
Tavares et al. attributed to reduced FASL-depended cell death due to increased Bcl-xL 
expression in the absence of A20 in vitro [254]. Loss of A20 and over expression of NIK 
could result in B-cell that is more sensitive to cell death [79, 277] (discussed 
previously). Taken together, all the evidence points to a dominant negative role of NIK 
in GC B-cells that cannot be rescued by loss of A20, that is NIK-dependent but may be 
independent of alternative NF-B activation.  
 
Finally, the lower levels of ICOS-L expression in the A20F/F NIK-tg B-cells point towards 
an improper B-T-cell synapse. In spite of the increased number of TFH observed in these 
mice (Figure 20), the reduced interaction with TFH might be insufficient for proper 
signals required for GC reaction.  
 





There are many open questions regarding the role of strong NF-B activation and the GC 
reaction. Is it likely that the pre-activated state of the mature B-cells in these mice 
renders them unresponsive to further stimuli? Would further signals from TFH be able to 
drive them into the GC reaction? Are these cells able to respond to antigen presentation, 
of have they become anergic? As a first step, ex vivo stimulation with T-cell independent 
and T-cell dependent stimuli will provide further information about their 
responsiveness and activation potential. Recently, the in vitro germinal centre B-cell 
culture has been used as a tool to further study aspects of the biology of GC B-cells [99]. 
Assessing the capability of NIK+ B-cells to establish GC B-cell cultures would be another 
means to assess the role of strong alternative NF-B activation in the GC reaction. 
Moreover, immunization of mice with T-cell specific antigens could address the role of 
B-cells as APCs and GC B-cells.  
 
 
To summarize, my data supports the notion that loss of A20 results not only in 
prolonged NF-B activation but also makes B-cells more susceptible to cell death most 
likely driven by external stimuli [240, 254, 274, 275, 301-306]. This highlights the 
importance of A20 in protecting against cell death. The model I proposed here is that 
aberrant NF-B activation in B-cells leads to an atypical B-cell phenotype and I speculate 
that this triggers a T-cell immune response. The release of cytokines and signals coming 
from the activated T-cells to the B-cells with hyperactive phenotype could drive the 
extrinsic cell death program in these cells. In the absence of the protective role of A20, 
death stimuli that under normal consequences would result in B-cell survival now result 
in B-cell death. Thus, without A20 driving the balance towards survival, the B-cells are 
no longer protected and become prone to cell death. Additionally, it still remains to be 
proven whether the novel pro-apoptotic role of NIK also plays a role in mature B-cell 
death observed here.  
 





V.2 ROLE OF CANONICAL NF-B IN B-CELL TRANSFORMATION 
 
The members of the family of NF-B transcription factors regulate the expression of 
genes involved in survival, differentiation and inflammation that play a key role in the 
development of the immune system and particularly B-cells. Thus it is surprising that no 
direct evidence has linked deregulated canonical NF-B signalling to spontaneous 
transformation in B-cells. Here, I show for the first time B-cell lymphomagenesis in mice 
as a direct consequence of constitutive canonical NF-B activation. My data shows that 
constitutive canonical NF-B activation in B-cells resulted in the expansion of the B1a 
subset in mice that with age developed into a disease with characteristics of human 
small cell lymphocytic lymphoma (SLL). Moreover, my data further supports the 
importance of canonical NF-B activation in CLL, by using the TCL1tg chronic 
lymphocytic leukaemia (CLL) mouse model. And finally, my data provides compelling 
evidence for the requirement of additional activation signals other than canonical NF-B 
activation in CLL-cells to overcome the dependence of the niche for prolonged survival.  
  
CANONICAL NF-B ACTIVATION IN B1-CELL DEVELOPMENT 
The B1 B-cell compartment is composed of B1a and B1b B-cells that play an important 
role in the innate immune response. B1-cells are of foetal liver origin and have self-
replenishing ability [278]. However, it is clear from bone marrow chimera experiments 
that hematopoietic stem cells also have the ability to replenish the B1 compartment 
[110]. Additionally, there is consensus that strong BCR signals are required for B1a 
development [81, 282, 307]. 
 
This thesis provides direct evidence on role of canonical NF-B signalling in B1a biology. 
My data shows that constitutive canonical NF-B activation in B-cells by the conditional 
expression of a constitutive active IKK2 resulted in the expansion of the B1-cell 
compartment in mice, favouring the B1a subset. My results are in agreement with 
previous studies on the requirement of canonical NF-B activation in B1a B-cell 
development [35, 78, 120, 308]. Furthermore, they demonstrate that uncontrolled 
enhanced canonical NF-B activation results in B1a-cell expansion, in line with previous 
experimental indications in this direction [122]. Paradoxically, overexpression of BCL10 
in B-cells, required for NF-B activation, results in reduced B1a-cell numbers but 
increased B1b-cell numbers in the peritoneum [185]. Moreover, BCL10 overexpression 





in B-cells resulted not only in c-Rel-dependent activation of the canonical NF-B but also 
p52-dependent activation of alternative NF-B pathway [185]. Therefore, the additional 
activation of the alternative NF-B pathway could skew the development into the B1b 
lineage. Interestingly, although constitutive canonical NF-B activation in B-cells 
preferentially expanded the B1a subset, I also observed expansion of B1b-cells in both 
R26-IKK2ca C1cre mice and R26-IKK2ca CD19cre mice, suggesting that canonical NF-
B activation also plays a role in B1b-cells. Taken together, these findings demonstrate 
that canonical NF-B activation critically dictates the output of normal B1-cell 
development.  
 
As motioned above, my results prove the direct link between enhanced canonical NF-B 
activation and B1a expansion in mice, suggested by previous reports. Previously, Ding et 
al. (2007) reported that Siglec-G controls the level of activation of canonical NF-B in 
B1a-cells, and in its absence B1a-cells expanded as a result of enhanced canonical NF-B 
activation [122]. Moreover, Hahn et al. (2017) showed that the overexpression of the 
short (s)CYLD isoform in mouse B-cells resulted in Bcl3 dominated NF-B activation 
[309]. Mice that expressed sCYLD in B-cells developed B1a expansion in old age [310]. 
Therefore, these findings indicated that enhanced NF-B-associated signalling can be 
associated with B1a-cell expansion suggesting that a tight control of NF-B activation is 
required for the normal homeostasis of the B1a compartment. 
 
Previous studies demonstrated that the development of the B1a compartment requires 
the expression of a functional BCR signalling complex [282]. Moreover, it has been 
proposed that strong BCR signalling is required for B1a activation [81, 112, 250, 282]. 
My preliminary results show that strong canonical NF-B activation by expression of 
two copies of IKK2ca resulted in in vitro proliferation of resting B1a-cells, suggesting 
that canonical NF-B activation modulates the proliferation of B1a-cells. Although it still 
remains to be confirmed whether constitutive canonical NF-B activation results in 
higher B1a proliferation that translates into an expansion of B1a-cells, my preliminary 
results suggest that constitutive canonical NF-B activation in B1a-cells could act as a 
surrogate for NF-B activation downstream strong BCR signals during the positive 
selection in B1a development. Consistently, Morimoto et al. (2016) have suggested that 
the absence of B1a-cells in leucine-rich repeat kinase 1 (LRRK1)-deficient mice is due to 
the failure of strong BCR signalling to induce canonical NF-B activation required for the 
positive selection and survival of these cells [308]. Interestingly, Sasaki et al. (2013) 





reported that although NF-B signalling downstream of the BCR is not affected in 
LUBAC mutant mice, they have reduced B1a-cell numbers [35], implying that although 
canonical NF-B signalling is required for B1a development, NF-B activation 
downstream of BCR signalling is not the main driving force. One limitation in both 
studies is that due to the absence of B1a-cells in these mutant mice, the NF-B activation 
downstream of BCR signalling was assessed in B2-cells and the physiological response 
of B1a-cells to BCR crosslinking may differ from that of B2-cells. Therefore, they were 
not able to address the requirement of canonical NF-B activation after BCR signalling in 
B1a-cells. As mentioned previously, loss of Siglec-G in B-cells resulted in expanded B1a 
population [121, 122]. Moreover, Hoffmann et al. (2007) have showed that loss of 
Siglec-G in B-cells results in higher calcium mobilization in B1a-cells after BCR 
stimulation, however it is associated with reduced proliferation [121]. They suggest that 
the higher BCR-mediated calcium signalling responses promote the expansion of B1a-
cells most likely by increasing the cell life span [121]. Given that this study did not 
address the status of NF-B activation, it cannot be ruled out that the higher calcium 
mobilization associated responses are related to the enhanced NF-B activation seen by 
Ding et al. (2007). Also TRAF6 is indispensible for B1a-cell development [120] 
suggesting that additional signals independent of strong BCR signalling are required for 
normal B-cell development and associated with canonical NF-B activation. Therefore, 
these findings imply that constitutive canonical NF-B activation might replace the 
requirement of strong BCR signals in B1a development while enhanced canonical NF-B 
activation might amplify downstream signals of weaker BCR activation strength. Taken 
together, these findings suggest that canonical NF-B activation in B1a-cells plays a role 
in proliferation and survival.  
 
Mouse genetic studies have proven the strict requirement of BAFF for the development 
and survival of follicular and marginal zone mature B-cells [72, 85]. On the other hand, 
BAFF and its main receptor BAFF-R are not required for peritoneal B1-cell development. 
Nevertheless, subsequent studies provided evidence for a role of enhanced BAFF and 
APRIL signalling also in B1-cell survival and development [236, 311, 312]. 
Mechanistically, amongst other studies, Almaden et al. (2016) demonstrated that BAFF 
activates both canonical and alternative NF-B signals in B-cells [36]. Moreover, since 
constitutive active IKK2-mediated constitutive canonical NF-B activation in B-cells 
replaces the cell-intrinsic requirements for BAFF signals [37], constitutive canonical NF-
B activation could also replace homeostatic requirements in B1a-cells. My results 





provide preliminary evidence for the role of BAFF in conjunction with canonical NF-B 
activation in B1a proliferation in vitro. Therefore, the B1a expansion observed by 
constitutive canonical NF-B activation may also imply the involvement of BAFF/APRIL 
signals in B-cell survival and proliferation in vivo. 
 
CANONICAL NF-B ACTIVATION IN B-CELL LYMPHOMA 
Molecular studies in samples from patients with immune diseases as well as B-cell 
lymphomas have pointed to the importance of deregulated canonical NF-B activation 
in disease pathogenesis [1, 5-8, 313]. Here, I show that constitutive activation of the 
canonical pathway by expression of constitutive active IKK2 in B-cells results in B-cell 
lymphoma with features reminiscent of human SLL or CLL. My results add to previous 
findings on the role of constitutive canonical NF-B activation in B-cells driving mature 
B-cell hyperplasia [37] and plasma cell hyperplasia [164] building a more 
comprehensive understanding on the role of canonical NF-B activation in B-cell 
biology. 
 
My finding that enhanced constitutive canonical NF-B activation in B-cells promotes 
the expansion of CD5+ B220lo B-cell lymphoma in mice is in agreement with previous 
studies suggesting a role of canonical NF-B activation in CLL pathogenesis [199, 200, 
310]. Human CLL is a very heterogeneous disease where diverse genetic aberrations 
result in the expansion of CD5+ IgM+ small B-lymphocytes [193, 314-316]. Although few 
mutations related to NF-B activation have been reported in CLL patients samples [193, 
194, 317], previous reports demonstrated that in general samples from CLL patients 
contain higher NF-B activation compared to B-cells from healthy donors [195, 318]. 
Canonical NF-B activation in CLL samples could be due to stimulation of CLL-cells with 
extrinsic signals such as BCR crosslinking [207, 319], TNF- [320], NOTCH [221, 321], 
APRIL and BAFF [203, 236, 237, 322]. Moreover, additional signals from the 
surrounding cells can activate canonical NF-B in CLL-cells [197, 323]. Previously, a 
gene expression profile study by Herishanu et al. (2011) identified that CLL samples 
from the lymph nodes have a higher expression of NF-B related genes compared to 
samples from other organs [141]. Additionally, the oncogene T-cell leukaemia 1 (TCL1), 
which is highly expressed in CLL patient samples [324-326] and whose overexpression 
causes a CLL-like disease in mice [229], has the ability to activate canonical NF-B in B-
cells [231, 233]. Therefore, several mechanisms for canonical NF-B activation in CLL-





cells have been identified supporting the association between enhanced canonical NF-
B activation and human CLL development. Interestingly, the NF-B subunits that 
dominated the enhanced canonical NF-B activation detected in CLL-cells, RelA and p50 
[198, 327, 328], are also predominantly activated by the expression of the IKK2 
constitutive active mutant in B-cells [37]. This suggests that similar mechanism may be 
involved in the development of human CLL and the murine malignant CLL-like B1a-cell 
expansion caused by constitutive activation of canonical NF-B. Finally, inactivating 
mutations in the NF-B inhibitory protein IB that result in NF-B activation have been 
identified in CLL patients samples [143]. Interestingly, Sasaki et al. (2006) reported that 
B-cells with constitutive canonical NF-B activation caused by expression of the IKK2 
constitutive active mutant have higher IB protein levels [37]. It is possible that the 
higher expression of IB in my current lymphoma model may interfere with additional 
NF-B related pathogenicity observed in human CLL. Taken together, all the evidence 
presented here suggests that enhanced canonical NF-B activation in B-cells in CLL 
plays an important role in disease pathogenesis. My results further demonstrate that 
constitutive canonical NF-B activation in B-cells is sufficient to promote enhanced B-
cell survival and proliferation that can eventually develop into a CLL-like disease in 
mice.  
 
CANONICAL NF-B ACTIVATION COOPERATES WITH TCL1 IN MURINE CLL DISEASE 
PROGRESSION 
My results demonstrate that constitutive canonical NF-B activation dramatically 
cooperates with the TCL1 oncogene in CLL pathogenesis in mice, accelerating the 
disease progression in a dose dependent manner. Previous studies in the TCL1tg mouse 
model on the role of canonical NF-B activation corroborate my findings [329, 330]. One 
major finding supporting the cell-intrinsic importance of enhanced canonical NF-B 
activation in TCL1-driven CLL-like disease in mice was that mutant IKK2-mediated 
constitutive canonical NF-B activation in a small percentage of B-cells defined by 
C1cre and AIDcre had a similar disease course, with similar median survivals, as 
observed for the expression of IKK2ca in over 80% of the B-cells mediated by CD19cre. 
This suggests that canonical NF-B activation in TCL1tg cells dramatically enhances 
their competitive fitness by either prolonged survival or higher proliferation compared 
to TCL1tg+ only CLL-cells. It is unlikely that the murine CLL-like cells identified in the 
experiments with C1cre and AIDcre were products of the germinal centre reaction. I 





rather believe that Cre-mediated recombination leads to induction of IKK2ca in a small 
subset of TCL1tg B-cells, most likely B1-cells. Accordingly, recent evidence suggests that 
the AID enzyme is expressed in a small percentage of CLL-cells in humans [331-333], 
supporting my finding that AIDcre recombination takes place in a small percentage of 
TCL1+ B-cells, most likely pre-leukemic. Additionally, it has been reported that AID is 
expressed in a fraction of B1a-cells in mice [261]. Casola et al. (2006) suggested that 
cytokines could induce expression of Cre in C1-cre mice [243]. It has been reported that 
the cytokine IL-4 [46] and CD40 signalling can trigger the expression of the AID enzyme 
as well as the expression of the germline C1 region of the BCR [99]. Furthermore, 
signalling through CD38 in B-cells induces expression of the c1 germline transcripts 
[334]. Since CD38 is a prognostic factor in CLL [335-337], signalling through CD38 might 
induce the expression of the c1 germline transcripts in CLL-cells as seen in normal B-
cells. Therefore, any of the above-described mechanisms would explain the induction of 
IKK2ca through Cre-mediated recombination in a small percentage of C1cre and AIDcre 
TCL1+ B-cells. My data suggests that in the murine TCL1 model there is pre-malignant 
TCL1+ B-cell in 3 months old mice. Taking these into consideration, I hypothesise that at 
this pre-leukemic stage, either by direct interaction with the niche or by bi-directional 
remodelling of both the niche and the pre-leukemic CLL, the microenvironment 
promotes AID and c1 germline expression in a small percentage of cells, most likely 
proliferating cells, that induces expression of Cre protein and ensuing expression of the 
IKK2 mutant and therefore constitutive canonical NF-B activation. The constitutive 
canonical NF-B activation in IKK2ca+;TCL1+ pre-leukemic B-cells confers a striking 
competitive advantage over TCL1+ pre-leukemic B-cells.  
 
My findings that IKK2ca B-cells show higher in vitro survival and spontaneous 
proliferation, and additionally have a higher expression of BCL2 anti-apoptotic proteins 
suggests that constitutive canonical NF-B activation in B1a-cells promotes both cell 
survival and proliferation. Human CLL is characterized by a slow accumulation of CD5+ 
B-cells that are resistant to apoptosis and have slow proliferation rates. Several results 
associate enhanced canonical NF-B activation in human CLL with the expression of 
anti-apoptotic proteins BCL2, BCL-XL, MCL1 and the inhibitors of Caspase XIAP and cIAP 
[197, 313, 321, 323, 328]. My preliminary results of reduced in vitro apoptosis 
accompanied by a higher expression of the anti-apoptotic protein BCL2 in B1a-cells 
suggest that constitutive canonical NF-B activation prolongs B-cell survival by 
protecting cells against cell death by apoptosis. Recent evidence suggest that CLL-cells 





have a higher proliferative rate than previously thought [338, 339], bringing the 
question of whether canonical NF-B activation in CLL-cells also provides proliferation 
advantage. Igawa et al (2011) reported that NF-B activation supports the expression of 
Cyclin D2 in CLL-cells, which is required for their proliferation [127]. The preliminary 
evidence of in vitro proliferation of IKK2ca+ and IKK2ca+;TCL1tg+ B-cells, but not 
TCL1tg+ B1a-cells in the absence of stimuli suggest that enhanced NF-B activation may 
drive the expression of genes related with proliferation. Consistently, Enzler et al. 
(2009) reported that in the TCL1tg CLL mouse model TCL1+ CLL-like cells display 
higher proliferative activity compared to non-leukemic TCL1+ B-cells but also show 
higher apoptosis rates [322]. They propose that this high cell turnover is the cause of 
the slow disease progression in the TCL1tg mouse model [322]. Moreover, they showed 
that BAFF could rescue the increased apoptosis and in vitro promote expression of BCL2 
and Mcl1 in a RelB and RelA dependent mechanism, resulting in higher CLL burden and 
accelerated disease progression [322]. In a later study, they additionally showed that 
APRIL-tg TCL1tg double transgenic mice also presented with an earlier disease onset 
and a shorter life span [237]. Interestingly, my preliminary results that at least in vitro 
stimulation of B1-cells with BAFF resulted in increased proliferation suggest that BAFF 
and constitutive canonical NF-B activation may cooperate in B1 cell proliferation. One 
study in human CLL samples reported the expression of BAFF and APRIL in CLL-cells 
suggesting an possible autocrine stimulation [340]. Given that B1a-cells with 
constitutive canonical NF-B activation seem to proliferate in vitro in the absence of any 
stimuli and are responsive to BAFF, it would be interesting to assess whether 
constitutive canonical NF-B activation in B-cells has a similar effect on BAFF and April 
production and if BAFF and APRIL neutralizing antibodies have an effect in vitro. 
Although my results are preliminary and need to be confirmed, the development of CLL-
like disease in mice by constitutive canonical NF-B activation and the additional 
shorter disease progression in TCL1tg mice could both be a result of enhanced B-cell 
proliferation and higher resistance to apoptosis. Additional studies assessing cell turn 
over by 5-bromo-2-deoxyuridine (Br-dU) incorporation in vivo, staining of the 
proliferation marker Ki-67 and assessing Caspase activation would complement my 
preliminary results regarding in vitro proliferation and survival and bring further 
understanding on the mechanism of NF-B activation in CLL disease.  
 





CONSTITUTIVE CANONICAL NF-B ACTIVATION IN TCL1TG CLL-LIKE CELLS DOES NOT 
REPLACE SURVIVAL SIGNALS FROM THE SUPPORTIVE NICHE 
My results show that constitutive canonical NF-B activation in the TCL1 CLL mouse 
model is not sufficient to overcome the absence of required survival signals from the 
microenvironment in PKC- KO mice. Herishanu et al. (2011) reported that the 
microenvironment affects the expression of genes in human CLL [141], supporting the 
notion that the tumour microenvironment plays a role in the disease pathogenesis. It is 
now accepted that a bidirectional remodelling between the CLL-cell and its surrounding 
microenvironment takes place in CLL and is required for the disease development and 
progression. Lutzny et al. (2013) demonstrated that direct contact of the CLL-cell leads 
to expression of the PKC-II splice isoform in the microenvironment, which is required 
for the supportive role of the microenvironment in the development of CLL [167]. In the 
absence of PKC-, transplants of murine TCL1tg CLL-cells into PKC- KO mice fail to 
develop into CLL [167]. Given the aggressive CLL characteristics observed in the lymph 
nodes [341], with the notion that proliferation takes place mainly in the lymph nodes 
[338] and that there is higher NF-B activity in CLL-cells from the lymph nodes, it was 
suggested that canonical NF-B activation driven by the microenvironment is required 
for the proliferation and survival of the CLL-cells [141, 323]. My findings that 
transplanted TCL1tg CLL-cells with constitutive canonical NF-B activation fail to 
produce CLL in PKC- KO mice suggests that additional supportive signals from the 
microenvironment other than canonical NF-B activation are required for the survival 
and proliferation of CLL-cells in these mice.  
 
 
In summary, I demonstrated that strong constitutive canonical NF-B activation results 
in the aberrant expansion of B1a-cells that with age develop into a disease similar to 
human SLL/CLL in mice. My findings suggest a role for enhanced canonical NF-B 
activation as a driver in CLL and demonstrate that canonical NF-B accelerates disease 
progression of the established TCL1tg CLL mouse model in a dose dependent manner. 
Furthermore, my results provide further support for the hypothesis that canonical NF-
B activation is a potential therapeutic target in CLL. But they also suggest that CLL-cells 
receive strong pro-survival signals from their microenvironment that are not mediated 
through NF-B activation and might represent attractive targets in future therapeutic 
approaches.  
 










Figure S 1. Reduced A20-/-;NIK+ B-cell numbers in mesenteric lymph nodes of young 
mice  
Ex vivo analysis of B-cells from mesenteric lymph nodes of young mice using flow cytometry. (A) Total 
mesenteric lymph nodes cell numbers. Contour plots depict percentages and bar charts indicate total 
cell numbers for (B) B-cells and (C) eGFP expressing B-cell. All flow cytometry contour plots are 
representative of at least 2 experiments. Bar charts represent medians and values are indicated below 
each histogram. Statistical analysis was done using One-way ANOVA (** p<0.01, **** p<0.0001). 
LN (lymph node), mLN (mesenteric lymph nodes), eGFP (enhanced green fluorescent protein), pos 



















































































































































































Figure S 2. Reduced A20-/-;NIK+ B-cell numbers in Peyer’s patches of young mice 
Ex vivo analysis of B-cells from Peyer’s patches of young mice using flow cytometry. (A) Peyer’s 
patches total cell numbers. Contour plots depict percentages and bar charts indicate total cell numbers 
for (B) B-cells and (C) eGFP expressing B-cells. All flow cytometry contour plots are representative of at 
least 2 experiments. Bar charts represent medians and values are indicated below each histogram. 
Statistical analysis was done using One-way ANOVA (* p<0.05, ** p<0.01).  
PP (Peyer’s patches), eGFP (enhanced green fluorescent protein), pos (positive), B-cells (B220+) and 





















































































































































































Figure S 3. Abnormal marginal and follicular A20-/-;NIK+ B-cells  
Ex vivo analysis of mature B-cells from spleens of young mice using flow cytometry. (A) Histograms 
depict the expression of the surface markers CD21, CD1d and CD23 on mature eGFP positive B-cells. 
Contour plots depict 3 different gating strategies for marginal zone B-cells: (B) CD1d high CD21 high, 
(C) CD23 negative CD21 high or (D) CD23 negative CD1d high. All flow cytometry plots are 
representative of at least 2 experiments. 
eGFP pos. Mat. B-cells (B220+ AA4.1- eGFP+), Mat. B-cells (B220+ AA4.1-), MZB (marginal zone B-


































































































































































































































































































































































































































































































































































































































































































































Figure S 4. Transitional B-cells are not affected by combination of A20-deficiency and 
NIK overexpression 
Ex vivo analysis of immature B-cells from spleen of young mice using flow cytometry. (A) Histograms 
depict the expression of the surface markers CD21 and CD23 in eGFP positive immature B-cells. 
Contour plots depict the percentages and bar charts indicate percentages of eGFP positive cells and 
total cell numbers for (B, E) CD23 negative T1 and CD23 positive T2, (C, F) CD21 negative T1 and 
CD21 positive T2, and (D, G) CD23/CD21 low transitional 1 and CD23/CD21 h high transitional 2 B-cell 
subsets. All flow cytometry plots are representative of at least 2 experiments. Bar charts represent 
medians and values are indicated below each histogram. Statistical analysis was done using One-way 
ANOVA (* p<0.05, ** p<0.01, ***p<0.001, **** p<0.0001) or Kruskal-Wallis (¥ p<0.05). 
eGFP (enhanced green fluorescent protein), eGFP pos. Imm. B-cells (eGFP positive immature B-cells, 
B220+ AA4.1+ eGFP+), Imm. B (Immature B-cells, B220+ AA4.1+), T1CD23 (CD23 negative T1, B220+ 
AA4.1+ CD23-), T2CD23 (CD23 positive T2, B220+ AA4.1+ CD23+), T1CD21 (CD21 negative T1, B220+ 
AA4.1+ CD21-), T2CD21 (CD21 positive T2, B220+ AA4.1+ CD21+), T1 (Transitional 1, B220+ AA4.1+ 







Figure S 5. No increase in apoptosis observed in germinal centre A20-/-;NIK+ B-cells  
 Ex vivo analysis of B-cells from spleen of young mice using flow cytometry. (A) Histograms depict 
CD95 expression in ex vivo B-cells, MFI are indicated for each population. (B) Bar chart shows the 
percentage of ex vivo active pan-Caspases GC B-cells in spleen. Bar charts represent medians and 
values are indicated below each histogram. 
MFI (median fluorescence intensity), GC B (germinal centre B-cell, B220+ CD38- CD95+), eGFP 
(enhanced green fluorescent protein), activated pan-Caspases (Red-VAD-FMK+ 7AAD-). 
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A20F/F NIK-tg CD19cre, eGFP  pos
A20F/wt NIK-tg CD19cre, eGFP  pos
NIK-tg CD19cre, eGFP pos
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Figure S 6. Aberrant pre-activated antigen presenting cell phenotype in eGFP+;A20-/-
:NIK+ B-cells 
 Expression of activation markers, receptors and transcription factors in B-cells from spleens of young 
mice. Ex vivo analysis of B-cells from spleen of young mice using flow cytometry. Scatter plots depict 
absolute MFIs and box plots show the MFI relative to wild type for (A) receptors and ligands: ICOS-L, 
CD119, CD25, CD44 and CD95/FAS; (B) B-cell activation markers: CD69, CD80, CD86 and MHC-II; 
and (C) transcription factors BCL6 and IRF4. In the box plots, the median is represented as a horizontal 
line, the box represents the 25th and 75th percentiles and the whiskers the minimum and maximum 
points. All individual values are plotted in the graph. 
MFI (Median fluorescent Intensity), eGFP (enhanced green fluorescent protein), B-cells (B220+). 
  






Figure S 7. Aberrant alpha-L and beta-2 integrin expression in eGFP+:A20-/-;NIK+ B-
cells 
 Ex vivo analysis of integrin expression in B-cells from spleens of young mice using flow cytometry. (A) 
Scatter plots depict the absolute MFIs and box plots show the MFIs relative to wild type of (A) alpha-
integrins: alpha-4, alpha-5, alpha-V, Alpha-L, alpha-M and alpha-X; and (B) beta-integrins: beta-1, beta-
2, beta-3 and beta-7. In the box plots, the median is represented as a horizontal line, the box represents 
the 25th and 75th percentiles and the whiskers the minimum and maximum points. All individual values 
are plotted in the graph. Statistical analysis was done using One-way ANOVA (* p<0.05, ** p<0.01, *** 
p<0.001, **** p<0.0001). 
MFI (Median fluorescent Intensity), eGFP (enhanced green fluorescent protein) and B-cells (B220+). 






Figure S 8. Expanded CD25+ CD4+ T-cells in A20-deficient NIK-tg CD19cre mice express 
the transcription factor FOXP3 
Ex vivo analysis of the expression of the transcription factor FoxP3 in splenic CD4 T-cells using flow 
cytometry. Flow cytometry histograms depict the intracellular expression of the FoxP3 transcription 
factor in CD25+ CD4+ T-cells (blue, open) and conventional CD4+ T-cells (grey, filled). Flow cytometry 
histograms in (B) are representative of at least 2 experiments, while in (A) represents a single 
experiment. 
MFI (median fluorescence intensity), CD25+ CD4 T (TCR+ CD4+ CD25+) and conventional CD4 T-cells 





Figure S 9. Expression of the transcription factor BCL6 in splenic PD1high CXCR5high 
CD4 T-cells 
Ex vivo analysis of the expression of the transcription factor BCL6 in splenic CD4 T-cells using flow 
cytometry. Flow cytometry histograms depict the intracellular expression of the BCL6 transcription factor 
in PD1high CXCR5high CD4+ T-cells (blue, open) and PD1lo CXCR5lo CD4+ T-cells (grey, filled). Flow 
cytometry histograms are representative of single experiments, where the A20F/F NIK-tg CD19cre 
histogram belongs to a different experiment. 
CD4 T (TCR+ CD4+)  







Figure S 10. T-cell hyperplasia in bone marrow of A20F/F NIK-tg CD19cre young mice 
 Ex vivo analysis of T-cells from bone marrow of young mice using flow cytometry, for one leg after red 
blood cell lysis. Bar charts indicate cell numbers for (A) T-cells, (B) T-cell subsets: conventional CD4, 
CD8, and CD25+ CD4 T-cells; and activation in (C) conventional CD4 and (D) CD8 T-cells. Bar charts 
represent medians and values are indicated below each histogram. Statistical analysis was done using 
One-way ANOVA (* p<0.05, ** p<0.01). 
BM (bone marrow), T-cells (TCR+), cCD4 T (conventional CD4, TCR+ CD4+ CD8- CD25-), CD8 T 
(TCR+ CD4- CD8+), CD25+ CD4 T (TCR+ CD4+ CD25+), Naïve (CD62L+ CD44-), Effector (CD62L- 










































































































































































Figure S 11. T-cell expansion in lymph nodes of A20F/F NIK-tg CD19cre young mice 
 Ex vivo analysis of T-cells in lymph nodes of young mice using flow cytometry, normalized to one lymph 
node. Bar charts indicate cell numbers for (A) T-cells, and (B) T-cell subsets: CD4 and CD8. Bar charts 
represent medians and values are indicated below each histogram. Statistical analysis was done using 
One-way ANOVA (*p<0.05). 
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Figure S 12. Expansion of CD25+ CD4, effector-like CD4 and effector like CD8 T-cells in 
lymph nodes of A20F/F NIK-tg CD19cre young mice 
 Ex vivo analysis of T-cells in lymph nodes of young mice using flow cytometry, normalized to one lymph 
node. (A) Number of conventional CD4 T-cells and CD25+ CD4 T-cells. Cell numbers of naïve-, 
memory- and effector-like activation states for (B) cCD4 and (C) CD8 T-cells. Statistical analysis was 
done using T-test (* p<0.05).  
cCD4 T (TCR+ CD4+ CD8- CD25-), CD25+ CD4 T (TCR+ CD4+ CD8- CD25+), CD8 T-cells (TCR+ 

















































































































































































Figure S 13. Myeloid cells are not affected by A20-/-;NIK+ B-cells in young mice  
Ex vivo analysis of myeloid cells in spleen and bone marrow from young mice using flow cytometry. (A) 
Percentage and (B) total cell number of myeloid cells in spleen of young mice. (C) Myeloid populations 
cell numbers in bone marrow, after red blood cell lysis for one leg. Bar charts depict medians and values 
are indicated below each histogram. Statistical analysis was done using Kruskal-Wallis test (¥ p<0.05).  
SPL (spleen), BM (bone marrow), DC (dendritic cells, CD11c+), Eos (eosinophils, CD11c+ CD11b+ 
SiglecFhi F4/80hi), Mono (monocytes, CD11c+ CD11b+ SiglecFlo F4/80hi Gr1int) and Neu (neutrophils, 











Figure S 14. A20-/-;NIK+ B-cells do not elicit an natural killer or natural killer T-cell 
response 
Natural killer and natural killer T-cells in spleen of aged mice. Contour plots depict the percentage (A, B, 
C) natural killer cells and (C) natural killer T-cells. (D) Bar charts show natural killer and natural killer T-
cell numbers. Bar charts depict medians and values are indicated below each histogram.  
NK (natural killer cell, CD3- NK1.1+, NK1.1+ NKp46+ or TCR- NK1.1+), T-cells (TCR+ NK1.1-) and 
NKT (natural killer T-cell, TCR+ NK1.1+). 
  







Figure S 15. A20-/-;NIK+ B-cell numbers correlate with PD1 high CD8 T-cells 
 Correlation between B-cell and PD1high CD8 T-cells in A20F/F NIK-tg CD19cre mice. Pearson 
correlation of (A) B-cell numbers (p=0.017) and (B) eGFP positive B-cell numbers (p=0.039) with 
number of PD1 positive CD8 T-cell numbers.  






Figure S 16. IKK2ca enhances B-cell numbers 
Ex vivo analysis of B-cells in spleens from 2-3-month-old mice using flow cytometry. Bar chars show (A) 
the age of the mice analysed, (B) the liver and spleen mass, and (C) the number of splenocytes. (D) 
Flow cytometry plots depict percentages and (E) bar charts show cell numbers for B-cells and eGFP 
positive B-cells. All flow cytometry contour plots are representative of at least 2 experiments. 
Histograms depict medians, and values are indicated below each histogram. Statistical analysis was 
done using One-way ANOVA (* p<0.05, *** p<0.001, **** p<0.0001). 
N.D. (not done), Spl (spleen), Lymph. (lymphocytes), B-cells (CD19+), and eGFP pos. (CD19+ eGFP+). 















































































A20F/F NIK-tg CD19cre mice
A B







Figure S 17. IKK2ca promotes B1 cell numbers in the peritoneal cavity 
Ex vivo analysis of B-cells in peritoneal cavity from 2/3-month-old mice using flow cytometry. (A) Bar 
chart shows total cell numbers after lavage. (B) Contour plots depict percentages and (C) bar chats 
show cell numbers for B-cells and eGFP positive B-cells in the peritoneal cavity after lavage. (D) Flow 
cytometry contour plots depict percentages for subsets B2, B1, B1a and B1b in the peritoneal cavity. (E) 
Bar charts show cell numbers for the B-cell subsets B2, B1a and B1b in the peritoneal cavity of young 
mice. All flow cytometry contour plots are representative of at least 2 experiments, except for the R26-
IKK2ca CD19cre mice. Histograms depict medians, and values are indicated below each histogram. 
Statistical analysis was done using One-way ANOVA (** p<0.01, *** p<0.001). 
PC (peritoneal cavity), Lymph. (lymphocytes), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), B2 (CD19+ 
B220hi), B1 (CD19+ B220lo), B1a (CD19+ B220lo CD5hi) and B1b (CD19+ B220lo CD5-).  







Figure S 18. IKK2ca promotes B1 cell numbers in the spleen 
Ex vivo analysis of B-cell subsets in spleens from 2/3-month-old mice using flow cytometry. (A) Flow 
cytometry plots depict the percentage of B1a-cells in spleens. (B) Bar chats show cell numbers for the 
B-cell subsets B2, B1a and B1b in spleens of young mice. All flow cytometry contour plots are 
representative of at least 2 experiments. Histograms depict medians, and values are indicated below 
each histogram. Statistical analysis was done using One-way ANOVA (* p<0.05, ** p<0.01, **** 
p<0.0001). 
Spl/SPL (spleen), Lymph. (lymphocytes), B2 (CD19+ B220hi), B1a (CD19+ CD5hi or CD19+ B220lo CD5hi) 
and B1b (CD19+ B220lo CD5-). 
  







Figure S 19. IKK2ca expression leads to B1a expansion in aged mice 
Ex vivo analysis of B-cell subsets in spleens from aged mice (> 9 months) using flow cytometry. (A) 
Flow cytometry contour plots depict percentages and (B) bar charts show cell numbers for the B-cell 
subsets B2, B1, B1a and B1b in spleen. All flow cytometry contour plots are representative of at least 2 
experiments. Histograms depict medians, and values are indicated below each histogram. Statistical 
analysis was done using One-way ANOVA (**** p<0.0001) or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ 
p<0.001, ¥¥¥¥ p<0.0001). 
Spl (spleen), B-cells (CD19+), B2 (CD19+ B220hi), B1 (CD19+ B220lo), B1a (CD19+ B220lo CD5hi) and 
B1b (CD19+ B220lo CD5-). 
 
  







Figure S 20. Effects on IKK2ca expression in lymph nodes 
Ex vivo analysis of B-cell subsets in draining lymph nodes from aged mice (> 9 months) using flow 
cytometry. Draining inguinal, axillary, and superficial cervical lymph nodes were pooled and analysed 
together. Flow cytometry contour plots depict percentage of (A) B2 and B1, and (B) B1a-like and B1b 
subsets. B1a-like and B1b as percentages of B-cells are indicated above the contour plots. All flow 
cytometry contour plots are representative of at least 2 experiments.  
LN (lymph nodes), Lymph. (lymphocytes), B-cells (CD19+), B2 (CD19+ B220hi), B1 (CD19+ B220lo), B1a-
like (CD19+ B220lo CD5hi) and B1b (CD19+ B220lo CD5-). 
 
 







Figure S 21. Effects of IKK2ca expression in mesenteric lymph nodes 
Ex vivo analysis of B-cells in mesenteric lymph nodes from aged mice (> 9 months) using flow 
cytometry. (A) Bar charts show total cell numbers. (B) Bar charts show cell numbers and (C) flow 





cytometry contour plots depict percentages for B-cell and eGFP positive B-cells. (D) Bar charts show 
the number of B2, B1a and B1b subsets. (E) Flow cytometry contour plots depict percentage of B1a-like 
cells of lymphocytes. All flow cytometry contour plots are representative of at least 2 experiments. All 
contour plots for the R26-IKK2ca CD19cre mouse belong to a different experiment. Histograms depict 
medians, and values are indicated below each histogram. Statistical analysis was done using Kruskal-
Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
mLN (mesenteric lymph nodes), Lymph. (lymphocytes), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), B2 







Figure S 22. Effects of IKK2ca expression in the bone marrow 
Ex vivo analysis of B-cells in bone marrow from aged mice (> 9 months) using flow cytometry, for one 
leg after red blood cell lysis. Bar charts show (A) total cell numbers, (B) B-cells and eGFP positive B-
cells numbers, and (C) B2, B1a and B1b subsets cell numbers. Histograms depict medians, and values 
are indicated below each histogram. Statistical analysis was done using One-Way ANOVA (** p<0.01, 
*** p<0.001) or Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
BM (bone marrow), B-cells (B220+ CD19-, B220+ CD19+ and B220- CD19+), eGFP pos. (eGFP+), B2 
(CD19hi B220hi), B1a (CD19+ B220lo CD5hi) and B1b (CD19+ B220lo CD5-). 







Figure S 23. Co-operation between IKK2ca and TCL1 in CLL-like disease 
Ex vivo analysis of peripheral blood from TCL1tg compound mice using flow cytometry, after red blood 
cell lysis. Scatter plots show the percentage of CD5+ B1a-like cells (CD19+ B220lo CD5+) in the 
peripheral blood of (A) TCL1tg CD19cre, (B) TCL1tg R26-IKK2ca CD19cre and (C) TCL1tg R26-
IKK2ca/ca CD19cre mice. The connecting lines represent means for each time point. 
  







Figure S 24. Co-operation between IKK2ca and TCL1 in splenic B-cells 
Ex vivo analysis of spleen from burdened TCL1tg compound mice using flow cytometry. Contour plots 
depict the percentage of (A) B-cells, (B) eGFP positive B-cells, (C) B2 and B1 subsets, and (D) CD5+ 
B1a-like cells. All flow cytometry contour plots are representative of at least 2 experiments. The age of 
the mouse, in months, at the time of analysis is indicated in (A). 
Spl. (spleen), Lymph. (lymphocytes), mo. (months), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), B2 
(CD19+ B220hi), B1 (CD19+ B220lo) and B1a (CD19+ B220lo CD5hi).  
 
  






Figure S 25. Co-operation between IKK2ca and TCL1 in splenic B-cells II 
Ex vivo analysis of spleen from burdened TCL1tg R26-IKK2ca/ca CD19cre and aged matched controls 
mice using flow cytometry. Bar charts indicate (A) age at the time of the analysis, (B) spleen and liver 
mass, (C) splenocytes cell numbers, (D) B- and T-cell numbers, and (E) B-cell subsets cell numbers. 
Histograms depict medians, and values are indicated below each histogram. Statistical analysis was 
done using One-Way ANOVA (**** p<0.0001) or Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ 
p<0.0001). 
N.D. (not done), B-cells (CD19+), T-cells (CD19- CD5+), B2 (CD19+ B220hi), B1a-like (CD19+ B220lo 
CD5hi) and B1b (CD19+ B220lo CD5hi).  






Figure S 26. Co-operation between IKK2ca and TCL1 in splenic B-cells III 
Ex vivo analysis of spleen from burdened TCL1tg R26-IKK2ca CD19cre and aged matched controls 
mice using flow cytometry. Bar charts indicate (A) age at the time of the analysis, (B) spleen and liver 
mass, (C) splenocytes cell numbers, (D) B- and T-cell numbers, and (E) B-cell subsets cell numbers. 
Histograms depict medians, and values are indicated below each histogram. Statistical analysis was 
done using Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
B-cells (CD19+), T-cells (CD19- CD5+), B2 (CD19+ B220hi), B1a-like (CD19+ B220lo CD5hi) and B1b 
(CD19+ B220lo CD5hi).  







Figure S 27. Co-operation between IKK2ca and TCL1 in peritoneal B-cells 
Ex vivo analysis of B-cells in the peritoneal cavity from burdened TCL1tg compound mice using flow 
cytometry. Flow cytometry contour plots depict the percentage of (A) B-cells, (B) eGFP positive B-cells, 
(C) B2 and B1 subsets, and (D) B1a-cells. All flow cytometry contour plots are representative of at least 
2 experiments. The age of the mouse, in months, at the time of analysis is indicated in (A). 
PC (peritoneal cavity), Lymph. (Lymphocytes), mo. (months), B-cells (CD19+), eGFP pos. (CD19+ 
eGFP+), B2 (CD19+ B220hi), B1a (CD19+ B220lo CD5hi).  
  







Figure S 28. Co-operation between IKK2ca and TCL1 in lymph node B-cells 
Ex vivo analysis of B-cells in draining lymph nodes from burdened TCL1tg compound mice using flow 
cytometry. Draining inguinal, axillary, and superficial cervical lymph nodes were pooled and analysed 
together. Flow cytometry contour plots depict the percentage of (A) B-cells, (B) eGFP positive B-cells, 
(C) B2- and CD5+ B1a-like cells, (D) B2 and B1 subsets, and (E) CD5+ B1a-like cells. All flow cytometry 
contour plots are representative of at least 2 experiments. The age of the mouse, in months, at the time 
of analysis is indicated in (A). 
LN (lymph nodes), Lymph. (lymphocytes), mo. (months), B-cells (CD19+), eGFP pos. (CD19+ eGFP+), 
B2-like (CD19+ B220hi), B1a-like (CD19+ B220lo CD5hi), B2 (CD19+ B220hi), and B1 (CD19+ B220lo).  
 







Figure S 29. Co-operation between IKK2ca and TCL1 in mesenteric lymph node B-cells 
Ex vivo analysis of B-cells in mesenteric lymph nodes from burdened TCL1tg compound mice using flow 
cytometry. Bar chart shows (A) total, (B) B-cell, and (C) B-cell subsets cell numbers. Burdened TCL1tg 
R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre mice cohorts were analysed at 3-4 months 
and 5-6 months of age, respectively. Burdened TCL1tg CD19cre mice and aged matched controls were 
analysed at 9-12 months of age. Histograms depict medians, and values are indicated below each 
histogram. Statistical analysis was done using Kruskal-Wallis (¥p<0.05, ¥¥¥ p<0.001). 
mLN (mesenteric lymph nodes), m. (months), B-cells (CD19+), B2 (CD19+ B220hi CD5-), B1a-like 











Figure S 30.Co-operation between IKK2ca and TCL1 in bone marrow B-cells 
Ex vivo analysis of bone marrow in terminally sick mice using flow cytometry, for one leg after red blood 
cell lysis. Bar chart shows (A) total, (B) B-cell and eGFP positive B-cells, and (C) B-cell subsets cell 
numbers. As indicated, burdened TCL1tg R26-IKK2ca CD19cre and TCL1tg R26-IKK2ca/ca CD19cre 
mice cohorts were analysed between 3-4 months and 5-6 months of age, respectively. TCL1tg CD19cre 
mice and aged matched controls were analysed between 9-12 months of age. Histograms depict 
medians, and values are indicated below each histogram. Statistical analysis was done using One-Way 
ANOVA (* p<0.05, ** p<0.01, *** p<0.001, ****p<0.0001) or Kruskal-Wallis (¥p<0.05, ¥¥ p<0.01, ¥¥¥ 
p<0.001). 
BM (bone marrow), B-cells (B220+ CD19-, B220- CD19+, B220+ CD19+), eGFP pos. (eGFP+), B2-like 











Figure S 31. IgH VDJ rearrangement analysis by PCR 
Amplification of the VDJ rearrangements of the immunoglobulin heavy chain. (A) The scheme depicts 
the germ line locus for the IgH in the mouse C57BL/6 background and the four possible rearrangements 
into the different joining-gene segments. The rearrangements can be amplified by PCR using the 
primers MsVHE AH and JH4E that bind at the beginning of most commonly used VH-gene segments 
and at the end of the JH4-gene segment, respectively. The expected amplicon sizes for the 
rearrangements into the different JH-gene segments are indicated. (B) Visualization the VDJ 
rearrangements amplicons from tumour and control samples by separation in a 1.5% agarose 
electrophoresis.  
VH (variable, yellow), DH (diversity, green), JH (joining, pink), CH (constant, blue), Kb (kilo bases), bp 
(base pairs) and PCR (polymerase chain reaction), 
  







Figure S 32. Cloning of IgH VDJ rearrangements 
Amplification of individual VDJ rearrangements of the immunoglobulin heavy chain. (A) The scheme 
depicts the germ line locus for the IgH in the mouse C57BL/6 background and the binding site of the 
primers used to amplify the individual rearrangements into the different JH-gene segments. (B and C) 
The amplicons were separated and visualizes in a 2% agarose electrophoresis. (B) The amplification of 
VDJ rearrangements into JH1 and JH4 produced amplicons of three different sizes: JH1 and JH4 
amplicons have a size of 350bp; amplicons of 1.3Kb and 0.9Kb can also be observed, corresponding to 
JH2 and JH3 rearrangements, respectively. (C) The amplification of VDJ rearrangements into JH2 and 
JH3 produced amplicons of two different sizes: JH2 and JH3 amplicons have a size of 350bp; 
additionally an amplicons of 0.6Kb can be observed, corresponding to JH1 rearrangement. 
VH (variable, yellow), DH (diversity, green), JH (joining, pink), CH (constant, blue), Kb (kilo bases), bp 
(base pairs) and PCR (polymerase chain reaction). 
  







Figure S 33. Immunophenotyping of bone marrow B2- and B1a-like cells in burdened 
mice 
Immunophenotyping of B-cells subsets B2- and B1a-like cells in bone marrow of burden mice using flow 
cytometry. Box plots show MFI relative to CD19cre B2-cells controls for (A-F) immune-receptors; (G) 
CD69 cell surface receptor, (H-I) chemokine associated receptors, (J-L) regulators of apoptosis, (M) 
IRF4 transcription factor and (N-O) CLL associated proteins. In the box plots, the median is represented 
as a horizontal line, the box represents the 25th and 75th percentiles and the whiskers the minimum and 
maximum points. All individual values are plotted in the graph. Statistical analysis was done using 
Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001). 
BM (Bone marrow), B2-like (CD19Hi B220Hi, white background), B1a-like (CD19Hi B220Lo CD5+, grey 
background), N.D. (not done).  







Figure S 34. Immunophenotyping of splenic B2- and B1a-like cells in burdened mice 
Ex vivo immunophenotyping of B-cells subsets B2- and B1a-like cells in spleen of burden mice using 
flow cytometry. Box plots show MFI relative to CD19cre B2-cells controls for (A-F) immune-receptors; 
(G) CD69 cell surface receptor, (H-I) chemokine associated receptors, (J-L) regulators of apoptosis, (M) 
IRF4 transcription factor and (N-O) CLL associated proteins. In the box plots, the median is represented 
as a horizontal line, the box represents the 25th and 75th percentiles and the whiskers the minimum and 
maximum points. All individual values are plotted in the graph. Statistical analysis was done using One-
Way ANOVA (* p<0.05) or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001). 
B2-like (CD19+ B220Hi, white background), B1a-like (CD19+ B220Lo CD5+, grey background), N.D. (not 
done).  







Figure S 35. Immunophenotyping of peritoneal B2- and B1a-like cells in burdened mice 
Ex vivo immunophenotyping of B-cells subsets B2- and B1a-like cells in the peritoneal cavity of burden 
mice using flow cytometry. Box plots show MFI relative to CD19cre B2-cells controls for (A-F) immune-
receptors; (G) CD69 cell surface receptor, (H-I) chemokine associated receptors, (J-L) regulators of 
apoptosis, (M) IRF4 transcription factor and (N-O) CLL associated proteins. In the box plots, the median 
is represented as a horizontal line, the box represents the 25th and 75th percentiles and the whiskers the 
minimum and maximum points. All individual values are plotted in the graph. Statistical analysis was 
done using Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01). 
PC (Peritoneal cavity), B2-like (CD19+ B220Hi, white background), B1a-like (CD19+ B220Lo CD5+, grey 
background), N.D. (not done).  






Figure S 36. Immunophenotyping of lymph node B2- and B1a-like cells in burdened 
mice 
Ex vivo immunophenotyping of B-cells subsets B2- and B1a-like cells in draining lymph nodes of burden 
mice using flow cytometry. Draining inguinal, axillary and superficial cervical lymph nodes were pooled 
and analysed together. Box plots show MFI relative to CD19cre B2-cells controls for (A-F) immune-
receptors; (G) CD69 cell surface receptor, (H-I) chemokine associated receptors, (J-L) regulators of 
apoptosis, (M) IRF4 transcription factor and (N-O) CLL associated proteins. In the box plots, the median 
is represented as a horizontal line, the box represents the 25th and 75th percentiles and the whiskers the 
minimum and maximum points. All individual values are plotted in the graph. Statistical analysis was 
done using One-Way ANOVA (** p<0.01, **** p<0.0001) or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ 
p<0.001).  





LN (Lymph nodes), B2-like (CD19+ B220Hi, white background), B1a-like (CD19+ B220Lo CD5+, grey 
background), N.D. (not done). 
 
Figure S 37. Immunophenotyping of B2- and B1a-like cells in 5/6-month-old mice 












Figure S 37 (continued): Immunophenotyping of B2- and B1a-like cells in 5/6-month-old mice 
Ex vivo immunophenotyping of subsets B2- and B1a-like in 5-6 months old burden TCL1tg R26-IKK2ca 
CD19cre and aged matched control mice, using flow cytometry. Box plots show MFI relative to CD19cre 
B2 controls for (A-F) immunoreceptors; (G) CD69 cell surface receptor, (H) CXCR4 chemokine receptor; 
(I-K) regulators of apoptosis, (L) IRF4 transcription factor and (M) CLL associated proteins, and (N) CLL 
associated proteins. In the box plots, the median is represented as a horizontal line, the box represents 
the 25th and 75th percentiles and the whiskers the minimum and maximum points. All individual values 
are plotted in the graph. Statistical analysis was done using One-Way ANOVA (** p<0.01, *** p<0.001, 
**** p<0.0001) or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
BM (Bone marrow), SPL (Spleen), PC (Peritoneal cavity), LN (Lymph nodes), B2-like (CD19+ B220Hi, 
white background), B1a-like (CD19+ B220Lo CD5+, grey background). 
  







Figure S 38. Immunophenotyping of B2- and B1a-like cells in 3/4-month-old mice 






Figure S 38 (continued): Immunophenotyping of B2- and B1a-like cells in 3/4-month-old mice 
Ex vivo immunophenotyping of subsets B2- and B1a-like in 3-4 months old burden TCL1tg R26-IKK2ca 
CD19cre and aged matched control mice, using flow cytometry. Box plots show MFI relative CD19cre 
B2-cells controls for (A-G) immunoreceptors; (H) CD69 cell surface receptor; (I) CXCR4 chemokine 
receptor; (J) regulator of apoptosis BCL2, (K) IRF4 transcription factor and (L) CLL associated protein 
Zap70. In the box plots, the median is represented as a horizontal line, the box represents the 25 th and 
75th percentiles and the whiskers the minimum and maximum points. All individual values are plotted in 
the graph. Statistical analysis was done using One-Way ANOVA (** p<0.01, *** p<0.001, **** p<0.0001) 
or Kruskal-Wallis (¥ p<0.05, ¥¥ p<0.01, ¥¥¥ p<0.001, ¥¥¥¥ p<0.0001). 
BM (Bone marrow), SPL (Spleen), PC (Peritoneal cavity), LN (Lymph nodes), B2-like (CD19+ B220Hi, 
white background), B1a-like (CD19+ B220Lo CD5+, grey background). 
 
  







Figure S 39. In vitro survival of resting B2-cells  
Sorted B2-cells were cultured in B-cell media in resting conditions for 9 days. In vitro cell proliferation 
and cell survival was assed by flow cytometry. (A) Bar charts show the percentage of apoptotic cells 
present in the culture as mean and SEM. (B) Histograms depict the in vitro proliferation of B2-cells. (C) 
Scatter plot shows the absolute number of living B2-cells in culture.  
B2 (CD19+ B220+), Apoptotic cells (Annexin-V+ 7AAD-/Annexin-V+ 7AAD+) and Living cells (Annexin-V- 
7AAD-). 
  







Figure S 40. B2-cells proliferate in vitro in response to B-cell receptor stimulation  
Purified B-cells from 3-months-old mice were stimulated in vitro with 15ug/ml anti-BCR and cultured for 
three days. (A) Histograms depict the expression of the activation markers CD86 and MHC-II after 12 
hours of stimulation in B2-cells. (B) Histograms depict the in vitro proliferation of B2-cells, three days 
after stimulation. (C) Table shows the division index (Div. Index), proliferation index (Prol. Index) and 
percentage of divided cells (% Divided) values for B2-cells after three days of stimulation.  
 







Figure S 41. BCR crosslinking modulates B1a-like cells in vitro proliferation  
Sorted B1a-like cells were stimulated in vitro with either 2.5ug/ml or 5ug/ml anti-BCR and cultured for 
nine days. (A) Histograms depict the in vitro proliferation of B1a-like cells at days one, three and nine 
after stimulation. (B) Histograms depict the expression of the activation markers CD86 and MHC-II after 
24 hours of stimulation in B1a-like cells. (C) Table shows the division index (Div. Index), proliferation 
index (Prol. Index) and percentage of divided cells (% Divided) values for B1a-like cells after three and 












Figure S 42. BAFF in vitro stimulation promotes B1 cell proliferation 
Spleen purified B-cells were stimulated in vitro with 100ng/mL BAFF and cultured for three days. 
Histograms depict the in vitro proliferation of (A) B2-cells and (B) B1-cells 72 hours after stimulation. (C) 
Table shows the division index (Div. Index), proliferation index (Prol. Index) and percentage of divided 
cells (% Divided) values for B1-cells after 3 days of stimulation.  
B2 (CD19+ B220+) and B1 (CD19+ B220-). 
 
 







Figure S 43. Transplanted TCL1tg CLL-cells infiltration and homing in PKC-+/- 
recipients 
Ex vivo analysis of burdened CLL- transplanted PKC-+/- recipient mice and aged matched controls 
using flow cytometry. Bar chart shows cell numbers, B1a-like cell numbers and B1a-like cells as 
percentages of B-cells for (A) peritoneal cavity; (B) draining lymph nodes and (C) bone marrow in PKC-
+/- mice. Histograms depict medians, and values are indicated below each histogram. Each bar 
represents a CLL-like lymphoma of the indicated genotype transplanted into multiple recipients. 
PC (peritoneal cavity), LN (draining lymph nodes), BM (bone marrow), B1a-like (CD19+ B220- CD5+) 
and B-cells (CD19+). 
  








Figure S 44. Conditional IKK2ca expression by C1cre co-operates with TCL1 in splenic 
B-cells 
Ex vivo analysis of TCL1tg R26-IKK2ca C1cre burdened mice and aged matched controls using flow 
cytometry. Bar chart show (A) spleen mass, and (B) total and B-cell numbers. Histograms depict 
medians, and values are indicated below each histogram.  
B-cells (CD19+). 
 






Figure S 45. Conditional IKK2ca expression by C1cre promotes B1 cell expansion in 
the peritoneal cavity with age 
Ex vivo analysis of 1-year-old R26-IKK2ca C1cre and aged matched control mice using flow cytometry. 
Contour plots depict the percentage of (A) B2 and B1 subsets, and (B) B1a and B1b subsets in the 
peritoneum. (C) Dot plot depicts the expression of IgM and IgD in B2, B1a and B1B-cell subsets.





Figure S 45 (continued). (D) Contour plots depict the percentage of eGFP+, eGFP+;CAR+ and CAR+ 
expressing cells for the different B-cell subsets in the peritoneum. Flow cytometry plots are 
representative of at least 2 experiments. 
PC (peritoneal cavity), B-cells (CD19+), B2 (CD19+ B220+), B1 (CD19+ B220lo), B1a (CD19+ B220lo 







Figure S 46. Conditional IKK2ca expression by C1cre promotes B1 cell numbers in the 
peritoneal cavity of 1-year-old mice 
Ex vivo analysis of 1-year-old R26-IKK2ca C1cre and aged matched control mice using flow cytometry. 
(A) Bar charts show B2, B1a and B1b total and CAR+/eGFP+ recombined cell numbers in the peritoneal 
cavity. Dot pots show the paired connected B1a- and B1b-like cell numbers for 1-year-old (B) C1cre 
control mice and (C) R26-IKK2ca C1cre mice. Histograms depict medians.  










Figure S 47. eGFP+;IKK2ca+ C1cre-dependent expression in B1-cells in the peritoneal 
cavity of young mice 
Ex vivo analysis of 2-months-old R26-IKK2ca C1cre and control mice using flow cytometry. Histograms 
depict the percentages of eGFP+;IKK2ca+ cells as a result of C1cre-dependent recombination for the 
different B-cell subsets present in the peritoneal cavity. Flow cytometry plots are representative of at 
least 2 experiments. 
PC (peritoneal cavity), mo. (months), B2 (CD19+ B220+), B1 (CD19+ B220lo), B1a (CD19+ B220lo CD5+) 
and B1b (CD19+ B220lo CD5-). 
  







Figure S 48. IKK2ca expression reduces GC B-cells in aged mice 
Ex vivo analysis of 1-year-old R26-IKK2ca CD19cre compound mice using flow cytometry. Contour plots 
depict the percentage of (A) germinal centre B-cells and (C) GL7hi germinal centre B-cells in spleen. 
Histograms depict the percentage of eGFP+;IKK2ca+ (B) germinal centre B-cells and (D) GL7hi 
germinal centre B-cells in spleen. (E) Bar charts show the number of total germinal centre B-cells in 
spleen, lymph nodes, mesenteric lymph nodes and Payer’s patches. Flow cytometry plots are 
representative of at least 2 experiments. Histograms in bar charts depict medians, and values are 
indicated below each histogram. Statistical analysis was done using One-Way ANOVA (* p<0.05) or 
Kruskal-Wallis (¥¥ p<0.01). 
Spl (spleen), LN (lymph nodes), mLN (mesenteric lymph nodes), PP (Payer’s patches), B-cells (CD19+), 
GCB (germinal centre B-cell, CD19+ CD95+ CD38-), GL7hi (CD19+ CD95+ CD38- GL7hi). 
  







Figure S 49. Conditional IKK2ca expression by C1cre reduces GC B-cells 
Ex vivo analysis of 1-year-old R26-IKK2ca C1cre and aged matched control mice using flow cytometry. 
(A) Contour plots depict the percentage of germinal centre B-cells in spleen. (B) Contour plots depict the 
percentage of eGFP+;IKK2ca+, CAR+;eGFP+;IKK2ca+ and CAR+ as a result of C1cre-dependent 
recombination for germinal centre B-cells and non germinal centre B-cells. Flow cytometry plots are 
representative of at least 2 experiments. Histograms depict medians. 
Spl (spleen), LN (lymph nodes), B-cells (CD19+), GCB (germinal centre B-cell, CD19+ CD95+ CD38-), 
nonGCB (CD19+ CD95- CD38+). 
  







Figure S 50. Conditional IKK2ca expression by AIDcre co-operates with TCL1tg in 
splenic B-cells 
Ex vivo analysis of TCL1tg R26-IKK2ca AIDcre burdened mice and aged matched controls using flow 
cytometry. (A) Contour plots depict the percentage of B1a-like cells in spleen. (B) Histograms depict the 
percentages of eGFP+;IKK2ca+ cells as a result of AIDcre-dependent recombination for B2- (grey) and 
B1a-like (blue) cells in spleen. (C) Contour plots depict the expression of IgM and IgD in B2- and B1a-
like cells. Flow cytometry plots are representative of at least 2 experiments. 
Spl (spleen), mo. (months), B2 (CD19+ B220+) and B1a (CD19+ B220lo CD5+). 
 






Figure S 51. AIDcre-depended recombination in GC and B1-cells (Reproduced with 
permission of C. Steinecke)[262] 
Ex vivo analysis of 2-month-old R26-dtTomato AIDcre mice using flow cytometry. Histograms depict the 
percentages of dtTomato+ cells as a result of AIDcre-dependent recombination in (A) germinal centre 
cells and GL7hi germinal centre B-cells in the spleen; and (B) the different B-cell subsets in the spleen 
and peritoneal cavity. Bar charts show the total number and dtTomato+ cells numbers in (C) germinal 
centres in the spleen; and (D) B-cell subsets present in the spleen and peritoneal cavity. Flow cytometry 
histograms are representative of 3 biological replicates and data are represented as mean ± SEM. 
Histograms in bar charts depict medians. 





Figure S 51 (continued). SPL (spleen), GCB (germinal centre B-cell, CD19+ CD95+ CD38-), GL7hi 
(CD19+ CD95+ CD38- GL7hi), PC (peritoneal cavity), B2 (CD19+ B220+), B1a (CD19+ B220lo CD5+) and 






Figure S 52. eGFP+;IKK2ca+ AIDcre-dependent expression in B1-cells in the peritoneal 
cavity  
Ex vivo analysis of 7-months-old R26-IKK2ca AIDcre and control mice using flow cytometry. Histograms 
depict the percentages of eGFP+;IKK2ca+ cells as a result of AIDcre-dependent recombination for the 
different B-cell subsets present in the peritoneal cavity.  
B2 (CD19+ B220+), B1 (CD19+ B220lo), B1a (CD19+ B220lo CD5+) and B1b (CD19+ B220lo CD5-). 
 
 







Table S 1. Colony numbers of IgH VDJ rearrangements cloning from wild type samples  
Sample Plasmid 
Number of white colonies 
10% plate 90% plate 100% plate Total Picked Informative 
1 
JH1 CS 300 2700 N.D. 3000 12 11 
JH2 CS 600 2300 N.D. 2900 12 12 
JH3 CS 500 2300 N.D. 3800 12 12 
JH4 CS 600 2300 N.D. 2900 12 12 
2 
JH1 CS 118 1000 N.D. 1118 12 12 
JH2 CS 52 349 N.D. 401 12 12 
JH3 CS 125 1000 N.D. 1125 12 11 
JH4 CS 52 450 N.D. 502 12 12 
3 
JH1 CS N.D. N.D. 133 133 24 24 
JH2 CS N.D. N.D. 838 838 24 23 
JH3 CS N.D. N.D. 1057 1057 24 24 
JH4 CS N.D. N.D. 280 280 24 21 
4 
JH1 CS N.D. N.D. 118 118 24 22 
JH2 CS N.D. N.D. 566 566 24 24 
JH3 CS N.D. N.D. 360 360 24 23 
JH4 CS N.D. N.D. 464 464 24 22 









Table S 2. Analysis of IgH VDJ rearrangements cloned from splenocytes of wild type 
mouse control 1  












Clone_01 Productive V1-85 D1-2 JH1 98.96 14 CAIITTGSGNWYFDVW 1 
Clone_02 Productive V5-17 D2-12 JH1 98.96 14 CARHTHYSNPWYFDVW 1 
Clone_03 Productive V1-42 D1-1 JH1 99.31 16 CARRPPNYYGSSMDFDVW 1 
Clone_04 Productive V1-85 D2-2 JH1 98.96 11 CARVGYYGYFDVW 1 
Clone_05 Productive V1-54 D4-1 JH1 92.36 12 CARYLTGTWYFDVW 1 
Clone_06 Productive V1-80 D3-3 JH1 98.96 11 CASRELYWYFDVW 1 
Clone_07 Productive V5-17  JH1 99.31 7 CATRYFDVW 1 
Clone_08 Productive V1-15 D2-3 JH1 98.61 13 CTPIRGDGNWYFDVW 1 
Clone_09 Unknown V1-85   97.92 X  1 
Clone_10 Unproductive V1-85 D1-1 JH1 94.1 X CARGAYGSSYE#WYFDVW 1 












Clone_12 Productive V1-42 D2-4 JH1 99.31 12 CARRDYDNWYFDVW 1 
Clone_13 Productive V1-82 D1-1 JH1 98.96 15 CARSGYYYGSSWYFDVW 1 
Clone_14 Unproductive V1-83 D1-1 JH1 98.96 X CARTTVV#YWYFDVW 1 
Clone_15 Unproductive V5-2 D1-1 JH1 99.31 X CASPLMSSY#YFDVW 1 
Clone_16 Productive V1-81 D2-2 JH2 96.88 12 CAIGLRRGYYFDYW 1 
Clone_17 Productive V1-81 D1-1 JH2 98.96 8 CAPTVRGEKW 1 
Clone_18 Productive V1-84 D2-3 JH2 98.61 10 CARAYDGYFDYW 1 
Clone_19 Productive V1-39 D1-1 JH2 98.96 11 CARSSSLYYFDYW 1 
Clone_20 Productive V1-82 D2-3 JH2 98.96 9 CARWLLREDYW 1 
Clone_21 Unproductive V5-2 D2-5 JH2 98.96 X CARRALL**LQLG##YFDYW 1 
Clone_22 Unproductive V5-2 D1-1 JH2 99.31 X CARRGVTTF#YFDYW 1 












Clone_24 Productive V1-82 D2-5 JH3 98.96 13 CAISYSNYGAWFAYW 1 
Clone_25 Productive V1-4 D2-4 JH3 98.96 13 CARCGGDYDEGFAYW 1 




D2-3 JH3 99.31 15 CARHRGYDGRHGGFAYW 1 
Clone_28 Productive V1-85 D1-2 JH3 98.96 10 CATLLRGGFAYW 1 
Clone_29 Productive V10-1 D3-3 JH3 98.64 7 CVRGDFAYW 1 
Clone_30 Unproductive V1-39 D1-1 JH3 98.96 X CARALYGSS#AWFAYW 1 




D1-1 JH3 98.96 X CARHEEGFTTVVARG##WFAYW 1 
Clone_33 Unproductive V1-81 D2-4 JH3 98.96 X CARRGIT#AWFAYW 1 
Clone_34 Unproductive V1-67 P D2-2 JH3 98.96 X CARRGY#* 1 












Clone_36 Unproductive V1-42 D2-1 JH2 99.31 X CARWESLW*LRP#FDYW 1 
Clone_37 Productive V1-80 D5-5 JH3 97.92 10 CARDDLSSLAYW 1 
Clone_38 Productive V1-80 D2-4 JH3 98.96 13 CARSKDYDEAWFAYW 1 
Clone_39 Unproductive V1-37 D2-3 JH3 99.31 X CASMMVTTW#AYW 1 




D2-1 JH4 98.96 12 CARHGGNYRAMDYW 1 
Clone_42 Productive V1-31 D1-1 JH4 99.31 16 CARSLYYYGSSNYAMDYW 1 
Clone_43 Productive V1-81 D2-10 JH4 98.96 17 CARSRSSYGNYVLYAMDYW 1 
Clone_44 Productive V1-9 D2-4 JH4 98.96 15 CARYDYDGGYYYAMDYW 1 
Clone_45 Productive V1-66 D2-4 JH4 97.22 12 CARYYDYGGAMDYW 1 
Clone_46 Productive V1-66 D2-3 JH4 98.96 12 CASDGYDGYAMDYW 1 
Clone_47 Unproductive V1-67 P D2-5 JH4 98.96 X CARRR**#YYAMDYW 1 
     § Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frameshift for out-of-frame junctions 
  





Table S 3. Analysis of IgH VDJ rearrangements cloned from splenocytes of wild type 
mouse control 2 












Clone_01 Productive V1-39 D2-2 JH1 99.0 11 CARGGYYWYFDVW 3 
Clone_02 Productive V1-80 D2-3 JH1 99.0 13 CARSGDGYYRYFDVW 1 
Clone_03 Productive V1-42 D1-1 JH1 99.3 13 CARYYYGRNWYFDVW 1 
Clone_04 Productive V1-80 D1-1 JH1 99.0 12 CHYYGSSYWYFDVW 1 
Clone_05 Unproductive V5-2 D2-3 JH1 99.3 X CAR*WLLR#YFDVW 1 
Clone_06 Unproductive V1-4 D1-1 JH1 99.0 X CARDKDGYYGR##YFDVW 1 
Clone_07 Unproductive V1-67 P D6-2 JH1 99.0 X CASGL*##WYFDVW 1 
Clone_08 Unproductive V14-2  JH1 96.5 6 GFRYFDVW 1 












Clone_10 Productive V5-17 D6-3 JH1 99.3 11 CARELPVRYFDVW 1 
Clone_11 Unproductive V3-8  JH1 99.3 X CAR##YFDVW 1 
Clone_12 Productive V1-39 D2-5 JH2 99.0 11 CAREGYSNYVDYW 1 
Clone_13 Productive V1-42 D1-1 JH2 99.3 11 CARLGSNYYFDYW 1 
Clone_14 Productive V1-7 D3-3 JH2 99.0 8 CARSGPFDYW 1 
Clone_15 Productive V1-4 D1-1 JH2 99.0 15 CARYPLLDYGKGYFDYW 1 
Clone_16 Unproductive V5-17  JH2 99.3 X CA#CGYW 1 
Clone_17 Unproductive V1-63 D2-3 JH2 95.8 X CARASSMMVT#YFDYW 1 
Clone_18 Unproductive V5-2  JH2 99.3 X CARH#YFDYW 1 
Clone_19 Unproductive V5-2 D4-1 JH2 99.0 X CARHGKG#YW 1 
Clone_20 Unproductive V1-9 D2-2 JH2 99.0 X CAYLLWLRRR#FAYW 1 












Clone_22 Productive V1-39 D2-4 JH3 95.8 8 CANDYGFAYW 1 
Clone_23 Productive V1-47 D3-2 JH3 99.0 9 CARGGSWFAYW 1 
Clone_24 Productive V5-17 D2-5 JH3 99.3 12 CARGYYSNYGFAYW 1 
Clone_25 Productive V1-80 D1-1 JH3 99.0 14 CARLGYYGSSAWFAYW 1 
Clone_26 Productive V1-67 P D3-3 JH3 99.0 7 CARRGFAYW 1 
Clone_27 Productive V10-3 D2-4 JH3 98.6 12 CVRDNYDRTWFAYW 1 
Clone_28 Unproductive V1-67 P D2-4 JH3 99.0 12 CARDLL*LRRFAYW 1 
Clone_29 Unproductive V4-2 D2-12 JH3 98.6 X CARQG**LL##WFAYW 1 
Clone_30 Unproductive V5-2 D2-5 JH3 99.3 X CARRFYSNY#FAYW 1 
Clone_31 Unproductive V5-2 D2-2 JH3 99.3 X CARRYYGYG#FAYW 1 












Clone_33 Productive V1-80 D2-10 JH3 99.0 11 CAREGVWYPFAYW 1 
Clone_34 Productive V1-42 D1-1 JH4 99.3 13 CANPGGRSLYAMDYW 1 
Clone_35 Productive V1-39 D1-1 JH4 99.0 13 CAREDGSNYYAMDYW 1 
Clone_36 Productive V1-84 D1-1 JH4 98.6 16 CAREGYYYGSSPYAMDYW 1 
Clone_37 Productive V1-47 D1-1 JH4 99.0 12 CARGSSYYYAMDYW 1 
Clone_38 Productive V1-39 D2-3 JH4 99.0 10 CARSHDGSMDYW 1 
Clone_39 Productive V1-80 D2-4 JH4 99.0 14 CARYYDYDGYYAMDYW 1 
Clone_40 Productive V1-47 D1-1 JH4 99.0 14 CATYGSSSYYYAMDYW 1 
Clone_41 Unproductive V5-2 D1-1 JH4 97.2 X CANLLW**R#AMDYW 1 
Clone_42 Unproductive V5-2 D2-1 JH4 99.3 X CANLLW*RR##AMDYW 1 
Clone_43 Unproductive V5-2 D3-3 JH4 99.3 X CAREEPS##YAMDYW 1 
Clone_44 Unproductive V5-2 D2-5 JH4 99.3 16 CARHPLL**PHYYAMDYW 1 
§ Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frameshift for out-of-frame junctions 
 





Table S 4. Analysis of IgH VDJ rearrangements cloned from splenocytes of wild type 
mouse control 3 












Clone_001 Productive V5-17 D1-1 JH1 99.3 15 CAKVSSTVVEDWYFDVW 1 
Clone_002 Productive V1-7 D2-1 JH1 99.3 11 CARDGNYWYFYVW 1 
Clone_003 Productive V5-4 D1-1 JH1 99.3 12 CARDYGSSWYFDVW 1 
Clone_004 Productive V5-4 D2-3 JH1 99.3 13 CAREGYDGNWYFDVW 1 
Clone_005 Productive V1-82 D1-1 JH1 99.3 15 CARGDYYGSSYGYFDVW 2 
Clone_006 Productive V1-39 D1-1 JH1 99.0 17 CARGHYYGSSYFYWYFDVW 2 
Clone_007 Productive V1-81 D1-1 JH1 99.3 10 CARGRRWYFDVW 2 
Clone_008 Productive V1-82 D1-1 JH1 98.3 16 CARPITTVVARFGYFDVW 1 
Clone_009 Productive V1-4 D2-3 JH1 99.0 14 CARSGGYSSYWYFDVW 1 
Clone_010 Productive V1-83 D1-1 JH1 99.3 12 CARTVATDWYFDVW 1 
Clone_011 Productive V14-2 D1-1 JH1 99.3 13 CARYYGSSYWYFDVW 1 
Clone_012 Productive V1-22 D1-1 JH1 99.0 13 CARYYYGSSRYFDVW 1 
Clone_013 Productive V5-17 D5-7 JH1 99.3 12 CASQAGNYGYFDVW 1 
Clone_014 Productive V1-37 D1-2 JH1 99.0 13 CGSVSLLRPWYFDVW 2 
Clone_015 Productive V14-4 D1-3 JH1 99.3 11 CTTRGKYWYFDVW 1 
Clone_016 Unproductive V5-17 D1-1 JH1 99.3 X CAKALLR**##WYFDVW 1 
Clone_017 Unproductive V5-17 D1-1 JH1 99.3 X CARPKITTVVATP#WYFDVW 1 
Clone_018 Unproductive V5-2  JH1 99.3 X CARQ#YFDVW 1 
Clone_019 Unproductive V5-2 D2-5 JH1 99.3 X CASPPTIVT#YWYFDVW 1 












Clone_22 Productive V14-2 D5-5 JH1 99.3 10 CARYYLWYFDVW 1 
Clone_23 Unproductive V5-17 D1-1 JH1 99.3 X CARGGTTVVATL##YFDVW 1 
Clone_24 Unproductive V14-2 D1-1 JH1 99.3 X CARGTTVVA#YWYFDVW 1 
Clone_25 Unproductive V1-37 D2-4 JH1 99.3 14 CARRI*NDYFWYFDVW 2 
Clone_26 Productive V1-39 D2-4 JH2 99.0 15 CAKEGDYDYDRDYFDYW 1 
Clone_27 Productive V14-1 D3-2 JH2 99.3 11 CARDSSGFHFDYW 1 
Clone_28 Productive V1-54 D1-1 JH2 94.0 12 CARNGGYYSYFDYW 1 
Clone_29 Productive V1-19 D2-5 JH2 99.0 15 CARRGKLDSNSAYFDYW 1 
Clone_30 Productive V1-42 D1-1 JH2 97.5 11 CARRYYGPLLDHW 1 
Clone_31 Productive V1-82 D2-1 JH2 98.3 11 CARSPLGNYFDYW 1 
Clone_32 Productive V14-4 D1-1 JH2 99.3 11 CTRRDYYGRGDYW 1 
Clone_33 Productive V14-4 D2-1 JH2 99.3 9 CTTNYGNLDYW 1 




D2-5 JH2 99.3 X CARHLL**LR#YFDYW 1 
Clone_36 Unproductive V5-2 D2-2 JH2 99.0 X CARHWGGR#DYW 1 
Clone_37 Unproductive V5-17 D2-3 JH2 99.3 X CARKG*W##YFDYW 1 
Clone_38 Unproductive V5-2 D2-2 JH2 99.3 X CARLWLR##YYFDYW 2 
Clone_39 Unproductive V5-17 D1-1 JH2 99.3 X CARRGGLLR*G#YYFDYW 1 




D2-5 JH2 99.3 X CARSYYSNT*#FDYW 1 
Clone_42 Unproductive V1-39 D1-1 JH2 91.5 X CPRSLTVVAR#FDCW 1 
§ Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frame shift for out-of-frame junctions 
  





Table S 4 (continued). Analysis of IgH VDJ rearrangements cloned from splenocytes of 
wild type mouse control 3  












Clone_43 Productive V1-4 D6-2 JH1 97.2 12 CARRTVVHWYFDVW 1 




D3-3 JH3 99.3 10 CAREGGPWFAYW 1 
Clone_46 Productive V1-9 D2-5 JH3 99.3 13 CARGAYYSIPWFAYW 1 




D1-1 JH3 99.3 17 CARHEETYYGSSYAWFAYW 1 
Clone_49 Productive V1-81 D1-1 JH3 99.3 16 CARRWSFTTVVAPYFDYW 2 
Clone_50 Productive V1-9 D1-1 JH3 99.3 13 CARYYYGSSYVFDYW 1 
Clone_51 Productive V1-85 D3-1 JH3 99.3 8 CASLGGFAYW 1 
Clone_52 Productive V14-4 D1-1 JH3 99.3 12 CTIRYYGSSYEDYW 1 
Clone_53 Productive V14-4 D1-1 JH3 99.3 12 CTTNYYGSSWFAYW 1 
Clone_54 Productive V14-4 D1-1 JH3 99.3 13 CTTPYYGSSYWFAYW 1 
Clone_55 Unproductive V1-9 D2-3 JH3 99.3 X CANDGYYV#FAYW 1 
Clone_56 Unproductive V5-2 D2-5 JH3 99.0 X CARL**#FDYW 1 
Clone_57 Unproductive V5-2 D5-7 JH3 99.3 X CARLLYSA#FAYW 1 
Clone_58 Unproductive V5-17 D3-2 JH3 99.3 X CAST##AYW 3 
Clone_59 Unproductive V14-4 D1-1 JH3 99.3 X CTT*LLR**LQ#WFAYW 1 












Clone_061 Productive V1-9 D2-1 JH2 99.3 10 CARTIDYGPDYW 1 
Clone_062 Productive V1S26  JH3 94.7 11 CAREGYSNYFAYW= 1 
Clone_063 Productive V1-85 D2-1 JH3 99.3 12 CARVDLLRAWFAYW 1 
Clone_064 Unproductive V14-1 D2-2 JH3 99.0 X CIILLWLRR#FAYW 1 
Clone_065 Productive V1-81 D5-7 JH4 99.3 10 CAGPIYSAADSW 1 
Clone_066 Productive V1-82 D1-1 JH4 99.3 11 CARGSYLYAMDYW 1 
Clone_067 Productive V1-39 D1-1 JH4 99.0 14 CARIYYGSSYDGMDYW 1 
Clone_068 Productive V1-85 D1-1 JH4 99.3 9 CARKVVSMDYW 1 
Clone_069 Productive V1-7 D1-2 JH4 99.3 12 CARLLGLYYAMDYW 1 
Clone_070 Productive V1-82 D2-1 JH4 99.3 14 CARRDGNPFYYAMDYW 1 
Clone_071 Productive V14-2 D1-1 JH4 99.3 14 CARRDYYGSYYAMDYW 1 
Clone_072 Productive V1-54 D2-4 JH4 99.3 17 CARREPIYYDSYYYAMDYW 1 
Clone_073 Productive V1-69 D1-2 JH4 98.3 11 CARRLRYYAMDYW 1 
Clone_074 Productive V1-39 D2-12 JH4 99.3 10 CARRSFTSMDYW 1 
Clone_075 Productive V1-39 D2-3 JH4 97.9 12 CARSPDGYSAMDYW¶ 2 




 JH4 99.3 X CAK#YW 1 
Clone_078 Unproductive V5-2 D2-2 JH4 99.3 X CARGATMVTTG#YYYAMDYW 1 
Clone_079 Unproductive V1-67  JH4 99.3 X CARK#AMDYW 1 
Clone_080 Unproductive V5-2 D4-1 JH4 99.3 X CARPPTGT#YYAMDYW 1 
§ Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frame shift for out-of-frame junctions,  
= IMGT/Junction Analysis gives no results for this JUNCTION, ¶ Same CDR3 AA sequence, VH-gene gDNA sequence differs in 3 bases (99% identical) 
  





Table S 5. Analysis of IgH VDJ rearrangements cloned from splenocytes of wild type 
mouse control 4 
















D1-1 JH1 98.96 14 CARHEAGSSLWYFDVW 1 
Clone_03 Productive 
V1-62-2 
 (or V1-71) 
D2-4 JH1 98.96 14 CARHEGYDYDGYFDVW 1 
Clone_04 Productive 
V1-62-2 
 (or V1-71) 
D2-4 JH1 98.95 17 CARHEQGPLYDYDWYFDVW 1 
Clone_05 Productive V1-9 D1-1 JH1 98.96 15 CARPYYYGSTNWYFDVW 2 
Clone_06 Productive V5-17 D2-3 JH1 99.31 16 CARRGIYDGYYDWYFDVW 2 
Clone_07 Productive V1-85 D2-2 JH1 98.26 14 CARRGKWLPYWYFDVW¶ 2 
Clone_08 Productive 
V1-20 
 (or V1-39) 




D2-10 JH1 94.44 13 CARSSYGNYWYFDVW 2 
Clone_10 Productive V5-2 D1-1 JH1 99.31 12 CARTGSSYWYFDVW 1 
Clone_11 Productive V14-1 D2-14 JH1 99.31 9 CTTVGTDFDVW 2 
Clone_12 Unproductive V2-9 D1-1 JH1 94.39 17 CARNPLLLLR**LRYFDVW 1 
Clone_13 Unproductive V5-2 D2-2 JH1 99.31 16 CARQRGLLW*GGWYFDVW 1 












Clone_15 Productive V1-81 D1-1 JH1 98.96 15 CARDYYGSSWGWYFDVW  1 
Clone_16 Productive V1-67 D1-1 JH1 98.96 14 CARFYYGSSYWYFDVW 1 
Clone_17 Unproductive V1-66 D2-5 JH1 98.96 X CAR*GSIVTT#YWYFDVW 1 
Clone_18 Productive V1-42 D1-1 JH2 99.3 11 CAILITTVVAPLW 1 
Clone_19 Productive V1-9 D2-4 JH2 98.96 15 CALYYDYDEGFYYFDYW 1 
Clone_20 Productive V1-9 D1-1 JH2 98.96 11 CAREDYYGSSHYW 1 








D1-1 JH2 98.96 16 CARHEEGYYGSSSYFDYW 1 
Clone_24 Productive V5-17 D1-1 JH2 99.31 10 CARPTTVGFDYW 1 




 JH2 99.31 7 CARRVFDYW 1 
Clone_27 Productive V1-80 D3-3 JH2 98.96 12 CARSGPSKRYFDYW 1 
Clone_28 Productive V1S34  JH2 100 9 CARSRGNPDYW= 1 
Clone_29 Productive V14-4 D2-5 JH2 99.31 12 CTTSPYSNYEGYYW 3 
Clone_30 Productive V14-4 D3-3 JH2 99.31 11 CTTWEIEGYFDYW 2 
Clone_31 Unproductive V3-8 D2-5 JH2 99.3 X CARDYSNP#YFDYW 1 




D1-1 JH2 97.21 X PGP#FDYW∞ 2 
§ Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frame shift for out-of-frame junctions, ¶ Same 
CDR3 AA sequence, VH-gene gDNA sequence differs in 3 bases (99% identical), ✚ Insert had only 85 bp,   Identical genomic DNA sequence and CDR3 










Table S 5 (continued). Analysis of IgH VDJ rearrangements cloned from splenocytes of 
wild type mouse control 4  












Clone_15 Productive V1-81 D1-1 JH1 98.96 15 CARDYYGSSWGWYFDVW  1 
Clone_34 Productive V1-47 D3-1 JH2 98.96 11 CARREYSYYFDYW 1 
Clone_35 Productive V1-80 D2-4 JH3 98.96 10 CAGGLRRGFDYW 1 
Clone_36 Productive V14-2 D3-2 JH3 99.31 12 CARDTAQATRFAYW 1 
Clone_37 Productive 
V1-62-2 
 (or V1-71) 
D2-2 JH3 98.96 20 CARHEEEGIYYGYDEEAWFAYW 2 
Clone_38 Productive V14-2 D2-3 JH3 99.31 11 CARLDGYYEFAYW 1 
Clone_39 Productive V1-42 D3-3 JH3 99.31 7 CARRGFAYW 1 
Clone_40 Productive V1-7 D1-1 JH3 98.96 17 CARSGDYYGSSYPAWFAYW 1 
Clone_41 Productive V1-82 D1-1 JH3 98.96 11 CARSRDYGSSPYW 1 
Clone_42 Productive V1-67 D1-2 JH3 98.96 8 CARWGLGYYW 1 
Clone_43 Productive V14-4 D3-2 JH3 99.31 10 CTTPQATGFAYW 1 
Clone_44 Productive V14-4 D2-1 JH3 98.96 13 CTTYSYGKGVWFAYW 1 
Clone_45 Unproductive V5-2 D2-13 JH3 99.31 X CAGYYGGY#YW 2 
Clone_46 Unproductive V1-4 D4-1 JH3 98.96 X CAPAGTL#WFAYW 1 
Clone_47 Unproductive V1-37 D1-1 JH3 99.31 8 CARGGG*NYW 1 




D2-2 JH3 99.31 X CARQSTMVTT#VAYW 2 




D1-1 JH3 99.3 X CARVLLR**L#FAYW 1 












Clone_53 Productive V1-7 D2-5 JH3 98.96 15 CARPNYSNYVRTWFAYW 1 
Clone_54 Productive V1-82 D2-2 JH3 98.96 10 CASGTGSWFAYW 1 
Clone_55 Productive V1-67 D1-1 JH4 97.92 5 CAIYFYW 1 
Clone_56 Productive V2-9 D1-1 JH4 98.95 16 CAKHHYYGSSYGYAMDYW 1 
Clone_57 Productive V1-85 D2-4 JH4 98.96 13 CAREITTRYYAMDYW 1 
Clone_58 Productive V1-63 D1-1 JH4 98.96 12 CARGGGYYYAMDYW 1 
Clone_59 Productive V1-20 D1-1 JH4 98.96 10 CARGGNYAMDYW 1 
Clone_60 Productive V1-5 D2-10 JH4 97.57 12 CARGGYGNYAMDYW$ 1 
Clone_61 Productive V1-81 D2-10 JH4 98.96 12 CARGGYGNYAMDYW$ 1 
Clone_62 Productive V14-2 D1-1 JH4 99.31 12 CARGGYYGYAMDYW 1 
Clone_63 Productive V1-54 D3-3 JH4 98.96 11 CARGLANYAMDYW 1 
Clone_64 Productive V1-9 D4-1 JH4 96.88 11 CARYWDVYAMDYW 1 
Clone_65 Productive V14-2 D6-2 P JH4 99.31 11 CASAYSLYAMDYW 2 
Clone_66 Productive V1-36 D1-2 JH4 96.18 10 CASNDGGAMDYW 1 
Clone_67 Productive V1-83 D3-1 JH4 97.57 10 CASPGYYAMDYW 1 
Clone_68 Productive V1-14 D4-1 JH4 98.61 9 CATTGDAMDYW 1 
Clone_69 Unproductive V1-9 D1-1 JH4 98.96 X CAIGYYYGSSP#YAMDYW 1 




D2-5 JH4 99.31 X CARPSNG#AMDYW 1 
Clone_72 Unproductive V1-47 D2-5 JH4 98.96 X CPYSNYE#YYAMDYW 1 
Clone_73 Unproductive V1-63 D2-1 JH4 97.57 12 ST**LPHYYAMDYW 1 
§ Number of colonies with identical sequences, * Stop codon in CDR3 region, out-of-frame CDR3, # restored frame shift for out-of-frame junctions,  
  Identical CDR3 and genomic DNA sequence, but different Vector, $ Same CDR3 amino acid sequence, but different VH-gene,  
  





Table S 6. Colony numbers of IgH VDJ rearrangements cloning from splenocytes of 
TCL1tg CD19cre burdened mice 
Mouse ID Plasmid 
Number of white colonies 
10% plate 90% plate Total Picked Informative 
CLL_32284 
JH1 CS N.D. N.D. 700 8 8 
JH2 CS N.D. N.D. 800 8 8 
JH3 CS N.D. N.D. 2800 8 8 
JH4 CS N.D. N.D. 1400 8 7 
CLL_00425 
JH1 CS N.D. N.D. N.D. N.D. N.D. 
JH2 CS N.D. N.D. 1137 30 30 
JH3 CS N.D. N.D. 93 30 30 
JH4 CS N.D. N.D. N.D. N.D. N.D. 





Table S 7. Colony numbers of IgH VDJ rearrangements cloning from splenocytes of 
TCL1tg R26-IKK2ca CD19cre burdened mice  
Mouse ID Plasmid 
Number of white colonies 
10% plate 90% plate Total Picked Informative 
CLL_01140 
 
JH1 CS N.D. N.D. 7 6 6 
JH2 CS N.D. N.D. N.D. N.D. N.D. 
JH3 CS N.D. N.D. N.D. N.D. N.D. 
JH4 CS N.D. N.D. 91 30 30 
CLL_32100 
 
JH1 CS N.D. N.D. 3600 10 10 
JH2 CS N.D. N.D. 7000 10 8 
JH3 CS N.D. N.D. 500 10 10 
JH4 CS N.D. N.D. 130 10 10 
CLL_32351 
 
JH1 CS N.D. N.D. 800 8 8 
JH2 CS N.D. N.D. N.D. N.D. N.D. 
JH3 CS N.D. N.D. N.D. N.D. N.D. 
JH4 CS N.D. N.D. N.D. N.D. N.D. 
CLL_31937 
 
JH1 CS N.D. N.D. N.D. N.D. N.D. 
JH2 CS N.D. N.D. 5000 8 8 
JH3 CS N.D. N.D. 500 N.D. N.D. 
JH4 CS N.D. N.D. N.D. N.D. N.D. 
CLL_32371 
 
JH1 CS 500 2500 3000 8 7 
JH2 CS 600 2500 3100 8 8 
JH3 CS 300 2500 2800 8 8 
JH4 CS 144 450 594 8 8 
CLL_31938 
 
JH1 CS N.D. N.D. 400 8 7 
JH2 CS N.D. N.D. 900 8 7 
JH3 CS N.D. N.D. 2600 8 7 
JH4 CS N.D. N.D. 200 8 8 









Table S 8. Colony numbers of IgH VDJ rearrangements cloning from splenocytes of 
TCL1tg R26-IKK2ca/ca CD19cre burdened mice 
Mouse ID Plasmid 
Number of white colonies 
10% plate 90% plate Total Picked Informative 
CLL_32299 
 
JH1 CS N.D. N.D. 250 10 10 
JH2 CS N.D. N.D. 500 10 10 
JH3 CS N.D. N.D. 450 10 10 
JH4 CS N.D. N.D. 110 10 10 
CLL_32274 
JH1 CS N.D. N.D. 115 12 12 
JH2 CS N.D. N.D. 22 12 10 
JH3 CS N.D. N.D. 14 12 10 
JH4 CS N.D. N.D. 19 12 7 
CLL_32987 
 
JH1 CS 345 2000 2345 12 11 
JH2 CS 350 2900 3250 12 12 
JH3 CS 500 2000 2500 12 12 
JH4 CS 400 2100 2500 12 11 
  N.D. Not done 
 







Genotyping PCR for CD19cre 
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 15mM MgCl2 
(Metabion), 0.4mM dNTPs (Invitrogen, US), 1mM MgCl2, 0.08M of each primer, 
Ampuwa water and 1L of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 95° C x 3min  
Denaturation  95° C x 30s 
X 35 cycles Annealing 60° C x 30s 
Extension 72° C x 50s 
Final extension 72° C x 2min  
 10° C hold  
 
Genotyping PCR for C1cre PCR 
The PCR reaction was done using Metabion Taq (Metabion), the 10X PCR Buffer with 
1.5mM MgCl2 (Metabion), 0.2mM dNTPs (Takara, US), 1mM MgCl2, 0.08M of each 
primer, Ampuwa water and 1L of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 94° C x 2 min  
Denaturation  94° C x 60 s 
X 35 cycles Annealing 65° C x 60 s 
Extension 72° C x 30 s 
Final extension 72° C x 15min  
 10° c hold  
 
Genotyping PCR for Rosa26-Knock-in 
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 1.5mM MgCl2 
(Metabion), 0.2mM dNTPs (Takara, US), 1mM MgCl2, 0.08M of each primer, Ampuwa 
water and 1L of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 95° C x 3 min   
Denaturation  95° C x 30 s  
X 12 cycles Annealing 68° C x 30 s -1º C/step 
Extension 72° C x 30 s  
Denaturation  95° C x 30 s  
X 20 cycles Annealing 56° C x 30 s  
Extension 72° C x 20 s  
Final extension 72° C x 5min   









Genotyping PCR for R26-CAR: 
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 1.5mM MgCl2 
(Metabion), 0.2mM dNTPs (Takara, US), 1mM MgCl2, 0.08M of each primer, Ampuwa 
water and 1L of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 95° C x 3 min   
Denaturation  95° C x 30 s  
X 10 cycles Annealing 69° C x 30 s -1º C/step 
Extension 72° C x 60 s  
Denaturation  95° C x 30 s  
X 20 cycles Annealing 59° C x 30 s  
Extension 72° C x 20 s  
Final extension 72° C x 5min   
 10° c hold   
 
Genotyping PCR for TCL1tg: 
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 1.5mM MgCl2 
(Metabion), 0.2mM dNTPs (Takara, US), 1mM MgCl2, 0.08M of each primer, Ampuwa 
water and 1L of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 95° C x 5 min  
Denaturation  95° C x 45 s 
X 35 cycles Annealing 54° C x 45 s 
Extension 72° C x 60 s 
Final extension 72° C x 5 min  
 10° c hold  
 
Genotyping A20 PCR 
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 1.5mM MgCl2 
(Metabion), 04mM dNTPs (Invitrogen, US), 0.08M of each primer, Ampuwa water and 
1ul of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 95° C x 3 min  
Denaturation  95° C x 30 s 
X 10 cycles Annealing 65° C x 30 s 
Extension 72° C x 60 s 
Denaturation  95° C x 30 s  
Annealing 55° C x 30 s X 20 cycles 
Extension 72° C x 60 s  
Final extension 72° C x 5min  









Genotyping PCR for PKC-KO  
The PCR reaction was done using homemade Taq, the 10X PCR Buffer with 1.5mM MgCl2 
(Metabion), 04mM dNTPs (Invitrogen, US), 0.08M of each primer, Ampuwa water and 
1ul of genomic DNA. Thermal cycling conditions were: 
Initial denaturation 94° C x 5 min  
Denaturation  94° C x 30 s 
X 40 cycles Annealing 58° C x 30 s 
Extension 72° C x 60 s 
Final extension 72° C x 10min  
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